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Malaria persists today as a significant burden for a large part of the world. However, over the 
past few decades, a concerted effort by governments, non-governmental organizations, 
researchers, and community health workers worldwide has yielded progress in reducing the 
deadly impact of this disease. Today, some of these gains are threatened by the rise of 
antimalarial drug resistance, a recurring problem that has impeded global malaria reduction 
efforts before. Research on Plasmodium falciprum resistance to the numerous antimalarial 
compounds used today and in the past has made significant progress on determining which 
specific mutations modulate drug susceptibility and to what degree they do so. To gain a 
comprehensive understanding of drug resistance, we need to elucidate how and why it arises. 
 
Therefore, it is important to elucidate whether some malaria parasites acquire resistance-
conferring mutations faster than others and why the native function of the genetic factors 
involved lend themselves to modulating drug resistance. For instance, resistance to multiple 
antimalarial therapies has repeatedly emerged in Southeast Asia. We investigated the long-held 
hypothesis that this was due to the ability of these parasites to mutate significantly faster than 
non-Southeast Asian strains. Elucidating whether this hypermutability phenotype accurately 
represents Southeast Asian parasite evolvability is important, as it can inform when resistance 
would be expected to next arise, particularly in the Greater Mekong Subregion in Southeast Asia. 
  
 
Here, we have adapted a fluctuation assay to Plasmodium falciparum and determined that some 
contemporaneous Cambodian parasites exhibit a mild mutator, but not a hypermutator, 
phenotype. We also show that this is likely driven by mutations in DNA repair genes carried 
predominantly by multidrug resistant Southeast Asian parasites. 
 
One of the most common genes in which drug resistance-conferring mutations occurs is the P. 
falciparum chloroquine resistance transporter (pfcrt). Mutations in pfcrt are associated with 
parasite susceptibility to many of the antimalarial compounds that have been used in a clinical 
setting to date. However, beyond its role in drug resistance, little is known about the native 
function of PfCRT. To facilitate the study of pfcrt, we have designed a zinc-finger nuclease 
(ZFN)-based gene engineering system that introduces a single double-strand break in intron 1 of 
pfcrt. Our ZFN strategy enables replacing nearly any endogenous pfcrt locus with a user-defined 
recombinant pfcrt allele. We show that our method of pfcrt allelic replacement is fast, efficient, 
and reliable. 
 
We used this system to generate a unique mutant parasite encoding a pfcrt-L272F mutation, 
which enlarges the parasite digestive vacuole, the lysosome-like organelle used to catabolize 
host-derived hemoglobin for amino acid salvage. Our results provide clear evidence that PfCRT 
is associated with the terminal steps of hemoglobin degradation, overall parasite fitness, and the 
balance of osmolytes across the digestive vacuole membrane. Bringing clarity to the native 
function of PfCRT can reveal how and why this single genetic factor has been and continues to 
be involved in the resistance to many different antimalarial compounds. 
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CHAPTER 1. INTRODUCTION 
1.1. Malaria – brief overview 
Without infectious diseases, we as human beings would be living in a very different world today. 
The persistent threat of infectious diseases has shaped our genetics, evolution, cultures, 
traditions, economics, philosophies, arts, and ultimately history. Malaria is one such disease that 
has co-evolved with and influenced humanity for thousands of years (1). It was referenced by 
Greek poets; plagued ancient Egyptians; killed two Holy Roman Emperors; stopped Confederate 
army advances during the U.S. Civil War; selected for hemoglobinopathies on the African 
continent; and in 2015, killed an estimated 430,000 people (1, 2). 
 
Human malaria is caused primarily by four species of the Plasmodium genus: P. falciparum, P. 
vivax, P. malariae, and P. ovale. P. falciparum is the most virulent species and the major cause 
of mortality (2). Today, the global malaria burden caused by P. falciparum is heavily skewed to 
sub-Saharan Africa. 88% of all malaria cases occur in this region (Figure 1.1), 40% of which 
come from just two countries: the Democratic Republic of the Congo and Nigeria (2). 
 
Over the past 15 years, a concerted effort by governments, non-governmental organizations, 
researchers, and clinicians has yielded significant progress in reducing the global malaria burden. 
Overall, the incidence of malaria has been reduced roughly 37% since 2000, averting 1.2 billion 
cases and 6.2 million deaths. This success is largely due to the distribution of insecticide-treated 
bed nets (69%), administration of artemisinin-based combination therapies (ACTs) (21%), and 





Figure 1.1 Malaria deaths reported globally in 2014 
99,542 (of the estimated 438,000 total) deaths from malaria in 2014 were reported by 95 
countries and territories with ongoing malaria transmission. Reported malaria deaths represent 
deaths identified in the health care system and reported through each country’s surveillance 
system. In many malaria endemic countries, most deaths occur outside the health system. 
Furthermore, due to uncertainties in determining the cause of death and incomplete reporting, the 
number of reported deaths is unlikely to represent the true number. Figure reproduced from (3). 
 
Despite this significant progress in malaria prevention or treatment, the disease remains a 
persistent burden. Malaria is often a difficult disease to diagnosis clinically. Patients typically 
exhibit headaches, fevers, chills, and fatigue: symptoms that are common with most infectious 
diseases (4). Accurate diagnosis of malaria requires confirmation by microscopy, where Giemsa 
stained blood is visually inspected for parasites, or rapid diagnostic testing where parasite 
antigens are detected in an immunochromatographic assay with monoclonal antibodies (5). 
 
Malaria infections do not always cause death. In areas of high parasite transmission, immunity 
can be common among adults and infections can be largely asymptomatic. However, in immune 
compromised or immunodeficient individuals, such as children, malaria infections can lead to 




For instance, high parasitemia (the percentage red blood cells (RBCs) infected with parasites) 
can cause severe anemia. Additionally, modulation of the infected RBC (iRBC) membrane by 
the parasite within produces electron-dense protrusions, which enable iRBCs to sequester in the 
microvasculature of organs including the brain. iRBC sequestration can lead to organ failure, 
cerebral malaria, and death (6). Together, these effects of P. falciparum infection contribute to 
the estimated 292,000 deaths in African children under the age of 5 in 2015 (2). 
 
 
Figure 1.2 Percentage 
decrease in (a) estimated 
malaria case incidence 
and (b) malaria death 
rate, by WHO region, 
2000–2015 
AFR, Africa; AMR, 
Americas; EMR, Eastern 
Mediterranean; EUR, 
Europe; SEAR, South-East 
Asia; WPR, Western 
Pacific. *There were no 
recorded deaths among 
indigenous cases in Europe 
for the years shown. 
Reproduced from (2). 
 
1.2. The Plasmodium life cycle 
An infected female Anopheles mosquito while taking a bloodmeal will secrete its saliva along 
with Plasmodium sporozoites into the dermis of its new host (7) (Figure 1.3). Within an hour, 
these sporozoites migrate to the host’s liver and invade hepatocytes. The sporozoites then 
replicate forming up to tens of thousands of merozoites, which burst from the hepatocytes to 
enter the peripheral circulation. Merozoites will quickly invade erythrocytes, starting the 48-hour 




Figure 1.3 The Plasmodium Life Cycle 
A malaria infection begins with the transmission of a Plasmodium parasite via a female 
Anopheles mosquito (left) to a human (right) host. After the initial liver stage, the parasite begins 
its asexual intraerythrocytic cycle. Sexual forms, which develop from the intraerythrocytic 
parasites, can be transmitted to another mosquito. In the mosquito, parasites undergo meiotic and 
mitotic replication to form sporozoites, which can infect another human host. 
 
There are three stages in the intraerythrocytic cycle: ring, trophozoite, and schizont (Figure 1.4). 
During the ring stage, parasites begin to acquire nutrients (9), to deplete nucleosome occupancy 
at promoters (10), and to initiate a cascade of programmed transcription (11). The trophozoite 
stage is marked by the appearance of the digestive vacuole (DV), where hemoglobin (Hb) 
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catabolism occurs (discussed in 1.2.1). During this stage, the haploid genome transitions from 
G1/G0 phase of the cell cycle to S phase, where DNA replication begins (Figure 1.4). The 
parasite can undergo up to roughly 4 to 5 rounds of asynchronous replication, generating roughly 
24 sister chromatids (12). This is followed by the schizont stage, where each genome is packaged 
into daughter merozoites, which then egress the erythrocyte to re-initiate a new round of asexual 
replication. This coordinated invasion and egress of erythrocytes manifest in non-immune 
individuals as periodic fevers and anemia. 
 
Figure 1.4 The Plasmodium asexual erythrocytic cycle. 
A haploid (1n) merozoite invades a red blood cell (RBC) and develops as the “ring” form from 0 
hour to about 24 hour post-invasion, corresponding to G1 of the cell cycle. As the parasite 
transitions from rings to trophozoites, its metabolic activity increases in preparation for DNA 
replication. Prior to S phase and DNA replication, the parasite is still haploid, allowing for 
possible alternative EJ pathways. DNA replication produces multiple copies of the genome in an 
intact nucleus that does not undergo membrane degradation, providing homologous templates for 
HR. Plasmodium DNA replication is asynchronous and can produce a range of sister chromatids, 
up to about 24n. Nearing the end of the 48-hour cycle, each genome is packaged into separate 
daughter merozoites, which then egress and invade another RBC. 
 
Intraerythrocytic parasites can also adopt an alternative, sexual stage developmental pathway, in 
which they form male or female gametocytes. Over a two-week period these stages mature and 
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become infectious for mosquitoes (13). Upon transmission, gametocytes convert into gametes 
that can then mate to form a zygote (7). Following meiosis, zygotes convert into motile ookinetes 
that exit the bloodmeal confines and traverse the midgut epithelium, after which they lodge 
under the basal lamina and form oocysts. During the process of sporogony inside an oocyst, the 
parasite undergoes multiple rounds of replication to generate thousands of haploid sporozoites, 
which migrate to the mosquito salivary glands to await the next bloodmeal. 
 
1.2.1 The digestive vacuole (DV) 
During the Plasmodium asexual erythrocytic cycle, a parasite invades and begins to alter the host 
RBC from within a parasitophorous vacuole. This remodeling process involves decreasing the 
deformability of the RBC membrane by altering the profile of membrane integral proteins (14), 
increasing the permeability of low molecular weight solutes (15), and redistributing ions within 
the parasite and RBC (16). 
 
One of the key steps taken in the ring stage of the 48-hour life cycle is the start of the formation 
of the digestive vacuole (DV). Live-cell imaging and multi-section electron tomography have 
shown that invaginations in the parasitophorous vesicle membrane and parasite plasma 
membrane form cytostomes containing contents of the host RBC cytosol (primarily hemoglobin), 
which then generate double-membrane bound vesicles in the parasite cytosol (9). Cytostome 
acidification occurs immediately by a V-type H+-ATPase and a H+-pyrophosphatase (17). These 




One primary function of the DV is the catabolism of hemoglobin (Hb) into amino acids and 
peptides for use in cellular processes (Figure 1.5). Hb encodes all amino acids except isoleucine, 
which must be acquired from an exogenous source (19). The degradation of Hb is essential for 
parasite survival, and the parasite digests up to 75% of the RBC Hb, but only utilizes 15% for 
protein biosynthesis, effluxing the remainder out of the iRBC in order to maintain osmotic 
stability and prevent premature hemolysis (20-22).  
 
 
Figure 1.5 Hemoglobin catabolism in the digestive vacuole 
The process of hemoglobin (Hb) catabolism follows a roughly linear path where Hb is first 
degraded into globin peptides by plasmepsins and falcipains, releasing free heme as a toxic 
byproduct. These proteases can be inhibited by ALLN and E64, producing enlarged, dark-
staining DVs. Globin peptides are further degraded to oligopeptides by the histo-aspartic 
protease and falcilysin. The terminal steps in Hb catabolism involve three peptidases (PfDPAP1, 
PfAPP, and PfA-M1), which reduce peptide length to short peptides and amino acids with few 
restrictions on substrate specificity. Toxic free heme released by Hb catabolism is converted the 
inert hemozoin crystal. This process is inhibited by chloroquine (CQ). CQ can be effluxed by 
CQ-resistant (CQR) allele of the P. falciparum chloroquine resistance transporter (PfCRT, blue), 
but not by the CQ-sensitive (CQS) allele (white). ALLN: N-acetyl-leucinyl-leucinyl-norleucinal, 





Hb catabolism occurs in a semi-ordered process involving multiple proteases. Cleavage of Hb is 
initiated by the aspartic proteases plasmepsins (I and II) (24), followed by the papain-family 
cysteine proteases falcipains (2, 2’, and 3) (25), and plasmepsin IV and histo-aspartic protease 
(HAP) (24). The function of these proteases is redundant and their substrate specificity is broad. 
For instance, plasmepsins I, II, and IV, HAP and falcipain-2 can be independently knocked out 
(26, 27). Therefore, while these proteases initiate Hb degradation into globin peptides and 
oligopeptides, there is no defined order in which this process occurs. 
 
Degradation of the tertiary structure by proteases releases the heme moiety in Hb. Free heme is a 
toxic substrate that generates free radicals and promotes lipid peroxidation and protein oxidation 
(28, 29). To detoxify free heme, the parasite converts it to the hemozoin crystal (β-hematin) in a 
hemozoin formation complex, which consists of plasmepsins II and IV, falcipain-2, HAP, and 
the heme detoxification protein (30). Inhibition of the heme detoxification process is the 
mechanism of action for the quinoline class of antimalarials (31). 
 
Once oligopeptides are generated, Hb catabolism is accessible to four ion-dependent peptidases: 
(A) falcilysin, a member of the M16 family oligoendopeptidases (32), (B) P. falciparum 
dipeptidyl peptidase 1 (PfDPAP1) (33, 34), P. falciparum aminopeptidase N (PfA-M1) (35), and 
P. falciparum aminopeptidase P (PfAPP) (36, 37). Like the initial proteases above, these 
peptidases do not exhibit defined substrates or order in which cleavage occurs amongst them. At 
the completion of Hb catabolism, the amino acids and short peptides generated are transported to 




1.3. Antimalarial therapies 
1.3.1 Contemporary and future antimalarial therapies 
Artemisinin, artemisinin derivatives, and artemisinin-based combination therapies (ACTs) 
Artemisinin has been used in treating malaria symptoms for hundreds of years in Chinese 
medicine.  Ge Hong's A Handbook of Prescriptions for Emergencies written around 300 BC 
stated: “A handful of qinghao [Artemisia annua] immersed with 2 liters of water, wring out the 
juice and drink it all.” The molecule artemisinin (“qinghaosu”) was isolated and shown to be the 
causative agent in alleviating malaria in the 1970s (38).  
 
Isolating artemisinin was a significant step in treating malaria. Since 2001, the WHO has 
recommended artemisinin-based combination therapies (ACTs) as the first-line antimalarial 
treatment (39). These ACTs consist of an artemisinin derivative and a partner drug. In these 
formulations, the artemisinin derivative provides rapid clearance of the majority of parasites 
before the drug is eliminated, while the partner drug resists degradation and clears the remainder 
of the infection (40, 41). 
 
The efficacy of ACTs has significantly contributed to the reduction of the global malaria burden 
and these therapies have a reported treatment failure rate of less than 10% (2). However, as is the 
case for most antimicrobial compounds, resistance to artemisinin inevitably emerged. 
Artemisinin resistance in vivo is defined as the delay in parasite clearance after artemisinin 
derivative treatment. It is often represented as an increase in parasite clearance half-life (42). The 
first confirmation of artemisinin resistance in vivo came in 2008, where a subset of patients in 
Western Cambodia exhibited either delayed parasite clearance or recrudescence of infection after 
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artemisinin-derivative (artesunate) monotherapy (43, 44).  Resistance to artemisinin is conferred 
by a number of individual mutations in the k13 gene, a putative regulator of the parasite’s 
responses to cellular stress (45, 46). 
 
ACT partner drugs 
Artemisinin alone is an efficacious compound, but it is co-formulated with partner drugs for two 
major reasons (47). (1) Artemisinin rapidly clears most parasites, but has a short plasma half-life 
(1 to 3 hours). Therefore, a longer-lasting partner drug is required to clear the remainder of the 
infection. (2) Mutations conferring resistance to two unrelated drugs have a lower probability of 
occurring than to a single drug.  
 
Currently, there are six possible ACTs available: artemether-lumefantrine, dihydroartemisinin-
piperaquine, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-
pyrimethamine, and artesunate-pyronaridine. 
 
Sulfadoxine-pyrimethamine is a combination of two antifolates, which target the Plasmodium 
dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), respectively. 2 DHPS 
and 3 DHFR mutations reliably lead to treatment failure in patients treated with sulfadoxine-
pyrimethamine (48). 
 
Pyronaridine is an acridine-derived compound related to chloroquine, but not associated with any 
known mutation in PfCRT (49). Trials of artesunate-pyronaridine show that it does meet the 




Lumefantrine, mefloquine, piperaquine, and amodiaquine are quinoline or quinoline-related 
compounds that, to variable extents, inhibit the detoxification of heme, a byproduct of 
hemoglobin catabolism in the parasite digestive vacuole, similar to chloroquine (see 1.4.2) (31). 
Resistance to all three compounds has been linked to mutations in the P. falciparum chloroquine 
resistance transporter (PfCRT) but also associate with the P. falciparum multidrug resistance 1 
transporter (PfMDR1) (51-57). 
 
Anticipating the inevitable rise of drug resistance, public and private institutions have made 
significant investment in drug discovery (58). Technological advances in high-throughput 
screening have enabled the discovery and testing of a diverse set of novel compounds, such as 
the spiroindolone KAE609, the imidazolopiperazine KAF156, and the synthetic trioxolane 
OZ439 (58, 59). These compounds are beneficial in two main ways: they are not affected by 
PfCRT or PfMDR1 and they can often reduce parasite burden in multiple life cycle stages, not 
just the 48-hour asexual cycle.  
 
1.3.2 Chloroquine (CQ) 
Chloroquine (CQ) is a 4-aminoquinoline compound, based on quinine—extracted from the 
cinchona tree bark and used to treat malaria since at least the 1600s (Figure 1.6) (60). Originally 
named resochin, CQ was first synthesized in Germany in 1934 by Hans Andersag while working 
for Bayer IG Farbenindustrie (61). It was originally thought to be too toxic for human use, and a 
related molecule, Sontochin, was chosen for clinical trials in Axis-controlled Tunisia. In 1943, 
Allied forces invaded North Africa, and researchers conducting Sontochin clinical trials 
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transferred 5,000 tablets and data to US military forces (62). Sontochin was found to be identical 
to a molecule (SN-6911) synthesized by the Winthrop Chemical Company in the US. This 
discovery spurred research into related compounds, which quickly yielded CQ. Trials in treating 
avian malaria P. gallinaceum and P. vivax showed it was an inexpensive, effective antimalarial 
treatment and this drug was distributed for military-wide use by 1947 (62). 
 
CQ has multiple cytocidal and cytostatic mechanisms of action on the parasite. CQ is a weak 
base that freely diffuses across plasma membranes and down the parasite pH gradient (63, 64). It 
travels to the parasite cytoplasm where it its protonated (CQH+), and then accumulates in the 
DV, where it is protonated again (CQH2+) (Figure 1.5). In the DV, CQH2+ has been shown to 
interfere with the heme detoxification process in which heme is converted into the inert 
hemozoin crystal (31). Lethal doses of CQ might also trigger an autophagy-like process in 
parasites (65). 
 
                           
Chloroquine                                                           Quinine 
Figure 1.6 The structures of chloroquine and quinine 
 
CQ’s efficacy, safety, and cost led to its global use in malaria treatment and prophylaxis, in 
conjunction with the insecticide DDT, in the WHO Global Malaria Eradication Programme 
(GMEP) of 1955 (66). However, within a decade of its first widespread use in 1947, CQ had 
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begun to select for resistance in parasites from Southeast Asia and South America (discussed 
further in CHAPTER 3). 
 
1.4. The Plasmodium falciparum chloroquine resistance transporter (PfCRT) 
Resistance to CQ is conferred by mutations in the P. falciparum chloroquine resistance 
transporter (PfCRT). PfCRT is a 424 amino acid, 48.6 kDa, and ten transmembrane domain 
protein that localizes to the DV membrane (67) (Figure 1.7). Bioinformatic analysis suggests that 
PfCRT is a member of the drug/metabolite transporter superfamily (68), however its native 
function has yet to be fully elucidated (discussed in 1.4.3). The pfcrt gene was mapped to 
chromosome 7 and implicated as the central determinant of CQ resistance through a genetic 
cross between the CQ resistant parasite (CQR) Dd2 and the CQ sensitive (CQS) parasite HB3 
(67). HB3 was isolated from a Honduran patient (69), while Dd2 was derived from the Southeast 
Asian CQR clone W2 (70). PfCRT’s role in conferring resistance to CQ has been genetically 
validated in strains engineered to express either CQR or CQS haplotypes in isogenic 





Figure 1.7 PfCRT 
polymorphisms and 
predicted topology 
Schematic of PfCRT in 
the digestive vacuole. 
PfCRT consists of 10 
transmembrane domains 
embedded in the 
membrane between the 
DV and the parasite 
cytoplasm. Residues 
associated with drug 
resistance are noted as 
green dots. 
 
1.4.1 The spread of chloroquine resistance 
To date, there are 53 unique, naturally occurring isoforms of pfcrt that modulate CQ resistance 
and overall parasite fitness (72). Most CQ resistant haplotype today stem from the independent 
emergence of resistance from two major geographic regions: Southeast Asia and South America 
(Figure 1.8) (73). The Southeast Asian pfcrt haplotype has had the largest global impact, as it 
migrated from Southeast Asia to Africa, where the majority of malaria deaths occur (74).  
 
PfCRT requires at minimum four mutations (K76T, A220S, N326D, and I356L) to confer 
resistance to CQ (75), but can encode an additional five mutations to modulate resistance and 






Figure 1.8 The spread of 
drug resistance 
World map showing the 
years and locations of the 
spread of CQ resistance 
showing two major 
epicenters, Southeast Asia 
and South America. Figure 
reproduced from (76). 
 
1.4.2 The role of PfCRT in drug resistance 
Experimental investigations into the role of PfCRT in drug resistance fall into three categories: 
(A) monitoring drug transport in either whole iRBCs or detergent-extracted parasites (77), (B) 
measuring the 72-hour half-maximal inhibitory concentrations (IC50) or half-lethal doses (LD50) 
of drug in vitro (57, 78), and (C) heterologously expressing PfCRT in S. cerevisiae (72), 
Dictyostelium discoideum (79), Xenopus oocytes (80), or proteoliposomes (81) to measure the 
transport of drugs (and other molecules, e.g. short peptides). 
 
Each system is designed to compare how mutations in PfCRT affect drug transport, inhibition of 
cell growth, and cell death. Typically, the canonical wildtype 3D7 PfCRT haplotype is used as a 
CQS control, while the Southeast Asian Dd2 PfCRT haplotype is the standard CQR control. As 
mentioned above, CQ travels down the cellular pH gradient and accumulates in the DV (pH ~5.2 
– 5.8 (18)), where it inhibits the detoxification of heme (31, 82). CQR PfCRT then transports CQ 
out of the DV in a passive, membrane potential-dependent mechanism (Figure 1.9) (63, 72, 83). 
CQ transport is associated with a proton leak either in symport with CQ or via the deprotonated 
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form (84, 85). CQR PfCRT-mediated transport of CQ and other quinoline drugs has been shown 
to be inhibited by the addition of the L-type Ca2+ channel blocker Verapamil (VP) (57, 86, 87). 
 
While CQ transport is dependent on at least four PfCRT mutations (75), the removal of the 
positive charge contributed by the lysine at residue 76 (e.g. K76T, K76N, or K76I) is the critical 
mutation that likely reduces steric hindrance between CQH2+ and lysine, thereby enabling CQ 
efflux out of the DV (88, 89). Kinetic studies in PfCRT heterologously expressed in Xenopus 
oocytes suggest that PfCRT-mediated drug efflux occurs by a mixed-type inhibition model 
where the transport of CQ and other quinoline drugs requires binding to PfCRT in distinct, but 
interdependent regions (90). VP is thought to block CQ transport by this same model, where it’s 
binding sites in PfCRT overlap with those of CQ (90). 
 
Figure 1.9 PfCRT-mediated resistance to quinoline compounds  
a. CQ, quinine (QN), and mefloquine (MQ) are weak bases and accumulate in the acidic DV in 
their diprotonated forms. CQS PfCRT (blue) does not permit the efflux of these compounds to 
the cytosol. CQ accumulation therefore inhibits hemozoin formation. c. CQR PfCRT haplotypes 
(red) effectively efflux CQ and to a lesser extent QN and MQ to the cytosol. CQ efflux prevents 





1.4.3 The role of PfCRT in the digestive vacuole 
The mixed-type inhibition model of PfCRT drug transport (90) is consistent with growing 
evidence surrounding the native function of PfCRT, however the specific endogenous substrates 
of PfCRT have yet to be fully elucidated. In parasite and Xenopus experiments, PfCRT was 
shown to transport glutathione (92). Evidence in studies reconstituting PfCRT in 
proteoliposomes suggest it can transport amino acids, peptides, polyamines, ions, and 
antimalarial compounds (81, 83, 93). Peptides have also been shown to inhibit CQ transport in 
PfCRT heterologously expressed in Xenopus oocytes and proteoliposomes (81, 89).  
 
Recently, metabolic quantitative loci (mQTL) analysis of progeny from the HB3 × Dd2 genetic 
cross and peptidomic analysis of engineered CQR and CQS strains showed a link between 
PfCRT haplotype and the accumulation of short, hemoglobin-derived peptides in the DV, 
suggesting an impairment of peptide transport via mutant PfCRT (94). Together, these studies 
offer support for the poly-specific transporter model of PfCRT where its substrates can vary, but 
include essential factors for parasite survival (95). 
 
1.5. The Accelerated Resistance to Multiple Drugs (ARMD) phenotype 
The emergence of PfCRT-mediated resistance to CQ in Southeast Asia was followed by the 
implementation of and subsequent emergence of resistance to sulfadoxine-pyrimethamine, 
mefloquine, and currently artemisinin (96-100). This phenomenon where Southeast Asia was and 
continues to be the epicenter of drug resistance was hypothesized to be due to the ability of local 
strains to hypermutate, thereby selecting for resistance-conferring single nucleotide 
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polymorphisms (SNPs) at a higher rate than non-Southeast Asian strains. This hypermutability 
phenotype was termed the “Accelerated Resistance to Multiple Drugs” (ARMD) (101). 
 
To date however, evidence for the existence ARMD phenotype has been conflicting. Recent 
long-term in vitro culturing and whole-genome sequencing of laboratory-adapted Southeast 
Asian (W2, Dd2) and non-Southeast Asian (3D7, HB3) strains indicated no correlation between 
geographic origins and mutability (102, 103). In contrast, a report describing an in vitro plasmid 
mismatch repair assay suggested that the Mismatch Repair (MMR) pathway was less functional 
in Southeast Asian strains (W2 and Dd2) compared to non-Southeast Asian strains (HB3) (104). 
Recently, whole-genome sequencing of Southeast Asian and African parasite isolates between 
2007 and 2011 indicated that contemporaneous Cambodian artemisinin-resistant parasites 
preferentially harbor mutations in DNA repair genes, specifically MMR factors Mlh1, Pms1, and 
Exo1, in addition to homologous recombination genes Rad50 and the Werner helicase (WRN) 
(45), suggesting a role for defective DNA repair in the emergence of artemisinin-resistance. 
 
1.5.1 Mismatch repair (MMR)  
To date, research of MMR in Plasmodium is limited to a handful of studies. However, 
bioinformatic analysis indicates that the molecular factors involved in MMR are conserved in 
Plasmodium spp. Therefore, MMR in parasites is expected to function as it does in other 






Figure 1.10 Schematic of mismatch repair (MMR) 
Schematic of MMR. Heteroduplex DNA is recognized by the Msh2-Msh6 complex, which can 
be recruited by PCNA. Msh2-Msh6 and PCNA then recruits the Mlh1-Pms1 complex, which 
generates nicks in the DNA duplex. In an Exo1-dependent pathway, nicks can serve as the entry 
point for Exo1, which catalyzes strand excision and re-synthesis by a DNA polymerase. In an 
Exo1-independent pathway, PCNA can stimulate Mlh1-Pms1 to repeatedly generate nicks, 
which can initiate strand removal and re-synthesis by a DNA polymerase. Figure reproduced 
from (105). 
 
In eukaryotes, a mismatched base pair or short insertion/deletion (indel) is first recognized by the 
heterodimeric complex MSH2-MSH6 (MutSα) (106, 107). Longer indel loops are recognized by 
the MSH2-MSH3 (MutSβ) complex (108) (Figure 1.10). P. falciparum encodes two MSH2 
paralogs (MSH2-1 and MSH2-2, PF3D7_1427500 and PF3D7_0706700, respectively) and one 
MSH6 ortholog (PF3D7_0505500). There does not appear to be an MSH3 ortholog. Therefore it 
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is possible that bioinformatic analysis cannot identify the Plasmodium MSH3 homolog or that 
MutSα complex serves to repair all MMR substrates. 
 
In an in vitro “DNA curtains” assay, yeast MutSα has been shown to scan for heteroduplex DNA 
in an ATP-independent fashion (109) and to be recruited to replicating DNA by the proliferating 
cell nuclear antigen (110, 111) (PCNA, P. falciparum paralogs PF3D7_1361900 and 
PF3D7_1226600). In the rodent malaria P. berghei, disruption of the MSH2-2 paralog does not 
have a noticeable effect on MMR of SNPs or microsatellites (112), suggesting that the MSH2 
paralogs serve as redundant MMR factors. 
 
Following heteroduplex recognition, the Mlh1-Pms1 (MutLα, P. falciparum orthologs Mlh1 
PF3D7_1117800 and Pms1 PF3D7_0726300) complex is recruited to the heteroduplex where its 
ATP-dependent endonuclease activity is stimulated by PCNA and MutSα in order to create nicks 
in the strand encoding the misincorporated base (113, 114). The directionality of PCNA loaded 
on the DNA duplex is suggested to correctly orient MutLα (115). In P. falciparum, Mlh1 is 
expressed during S phase (116). 
 
Excision of the misincorporated base can occur via two pathways: Exonuclease 1 (Exo1)-
dependent and Exo1-independent. Exo1 is a Rad2 family nuclease involved not only in MMR, 
but also other DNA repair pathways, such as homologous recombination (117). Crystal 
structures of yeast Exo1 has shown that it can interact with the C-terminal domain of Mlh1 
(118). In the Exo1-dependent MMR pathway, Exo1 catalyzes the 5’ nick-directed strand 
excision, generating a single-stranded DNA (ssDNA) template for a DNA polymerase (e.g. Pol 
  
 21 
δ) (119). In vitro reconstitution of MMR factors except Exo1 suggest that strand removal can 
occur by an Exo1-dependent mechanism where PCNA-stimulated MutLα generates repeated 
nicks and provides a template for polymerase-mediated strand removal and heteroduplex repair 
(120). The ability to excise the misincorporated base via redundant pathways is consistent with 
the mild effect on mutation rate in exo1Δ yeast strains (121). This is in contrast to the 
hypermutator effects observed in msh2Δ, msh6Δ, mlh1Δ, or pms1Δ yeast strains (121-123). 
 
1.6. Genome Engineering 
To investigate the genetic contributions of P. falciparum MMR genes in mutability, PfCRT in 
drug resistance, or any other factor in a wide range of molecular pathways, P. falciparum 
research requires rapid, efficient genome editing. To date, genetics in P. falciparum has become 
increasingly accessible with the near simultaneous arrival of new transfection-based gene editing 
technologies, which will undoubtedly deepen our understanding of parasite determinants of drug 
resistance, fitness, pathogenesis and overall cellular organization and developmental biology (46, 
71, 75, 124-127). The common factor amongst all the old and new technologies is the 
requirement for a double-strand break (DSB) to initiate homologous recombination (HR). It was 
recognized early in yeast and mammalian systems that the introduction of a single DSB 
significantly increases the rate of recombination (128, 129). Genetic research in malaria was not 
too far behind in recognizing the potential of DSBs, though several hurdles have prevented their 




1.6.1 DNA double-strand break repair (DSBR) 
In most eukaryotes, the DSBR response can be split into two main branches: the “error-free” 
Homologous Recombination (HR) pathway and the potentially “error-prone” end joining (EJ) 
pathways. During HR, a broken DNA duplex will utilize a homologous template (a sister 
chromatid, a homologous chromosome in diploids, a donor plasmid, or an ectopic donor if the 
DSB forms within a repeated sequence) for highly accurate repair. The EJ pathways do not use a 
homologous template, and instead ligate broken DNA ends together, resulting in a higher 
possibility of insertions or deletions (indels). Below, we outline DSBR and describe P. 
falciparum orthologs and experimental evidence when possible. We use S. cerevisiae 
nomenclature in reference to orthologs, omitting Homo sapiens nomenclature for clarity unless 
otherwise stated. For more in-depth reviews of DSBR, we refer the reader to several excellent 
publications (130-134). 
 
Mitotic recombination: mechanisms and evidence in Plasmodium 
Initial Double-Strand Break Sensing and Resection 
A DSB is first sensed by the Mre11-Rad50-Xrs2 complex (MRX, using the yeast nomenclature 
henceforth) (Figure 1.11a) (135). The MRX complex binds to double-stranded DNA (dsDNA) 
ends formed by a DSB, positions both ends in close proximity, and in collaboration with Sae2 
initiates 5’ to 3’ resection, creating short 3’-terminated ssDNA tails (Figure 1.11b). Initial 
resection is a rate-limiting step in HR, as it provides the substrates for further, extensive 
resection (136, 137). Mre11 and Rad50 show high homology with their Plasmodium orthologs, 





Initial resection is followed by 5’ to 3’ extensive resection by functionally redundant factors 
Exonuclease 1 (Exo1) or the Sgs1-Top3-Rmi1-Dna2 (STR-Dna2) complex (136, 137), which 
commits DSBR to HR and generates 3’ ssDNA tails (Figure 1.11c). Exo1 is a member of the 5’ 
structure-specific Rad2/XPG family of nucleases involved in most DNA repair pathways (e.g. 
Mismatch Repair (MMR) and NER), which degrades DNA from 5’ to 3’. Sgs1 is a RecQ 
helicase that unwinds linear dsDNA, creating a Y-shaped structure that is then cleaved by the 
flap endonuclease Dna2 (Figure 1.11c) (138). Sgs1 has two human homologs, BLM and WRN 
(mutated in Bloom’s and Werner’s Syndrome, respectively). BLM has been shown to be the 
primary resection protein in mammalian cells (139, 140), although Xenopus WRN-DNA2 can 
also resect linear DNA substrates in vitro (141). Both BLM and WRN have P. falciparum 
homologs (PF3D7_0918600 and PF3D7_1429900, respectively), though the P. falciparum WRN 
homolog lacks the 5’ to 3’ exonuclease domain that is characteristic of WRN in other eukaryotes. 
It is therefore possible that PF3D7_1429900 is, in fact, a different RecQ helicase.   
 
The extent of resection varies between species. Yeast can exhibit ssDNA tract lengths up to 2 to 
4 kb during mitotic HR and 850 bases during meiotic HR (131). Detailed analyses of resection 
have not been performed in Plasmodium.  Extensive ssDNA resection tracts are likely to signal 
cell cycle arrest and prevent unwanted recombination by exposing more unique sequence to 
search for a homologous template (131). In an A/T-rich organism with extensive regions of low 
complexity such as P. falciparum, long resection tracts may be beneficial for ensuring that a 





Figure 1.11 Canonical models of Homologous Recombination, Synthesis-dependent Strand 
Annealing, and Break Induced Replication.  
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Figure 1.11 cont. 
A double-strand break (DSB) in a chromosome (a.) is first sensed and tethered together by the 
MRX-Sae2 complex (b.). Resection by Exo1 (grey Pac-man) or the STR-Dna2 complex (yellow 
and red triangles, respectively) exposes 3’ ssDNA tails, which are then bound by RPA (c., green 
dots). RPA is replaced by Rad51 (d., grey helices), which forms a nucleoprotein filament that 
invades homologous templates (e.). Synthesis-dependent Strand Annealing (SDSA) uses the 
invading 3’ tail as a primer for DNA synthesis (f.). Once sufficient homology is synthesized, the 
invading strand can bridge the DSB to restore chromosome integrity. If the distal chromosome 
arm is lost, then Break Induced Replication can occur where DNA synthesis will continue 
conservatively until it reaches the end of the chromosome arm (l.). If both broken DNA ends are 
captured by a homologous template (g.), a Double Holliday Junction (dHJ) can be formed (h.). 
This structure can be resolved in a number of ways. Merging both Holliday Junctions together by 
the STR complex (yellow triangles) dissolves the dHJ in a hemicatenane structure, which is 
unlinked by the Top3 topoisomerase (i.). Cleavage of both Holliday junctions by structure-
specific resolvases (purple triangles) can unlink the dHJ to produce either Non-crossover (j.) or 
Crossover (k.) products. 
 
Rad51 Nucleoprotein Filament Formation and Strand Invasion 
3’ ssDNA tails generated by resection are first coated by the heterotrimeric Replication Protein A 
(RPA) complex (Figure 1.11c), protecting them from degradation and secondary structure 
formation (142). P. falciparum encodes all three subunits of RPA and an additional truncated 
version of the RPA1 subunit (RPA1S), which antagonizes the long form (RPA1L) during in vitro 
recombination (143). Yeast Rad52 (or the human breast cancer type II susceptibility protein, 
BRCA2) then displaces RPA and simultaneously delivers ATP-bound Rad51, the central HR 
recombinase, onto ssDNA allowing it to form a nucleoprotein filament (Figure 1.11d). Rad51 
catalyzes invasion and pairing between the ssDNA to which it is bound and the complementary 
sequence to form a displacement loop (D-loop) (Figure 1.11e).  
 
Rad52 homologs have not been found in Plasmodium (144), and the P. falciparum RPA1 
homologs lack similarity to the N-terminal domains of other eukaryotic RPA1 orthologs (145) 
that are necessary for Rad52 interactions (146). Caenorhabditis elegans, Drosophila 
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melanogaster, and Arabidopsis thaliana all lack Rad52, which may also be the case with P. 
falciparum. Mammals use BRCA2 in addition to Rad52, and BRCA2 sequence similarity even 
among mammals is relatively low. Nevertheless, BRCA2 homologs have been briefly mentioned 
for P. falciparum (PF3D7_1328200) and P. yoelii (PY17X_1348100), where homology is found 
only in 6 BRC repeats. These repeats are known to stimulate Rad51-ssDNA binding and prevent 
non-specific Rad51-dsDNA binding (147). Trypanosoma cruzi, T. brucei, and Leishmania major 
also have BRCA2 homologs with varying numbers of BRC repeats (148). Other BRCA2 regions 
(the oligonucleotide-binding (OB) fold that binds ssDNA and the Tower domain that binds 
dsDNA), however, have not been identified in these homologs. These regions also cannot be 
identified in the D. melanogaster BRCA2 homolog (147) and may be too divergent to 
bioinformatically detect as they can have low sequence conservation (149). Nevertheless, D. 
melanogaster BRCA2 remains proficient in homologous recombination (150), as is expected to 
be the case with Plasmodium parasites. In stark contrast to Rad52 and BRCA2, P. falciparum 
Rad51 shows high homology to Rad51 of many species. Predictably, it is upregulated in 
response to the DNA-damaging agent MMS, performs strand exchange on DNA substrates in 
vitro, and hydrolyzes ATP (87, 144).  
 
Efficient Rad51-mediated D-loop formation is enhanced by the Rad55-Rad57 heterodimer and 
the Rad54 motor protein. Rad55-Rad57 stabilizes the Rad51 nucleoprotein filament by 
preventing Rad51 displacement from ssDNA (151). Rad54 is a dsDNA-dependent ATPase that 
translocates along dsDNA, enhances Rad51-dependent strand exchange, and stabilizes Rad51 
filament formation on both ssDNA and dsDNA (152-154). Rad54, however, only dissociates 
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Rad51 from dsDNA. The synergistic effects of Rad54 on Rad51-mediated strand exchange are 
mirrored in in vitro assays using purified PfRad51 and PfRad54 (PF3D7_0803400) (143). 
 
D-loop formation is followed by Polymerase δ-dependent DNA synthesis primed from the 3’ OH 
group of the invading 3’ ssDNA tail (Figure 1.11e). Synthesis extends for ~250 bp in yeast 
(155), expanding the D-loop and incorporating any single nucleotide polymorphisms (SNPs). So 
far, extension of the invading arm has been found to incorporate SNPs 150 bases distal to the 
DSB with high frequency (71), and up to 900 bp at a lower but substantial level during gene 
editing in P. falciparum (156). More detailed frequencies and tract lengths have yet to be 
thoroughly delineated. 
 
Non-Crossovers and Crossovers 
Two basic options exist after D-loop formation: Synthesis Dependent Strand Annealing (SDSA) 
(Figure 1.11f) and double Holliday Junction (dHJ) formation (Figure 1.11h). During SDSA, the 
invading strand is extended to traverse the DSB, the D-loop is collapsed, and the extended strand 
bridges the DSB. The homologous template is left unchanged. Possible SNPs copied from the 
homologous template will generate heteroduplex DNA and be corrected by the MMR machinery. 
MMR tends to favor the donor as the “correct” template, but the mechanism of this proclivity has 
yet to be determined (155). 
 
If the D-loop captures the second 3’ ssDNA tail (Figure 1.11g), then the D-loop intermediate can 
form a double Holliday Junction (dHJ) (Figure 1.11h). dHJs are then processed by two distinct, 
canonical pathways. dHJs can be “dissolved” whereby they are merged together by the Sgs1-
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Top3-Rmi1 (STR) complex into a hemicatenane structure, which is unlinked by the 
topoisomerase Top3 to generate a Non-Crossover (NCO) product (Figure 1.11i). Alternatively, 
dHJs can be resolved by Mus81-Mms4, Yen1, or Slx1-Slx4 (157). Depending on the cleavage 
pattern of the dHJs, resolution will form NCO or Crossover (CO) products (Figure 1.11j and k, 
respectively). Currently, more intricate pathways branching from the canonical model of dHJ 
resolution are being elucidated (157, 158). Some of these nucleases, such as Mus81, Yen1, Rad1, 
and Rad10 have orthologs in P. falciparum. Orthologs could not be found for Mms4, Slx1, and 
Slx4. 
 
By definition, HR by any of these mechanisms is highly accurate, but errors can arise. For 
example, mitotic crossovers in diploids can lead to loss of heterozygosity. Non-Allelic HR 
(NAHR) between repeated sequences can generate copy number variants (CNVs) (discussed 
below) or translocations. Furthermore, if a chromosome arm is lost during repair, the invading 
strand intermediate can copy the homologous template until the site of its telomere, using a 
process termed Break Induced Replication (BIR) (Figure 1.11l). BIR can cause extensive loss of 
heterozygosity in diploids (159). In Plasmodium, BIR is one mechanism that is believed to 
generate novel var sequences (102). 
 
Meiotic Recombination: Mechanisms and Evidence in P. falciparum 
Meiotic recombination is important for the efficient production of sporozoites in Plasmodium 
(160); spores in budding yeast (161, 162); and gametes in mammals (163, 164). The basic 
mechanistic outcomes of meiotic recombination are largely similar to mitotic recombination, but 
involve a larger set of meiosis-specific proteins required for the programmed generation of 
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genetic diversity (162, 164). Here, we briefly discuss meiosis in Plasmodium and focus on the 
meiotic factors involved in recombination.  
 
The mosquito stage of the Plasmodium life cycle begins with transmission of male and female 
gametocytes via a bloodmeal (Figure 1.3). Almost immediately, the male microgametocyte 
undergoes three rapid rounds of DNA replication, producing eight haploid genomes (165). 
Exflagellation produces eight single microgametes (1n) (166). A microgamete can subsequently 
fertilize a female macrogamete (1n), producing a zygote (2n). A subsequent round of DNA 
replication (2n, 4c) is then followed by meiosis (167, 168) to form a tetraploid ookinete (2n, 4c). 
During meiosis, crossing over via HR is known to be important for the formation of yeast spores 
(161) and begins with the production of programmed DSBs by the meiosis-specific endonuclease 
Spo11 (169). Of note, Plasmodium orthologs of Spo11 exist, suggesting a conserved mechanism 
(170). In yeast, meiotic HR utilizes the Rad51 homolog Dmc1 to catalyze strand exchange, with 
Rad51 playing a supporting role (171). In P. berghei, a Dmc1 knockout produces fewer and 
smaller oocysts and substantially lower numbers of sporozoites (160), implicating marked 
defects in meiotic recombination. While a similar knockout has not been studied in P. 
falciparum, Dmc1 is expressed in gametocytes, prior to meiotic recombination, implicating a 
similar role (172).  
 
As with mitotic HR, successful strand invasion (Figure 1.11e) provides the choice between 
forming NCOs or COs by various pathways (Figure 1.11f and h). Spo11-induced DSBs are 
predominately repaired as NCOs (likely by SDSA) and COs at a 10:1 ratio in mammals (164). 
This relative excess of NCOs has also been seen in P. falciparum (173, 174). However, these 
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reports may still under-represent the number of NCOs, due to a lack of resolution or NCO 
products that are indistinguishable from either parental chromosome. 
 
In contrast to mitotic HR, resolution of meiotic dHJ intermediates in S. cerevisiae requires the 
MutL homologs, Mlh1 and Mlh3 along with Exo1 (161, 164). In the case of P. falciparum, 
whole-genome sequence analysis of artemisinin-resistant Cambodian parasite populations shows 
a high frequency of an Mlh1 (PF3D7_1117800) mutation (45), possibly implicating a defect in 
meiotic crossing over. In a yeast exo1Δ strain, the homologous Mlh1 mutation showed a mutator 
phenotype (121), consistent with a loss of function. No Mlh3 ortholog has been identified to date 
in P. falciparum. During meiotic recombination, each chromosome averages one crossover (173-
175) and has a genetic map unit distance of ~10 kb (175) to ~15kb per centimorgan (173). 
Meiosis is followed by many rounds of DNA replication inside oocysts to form thousands of 
genomes that segregate into individual haploid sporozoites (166, 176).  
 
Investigations into the process of meiotic recombination in Plasmodium have been limited to 
analyzing P. berghei DNA content during sexual reproduction (165, 167). Several other studies, 
nonetheless, have explored outcomes of meiotic recombination. P. falciparum genetic cross 
studies have analyzed the segregation of chromosomal markers (SNPs and microsatellites) 
spread out over the genome between geographically distinct parasite clones: 3D7 × HB3 (177), 
HB3 × Dd2 (173, 174, 178-180), and 7G8 × GB4 (175, 181, 182). These were instrumental in 
mapping the dihydrofolate reductase dhfr (183) and P. falciparum chloroquine resistance 
transporter pfcrt (67) drug resistance loci and identifying key determinants of host cell tropism 




End joining (EJ) 
Basic Mechanisms of End Joining 
Parallel to HR, the End Joining (EJ) pathways are comprised of the classical and alternative EJ 
pathways, where broken DNA ends are re-ligated without a homologous template for repair 
(Figure 1.12). The classical Non-homologous End Joining (NHEJ) pathway has been commonly 
referred to as the “error-prone” pathway, though it is likely rather error-free but accommodating 
of promoting genetic variability (184). 
 
In yeast, NHEJ can be performed just with the Ku70/80 (Ku) heterodimer and the DNA Ligase 
IV-Lif1-Nej1 complex (185). The Ku heterodimer binds broken DNA ends, which can protect 
them from end resection and commitment to HR (186) and act as a platform for NHEJ factor 
recruitment (185). Ku promotes EJ of a variety of substrates by sterically fitting in the grooves of 
the DNA double helix, as opposed to forming specific base interactions (187). In vertebrates, 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and the endonuclease Artemis are 
essential NHEJ factors. DNA-PKcs and Artemis bind Ku-bound ends and phosphorylation of 
Artemis by DNA-PKcs activates its endonuclease activity (188). Either nucleolytic degradation 





Figure 1.12 End Joining (EJ) Pathways 
Non-homologous End Joining (NHEJ) A. involves the joining of broken DNA ends with little-to-
no homology. Here, a simplified model of NHEJ depicts the restoration the original DNA 
sequence, introduction of small insertions, or small deletions (blue strands). Microhomology-
mediated End Joining (MMEJ) B. relies on minimal resection by proteins shared with HR to 
expose short homologies, up to 25 bp, which can anneal, deleting any intervening sequence. 
Single-strand Annealing (SSA) C. involves longer stretches of resection. Rad52 (not shown) in 
yeast displaces RPA and anneals longer homologies, generating larger deletions. 
 
The Absence of Non-Homologous End Joining in Plasmodium 
To date, bioinformatic analyses have failed to identify any Plasmodium homologs to NHEJ 
proteins (189). In contrast, another Apicomplexan parasite Toxoplasma gondii encodes a 
functional Ku-dependent NHEJ pathway (190), suggesting that despite relative evolutionary 
proximity to T. gondii, Plasmodium has lost its NHEJ machinery. In support of this hypothesis, a 
recent study showed the absence of any NHEJ products recovered from in vivo endonuclease-
generated DSBs in Plasmodium (71). Furthermore, other eukaryotic pathogens such as Giardia 
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lamblia (191), Encephalitozoon cuniculi (192), and Trichomonas vaginalis (193) also lack NHEJ 
components.  
 
Possible Alternative End Joining Mechanisms in Plasmodium 
If NHEJ has been lost during Plasmodium evolution, then alternative EJ pathways may still be 
active. In yeast, kuΔ mutants reveal pathways that occur at lower frequencies than NHEJ (194). 
These Ku-independent processes include Microhomology-Mediated End Joining (MMEJ) and 
Single-Strand Annealing (SSA) (195). Both pathways require resection to expose homologies 
internal to the DSB ends. MMEJ refers to joining between microhomologies (up to 25 bp), 
whereas SSA occurs between more extensive homologies. Yeast Rad52 promotes annealing of 
the complementary ssDNA during SSA (196) by displacing RPA coated on ssDNA (197), but 
plays little or no role in MMEJ. As discussed above, BRCA2, but not Rad52, is homologous to 
P. falciparum PF3D7_1328200. The Ustilago maydis BRCA2 homolog, Brh2, is reported to 
promote strand annealing similar to the reaction catalyzed by Rad52 (198), suggesting that the 
Plasmodium BRCA2 homolog could fulfill a similar role. Current evidence, nonetheless, 
suggests that SSA is not a major mechanism of DNA repair in Plasmodium (71). In another 
eukaryotic pathogen T. brucei, chromosomal and in vitro plasmid EJ assays only produce 
MMEJ-generated repair products (199-201). NHEJ is not used, and the T. brucei Ku only 
functions in telomere maintenance (202).  
 
A recent report (203) suggests that P. falciparum may be able to repair a DSB by an alternative 
EJ mechanism whereby a few bases are added to the broken ends, thereby providing 
microhomologies. The frequency of these events is very low and larger deletions (e.g. possible 
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SSA products) beyond the locus analyzed were not examined. Nevertheless, Plasmodium species 
encode all necessary components of the MMEJ machinery, many of which overlap with HR. 
However, given the general lack of NHEJ, MMEJ, and SSA products observed in Plasmodium, it 
seems unlikely that EJ processes occur to any significant extent in malaria parasites. 
 
Potential implications of the absence of end joining in Plasmodium 
The absence or at the least highly infrequent use of EJ pathways in P. falciparum may be an 
important factor in the production of a live, radiation-attenuated sporozoite vaccine. Haploid 
sporozoites in the Sanaria PfSPZTM Vaccine are metabolically active, yet non-replicating (204-
206). PfSPZTM is generated with sporozoites dissected from infected mosquitoes exposed to 15 
krad of γ-irradiation. Sufficient irradiation introduces DNA damage (207) without compromising 
hepatocyte invasion, gene expression, and initial trophozoite development, but prevents nuclear 
division (208). Estimations from yeast data suggest that the 15 krad dose would be sufficient to 
generate low but sufficient numbers of DSBs (209). Therefore, the crucial replication defect of 
irradiated sporozoites may result from the parasite’s lack of an efficient EJ pathway during this 
strictly haploid stage, and may manifest itself only when DNA replication occurs during liver 
stage proliferation. 
 
Studies of irradiated blood stage P. falciparum support this notion. Experimental analyses show 
that cellular distress is dose- (210) and cell cycle-dependent (211). Studies with parasites 
subjected to varying ionizing radiation (IR) doses throughout the asexual blood stage (Figure 
1.4) show that ring stage parasites and multinuclear schizonts with 1c chromosome cannot 
reconstitute an in vitro culture after IR exposure as efficiently as trophozoites, which have >2c 
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chromosome content (211, 212). Given that the trophozoite stage has numerous sister chromatids 
as templates for repair in a synctium, the IR-induced DNA damage is likely readily repaired by 
HR. Further studies are required to discern whether the segregation of chromosomes after DNA 
replication (176) inhibits efficient HR. Altogether, without a robust EJ pathway, it is possible 
that Plasmodium would be more sensitive to DNA damage than are other model organisms such 
as yeast and humans.  
 
1.6.2 Homologous recombination in P. falciparum 
Barring a few exceptions, DSBR in Plasmodium is rarely studied solely at a mechanistic level. 
Most published studies examine the products of such processes in the context of drug resistance, 
antigenic diversification, population structure, or genetic manipulation. Together, these studies 
each contribute to a larger picture of the consequences of Plasmodium DSBR, but few provide 
direct experimental evidence of its underlying molecular intricacies. Nevertheless, the compiled 
picture shows a unique organism where DSBR dictates a broad spectrum of phenotypes. 
 
Subtelomeric Regions and Antigenic Diversification 
Unlike in T. brucei, antigenic variation in the Plasmodium parasite does not occur by HR. 
Whereas T. brucei undergoes Rad51-dependent gene conversion to replace the active antigen-
encoding gene (the variant surface glycoprotein, VSG) with one of the many inactive 
pseudogenes (213) in order to evade host defenses, P. falciparum antigenic variation is mediated 
at the epigenetic level (214). P. falciparum Erythrocyte Membrane Protein I (PfEMP1), which is 
presented on the host infected erythrocyte and exposed to the immune system, is encoded by the 
clonally variant var gene family. var does not require a DSB to switch between its family 
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members and instead epigenetically silences all but one var cassette out of the ~60 total per 
parasite (214). 
 
Though recombination plays no role in antigenic variation, it does mediate var gene antigen 
sequence diversification and var gene family composition during mitotic (102, 215, 216) as well 
as meiotic replication (175, 217). var genes are located primarily in subtelomeric regions of 
chromosomes (218, 219), although some are also found clustered in central chromosomal regions 
(189, 219, 220). The subtelomeric regions are also home to the rifin and stevor multi-copy gene 
families, which also interact with host factors. Spatial positioning studies show that chromosome 
ends are clustered together at the nuclear periphery (219-221). In yeast, spatial proximity of a 
DSB to a donor template greatly enhances HR (222). Therefore, in addition to providing a 
mechanism for selective var expression, clustering of subtelomeric ends may provide the close 
proximity between heterologous chromosomes for recombination to generate novel var 
sequences (220). 
 
The rate of recombination in these subtelomeric regions has been shown to be much higher than 
in the core chromosome: for in vitro 3D7 cultures, the mitotic recombination rate is about 
9.5u10-6 events per base pair per generation, with over 80% of events occurring in the 
subtelomere (102). Parasite populations from different global regions reaffirm this notion (217). 
It is possible; nevertheless, that both mitotic and meiotic recombination could contribute to 
recombination in subtelomeric regions, as both can occur during the mosquito stages. This may 
provide parasites with the ability to persist longer in a single blood stage infection by forming 




Mechanistically, the diversification of var sequences and var gene family composition can be 
driven by a number of recombination pathways. Reports pinpointing the precise mechanisms 
driving these events have not been published, although insights can be gleaned by analyzing the 
recombination products. For example, a var allele can copy a portion of a donor allele to produce 
a novel, chimeric allele. In mitotically dividing P. falciparum cells, studies suggest that this 
process is mediated by an SDSA-mediated gene conversion event (102, 215) (Figure 1.11f) and 
BIR (Figure 1.11l) (102). Intragenic COs between two rif genes can create two novel sequences 
(215). Non-allelic Homologous Recombination (NAHR) may also delete or amplify large swaths 
of sequence in subtelomeric regions, thereby altering var gene family composition for a given 
parasite (102, 216).  
 
In the sexual stages, a recent study has shown that some hotspots for ectopic var recombination 
are energetically likely to form DNA secondary structures, which may act as substrates to 
generate DSBs (223). Analyses of parasite populations (217) and genetic crosses (174) (175) 
report that the subtelomeric regions show a high rate of recombination during the sexual stages. 
Further studies are needed to ascertain whether these events are occurring during meiosis or the 
numerous subsequent mitotic divisions in the mosquito vector.  
 
Copy Number Variation (CNV) 
One of the best-characterized phenotypes of gain-of-function events is the acquisition of drug 
resistance by copy number variation (CNV). CNVs, either amplifications or deletions, change 
the number of select genes within a genomic region in order to alter their total expression levels. 
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Original analyses primarily used Pulsed Field Gel Electrophoresis (PFGE) to separate 
chromosomes, but now CNV detection relies more heavily on quantitative real-time polymerase 
chain reaction (qRT-PCR) (224), high-density tiling microarrays (225), or whole-genome 
sequencing (102). 
 
The classic example of the relationship between CNVs and drug resistance is the increased 
tolerance to mefloquine conferred by the amplification of a genomic region (amplicon) on 
chromosome 5 containing the P. falciparum multi-drug resistant gene, pfmdr1, which encodes 
the P-glycoprotein homolog (Pgh-1). The W2 parasite, initially derived from a Southeast Asian 
isolate, was pressured in vitro with a step-wise increase of mefloquine over 96 weeks, generating 
the mefloquine-resistant parasite W2-mef (70). Characterization of W2-mef and its derived 
clones revealed that the key to resistance was the amplification of pfmdr1. This results in 
increased Pgh-1 expression that is thought to more effectively transport mefloquine into the 
digestive vacuole away from its primary site of action (226, 227). Amplifications in other regions 
in the genome can also lead to increased drug tolerance to a variety of antimalarials. 
 
Additionally, genomic deletions have been described in many parasites. Some prominent 
examples come from the deletion of unnecessary genes in culture-adapted parasites (e.g. Dd2). 
Continuous in vitro culture is absent of host-derived selective pressures; therefore, functions 
such as cytoadherance to endothelial cell surface receptors in the microvasculature (228, 229) or 




CNVs are generally believed to be detrimental to cell fitness due to the imbalanced dosage of 
gene products, thereby perturbing cellular homeostasis. For example, changes in gene dosage 
have been linked to cancer and neurological disorders, such as autism (231). In P. falciparum, 
the fitness costs to parasite growth have been observed with amplifications of gch1 (203) and 
pfcrt (our unpublished results). However, in the context of selective or diverse environments, 
CNVs can prove advantageous in promoting adaptability, as in the case of in vitro culture growth 
and drug resistance. Other CNVs such as an amplification of adjacent plasmepsin2 and hap 
(histo-aspartic protease) genes found in a Thai field isolate have been speculated to increase 
nutrient acquisition and may be beneficial for the parasite (229). Furthermore, increasing copies 
of genes that confer drug resistance can allow for one copy to maintain wild-type sequence and 
functionality while the additional copy may mutate to confer drug resistance (224). Therefore the 
investigation of parasite CNVs may prove to be increasingly important to study, particularly in 






Figure 1.13 Established technologies for genome editing 
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Figure 1.13 (cont.) 
A. Single-site crossover  (SSC) has been developed to utilize a region homologous to a genomic 
locus encoded on a transfected plasmid with a positive marker (green strands). SSC depends on a 
stochastic DSB in the genome to provide recombinogenic DNA ends that will use the plasmid 
region of homology as a template for repair. Formation of a dHJ and its resolution to yield a 
crossover product will lead to plasmid integration into the genome. B. An apparent Double 
Crossover requires the parasite to incorporate the positive marker placed between two regions 
homologous to the gene of interest. Recombination (e.g. by SDSA) can copy the positive marker 
and introduce this into the genome while avoiding the negative marker (dark grey strands). An 
alternative scenario (not shown) involves two independent crossover events. Here, the entire 
plasmid integrates into the genome by SSC and is followed by recombination between the 
homologous sequences flanking the negative marker, thereby looping it out. Selection for both 
positive and negative markers will select only for parasites that have incorporated the positive 
marker. 
 
1.6.3 Established genome engineering technologies  
Early transfection and mutant parasite generation began around the mid-1990s for both P. 
falciparum and P. berghei. Stable transfection of P. falciparum originated by introducing an 
episomal copy of the chloramphenicol acetyltransferase selectable marker (232). This was 
quickly followed by plasmid integration into the genome of a selectable marker, the 
dihydrofolate reductase-thymidylate synthase (dhfr-ts), by a method referred to as “single-site 
crossover” (233, 234) (Figure 1.13a). Simultaneously, transfections in P. berghei had also 
produced resistant dhfr-ts parasites both with episomal and integrated plasmids (235, 236). Both 
species were transfected by electroporation; ring stages in P. falciparum and merozoites in the 
case of P. berghei. 
 
Although the number of selectable markers has increased (237-239) and alternate transfection 
methods have been developed (240), genetic manipulation techniques and efficiency had not 
drastically changed much in P. falciparum aside from the introduction of the “double crossover” 
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technique (Figure 1.13b). This technique uses negative in addition to positive selection, to 
remove unwanted recombination events (241, 242). These methods still yield low efficiency, at 
best 1 per 105 parasites per transfection (243, 244), and take 2–3 months, at a minimum, to 
produce desired recombination events at a high enough rate to clone the appropriate parasites. 
Mechanistically, double crossovers may occur either by SDSA or by integration of the plasmid 
via single-site crossover, followed by crossover-based excision of the negative marker using 
homology within the plasmid. 
 
In contrast to the fate of P. falciparum genetic manipulation, methods in P. berghei have 
benefitted substantially from the success of linear DNA transfection. Linear DNA (displaying 
broken DNA ends) in P. berghei was readily incorporated into the genome via “ends-in” and 
“ends-out” methods, which mirror the standard methods utilized in yeast genetics (245, 246). 
Use of linear DNA and optimization of transfection technology has reduced the time required to 
generate mutant parasites to less than a week, with average efficiencies nearing 10-2 to 10-3 
parasites per transfection (247). In G. lamblia, which also lack NHEJ factors (191), linear DNA 
transfection is possible and always results in integration into the genome (248). 
 
In P. falciparum, transfection of linear DNA by nanosomes has shown modest luciferase 
expression lasting a few days, but no genomic integration was reported (249). To date, linearized 
DNA for gene editing has not been successful in P. falciparum, even when the plasmid is 
linearized in cells using Zinc-Finger Nucleases (ZFNs) (See APPENDIX 8). Bioinformatic 
studies to date have not identified any differences in DNA repair pathways between P. 
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falciparum and P. berghei that would explain the markedly different efficiencies in linear DNA-
based gene replacement. 
 
1.6.4 Engineered endonucleases: ZFNs and TALENs 
The recent development of three powerful gene editing technologies has spurred enthusiasm for 
the future of Plasmodium genetics, as ZFNs, Tal Effector-like Nucleases (TALENs), and the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system have been 
shown to be extremely useful in other research and translational settings. For example, TALENs 
have been designed for all protein-coding genes in the human genome (250), and ZFN-mediated 
inactivation of CCR5 in CD4 T cells can lower the HIV burden in treated patients (251). 
 
 
Figure 1.14 Schematic of a ZFN 
A ZFN pair consists of two 
heterodimeric nucleases. Each 
nuclease is comprised of an 
engineered DNA-binding zinc-
finger protein (ZFP) and a FokI 
nuclease domain. Dimerization of 
the ZFN heterodimers generates a 
DSB between the ZFP binding 
sites. Figure from (252). 
 
ZFNs and TALENs both act as heterodimers where each monomer contains a DNA-binding 
domain and the nuclease domain of the FokI endonuclease. The DNA-binding domain, also 
known as the Zinc-Finger Protein (ZFP) region, consists of an assembly of three to six C2H2 zinc 
fingers, which each bind on average three bases (252). TALENs share the same architecture as 
ZFNs, but differ in that the DNA-binding domain consists of a tandem array of 34-amino acid 
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repeat modules where each repeat is identical except for two amino acids, which bind a single 
base (NI binds Adenine, HD binds Cytosine, NG binds Thymine, and NN binds Guanine or 
Adenine) (253). The benefits of TALENs include its simple, modular design, which enables 
high-throughput construction of a large number of variants to recognize different targets. 
However, difficulties may arise due to the inherent repetitive nature of the DNA-binding domain 
sequence and the overall size of the nuclease. Fused to both the ZFN and TALEN DNA-binding 
domains is the FokI nuclease domain, which upon DNA-binding homodimerizes and creates a 
DSB, usually generating 4 or 5 bp 3’ overhangs, depending on the sequence that each monomer 
binds. Enhancements to the FokI domain have been made such that the nuclease heterodimerizes, 
lowering its potential off-target specificity (254). The resulting DSB can then be repaired from a 
plasmid template to transfer the desired sequence change to the genome. Repair in the absence of 
a homologous template can be used to generate indels through EJ, if such a pathway exists in the 
organism (252). 
 
The use of ZFNs in the Plasmodium field is currently gaining traction. Thus far, published genes 
targeted in P. falciparum include pfcrt (56, 71, 75, 124), a genome-integrated enhanced green 
fluorescent protein (egfp) (71), the phosphatidylinositol-4-OH kinase (156), artemisinin 
resistance molecular marker k13 (71), the P. vivax dhfr gene (255), and a number of unpublished 
reports. Due to the high A/T content of the P. falciparum genome, ZFN design is more difficult 
than in other species, but nevertheless feasible. Various factors impact the success of gene 
editing. ZFN cleavage activity in the parasite generally correlates with activity in yeast proxy 
assays ((254); our unpublished observations). Proximity of SNPs to be incorporated into the 
genome to the site of ZFN cleavage improves the chances of editing (256). The length of 
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homologous region on the plasmid positively correlates with the rate of recombination (257, 
258). Lengths of homologous regions in Plasmodium typically range around 1 kb (71), but can 
be longer (156), depending on plasmid size constraints. 
 
To date, TALENs have been designed in silico to target Plasmepsin V and have shown 
functionality in a yeast reporter cleavage assay (259), but no Plasmodium TALEN studies have 
been published to date. 
 
1.6.5 CRISPR/Cas in Plasmodium 
While successfully engineered and in vivo-validated ZFNs remains useful, researchers are 
currently shifting genome-engineering efforts to the CRISPR/Cas system. To date, successful 
CRISPR/Cas genome editing has been published twice in P. falciparum to edit the P. falciparum 
origin recognition complex 1 (orc1), k13, and the knob-associated histidine rich protein 
(KAHRP) (125, 126) and once in P. yoelli to edit the serine proteases Pysera1 and Pysera2 and 
the pyruvate dehydrogenase PyPDH (127). 
 
The CRISPR/Cas system modifies a prokaryotic viral-defense system to cleave a specific 
genomic sequence harboring a unique motif using an RNA-guided Cas9 endonuclease (260-262). 
Cas9 can bind a fusion RNA sequence (single guide RNA, sgRNA) where one segment is 
necessary for secondary structure formation and Cas9 binding, and the other is complementary to 
a given target DNA sequence, which Cas9 will cleave, forming a DSB (Figure 1.15) (260). This 
system circumvents the relatively more arduous engineering requirements inherent to ZFNs or 
TALENs. However, studies in other model systems show that the limitations of the CRISPR/Cas 
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system lie in the target genomic site criteria. Target genomic sites must encode a 3 bp NGG 




Figure 1.15 Schematic of Cas9-
mediate gRNA binding and DSB 
formation 
The sgRNA-bound Cas9 first 
recognizes the NGG PAM sequence 
at the target locus. It then unwinds 
the target allowing for sgRNA-DNA 
pairing. Binding of the 
complementary 20 bases in the 
target locus by the sgRNA catalyzes 
Cas9 to form a DSB. Formation of a 




The CRISPR/Cas systems in Plasmodium have thus far used two RNA polymerases to transcribe 
the sgRNA sequence: T7 and U6 (125-127). The T7 RNA polymerase is derived from the T7 
bacteriophage, while the U6 RNA polymerase is encoded in Plasmodium genomes. U6-based 
CRISPR/Cas systems benefit in that it does not need to be exogenously supplied on a transfected 
plasmid, unlike the T7 RNA polymerase. 
 
To date, success with the CRISPR/Cas system in Plasmodium has been mixed. However, as the 
experimental requirements to ensure highly efficient CRISPR/Cas-based genome editing in 
Plasmodium are delineated, it is likely that malaria research will soon benefit from this 
transformative technology. This nuclease system, combined with a high-throughput method of 
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design and cloning, may prove to be extremely valuable both for parasitology and for other 




CHAPTER 2. EXPERIMENTAL PROCEDURES 
2.1. Experimental Procedures for CHAPTER 3. Evidence of a Mild Mutator Phenotype in 
Cambodian Plasmodium falciparum Malaria Parasites 
2.1.1 Parasites 
Laboratory strains (3D7, W2, Dd2, and V1/S) were obtained from the Malaria Research and 
Reference Reagent Resource Center (MR4). All Cambodian clones (PH0167-C, PH0164-C, 
PH0306-C, PH0482-C, and PH0212-C) were isolated by Dr. Rick Fairhurst (NIAID/NIH) in 
Pursat, western Cambodia in 2010 (42, 46). The Exonuclease I-deficient Dd2 exo1Δ line was 
generated from Dd2, described below. A description of parasite origins is provided in S1 Table. 
 
2.1.2 Parasite culturing and DNA analysis 
Asexual blood stage parasites were maintained in human red blood cells in complete media: 
RPMI-1640 malaria culture media with 0.5% (w/v) Albumax II (Invitrogen) under 5% O2, 5% 
CO2, 90% N2 as described (268). 
 
2.1.3 Long-term parasite propagation  
Long-term culturing began at day 0 when each strain was cloned by limiting dilution in 96-well 
plates. For each strain, one clone was chosen at random and immediately expanded to obtain 
sufficient gDNA for whole-genome sequencing. This clone was then maintained in culture for 
202 (PH0306-C, PH0164-C, PH0482-C, and PH0212-C) or 211 (PH0167-C) days before 
recloning by limiting dilution. Two clones were chosen from each long-term cultured parental 
strain and expanded to obtain sufficient gDNA for whole-genome sequencing. In total, each 
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strain was maintained in culture for 243 (PH0167-C), 236 (PH0164-C), 230 (PH0306-C), or 231 
(PH0482-C, PH0212-C) days (Table 3.1). Mutation rates were calculated as described in (102) 
for each clone for each strain. Mutation rates between isogenic clones were then averaged (Table 
3.4). 
 
2.1.4 Whole-genome sequence analysis 
To prepare samples for sequencing, DNA libraries for each gDNA sample were prepped with the 
Nextera XT kit (Illumina), using the dual index protocol. Libraries were clustered using the 
RapidRun mode on an Illumina HiSeq 2500, and 100 base pairs were sequenced on either 
fragment end for each sample. Paired-end reads were aligned to the P. falciparum 3D7 reference 
genome (PlasmoDB v. 13.0), as described previously (269) with the exception that mutations 
were called using the GATK HaplotypeCaller instead of UnifiedGenotyper. Mutations, including 
single nucleotide polymorphisms (SNPs) and insertion/deletions (indels), were filtered based on 
general recommendations from GATK as follows: SNP filters: ReadPosRankSum > 8.0, < -8.0; 
QUAL < 500; QD < 2, MQRankSum < -12.5; DP < 5 and indel filters: ReadPosRankSum < -20; 
QUAL < 500; QD < 2, DP < 5. Additional filters were applied post HaplotypeCaller, which 
included removing candidate mutations when the read coverage was < 5 in the parent and 
samples had a heterozygous ratio > 0.2 (reference/total reads). 
 
 
Parasite trophozoite-infected erythrocytes were harvested and saponin-lysed. Parasite genomic 
DNA (gDNA) was extracted and purified with QIAGEN DNeasy Blood Kits. KAE609-resistant 
gDNA was extracted, and pfatp4 (PF3D7_1211900) was amplified by PCR using primers 5’-
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GTAGAAGAATCACCTAAATCTATAGG-3’ and 5’-CAAGCAAAATTTTTACCACATG-3’. 
PCR products were Sanger sequenced. 
 
2.1.5 Construction of the P. falciparum exo1Δ mutant 
To generate a P. falciparum exo1Δ knockout strain, we generated the pcamBSD-exo1 plasmid 
that was used to genetically disrupt the pfexo1 (PF3D7_0725000) open reading frame. First, a 
1187 bp fragment of pfexo1 encoding NotI and PstI restriction sites was PCR amplified from 
Dd2 gDNA using primers 5’-CTTGCGGCCGCGTAATGATTTTCATATAACTGGTATGGG-
3’ and 5’-CTTCTGCAGCATCGAAAGTATGTTCACACGTTCCG-3’. This fragment was then 
cloned into pcamBSD (52) using cloning sites NotI and PstI, which encodes the blasticidin-S-
deaminase (bsd) selectable marker, yielding pcamBSD-exo1. Dd2 parasites were transfected 
with purified circular pcamBSD-exo1 plasmid as described (268). One day post-electroporation, 
parasites were exposed to 2 μg/ml of blasticidin (Invitrogen). Blasticidin media was replaced 
daily until day 7 post-electroporation and every 2 days thereafter. Transformed parasites were 
detected by light microscopy 11 days post-electroporation, maintained in blasticidin-containing 
media, and periodically checked by PCR for single site crossover-based plasmid integration into 
the pfexo1 locus. This PCR screen used the primers 5’-TCACTAAAGGGAACAAAAGCTGG-
3’ and 5’-AAGGTCATCCTTCTTTTCCCAC-3’. Plasmid integration was detected on day 31 
post-electroporation. The mixed culture was then cloned by limiting dilution in a 96-well plate 
(270). To detect clones, plates were screened by flow cytometry on an Accuri C6 flow cytometer 
coupled to a HyperCyt autosampler, with iRBCs labeled using 1.6 μM Mito Tracker Deep Red 




2.1.6 KAE609 fluctuation assays 
On day 0, each parental parasite strain was first cloned by limiting dilution. Single clones were 
expanded to ~5×108 total infected red blood cells (iRBCs) and then seeded into two 96-well 
plates. Stocks were also cryopreserved at this time. The first plate was inoculated with 2.5×108 
total iRBCs of a parental clone at ~3% hematocrit in selective media containing 2.5 nM KAE609 
(kindly provided by Dr. Thierry Diagana, Novartis Institute of Tropical Diseases) (272). The 
second plate (0.8 parasites/well) was a control in which a parental clone was cloned again by 
limiting dilution in a 96-well plate (without drug pressure) to calculate an accurate starting 
culture density (iRBC/ml). KAE609-containing selective media (at 0.9% hematocrit) was added 
to drug-pressured 96-well plates daily for 4 days, followed by the addition of fresh selective 
media (without RBCs) every 48 hours. Fresh RBCs were added on days 14, 17, and 20. Drug-
resistant clones were detectable by flow cytometry generally around day 20 post-inoculation 
(matching the growth rate for unpressured clones).  
 
2.1.7 Fluctuation assay mutation rate calculation 
Mutation rates were calculated for both parasite and yeast fluctuation assays using the Ma-
Sandri-Sarkar Maximum Likelihood Estimator (MSS-MLE) Method via the online Fluctuation 
Analysis Calculator (FALCOR) (273). In this analysis, r is the total count of KAE609-resistant 
clones per parental clone tested, and Nt is the corrected starting number of parasites determined 
from each clone’s control plate. MSS-MLE is considered to be a more accurate method of 
calculating mutation rates as compared to the Lea-Coulson or other methods (274). Statistical 




2.1.8 In vitro susceptibility assays 
In vitro IC50 values were determined by incubating parasites for 72 hours across a range of 
KAE609 concentrations (0.2–100 nM). After 72 hours of incubation, parasitemia was measured 
by flow cytometry and IC50 values were calculated by non-linear regression analysis (271). 
 
2.1.9 Yeast plasmid and strain construction 
The mlh1Δ strain SJR0538 (MATa ade2-101oc his3Δ200 ura3ΔNco lys2ΔBgl mlh1Δ::URA3) 
has been previously reported (275). This strain was transformed by heat shock with three 
separate plasmids, namely pEAA213 (276), pEAA213-P157S, and pEAA213-K30A-E31A. 
pEAA213 encodes the full-length S288c MLH1 gene inserted in pRS415 (ARSH4 CEN6 LEU2 
KANMX). The MLH1 gene in pEAA213 was mutated by site-directed mutagenesis to generate 
the mlh1-P157S and mlh1-K30A-E31A expressing plasmids pEAA213-P157S and pEAA213-
K30A-E31A, respectively. These transformations yielded SJR0538-WT, SJR0538-P157S, and 
SJR0538-K30A-E31A. 
 
2.1.10 Yeast media and growth conditions 
SJR0538-WT, SJR0538-P157S, and SJR0538-K30A-E31A were all grown in YEP medium (1% 
yeast extract, 2% Bacto Peptone; 2.5% agar for plates) supplemented with 2% glycerol and 2% 
ethanol (YEPGE) and 200 Pg/ml G418 (Geneticin). Synthetic complete (SC) medium containing 




2.1.11 lys2ΔBgl fluctuation assays 
All yeast strains were propagated for three days on YEPD+G418 plates. Single clones were 
inoculated in 10ml of YEPGE+G418 liquid medium and propagated for 2 days at 30°C with 
constant shaking. Cells were harvested by centrifugation, washed once with ddH2O, and 
resuspended in 1ml of ddH2O. Dilutions were plated onto SC-Lys plates for 3 days at 30°C to 
select for Lys+ revertants, or control YEPD plates to calculate an accurate starting inoculum. 
Nine clones were tested for SJR0538-WT and SJR0538-P157S, and eleven for SJR0538-K30A-
E31A. 
 
2.2. Experimental Procedures for CHAPTER 4. Site-specific genome editing in 
Plasmodium falciparum using engineered zinc-finger nucleases. 
2.2.1 Zinc-finger nuclease engineering and plasmid construction 
ZFNs targeting pfcrt (MAL7P1.27) were designed and assembled using an archive of validated 
modules (252), and screened for activity using a yeast proxy system (277).  2A peptide-linked 
ZFN pairs 13/15 and 14/15 (Table 4.1) were subcloned into the pDC2-bsd expression vector by 
digesting them with the restriction enzymes NheI and XhoI and ligating them into the compatible 
restriction sites AvrII and XhoI. This placed a 2A peptide-linked ZFN pair under the control of a 
P. falciparum calmodulin promoter and heat shock protein 86 (hsp86) terminator. The resulting 
plasmid encoded either the 13/15 or 14/15 ZFN pair expression cassette and the bsd selectable 





2.2.2 Donor plasmid construction 
To generate the pcrtDd2-hdhfr donor plasmid for pfcrt allelic replacement (Figure 4.5) we first 
amplified intron 1 through exon 13 of pfcrt Dd2 cDNA and pbcrt 3′ UTR from an expression 
plasmid (278) using primers p33 + p34. The PCR product was cloned into the restriction sites 
NotI and SpeI of the pCC1 plasmid (containing a hdhfr cassette). The left homology region, 
comprising the pfcrt 5′ UTR to intron 1 sequence (431 bp), was subcloned from the pZFNcrt-76I 
plasmid with ApaI and SalI (see below). The pfcrt 3′ UTR served as right region of homology 
and was amplified from 106/1 gDNA using primers p35 and p36 (yielding a 1050 bp product) 
and then inserted into EcoRI and ClaI to generate the allelic replacement plasmid pcrtDd2-
hdhfr (Figure 4.5). 
 
Table 2.1 List of oligonucleotides used in CHAPTER 4 
Name Nucleotide Sequence (5’-3’) Description 
p11 CTTGGGCCCAAGTTGTACTGCTTCTAAGC pfcrt 5'UTR (-494-517) ApaI 
p12 CTTGAATTCATGGCTCACGTTTAGGTGGAG pfcrt exon 2 EcoRI 
p13 CTTATCGATAAGCAGAAGAACATATTAATAGGAATACTTA
ATTG 
pfcrt exon 3 ClaI 
p14 CTCGAGATGGTTGGTTCGCTAAACTGC hdhfr (+1-21) XhoI 
p15 TTGACCCTTATATATTCCACCCA pfcrt 3' UTR (+1285-1308) 
p16 CCAAGTTGTACTGCTTCTAAG pfcrt 5' UTR (-495-516) 
p33 CTTGCGGCCGCGGGCCCCTTGTCGACCTTAACAGATGGC pfcrt intron 1 exon 2 NotI ApaI  
p34 CTTACTAGTTATTTCAAAAATCTTAGCATAAGGATTC pbcrt 3' UTR (+1-28) SpeI 
p35 CTTGAATTCAATTATATCATTTATTTTTTTATATTTTTTATA
TTTTTTTTATTTTTCATG 
pfcrt 3' UTR (+1-51) EcoRI 
p36 CTTATCGATAACTGAAACTTGAAATAAGTGGCG pfcrt 3' UTR (+1025-1050) ClaI 
p3369 TGCCCTCTGGTTATGTGTGG -7bp from translation end of bsd 




2.2.3 Parasite Transfection 
Asexual blood stage parasites were electroporated with purified circular plasmid DNA as 
described (268). To replace the endogenous pfcrt allele, GC03 and 106/1 parasites were first 
electroporated with the donor plasmid pcrtDd2-hdhfr and selected with 2.5 nM WR99210 to 
enrich for episomally transformed parasites. These parasites (GCO3 + pcrtDd2-hdhfr or 106/1 + 
pcrtDd2-hdhfr) were then electroporated with pZFNcrt-bsd (Figure 4.5). On day one post-
electroporation, parasites were selected with 2 µg/ml blasticidin (Invitrogen) and 2.5 nM 
WR99210 for six days, followed by selection with only WR99210. Parasite clones were 
generated by limiting dilution where indicated. 
 
2.2.4 DNA analysis 
Allelic replacement of the endogenous GC03 pfcrt locus by the pcrtDd2-hdhfr donor sequence 
was confirmed by PCR of the target locus with primers p11 + p13 (GC03 parent: 1.4 kb, GC03crt-
Dd2recombinant: 1.2 kb, GC03 + pcrtDd2-hdhfr: 1.4 kb, pcrtDd2-hdhfr: no product); p12 + p13 
(GC03: 0.6 kb, GC03crt-Dd2: 0.4 kb, GC03 + pcrtDd2-hdhfr: 0.4 and 0.6 kb, pcrtDd2-hdhfr: 0.4 kb); 
and p14 + p15 (GC03: no product, GC03crt-Dd2: 2.5 kb, GC03 + pcrtDd2-hdhfr: no product, 
pcrtDd2-hdhfr: no product) (Figure 4.5A, C). 
 
2.2.5 Southern blot analysis 
Parasites lines obtained following pfcrt allelic replacement were analyzed on pairs of Southern 
blots, for which 2 µg of genomic DNA was digested with SalI + BstBI. Digests were 
electrophoresed on a 0.7% agarose gel and transferred onto a Nytran nylon membrane. 
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Hybridization was performed at 55°C with a 600 bp [32P]-labeled hdhfr probe amplified from 
pcrtDd2-hdhfr by PCR with primers p26 + p4. 
 
2.2.6 Generation of transgenic parasites 
Transgenic parasites were generated with zinc-finger nucleases (ZFN) targeting pfcrt as 
previously described (71). Briefly, parasites were electroporated first with a donor plasmid: 
pcrtDd2-hdhfr (for Dd2Dd2), pcrtDd2 Q352R-hdhfr (for Dd2Dd2 Q352R), pcrt7G8-hdhfr (for 7G87G8), or 
pcrt7G8 C350R-hdhfr (for 7G87G8 C350R). pcrtDd2 Q352R-hdhfr and pcrt7G8 C350R-hdhfr  were generated 
from their respective parental plasmids by site-directed mutagenesis (Agilent Technologies). 
Starting from 2 days post-electroporation, each culture was maintained under 2.5nM WR99210 
(Jacobus Pharmaceuticals) to enrich for parasites harboring the donor plasmid. Once fully 
recovered and enriched, parasites were electroporated with pZFNcrt-bsd, which encodes the pfcrt-
targeting ZFNs and the bsd selectable marker. Starting from 2 days post-electroporation, cultures 
were maintained under 2 μg/ml blasticidin S (Invitrogen) and 2.5nM WR99210 for 6 days, 
followed by 2.5nM WR99210 only thereafter. Once recovered, the cultures were cloned by 96-
well limiting dilution. To check for successful gene replacement, clones were first saponin-lysed, 
and genomic DNA was extracted and purified using DNeasy Blood kits (Qiagen). Gene 
replacement was confirmed by PCR analysis and Sanger sequencing of PCR products. 
 
2.2.7 In vitro susceptibility assays 
Half-maximal inhibitory concentration (IC50) values were determined after incubating parasites 
for 72 hours with CQ (2μM to 2.5nM) or IDI-3783 (100μM to 0.5nM). Parasite growth was 
determined using flow cytometry. Cells were 1.6μM Mito Tracker Deep Red and 1× SYBR 
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Green (Invitrogen) in 1× PBS. IC50 values were calculated using Prism 6 by nonlinear regression 
analysis and Mann-Whitney U tests for statistical analysis. 
 
 
2.3. Experimental Procedures for CHAPTER 5 Evidence for Regulation of Hemoglobin 
Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine 
Resistance Transporter 
2.3.1 Generation of ZFN-edited parasites 
Dd2Dd2 and Dd2Dd2 L272F were previously generated in (56) and Dd2GC03 in (71) using the Zinc-
Finger Nuclease (ZFN) editing methodology as described (71) (Figure 4.4). These lines express 
Dd2, GC03, or Dd2 L272F pfcrt on the same Dd2 genetic background. 
 
2.3.2 In vitro susceptibility assays 
In vitro IC50 values were determined by incubating parasites for 72 hours across a range of 
concentrations of CQ (0.4 nM to 193.9 nM); CQ + 0.8 μM VP (3.8 nM to 1938.5 nM); 
monodesethyl-chloroquine (0.3 nM to 171.7 nM); monodesethyl-amodiaquine (1.9 nM to 998.1 
nM); blasticidin (18.5 nM to 9468.8 nM); quinine (0.6 nM to 308.2 nM); lumefantrine (0.6 nM 
to 283.6 nM); piperaquine (0.9 nM to 466.8 nM); pyronaradine (0.4 nM to 193.0 nM); and 
mefloquine (0.5 nM to 254.3 nM). After 72 hours of incubation, parasitemia was measured by 
flow cytometry. Cells were stained with 1.6 μM Mito Tracker Deep Red and 2× SYBR Green 




2.3.3 In vitro fitness assays 
Synchronous late-stage cultures (late trophozoite/early schizont) of Dd2Dd2 and Dd2Dd2 L272F 
were mixed into a single flask (1:4 mixing ratio, respectively) and split into two replicate 
samples. Cultures were maintained for 40 days (i.e. ~20 generations). DNA was harvested at 48-
hour intervals and pfcrt was PCR amplified and Sanger sequenced. Allele frequencies were 
quantified by thymidine versus cytidine intensities corresponding to the pfcrt 814 nucleotide, 
corresponding to amino acid locus 272. A calibration curve was prepared using synthetic 
mixtures of genomic DNA at various concentrations to correct for inherent intensity differences 
between nucleotides as previously described (94). 
 
Allele frequencies were fit using a custom model of the Plasmodium intraerythrocytic life cycle 
written in in R statistical software (version 3.2.3). As described previously (94), the model fits 
starting allele frequencies, life cycle stage at first measurement, life cycle lengths, exponential 
growth rates, and amplification of the genome per generation. An optimal model was obtained by 
iterative grid searches guided by goodness of fit relative to the empirical data (R2).  
 
2.3.4 Amino acid dependency assay and calculations 
Asynchronous Dd2Dd2 and Dd2Dd2 L272F were washed with a variety of media formulations. Our 
control RPMI media, denoted “RPMI-VLA”, contained all amino acids except for valine, 
leucine, and alanine, as described in (279). This reconstituted medium was earlier observed to 
enable parasites to proliferate at the same rate as with RPMI culture medium containing all 
amino acids (268, 279). To test amino acid dependency, Dd2Dd2 and Dd2Dd2 L272F were cultured 
in RPMI-VLA medium supplemented with either 150 μM isoleucine (+I), or 150 μM isoleucine 
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plus: 101 μM methionine (+IM); 101 μM methionine and 200 μM cystine (+IMC); 200 μM 
cystine (+IC); 200 μM lysine and 200 μM arginine (+IKR); or 150 μM aspartic acid, 136 μM 
glutamic acid, 200 μM asparagine and 200 μM glutamine (+IDENQ). Every two days for 8 days, 
an aliquot was taken to measure parasitemia by flow cytometry (279) while a separate aliquot 
was subcultured. Growth rates were determined by averaging slopes of linear fits for three 
independent experiments for Dd2Dd2 and Dd2Dd2 L272F in each type of medium, where the natural 
log of the product of parasitemia and cumulative dilution factor was plotted against time (t) in 
hours. Data were fitted by linear regression to the equation: 
                         
where p = parasitemia × cumulative dilution factor, a = starting parasitemia and τ = doubling 
time. For each medium, mean doubling times were calculated from the three independent 
experiments. 
 
2.3.5 Metabolomics analyses 
All parasite culturing, metabolite extraction, mass spectrometry data acquisition, data analyses 
were conducted using previously established methods (94). Briefly, after double synchronization 
with 5% sorbitol, late-stage (~36-42 hours) P. falciparum trophozoites were magnetically 
purified using CS columns and a SuperMACS magnetic separator (Miltneyi Biotec). Eluted 
iRBCs were resuspended at 0.4% hematocrit and incubated for 2 h at 37°C. Following 
centrifugation, iRBC pellets were resuspended in cold (4°C) 90% methanol, homogenized by 
vortexing, and centrifuged at 10,000 × g for 5 minutes at 4°C. Supernatants were harvested and 
were stored at -80°C until metabolomics analysis. Just prior to analysis, samples were dried 
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under a stream of N2 and were resuspended at a 4:1 dilution (relative to the original iRBC pellet 
volume) in HPLC-grade water. High-resolution mass spectrometry data were acquired on a 
Thermo Fisher Exactive Mass spectrometer in negative mode using 25-minute reverse phase 
gradients using ion-pairing chromatography (280). Metabolites were identified relative to the 
known retention times of standards and metabolite signals were quantified using MAVEN (281). 
The absolute concentration of each peptide was quantified using calibration curves constructed 
from synthetic peptide standards, as described (94). All data analyses and statistical test were 
conducted using custom in-house software written in the R statistical software environment.  
 
2.3.6 Measurement of Intracellular Calcium 
Doubly sorbitol-synchronized 30-34 hours post invasion (hpi) trophozoite stage parasites were 
isolated from iRBCs with 0.05% saponin in 1× PBS and centrifuged at 8000 rpm for 10 minutes 
at 4°C to remove RBC membranes. Isolated parasites were then incubated for 1 hour at 37°C 
with the fluorescent, free Ca2+ indicator Fluo-4 AM (5 μM; Invitrogen) dissolved in Buffer A 
(116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 5.5 mM D-Glucose, 50 mM HEPES, 2 mM 
CaCl2 and 40 μM probenecid; pH 7.2). Probenecid was included as an inhibitor of organic anion 
transport (282). Cells were then washed three times in Buffer A to remove extracellular stain and 
resuspended in Buffer A only. Fluorescence for each sample was then measured every second for 
800 seconds using a F-4500 Hitachi spectrofluorimeter with excitation at 488 nm and emission at 
530 nm at 37oC. At t = 50 to 60 seconds, each parasite strain was treated with 25 μM Monensin, 
10 μM Nigericin, or 80 μM CQ. Control samples were treated with in N,N-Dimethylformamide 
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(DMF), DMSO, and Buffer A, respectively. Free Ca2+ concentration was calculated using the F-
4500 Intracellular Cation Measurement System, version 1.02 (Hitachi), where: 
             
       
      
  
kd = 345 nM, F = measured fluorescence intensity, Fmax = fluorescence in the presence of 
digitonin, and Fmin = fluorescence in the presence of digitonin and 15mM EGTA. Results are 
expressed as mean ± SEM of at least three individual experiments.  
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Malaria control efforts have been continuously stymied by drug-resistant strains of Plasmodium 
falciparum, which typically originate in Southeast Asia prior to spreading into high-transmission 
settings in Africa. One earlier proposed explanation for Southeast Asia being a hotbed of 
resistance has been the hypermutability or “Accelerated Resistance to Multiple Drugs” (ARMD) 
phenotype, whereby multidrug-resistant Southeast Asian parasites were reported to exhibit 
1,000-fold higher rates of resistance to unrelated antimalarial agents when compared to drug-
sensitive parasites. However, three recent studies do not recapitulate this hypermutability 
phenotype. Intriguingly, genome sequencing of recently derived multidrug-resistant Cambodian 
isolates has identified a high proportion of DNA repair gene mutations in multidrug-resistant 
parasites, suggesting their potential role in shaping local parasite evolution. By adapting 
fluctuation assays for use in P. falciparum, we have examined the in vitro mutation rates of five 
recent Cambodian isolates and three reference laboratory strains.  For these studies we also 
generated a knockout parasite line lacking the DNA repair factor Exonuclease I. In these assays, 
parasites were typed for their ability to acquire resistance to KAE609, currently in advanced 
clinical trials, yielding 13 novel mutations in the Na+/H+-ATPase PfATP4, the primary 
resistance determinant. We observed no evidence of hypermutability. Instead, we found evidence 
of a mild mutator (up to a 3.4-fold increase in mutation rate) phenotype in two artemisinin-
resistant Cambodian isolates, which carry DNA repair gene mutations. We observed that one 
such mutation in the Mismatch Repair protein Mlh1 contributes to the mild mutator phenotype 
when modeled in yeast (scmlh1-P157S).  Compared to basal rates of mutation, a mild mutator 
phenotype may provide a greater overall benefit for parasites in Southeast Asia in terms of 




Malaria infections caused by the eukaryotic pathogen Plasmodium falciparum place an immense 
burden on many under-resourced nations around the world, particularly in sub-Saharan Africa. 
Over the past 15 years, considerable progress towards reducing the global burden of malaria has 
been achieved through the widespread adoption of highly effective artemisinin-based 
combination therapies (ACTs) and mosquito control (283). These gains, however, are threatened 
by the emergence of ACT resistance in Western Cambodia (284), which has now spread across 
Southeast Asia (100).  
 
The emergence of artemisinin resistance in Southeast Asia recalls that of resistance to earlier 
first-line antimalarials, notably chloroquine (CQ) and sulfadoxine-pyrimethamine (96-99). CQ 
resistance spread from Southeast Asia to the far higher endemicity regions of Africa in the 
1980s, where CQ resistance still persists (97). It was earlier hypothesized that CQ-resistant 
Southeast Asian strains exhibited a hypermutability phenotype compared to non-Southeast Asian 
counterparts (45, 101), enabling the former to acquire single nucleotide polymorphisms (SNPs) 
and new drug resistance traits at an accelerated rate. 
 
Evidence supporting this hypermutability phenotype, termed “Accelerated Resistance to Multiple 
Drugs” (ARMD), came from resistance selection studies with the antimalarial compounds 5-
fluoroorotic acid (5-FOA) and atovaquone. Those data reported that the Southeast Asian 
multidrug-resistant W2 strain was much more mutable (by 10 to 1,000-fold) as compared to non-
Southeast Asian strains (101). However, detailed analyses of the mutation rates of the W2 strain 
or its clone Dd2, propagated in long-term in vitro culture, in comparison with reference strains, 
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have since shown no evidence in favor of an ARMD phenotype (102, 103). Furthermore, in 
silico analysis of contemporary P. falciparum genomes from Mali and Southeast Asia also found 
no evidence of an ARMD phenotype (285). 
 
These studies provide compelling evidence that the ARMD phenotype is not characteristic of 
Southeast Asian multidrug-resistant parasites. Nevertheless, recent whole-genome sequencing of 
Asian and African patient-derived isolates (obtained between 2007 and 2011) has revealed 
mutations in a number of DNA repair genes that are overrepresented in parasites from 
Cambodia, where artemisinin resistance first emerged (45). These mutations occurred primarily 
in the Mismatch Repair (MMR) factors Mlh1, Pms1, and Exo1. In bacteria found in natural 
environments, such as the human gastrointestinal system, mild mutator strains encoding MMR 
mutations have been shown to account for a larger percentage of total cells (25%) compared to 
hypermutators (1%), and the former associate with a higher degree of antibiotic resistance (286-
288). Furthermore, mild mutators can acquire drug resistance that requires multiple SNPs more 
efficiently than hypermutators (289). Long-term in vitro propagation has shown that bacterial 
hypermutators frequently display fitness costs associated with the accumulation of detrimental 
mutations, whereas mild mutators provide sufficient genetic diversity with minimal fitness costs 
(290, 291).  
 
Based on these observations, we hypothesized that Cambodian isolates encoding mutations in 
DNA repair genes could drive a mild mutator phenotype. To investigate this possibility, we have 
first calculated mutation rates for parasites maintained in long term in vitro culture. We then 
adapted a fluctuation assay for P. falciparum using the spiroindolone compound KAE609 (100, 
  
 66 
272), which scores for resistance-conferring SNPs in pfatp4 and enables the comparison of 
mutation rates for a diverse collection of parasite strains. Using this method, we observed two 
artemisinin-resistant Cambodian isolates that exhibit a mild mutator phenotype and 13 novel, 
resistance-conferring mutations in pfatp4. By modeling the MMR gene mutation (pfmlh1-P203S) 
in yeast, we observed that this alone can drive a mild mutator phenotype. 
 
3.3. RESULTS 
3.3.1 Cambodian parasites do not exhibit the ARMD phenotype in long-term in vitro 
culture 
To test the mutability of recently derived Cambodian parasites, we analyzed whole-genome 
sequences for five isolates (Table 3.1) maintained in long-term in vitro culture for 230 to 243 
days. Whole-genome sequences from parental clones of each isolate were compared to 
sequences of two daughter clones obtained at the end of the culturing period. By comparing 
whole-genome sequences of a parental clone to two daughter clones, this assay measures the 
accumulation of SNPs over the course of extended asexual blood stage growth where potential 
divergences from wild-type DNA repair and recombination would manifest themselves. 
 
We maintained Cambodian isolates in normal culturing conditions for a total time of 243 
(PH0167-C), 236 (PH0164-C), 230 (PH0306-C), or 231 (PH0482-C, PH0212-C) days. A total of 
37 unique SNPs and 6 indels (3 insertions, 3 deletions) were detected during long-term culturing 
in all clones (Table 3.2 and Table 3.3). Subtelomeric regions were observed to be more 
mutagenic than the core genome, consistent with previous reports (102, 103). 
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Table 3.1 DNA repair gene haplotypes, origins, and drug resistance haplotypes for 
Cambodian isolates used in CHAPTER 3  
Genea PH0167-Cb PH0306-Cb,c PH0164-Cb,c PH0482-Cb PH0212-Cb 










WT WT WT 
Pms1 WT WT WT S506Id S506Id 





















UvrD WT WT WT H1046Nd H1046Nd 









k13 WT WT R539T C580Y C580Y 
pfcrt Dd2f Dd2f Dd2f Dd2f Dd2f 
Origin Cambodia Cambodia Cambodia Cambodia Cambodia 
Year 2010 2010 2010 2010 2010 
a Gene names are derived from yeast homologs 
b Published in (42). Haplotypes determined using SNP dataset available in the Pf3k database (292) 
c Published in (46) 
d Published in (45). Haplotypes cluster with Cambodian artemisinin-resistant 
e Variant residue published in (45) 







Table 3.2 List of SNPs generated in long-term culturing of Cambodian isolates 
Strain Clone(s) Chr Position PlasmoDB ID Description Effect Ref.  Alt.  Change 
PH0167-C B8 4 10547 - - NC T C - 
B8 4 684956 0415300 CRK3 NC G T - 
D2 4 1179085 0426000 PfEMP1 NS A G F381S 
D2 6 1408581 - - NC T G - 
D2 8 1380619 - - NC A C - 
D2 9 1520487 - - NC G C - 
D2 10 2120 - - NC C A - 
D2 12 2266252 - - NC A T - 
B8/D2 13 2465907 1361500.2 unknown function NC C T  
PH0306-C D6 2 444564 0211000 unspecified S C T Y247Y 
D6 14 2946964 1472200 histone deacetylase NS A G S435G 
PH0164-C B9/E9 1 43321 0100300 PfEMP1 S T C L1010L 
B9/E9 4 10898 - - NC T C - 
B9/E9 4 10903 - - NC T A - 
E9 7 567971 0712600 PfEMP1 S T A A1801A 
E9 9 1525833 - - NC A T - 
E9 9 1525835 - - NC A C - 
B9 12 487701 1211000 kinesin-7 S T C L1112L 
B9/E9 12 1711251 1240400 PfEMP1 S A T V1875V 
B9/E9 13 63277 1300900 stevor S G A N55N 
PH0482-C F3 1 3999 - - NC C A - 
F3 3 9310 - - NC A G - 
F3 3 9313 - - NC T G - 
F3 7 5297 - - NC C T - 
F3 7 5299 - - NC T C - 
F3/G8 8 686919 - - NC C T - 
G8 9 1411 - - NC T C - 
G8 9 1419 - - NC A C - 
F3 9 1540051 - - NC C G - 
F3 11 6217 - - NC C T - 
F3 11 6220 - - NC A G - 
F3 11 6226 - - NC T A - 
F3 11 6228 - - NC G T - 
F3/G8 12 1641299 1239200 ApiAP2 NS G T R2202L 
PH0212-C B7 2 33701 0200200 rifin NS T C N112D 
B7 9 1539834 - - NC G A - 
B7 11 1837656 1146600 NFYB Stop G T E1086* 





Table 3.3 List of indels generated in long-term culturing of Cambodian isolate 
Strain PH0167-C PH0306-C PH0164-C 
Clone(s) D2 D2 D2 A3/D6 B9/E9 E9 
Chr. 4 9 11 11 1 7 
Position 1188619 1524092 1835477 1834484 6762 933382 
PlasmoDB 
ID 
- - 1146600 1146600 - - 
Description - - NFYB NFYB - - 
Effect NC NC FS FS NC NC 











NC = Non-coding, FS = Frame-shift. Whole-genome sequencing performed by V. Corey (UCSD). 
 
Out of the 37 total SNPs, 25 were subtelomeric—found in either virulence genes (pfemp1, rifin, 
and stevor) or intergenic regions—and 12 were in the core genome. One gene 
(PF3D7_1146600), a CCAAT-box DNA binding protein subunit (NFYB) involved in cell cycle 
and transcriptional regulation (293), encoded two distinct single base deletions in two separate 
strains (PH0167-C and PH0306-C) and a missense mutation in PH0212-C. 
 
We calculated in vitro culture mutations rates (102) using only the SNP counts observed during 
long-term culture for each daughter clone (Table 3.4). Average mutation rates for each 
Cambodian isolate were distributed over a fairly limited range: 9.7×10-10 (PH0306-C) to 8.2×10-
9 SNPs per bp per generation (PH0482-C). We then compared our mutation rates to the 3D7 
mutation rate (103). PH0482-C and PH0164-C (6.6×10-9 SNPs per bp per generation) exhibited 
rates nearly twice as high as those of 3D7 (1.9 and 1.6 fold respectively). PH0212-C and 
PH0306-C were lower than 3D7: 0.5 and 0.2 fold, respectively, while PH0167-C was nearly on 
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par with 3D7 at 1.1 fold. However, the statistical significance of these differences could not be 
determined.  
 
Table 3.4 Mutation rates of recently derived Cambodian isolates during in vitro asexual 
culture 












1 3 243 2.76 × 10-9 4.61 × 10-9 1.08 
2 7 243 6.45 × 10-9 
PH0306-C 
1 0 230 0.00 × 10-9 0.97 × 10-9 0.23 
2 2 230 1.95 × 10-9 
PH0164-C 
1 6 236 5.69 × 10-9 6.64 × 10-9 1.55 
2 8 236 7.59 × 10-9 
PH0482-C 
1 12 231 1.16 × 10-8 8.24 × 10-9 1.92 
2 5 231 4.85 × 10-9 
PH0212-C 
1 3 231 2.91 × 10-9 1.94 × 10-9 0.45 
2 1 231 9.69 × 10-9 
Bopp et al., PLoS Genetics 2013 (24) 
3D7 1.70 × 10-9 0.40 
Dd2 3.20 × 10-9 0.75 
Claessens et al., PLoS Genetics 2014 (32) 
3D7 4.28 × 10-9 1.00 
Dd2 3.82 × 10-9 0.89 
Hb3 3.98 × 10-9 0.93 
a SNPs are found in Table 3.2 
b One lifecycle is assumed to be 48 hrs. Genome size is 23.5 Mb 
c Fold change is relative to the 3D7 mutation rate (103) 
 
Together, our data showed that Cambodian isolates maintained in in vitro culture do not 
drastically differ in mutability when compared with well-established culture-adapted strains such 
as 3D7. This is consistent with recent studies reporting that the Southeast Asian strains W2 and 




However, whole-genome sequencing, particularly in P. falciparum, is often limited in terms of 
the percentage of the genome that is covered, depth of coverage, polymerase errors arising from 
genomic PCR amplification, and lack of appropriate reference genomes. As a result, calculating 
mutation rates by mutation accumulation analysis of Cambodian isolates maintained in long-term 
in vitro culture can only determine that a 1,000-fold difference in mutability, as originally 
defined by the ARMD phenotype, is not a true phenotype of contemporary Cambodian parasite 
isolates. 
 
3.3.2 5-FOA fluctuation assays do not reproduce the ARMD phenotype 
To determine mutation rates for a diverse selection of P. falciparum strains, we adapted the 
fluctuation assay, a common microbiological method to measure and compare mutation rates 
(121, 294, 295), to P. falciparum. Fluctuation assays estimate mutation rates based on the 
distribution of mutant clones that arise in parallel cultures subjected to selective pressure. 
 
As described above, the original report describing the ARMD phenotype found that W2 
exhibited up to a 1,000-fold difference in the frequency of resistance to 5-FOA when compared 
to 3D7 (101). 5-FOA is a fluorinated orotic acid analog that can be converted to the toxic 
metabolite 5-FU, which inhibits the thymidylate synthase portion of the bifunctional dihyrofolate 
reducatase-thymidylate synthase (dhfr-ts) gene and blocks de novo pyrimidine biosynthesis (296-
298).  
 
We performed fluctuation assays with 100 nM 5-FOA, focusing on the well-characterized 
culture-adapted strains 3D7, W2, and V1/S, to determine whether the ARMD phenotype could 
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be recapitulated in our system (Figure 3.1A). Prior to applying drug pressure, clones from each 
strain were expanded to increase the pool of potential mutants, with the prediction being that 
ARMD parasites (e.g. W2) would generate more mutants. 
 
Table 3.5 DNA repair gene haplotypes, origins, and drug resistance haplotypes for 
laboratory strains used in CHAPTER 3 
Genea 3D7b W2b Dd2b V1/Sb Dd2 exo1Δb  PlasmoDB ID 
Exo1 WT WT WT M752K Δ (KO) PF3D7_0725000 
Mlh1 WT WT WT WT WT PF3D7_1117800 




Pms1 WT WT WT S506Ie WT PF3D7_0726300 







Rad50 WT N1338Y N1338Y C2010Se N1338Y PF3D7_0605800 
RuvB WT N39D N39D N39D N39D PF3D7_1106000 



































k13 WT WT WT WT WT PF3D7_1343700 
pfcrt WT Dd2c Dd2c Dd2c Dd2c PF3D7_0709000 
Origin Netherlands Vietnam W2 Vietnam Dd2 - 
Year 1970s 1980 1980s 1980 2014 - 
a Gene names are derived from yeast homologs 
b Haplotypes determined using SNP dataset available on PlasmoDB 
c Dd2 pfcrt allele: 74I/75D/76T/220S/271E/326S/356T/371I 
 
 
3D7 and W2 were chosen as direct comparators to the original study, whereas V1/S was chosen 
as an additional Southeast Asian parasite with high-level multidrug resistance (299). Two 
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parental clones of each chosen strain were assayed. When propagated to 2.5×108 iRBCs and 
pressured with 100 nM 5-FOA, none of the strains (n = 2 clones for each) yielded 5-FOA-
resistant clones. In comparison, the original study found that 106 iRBCs of W2 were sufficient to 
yield resistant progeny following selection with 100 nM 5-FOA. These data provided further 
evidence that the original ARMD report describing a 1,000-fold increase in the frequency of 
resistance mischaracterized Southeast Asian parasites as hypermutators. 
 
3.3.3 Some Cambodian isolates exhibit a mild mutator phenotype 
To determine mutation rates for a diverse selection of P. falciparum strains, we adapted the 
fluctuation assay, a common microbiological method to measure and compare mutation rates 
(121, 294, 295), to P. falciparum. Fluctuation assays estimate mutation rates based on the 
distribution of mutant clones that arise in parallel cultures subjected to selective pressure. 
 
In our P. falciparum-adapted fluctuation assay (Figure 3.1), we pressured parasites with the 
spiroindolone compound KAE609 (also known as NITD609 or cipargamin) (58). We chose 
KAE609 for three major reasons: (1) Resistance to low-level (2.5 nM) KAE609 can be readily 
conferred by a number of unique SNPs in pfatp4 (272, 300-302). Given more than one 
independent SNP in pfatp4 can yield resistant clones, we were therefore able to capture a broad 
range of mutation rates, including for low or basal rates (e.g. that of the drug-sensitive reference 
3D7 strain). In the original ARMD report, only one of five strains pressured with 5-FOA yielded 
a frequency of resistance measurement (101). (2) Using KAE609 is much less time and resource 
intensive than using drugs that select for resistance at much lower frequencies (3). KAE609 is 
also fast acting (303). Mutations that impart resistance would therefore have to be present at the 
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time of drug exposure in order for parasites to survive. This speed of action was preferred to 
slower acting agents that might allow resistance-conferring SNPs to be encoded beyond the first 
generation of selective pressure, which would yield inflated mutation rates. 
 
 
In our KAE609 fluctuation assays (Figure 3.1), we assayed 3D7, W2, and Dd2, which have been 
shown to have similar basal mutation rates (102, 103), and therefore served as wild-type 
controls. As a benchmark for a mild mutator phenotype, we generated and assayed a P. 
falciparum Exonuclease I knockout strain (Dd2 exo1Δ). exo1Δ strains exhibit mild mutator 
phenotypes in other organisms, as Exonuclease I often mediates the fastest, although non-
 
Figure 3.1 Determination of mutation rates in a KAE609 fluctuation assay. 
A. Schematic of fluctuation assay protocol. B. KAE609 fluctuation assay mutation rates (light 
blue bars and bolded text) calculated by MSS-MLE for n independent clones. Two-tailed 
Student’s t-tests were performed for each strain relative to 3D7 with the exception of Dd2 
exo1Δ, which was compared to Dd2, its isogenic background parent (#). 95% confidence 
intervals (lower and upper limits) are denoted in brackets. Fold changes (fc) are listed relative 
to 3D7, except for Dd2 exo1Δ, which is compared to Dd2. * p = 0.02, ** p < 0.01.  
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essential, mechanism for many DNA repair pathways (121, 304). We also tested V1/S, a 
multidrug-resistant Vietnamese strain (299, 305) that carries two DNA repair gene mutations 
(Table 3.5) found in contemporary artemisinin-resistant Cambodian isolates, suggesting that it 
too may exhibit a mild mutator phenotype. Finally, we tested five recently derived Cambodian 
isolates that harbor various DNA repair mutations (45). These isolates were chosen to encompass 
the potential contributions of DNA repair mutations in Cambodian isolates. For instance, 
PH0167-C is artemisinin-sensitive and encodes no mutations overrepresented in artemisinin-
resistant isolates (Table 3.1). PH0167-C nonetheless harbors two unique DNA repair gene 
mutations, not associated with artemisinin resistance. In contrast, PH0212-C encodes four 
mutations associated with artemisinin resistance, in particular for the two factors Mlh1 and Pms1 
that are both essential for MMR. 
 
Parallel cultures of each strain were pressured and maintained in 2.5 nM KAE609 in 96-well 
plates until resistant clones were detectable by flow cytometry (See Materials and Methods). To 
confirm that our fluctuation assays yielded KAE609-resistant clones, we determined half-
maximal inhibitory concentration (IC50) values using 72 hour in vitro susceptibility assays for 
each parent and two randomly selected drug-pressured clones. Sanger sequencing of the pfatp4 
gene from resistant clones yielded 16 total mutations, 13 of which have not been previously 
reported (Table 3.6).  
 
As mentioned above, the polymorphic nature of pfatp4 in response to KAE609 allowed us to 
calculate mutation rates for all strains, including wild-type strains, which was previously not 
possible for 5-FOA (101). It is important to note that these mutation rates are specific to 
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KAE609, for which resistance in vitro can be mediated by single SNPs, and are useful for 
calculating relative differences between strains. However, the absolute KAE609 mutation rates 
should not be directly compared with those calculated using other drugs or methods of 
calculation unless the studies are conducted in parallel. As examples, selection for mefloquine 
resistance typically results in pfmdr1 gene amplification (70), for chloroquine multiple mutations 
in pfcrt are required (75), and for atovaquone mutations involve single SNPs in the genome of 
mitochondria, which are present as multiple copies per parasite (306).  
 
With all strains, mutation rates were compared to 3D7, except for Dd2 exo1Δ that was compared 
to its parental Dd2 strain. These data revealed no significant differences between 3D7, W2, and 
Dd2 in their KAE609 mutation rates. This result was not consistent with the original ARMD 
study, which reported that W2 was hypermutable relative to 3D7 (101). We also observed no 
significant differences in mutation rates amongst the three Cambodian isolates PH0167-C, 
PH0306-C, and PH0164-C that carried fewer DNA repair gene mutations compared to the two 
other isolates (Table 3.1, Figure 3.1). These observations provide additional evidence against an 
ARMD phenotype being present in the W2 strain.   
 
Results with our Dd2 exo1Δ line showed a statistically significant 2.5-fold increase in mutation 
rate relative to its isogenic background parent Dd2. This is similar to yeast exo1Δ strains, which 
exhibit a 3-fold increase in mutation rate in lys2ΔBgl fluctuation assays (307), and confirms the 








Figure 3.2 pfatp4 mutations that confer resistance to KAE609. 
A. Amino acid changes in PfATP4 determined from KAE609-resistant parasites in our study 
(denoted in red) and PfATP4 mutations from previously published studies. Previously reported 
mutations were identified when pressuring parasites with a GNF-Pf4492 (308), b MMV011567 
(302), c MMV007275 (302), d C2-1 (309), e KAE609 (272), f NITD678 (272), g KAE609 (301), h 
SJ733 (301), i SJ311 (301), j NITD678 (301), or k MMV772 (301). l The variant residue G1128R 
was found in some parental lines not pressured with KAE609 and was also reported in (302). 
PfATP4 domains were determined using the Pfam database of protein families, version 28.0 
(310). B. A PfATP4 homology model (C-score: -1.68, estimated TM-score 0.51±0.15, estimated 
RMSD 13.7±4.0Å) showing the 3D locations of the mutations found in this study (red spheres). 
Homology modeling was performed via the I-TASSER online server (311, 312) and visualized 
with Protean 3D (DNASTAR Lasergene version 12) and Adobe Illustrator CS4. 
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Table 3.6 pfatp4 mutations and IC50 values for parasites used in KAE609 fluctuation assay 
  Clone Pressured Mutations IC50 ± SEM (nM)e Fold 
Changef 
3D7 B2 No WT 0.79 ± 0.01 1.0 
 B3 Yes S312P 3.61 ± 0.47 4.6 
 E6 Yes T416N 8.00 ± 0.18 10.2 
W2a D2 No WT 0.78 ± 0.06 1.0 
 H6 Yes V414D 3.52 ± 0.09 4.5 
 E12 Yes S312P 2.78 ± 0.22 3.6 
Dd2a A7 No WT 0.58 ± 0.10 1.0 
 D9 Yes Q172Hb 3.52 ± 0.14 6.1 
Dd2 exo1Δa C11 No WT 0.49 ± 0.05 1.0 
 D7 Yes I379N 2.88 ± 0.27 5.8 
 E2 Yes I379N 2.70 ± 0.26 5.5 
V1/Sa B6 No WT 1.10 ± 0.13 1.0 
 B2 Yes V204L/L350Vc 7.34 ± 0.22 6.7 
 E4 Yes L938I 4.27 ± 0.23 3.9 
PH0167-Ca A2 No WT 0.41 ± 0.03 1.0 
 D9 Yes Q172Hb 4.66 ± 0.59 11.4 
PH0306-Ca A3 No WT 0.60 ± 0.07 1.0 
 D6 Yes V400A 5.42 ± 0.32 2.5 
 B9 Yes A421E 1.51 ± 0.13 9.0 
PH0164-C E8 No WT 0.55 ± 0.03 1.0 
 D1 Yes P966Ad 4.06 ± 0.22 7.4 
 F1 Yes E895K 1.91 ± 0.17 3.5 
PH0482-Ca F4 No WT 0.98 ± 0.11 1.0 
 C1 Yes A1207V 2.17 ± 0.07 2.2 
 A6 Yes A1158V 1.63 ± 0.13 1.7 
PH0212-Ca G2 No WT 0.73 ± 0.09 1.0 
 A6 Yes A1158V 3.50 ± 0.17 4.8 
 A1 Yes A967G 24.3 ± 0.76 33.4 
 B12 Yes A967G 20.9 ± 2.23 28.7 
 D3 Yes L350Hc 15.2 ± 2.58 21.0 
 C7 Yes V400A 9.61 ± 0.32 13.2 
a Additional pfatp4 polymorphism: G1128R.  
b Previously observed in (302), pressured with MMV007275. 
c Previously observed in (301), pressured with (+)-SJ733. 
d Previously observed in (301), pressured with KAE609. 
e n = 3 for each IC50 value. 
f Relative to isogenic parent. 




We observed mild mutator phenotypes in three additional strains. V1/S exhibited a non-
statistically significant 1.7-fold increase in mutation rate relative to 3D7. However, its mutation 
rate was very similar to Dd2 exo1Δ. PH0482-C and PH0212-C exhibited statistically significant 
2.3- and 3.4-fold increases relative to 3D7, respectively (Figure 3.1). As stated above, PH0482-C 
and PH0212-C encode the most DNA repair gene mutations that cluster with artemisinin 
resistance. These data suggest some correlation between DNA repair gene mutations and the 
mild mutator phenotype, which merits further investigation. 
 
3.3.4 The Cambodian mutant Mlh1 allele exhibits a minor mutator phenotype in yeast 
We sought to model the DNA repair gene mutations found in artemisinin-resistant parasites in a 
yeast system to test for a possible association between these mutations and mutator phenotypes. 
Among these mutations, only one gene, the MMR factor Mlh1, had a mutation (pfmlh1-P203S) 
that could be mapped to a yeast ortholog, in this case Mlh1 (scmlh1-P157S) (Figure 3.3). The 
ability to map the Mlh1 mutation is serendipitous for a number of reasons. First, Mlh1 is an 
essential MMR protein that plays a major role in the generation of SNPs (291, 313). Second, the 
pfmlh1-P203S mutation is found in the mild mutator P. falciparum strains PH0212-C and 
PH0482-C. Third, the homologous residue in yeast, scmlh1-P157, is located in a conserved 
region near motif IV of the essential N-terminal ATPase domain (Figure 3.3). Fourth, in yeast 
the mutation to lysine at residue P157 produces a strong mutator phenotype in an exo1Δ 
background, which amplifies the mutator effect (121). A mutation at the homologous residue in 
human MLH1 has also been associated with hereditary nonpolyposis colorectal cancer (314), a 
cancer mediated by mutations in MMR genes. Finally, among the 3,000 P. falciparum isolates 
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sequenced in the Pf3k database, the pfmlh1-P203S mutation has only been found in Southeast 
Asia (in Cambodia, Myanmar, Thailand, and Vietnam), and never in Africa or Bangladesh (292). 
 
To test the effect of scmlh1-P157S, we transformed a Mlh1 knockout yeast strain (SJR0538: 
lys2ΔBgl mlh1Δ) with plasmids encoding either wild-type scmlh1-WT, or scmlh1-P157S, or 
scmlh1-K30A E31A. In yeast, scmlh1-WT was shown to fully rescue MMR functionality, 
whereas the ATPase-dead scmlh1-K30A E31A plasmid phenocopied a full Mlh1 knockout (315). 
To test for mutability differences, each yeast strain also encoded an internal frameshift in LYS2 
(lys2ΔBgl), which rendered the strain auxotrophic for lysine. Reversion to lysine prototrophy 
requires a return to wild-type functionality, but not necessarily wild-type sequence, as a number 
of different reversion events in lys2ΔBgl can restore function. Therefore, the lys2ΔBgl 
fluctuation assay measures an artificially increased mutation rate (275), similar in concept to our 
KAE609 assay, as in both assays several distinct genetic changes can produce the selected 
phenotype. For each of the three scmlh1 strains, we measured mutation rates by measuring the 





Figure 3.3 Determination of mutation rates for a clinically relevant mlh1 allele in yeast.  
A. Schematic of the yeast Mlh1 (ScMlh1) amino acid sequence. Yellow domains represent 
the N-terminal region containing the GHL superfamily ATPase, ATPase motifs, and the 
essential residues K30 and E31. The ScMlh1-P157 (and homologous PfMlh1-P203) residue 
is denoted in the conserved N-terminal domain. Blue domains representing the conserved C-
terminal domain are also shown. “Dimerization” domains are important for dimerization with 
Pms1. The “Regulatory” region is important for Mlh1 regulation. The MIP binding sites are 
important for interactions with factors such as Exo1 (118). B. Yeast lys2ΔBgl fluctuation 
assay mutation rates (yellow bars and bolded text) comparing wild-type (WT), scmlh1-
P157S, and scmlh1-K30A E31A. Two-tailed Student’s t-test compared to wild-type. 95% 
confidence intervals (lower and upper limits) are denoted in brackets. Fold changes (fc) are 
listed relative to scmlh1-WT. *** p < 0.0001. 
 
Our wild-type and K30A E31A strains provided the lower and upper limits of our assay, 
respectively. K30A E31A had a mutation rate of 5.29×10-7 mutations per generation (95% 
confidence intervals (CI) [4.4×10-7, 6.2×10-7], n=11), which was 23.3-fold higher (p<0.0001, 
two-tailed Student’s t-test) than the wild-type, whose rate was calculated at 0.23×10-7 (95% CI 
[0.14×10-7, 0.33×10-7], n=9). Our scmlh1 P157S strain exhibited an elevated mutation rate of 
0.37×10-7 (95% CI [0.24×10-7, 0.52×10-7], n=9), a 1.6-fold increase compared to wild-type 
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(p<0.0001, two-tailed Student’s t-test). These data provide evidence that the scmlh1-P157S 
mutation can confer a mild mutator phenotype.  
 
Given the conservation of the region in which it lies, the mlh1-P203S mutation in P. falciparum 
likely also exhibits a mild mutator phenotype, particularly if compounded with additional DNA 
repair mutations (e.g. Pms1). Numerous attempts to introduce or remove the mlh1-P203S and 
pms1-S506I mutations or knock out either gene in the parasite genome using the CRISPR/Cas9 
system and ZFNs in order to examine the contributions of MMR mutations to mild mutator 
phenotypes in P. falciparum were unsuccessful (APPENDIX 5). 
 
3.4. DISCUSSION 
Here, we provide evidence of a mild mutator phenotype in Cambodian isolates in a fluctuation 
assay adapted for use in P. falciparum. These strains are artemisinin-resistant and encode 
multiple DNA repair gene mutations (Table 3.1). One such mutation, pfmlh1-P203S, drives a 
mild mutator phenotype when modeled in yeast (Figure 3.3). In describing this phenotype, we 
provide further evidence that the ARMD phenotype cannot be recapitulated, under the drug 
selection conditions adopted herein (Figure 3.1). As such, we posit that the focus in P. 
falciparum should be shifted from the ARMD phenotype to a deeper examination of mild 
mutator phenotypes. 
 
Since the ARMD phenotype was initially described (101), examining whether this is a consistent 
characteristic of multidrug-resistant parasites has focused on finding hypermutators with very 
large variations in mutability rates compared to drug-sensitive parasites. Studies in natural 
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bacterial populations present an alternative perspective. Hypermutators can and do acquire 
resistance to drugs quickly in vitro, but when propagated longer become outcompeted by mild 
mutators due to an accumulation of additional detrimental mutations (290, 291). Mild mutators 
can more readily provide an appropriate balance between the ability to adapt to drug pressure via 
the acquisition of resistance-conferring mutations and the need to maintain overall fitness (287, 
289, 291). This may be important for the acquisition of resistance to first-line antimalarial 
therapies such as CQ or ACTs that require the gradual acquisition of multiple mutations to build 
full resistance (75, 316). Further research will be necessary to determine to what extent a mild 
mutator phenotype in P. falciparum facilitates the acquisition of multidrug resistance in parasite 
populations, as has been observed in bacteria.  
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CHAPTER 4. Site-specific genome editing in Plasmodium falciparum using 
engineered zinc-finger nucleases. 
 
Straimer J, Lee MC, Lee AH, Zeitler B, Williams AE, Pearl JR, Zhang L, Rebar EJ, Gregory 
PD, Llinás M, Urnov FD, Fidock DA. 
 
Nature Methods. 2012 Oct;9(10):993-8. doi: 10.1038/nmeth.2143. 
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Malaria afflicts over 200 million people worldwide and its most lethal etiologic 
agent, Plasmodium falciparum, is evolving to resist even the latest-generation therapeutics. 
Efficient tools for genome-directed investigations of P. falciparum pathogenesis, including drug 
resistance mechanisms, are clearly required. Here we report rapid and targeted genetic 
engineering of this parasite, using zinc-finger nucleases (ZFNs) that produce a double-strand 
break in a user-defined locus and trigger homology-directed repair. First, we demonstrated that 
ZFNs engineered against the endogenous parasite gene pfcrt, responsible for chloroquine 
treatment escape, rapidly produced parasites carrying an allelic replacement. Second, we used 
this strategy to elucidate the role of the PfCRT Q352R and C350R mutations in modulating the 
dose response to chloroquine and the novel antimalarial compound IDI-3783. The efficiency, 
versatility and precision of this method will enable a diverse array of genome editing approaches 





Elucidating the mechanisms of resistance of antimalarial drugs, their modes of action, and the 
molecular pathways of pathogenesis in the malaria parasite requires the ability to rapidly and 
efficiently engineer the parasite genome. However, previous methods for enabling genomic 
modifications do not sufficiently scale to meet these challenges (317). To improve the efficiency 
and speed of genome engineering the malaria parasite, we sought to develop a novel method for 
engineering the P. falciparum chloroquine (CQ) resistance transporter, pfcrt, using customized 
zinc-finger nucleases (ZFNs). 
 
Genome editing with ZFNs, first achieved in Drosophila (318), has been successfully applied to 
a range of multicellular organisms (319). To achieve editing, pairs of zinc-finger proteins with 
unique specificity for adjacent sequences on either strand of the DNA helix are linked to an 
endonuclease (FokI) that functions as an obligate heterodimer (254, 320). Engineered zinc-finger 
proteins typically consist of tandem arrays of up to six individual fingers that recognize 3–4 bp 
of DNA. Nuclease activity is dependent on the left and right zinc-finger proteins binding to each 
side of the chromosomal target with a precise orientation and spacing (252). ZFNs induce a 
double-strand break (DSB) that can alter the target, either by activating the error-prone non-
homologous end-joining (NHEJ) pathway or by stimulating homologous recombination when a 
donor template is provided. In metazoans, NHEJ can produce nuclease-mediated gene 
disruptions (252). However, P. falciparum lacks several critical components of this pathway 
(Ku70/80 and DNA Ligase IV) (12). Thus, homologous recombination is likely the primary 
pathway of DSB repair in this parasite (117), and gene-targeting approaches using this process 
have been successful, albeit highly inefficient (317). We hypothesized that ZFNs could provide 
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the needed breakthrough in efficiency by introducing DSBs in a specified target site at a much 
higher frequency than occurs stochastically. 
 
We employed ZFNs for allelic replacement at an endogenous parasite locus. An important drug 
resistance determinant in P. falciparum is the chloroquine resistance transporter, PfCRT (67), 
which localizes to the digestive vacuole where hemoglobin degradation and formation of toxic 
CQ-heme adducts occurs (31, 80). The extensive worldwide use of CQ in malaria treatment has 
led to the selection of multiple mutations in pfcrt, generating geographically distinct alleles 
(321). Genetic engineering of isogenic parasites expressing various pfcrt alleles is required to 
fully analyze their phenotypic impact on drug response, but this has proven exceptionally time- 
and labor-intensive (57, 322). Here, we describe and validate a comprehensive plasmid design, 
transfection, and screening strategy to generate parasites encoding any pfcrt haplotype. We then 




4.3.1 Design for ZFNs targeting the pfcrt locus 
Our collaborators at Sangamo BioSciences, Inc. designed and selected three individual ZFNs 
based on the pfcrt binding site location, binding in an ELISA assay, and cleavage activity in a 
yeast proxy assay (2.2.1 and (254)). These ZFNs were 30413-ELD, 30414-ELD, and 30415-
KKR, referred to as “ “13,” “14,” and 15,” respectively (Table 4.1). ZFNs 13 and 14 are each 
paired with 15 to form the ZFN pairs 13/15 and 14/15. The ELD FokI nuclease domains on 
ZFNs 13 and 14 encode three negatively charged “ELD” mutant residues (Q486E, I499L, and 
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N496D), which enable them to bind to the positively charge “KKR” mutant residues (E490K, 
I538K, H537R) on the complementary KKR FokI monomer, thereby converting the FokI 
homodimer into an obligate heterodimeric nuclease (254). 
 
These FokI nuclease monomers are connected to DNA-binding zinc fingers via a short peptide 
linkage (Figure 1.14). ZFNs 14 and 15 each encode four zinc fingers, while ZFN 13 encodes six, 
where each individual zinc finger binds three adjoining DNA bases. While a diverse set of zinc 
fingers can bind the same three DNA bases, the selection of each zinc finger is optimized such 
that the order all fingers provides optimal DNA binding and cleavage in an ELISA assay and 
yeast proxy assay (252).  
 
Each ZFN pair binds at the border of intron 1 and exon 2 in the pfcrt locus (Figure 4.1). ZFNs 13 
and 14 bind at the same DNA sequence on the sense strand in intron 1. However, ZFN 13 binds 
an additional 4-bp at its 5’ end. ZFN 15 binds the antisense strand starting 4 bp from the start of 
exon 2. When paired, both 13/15 and 14/15 create the same DSB with a 4-bp 5’ overhang at the 
end of intron 1-exon2 border. 
 
Table 4.1 Amino acid sequences of designed zinc-finger recognition helices 
ZFN Finger 1 Finger 2 Finger 3 Finger 4 Finger 5 Finger 6 
30415-KKR RQDCLSL RNDNRKT TSGSLSR DRSNLSS QSSDLSR  
30413-ELD QSGNLAR RQEHRVA DRSNLSR DSSARNT RSDNLSV TSGSLTR 
30414-ELD RSDNLSV DRSNLSR DSSARNT RSDNLSV TSGSLTR  




Figure 4.1 ZFN 
binding sites in the 
pfcrt locus 
A visual representation 
of DNA binding for 
ZFNs 30413-ELD 
(red), 30414-ELD 
(red), and 30415-KKR 
(blue). Both ZFN pairs 
generate DSBs at the 
border of intron 1 and 
exon 2 (orange). ZFNs 
engineered by Sangamo 
BioSciences, Inc. 
 
4.3.2 Design for plasmids encoding ZFNs or pfcrt allele replacement and selectable 
marker 
Highly efficient allelic replacement of the pfcrt locus requires four basic elements (A) a complete 
pfcrt coding sequence to replace the endogenous locus, (B) regions of homology flanking the 
endogenous locus to serve as templates for strand invasion during HR, (C) a selectable marker 
cassette to ensure integrants outcompete non-edited cells, and (D) a ZFN cassette expressing 
ZFNs targeting the pfcrt locus. 
 
We separated the elements required for pfcrt allelic replacement onto two plasmids: (A) 
pZFNcrt-bsd: a “ZFN plasmid” encoding the ZFN pair 14/15 (Figure 4.2) and the bsd selectable 
marker cassette; (B) pcrtDd2-hdhfr: a “donor plasmid” encoding the pfcrt coding sequence, 





Figure 4.2 Design of the ZFN plasmid pZFNcrt-bsd  
pZFNcrt-bsd encodes two 2A peptide-linked ZFNs each Flag-tagged with nuclear localization 
sequences at the N-termini (pair 14/15 shown here). This coding sequence is under 
transcriptional control of the constitutive calmodulin (CAM) promoter. The selective marker bsd 
is placed in a separate cassette. The plasmid backbone is pDC2. The frozen stock number is 
gs3070. 
 
The donor plasmid, pcrtDd2-hdhfr (Figure 4.3), was constructed using elements from previous 
work in our laboratory (57, 278). To replace the endogenous pfcrt locus, two homology regions 
(HRI and HRII) were constructed such that they flanked the coding sequence of pfcrt and the 
hdhfr selectable marker cassette. HRI is a 417-bp stretch of sequence that extends from 150-bp 
upstream of the translation start sequence of pfcrt to the 3’ end of pfcrt intron 1. HRII is a 1050-
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bp region starting directly after the pfcrt translation stop sequence. These homology regions 
provide sequence necessary such that during HR, the entire endogenous sequence between pfcrt 
exon 2 and exon 13 is replaced. 
 
 
Figure 4.3 Design of the donor plasmid pcrtDd2-hdhfr for ZFN-mediated allelic replacement 
of pfcrt. 
pcrtDd2-hdhfr encodes two cassettes (red and green arrows) flanked by two homology regions 
(orange boxes). pfcrt cDNA (red arrows) is placed under the pfcrt promoter (blue arrow) such 
that it is only expressed when integrated in the genome. The plasmid is selected using the hdhfr 




The elements between HRI and HRII included two major elements: the pfcrt coding region and 
the hdhfr selectable marker cassette. The pfcrt coding region was comprised of the cDNA of the 
CQR pfcrt Dd2 haplotype from exon 2 through exon 13, followed by 704 bp of the P. berghei crt 
(pbcrt) 3’ UTR. The pbcrt 3’ UTR is sufficiently distinct from the pfcrt 3’ UTR such that it is not 
a region of homology in the pfcrt genome and therefore cannot be used during HR after ZFN 
cleavage. The pbcrt 3’ UTR is followed by an hdhfr selectable marker cassette, under the control 
of a calmodulin promoter and a histidine-rich protein 2 (hrp2) terminator (71). 
 
4.3.3 Transfection Strategy for ZFN-mediated replacement of the endogenous pfcrt locus 
Stable transfection by electroporation in P. falciparum is an inefficient method where it is 
estimated that ~100 parasites out of 10 million are successful in maintaining a plasmid (243, 
323). Stable maintenance of two separate plasmids after co-electroporation is notably even less 
efficient. 
 
To improve the probability and efficiency of ZFN-mediated allelic replacement of pfcrt, we 
designed a transfection strategy to improve the odds of successful gene editing (Figure 4.4). In 
this strategy, we electroporated CQS strains GC03 and 106/1 each with the donor plasmid 
pcrtDd2-hdhfr. Selection and propagation of transfectants with 2.5 nM WR99210-supplemented 




Figure 4.4 Transfection strategy for ZFN-mediated allelic replacement of pfcrt. 
Steps to generate pfcrt recombinants. A. Donor plasmid electroporation. B. Enrich with 2.5 nM 
WR99210. C. ZFN plasmid pZFNcrt-bsd transfection. D. Select with 2.5 nM WR99210 and 2 
μg/ml blasticidin. Screen for gene editing by PCR. E. Clone by limiting dilution. Screen for 
edited clones by PCR. * can encode any pfcrt haplotype 
 
Once enriched, these parasites were electroporated with the ZFN plasmid pZFNcrt-bsd. 
Therefore, successful GC03 and 106/1 transfectants harbored both pZFNcrt-bsd and pcrtDd2-hdhfr 
plasmids. Following the second electroporation, parasites were selected with both WR99210 and 
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2 μg/ml blasticidin for 6 days. We observed that selection with both WR99210 and blasticidin 
for 4 to 6 days is the optimal duration to ensure both plasmids are stably maintained. Less than 4 
days of dual drug selection resulted in an insufficient reduction of parasites that did not harbor 
the pZFNcrt-bsd plasmid. In contrast, dual drug selection for greater than 6 days provided no 
additional benefit in gene-editing outcomes for these plasmids and gene. 
 
4.3.4 Efficiency and validation of ZFN-mediated allelic replacement of the pfcrt locus 
As mentioned above, ZFN-mediated pfcrt allelic replacements were performed using the two 
CQS strains 106/1 and GC03. GC03 is a progeny clone from the HB3 × Dd2 genetic cross. 106/1 
is a Sudanese clone, which encodes all but one crucial mutation (K76T) of the CQR Dd2 pfcrt 
allele, thereby rendering it CQS (324). Both strains were transfected as described above. After 
removal of blasticidin selective pressure, while maintaining WR99210 supplementation, parasite 
proliferation was microscopically detected after 13 to 16 days. 
 
In bulk transfectant cultures, successful ZFN-mediated gene editing in both GC03 and 106/1 was 
first assessed by PCR using primers p11 + p13 and p14 + p15 (Table 2.1, Figure 4.5A and B), 
which yielded 1.4 kb and 2.5 kb PCR bands when run on an agarose gel. PCR bands obtained 
with primers p11 + p13 and p14 + p15 confirmed successful integration of the donor plasmid 
sequence at the 5’ and 3’ ends, respectively (Figure 4.5B). Bulk cultures of successful 





Figure 4.5 ZFN-driven allelic replacement of pfcrt 
A. Schematic of pfcrt allelic replacement strategy. pZFNcrt-bsd pfcrt-specific ZFNs. The pcrtDd2-
hdhfr donor plasmid contains the Dd2 pfcrt allele cDNA (dark purple boxes), followed by 
the pbcrt 3′ UTR and the hdhfr cassette (dark grey arrow). These cassettes are flanked by two 
pfcrt homology regions. ZFN-driven HR yielded the pfcrt-modified GC03crt-Dd2 locus. B. PCR 
analysis of two independent clones. Primer positions are shown in panel A and listed in Table 
2.1. C. Southern blotting of gDNA from the indicated parasite lines digested with SalI + BstBI 
and probed for hdhfr (black bar in panel A) Upper band is the episomal donor plasmid. Lower 
band is the integrated recombinant locus. D. The plot shows half-maximal inhibitory 
concentration (IC50 ± SEM) values for the indicated parasite lines. * p < 0.05 relative to GC03 




Table 4.2 Event outcomes of ZFN-mediated allelic replacement with pcrtDd2-hdhfr 
 Parasite transfected 
Event GC03 106/1 
Non-crossover (NCO) 4.8% (4) 15.6% (13) 
Non-crossover + ZFN (NCO + ZFN) 4.8% (4) 20.0% (16) 
Crossover (CO) 10.8% (9) 1.2% (1) 
Other 0.0% (0) 12.2% (10) 
No Event 79.6% (66) 51.2% (40) 
Quantification of outcomes for ZFN-mediated allelic replacement of pfcrt in two 
parasite background: GC03 and 106/1. Values for scoring represent percentage of 
total clones analyzed followed by the number of clones in parentheses. Clones 
were obtained from two independent transfections for each parasite. 
 
Clones obtained by limiting dilution were then screened by PCR with two additional primer pairs 
to distinguish between all possible outcomes of ZFN-mediated pfcrt gene editing. Using primer 
pairs p12 + p13 (which bind pfcrt exon 2 and exon 3, respectively, in Figure 4.5B) and p3369 + 
p3371 (which bind bsd and the pDC2 vector on the pZFNcrt-bsd plasmid), we categorized each 
clone into five possible HR outcomes (Table 4.2). (A) Non-Crossover (NCO): this was the 
desired outcome where pfcrt allelic replacement generated the desired recombinant locus likely 
by a NCO pathway in HR (e.g. SDSA) (Figure 4.5A). NCOs are defined by four PCR banding 
patterns (Figure 4.5b, clone G9 and H6): a single 435 bp PCR product using primers p12 + p13; 
a 1.2 kb product when using p11 + p13; a 2.5 kb product using p14 + p15, and no PCR product 
when using p3369 + p3371. (B) NCO + ZFN: this was an NCO outcome that maintained the 
ZFN plasmid pZFNcrt-bsd episomally and was undesirable as persistent ZFN expression can 
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generate DSBs in the recombinant locus and lead to further recombination. The PCR banding 
patterns for NCO + ZFN are identical to the NCO pattern except the p3369 + p3371 primers 
yield a 1.4 kb PCR product (C) Crossover (CO): in contrast to the NCO outcome, CO denoted 
recombinant loci where the pcrtDd2-hdhfr plasmid had fully integrated into the endogenous pfcrt 
locus. Although these recombinant loci express Dd2 pfcrt under the endogenous promoter, 
reversion to the CQS wildtype locus remained possible. CO events are identical to NCO PCR 
banding patterns, except primers p12 + p13 yield a doublet PCR product, 614 bp and 435 bp. (D) 
Other: this category contained all recombinant loci that are unable to be classified above. For 
instance, the recombinant pfcrt locus in a CO clone can be re-cleaved by persistent expression of 
pfcrt-targeting ZFNs, yielding a parasite encoding two copies of the recombinant Dd2 pfcrt and 
hdhfr cassettes in the genome. Banding patterns for Other events are any that diverge from the 
expected events above (E) No Event: this is when no ZFN-mediated recombination of any sort 
occurred at the endogenous pfcrt locus. PCR products for No Events match those seen for GC03 
in Figure 4.5b where primers p11 + p13 yield a 1.4 kb product, p12 + p13 yield a 614 bp 
product, and p14 + p15 do not yield a product. 
 
Using these criteria for ZFN-mediated recombination outcomes, we quantified the efficiency of 
pfcrt-targeting ZFNs in GC03 and 106/1 (Table 4.2). NCO events were observed in 13 out of 82 
(15.9%) 106/1 clones and 4 out of 83 (4.8%) GC03 clones. NCO + ZFN events were observed in 
16 out of 82 (20%) 106/1 clones and 4 out of 83 (2.8%) GC03 clones. CO events were observed 
in 1 out of 82 (1.2%) 106/1 clones and 9 out of 83 (10.8%) GC03 clones. Other events were 
observed in 10 out of 82 (12.2%) 106/1 clones and 0 out of 83 (0%) GC03 clones. Finally, ZFN-
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mediated editing was not observed in 14 out of 82 (51.2%) 106/1 clones and 66 out of 83 
(79.6%) GC03 clones. 
 
Therefore, ZFN-mediated recombination at the pfcrt locus of any outcome occurs in 48.8% and 
20.4% in 106/1 and GC03, respectively. These data suggest that (A) ZFN-mediated pfcrt allelic 
replacement is efficient in P. falciparum and (B) recombination is more efficient in 106/1 than 
GC03 when using a Dd2 pfcrt donor template. This may be due to the higher sequence similarity 
between 106/1 and Dd2 pfcrt haplotypes compared to GC03 and Dd2. 
 
We further validated successful editing and selection of NCO clones by Southern blot and 
response to CQ. Clones GC03crt-Dd2 G9 and GC03crt-Dd2 H6 (Figure 4.5B, C, and D) represent two 
NCO clones. Southern blotting of GC03crt-Dd2 G9 and GC03crt-Dd2 H6 demonstrated acquisition of 
the donor-provided CQR pfcrt allele in place of the parental allele (Figure 4.5C). Consistent 
with pfcrt replacement, GC03crt-Dd2 G9 and GC03crt-Dd2 H6 exhibited a 6.7 kb band. Clone GC03crt-
Dd2 G7 displayed a banding pattern matching an NCO parasite where the pcrtDd2-hdhfr donor 
plasmid was maintained episomally and linearized with SpeI (8.1 kb). GC03 + pcrtDd2-hdhfr and 
clone GC03crt-Dd2 C6 represented strains only transfected with the donor plasmid or transfected 
with both plasmids but unmodified (No Event). The pcrtDd2-hdhfr lane served as a control for 
plasmid digested with SpeI. 
 
We then confirmed the CQ resistance phenotype of the NCO clones GC03crt-Dd2 G9 and GC03crt-
Dd2 H6 by monitoring shifts in CQ IC50. Both clones displayed a 4 to 5 fold shift in CQ IC50 
values compared to either the GC03 parent or a control GC03 line (GC03 + pcrtDd2-hdhfr) that 
  
 99 
harbored the pcrtDd2-hdhfr donor plasmid as episomes and were comparable to the values 
obtained for the CQR strain Dd2 (Figure 4.5D). Therefore, ZFN-mediated pfcrt allelic 
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Chemotherapeutic approaches to malaria treatment inevitably lead to drug resistance. The current 
strategy to circumvent this issue is to switch antimalarials or employ combination therapies in 
order to delay the onset of drug resistance. This, however, requires a significant investment in 
screening, developing, and manufacturing novel antimalarial compounds. For instance, the 
former major first-line antimalarial compound to treat P. falciparum, CQ, is no longer used due 
to widespread resistance and is replaced today by artemisinin, to which resistance is slowly 
arising (316). One proposed solution to help combat perpetual drug development is to pressure 
parasites into an evolutionary loop using chemotherapies where resistance to one compound 




A recent high-throughput small molecule screen identified a novel benzothiazepine amine, IDI-
3783, which was shown to be highly active against CQR parasites, a significant boon given the 
omnipresence of CQ resistance today, but inactive against CQS parasites (325). To determine if 
this evolutionary loop could be exploited in contemporaneous parasite isolates, we tested 40 
recently derived Senegalese isolates (327) for susceptibility to both CQ and IDI-3783 (Park DJ 
and Lukens AK). Consistent with previous findings, CQR isolates were largely sensitive to IDI-
3783 while CQS isolates exhibited a varying degree of IDI-3783 resistance (Figure 4.6). These 
data indicated that CQ susceptibility status largely dictates the inverse relationship between CQ 
and IDI-3783. 
 
The diversity in the degrees of susceptibility to CQ and IDI-3783 despite similar pfcrt haplotypes 
amongst CQR Senegalese isolates and identical pfcrt haplotypes amongst CQS isolates 
suggested other genetic factors might contribute to IDI-3783 susceptibility. To determine if the 
anti-correlated relationship between CQ and IDI-3783 could be explained by a gene other than 
pfcrt, we performed quantitative trait locus mapping (328) using the CQ and IDI-3783 in vitro 
dose responses of progeny from the Dd2 × HB3 genetic cross and Senegalese isolates (Tan A 
and Checkley L). This analysis identified one major locus, pfcrt,  as the primary determinant of 
the anti-correlation between CQ and IDI-3783. PfMDR1 has been previously shown to be 
associated with CQ susceptibility (328). Together, this analysis indicated that the pfcrt haplotype 





Figure 4.6 Differential drug responses among recently derived Senegal isolates to CQ and 
IDI-3783 
72-hour in vitro susceptibility as defined by the half-maximal inhibitory concentration (EC50 or 
IC50) for Senegalese strains (beginning with Th, V, or P) and two controls strains: 3D7 (CQS) 
and Dd2 (CQR). Black bars indicate CQ resistance and IDI-3783 sensitivity while white bars 
indicate CQ sensitivity and IDI-3783 resistance. The center panel residues in PfCRT that differ 
from wild-type 3D7 for all strains. These data were generated by Daniel J Park and Amanda K 
Lukens (Harvard). 
 
Previous work has shown that CQR strains can become resistant to IDI-3783 (325). CQR Dd2 
parasites pressured in vitro with IDI-3783, yield resistant progeny exhibiting a 1000-fold 
increase in IDI-3783 IC50, conferred by a Q352R mutation in pfcrt. Intriguingly, these IDI-3783-
resistant parasites were sensitized to CQ. To genetically validate the role of the Q352R mutation 
in the inverse relationship between IDI-3783 and CQ, we used pfcrt-targeting ZFNs to engineer 
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the Q352R mutation into pfcrt. We generated a Dd2 strain expressing the pfcrt-Dd2 Q352R 
haplotype, Dd2Dd2 Q352R. To control for variability due to genetic background (e.g. pfmdr1), we 
previously generated a Dd2Dd2 recombinant control (56). 
 
 
Figure 4.7 In vitro susceptibility to IDI-3783 and CQ 
72-hour in vitro susceptibility assays for Dd2Dd2, Dd2Dd2 Q352R, 7G87G8, and 7G87G8 C350R in 
response to CQ and IDI-3783. Recombinant controls Dd2Dd2 and 7G87G8 are shown in light 
grey, while mutants Dd2Dd2 Q352R and 7G87G8 C350R are shown in dark grey. * p < 0.05, *** p < 
0.001, unpaired, two-tailed Student’s t-test. n = three independent assays. 
 
In 72-hour in vitro susceptibility assays, we provided genetic proof that the Q352R mutation 
alone confers resistance to IDI-3783 and reverses CQ resistance. Dd2Dd2 Q352R exhibited a 276-
fold increase in IDI-3783 IC50 (from 2.1 nM to 581 nM) relative to Dd2
Dd2 (Figure 4.7). In 
contrast, Dd2Dd2 Q352R showed a 7-fold reduction in CQ IC50 relative to Dd2
Dd2 (from 162 nM to 
23 nM) 
 
This PfCRT Q352R-mediated reduction in CQ resistance resembled a similar phenotype in CQR 
7G8 parasites in which a PfCRT C350R mutation sensitized an otherwise resistant pfcrt 
haplotype (329), where a 7G8 parasite was engineered to encode both the 7G8 pfcrt haplotype 
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with (7G87G8 C350R) and without the C350R mutation (7G87G8) (329). We observed that the 
C350R mutation (7G87G8 C350R) conferred a 1,111-fold increase in IDI-3783 resistance (from 
3.26 ± 0.76 nM to 3621.50 ± 582.57 nM) and a 4-fold reduction (from 95.19 ± 20.62 nM to 
21.74 ± 5.52 nM) in CQ resistance relative to the 7G87G8 (Figure 4.7). 
 
Together, these data show that most CQS strains can confer IDI-3783 resistance and CQ 
sensitivity. We also demonstrated that CQR strains that encode the Q352R mutation can be 
sensitized to CQ while becoming IDI-3783 resistant. Additionally, the nearby mutation at 
position 350 (C350R) can also produce the same inverse dose response phenotype. This 
highlights the possibility of additional mutations producing the same phenotype. Q352 and C350 
are only separated by a single residue, therefore it is possible that this region in transmembrane 
domain 9 of PfCRT is involved in binding IDI-3783. Utilizing CQ and IDI-3783 would likely 
produce additional novel mutations in PfCRT that reproduce the anti-correlation effect. 
Nevertheless, forcing parasites into an evolutionary loop remains a possible effective option to 
re-introduce CQ as a first-line antimalarial compound and extend its utility. 
 
4.4. DISCUSSION 
Gene engineering in the P. falciparum has long lagged behind other organisms such as S. 
cerevisiae, C. elegans, E. coli, mammalian cells, and even the rodent malaria P. berghei (12, 
129, 245). Genome modifications at researched-defined loci were generated using single-site 
crossover or double crossover methods (232-234), which often required long periods of in vitro 
culturing, repeated screening, and persistent drug selection to obtain a desired genetic mutant 
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(Figure 1.13). Alternatively, exogenous DNA could be introduced into the genome at a single, 
pre-defined locus using the attB/attP mycobacteriophage Bxb1 integrase system (330). 
 
Engineering of recombinant strains expressing varying pfcrt haplotypes (e.g. Dd2, 7G8) had 
previously been achieved with two rounds of single-site crossover (57). This method however 
was time- and resource-intensive and generated recombinant pfcrt loci that harbored at minimum 
three copies of the pfcrt coding sequencing, depending on the concatameric nature of the 
episomal plasmids maintained during in vitro culture. As a result, these recombinant loci were 
subject to reversion to wild-type without constant selective pressure. 
 
While this initial method of gene engineering was sufficient for studying the key pfcrt haplotypes 
(e.g. Dd2) that define the role of PfCRT in CQ resistance (57), it could not be scaled in an 
efficient manner to address the highly polymorphic nature of pfcrt (331) and the function of each 
mutation in drug response and parasite biology. Here, we have demonstrated for the first time the 
use of ZFNs in P. falciparum to generate recombinant pfcrt mutants rapidly and efficiently. We 
note that this is the first report of the development of ZFNs to genetically modify any eukaryotic 
pathogen. 
 
We showed that the introduction of a single DSB at the border of intron 1 and exon 2 of pfcrt is 
the rate-limiting step in successful genome editing. As a proof of concept, we engineered the 
CQR Dd2 haplotype into two CQS strains GC03 and 106/1. To maximize the rate of NCO events 
and ensure undesired events (NCO + ZFN, CO, Other) were avoided; we developed a dual 
plasmid transfection strategy (4.3.3) and PCR screening method (4.3.4). Using these methods, 
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we observed an efficiency rate of 4.8% and 15.6% in obtaining a desired NCO outcome in 
engineering the Dd2 haplotype into GC03 and 106/1, respectively. Together, we designed the 
foundational strategy for ZFN-mediated allelic replacement of pfcrt that enables the engineering 
of nearly any pfcrt haplotype into any parasite strain in a few months and with high efficiency. 
We applied this strategy to investigate a mutation in pfcrt (Q352R) involved in CQ resistance 
and resistance to a novel benzothiazepine amine compound, IDI-3783 (Figure 4.7). Using the 
ZFN-mediated pfcrt allelic replacement strategy, we first generated two strains, a recombinant 
control Dd2Dd2 and a mutant Dd2Dd2 Q352R. We validated the role of the Q352R mutation in 
altering CQ and IDI-3783 susceptibility status by observing a 276-fold increase in IDI-3783 IC50 
and 7-fold reduction in CQ IC50 relative to Dd2
Dd2 in in vitro susceptibility assays. We then 
showed that the PfCRT C350R mutation could mirror the Q352R drug response in vitro when 
the mutation is engineered into a 7G8 PfCRT-expressing 7G8 parasite (7G87G8 C350R), relative to 
a recombinant control (7G87G8). 
 
Together, these data show how ZFNs can be leveraged to rapidly and reliably generate variants 
of pfcrt, enabling detailed analyses of its biological function and drug resistance properties in 
isogenic parasite lines. To date, this strategy has been used in the studies described herein ((46) 
and Lukens et al., in preparation) as well as other studies both recently published and in 
preparation ((56, 75, 124, 329) and Lee et al., in preparation). We note that the ZFN-mediated 
allelic replacement approaches described above are not restricted to genes that confer drug 
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Malaria, a significant burden for much of the world, is predominantly caused by the eukaryotic 
pathogen Plasmodium falciparum. During symptomatic infection of the human host, the parasite 
cycles through red blood cell invasion, hemoglobin catabolism, and egress and can be cured with 
appropriate antimalarial therapy. However, drug usage eventually selects for resistance, reducing 
the efficacy of therapies, such that they are no longer effective. Chloroquine, the former first-line 
antimalarial, is one drug where resistance rendered it largely unusable for falciparum malaria. 
Resistance-conferring mutations in the P. falciparum chloroquine resistance transporter (PfCRT) 
enable parasites to efflux drug away from its site of action, the acidic digestive vacuole where 
hemoglobin catabolism occurs. Significant progress has been made in understanding how PfCRT 
modulates resistance to chloroquine and other clinically relevant therapies, but how it functions 
and impacts cellular processes is still not fully elucidated. Here, we utilize a unique PfCRT 
L272F mutation that produces enlarged, translucent digestive vacuoles to investigate PfCRT 
function in the parasite. First, we report that this mutation significantly affects drug susceptibility 
independently of verapamil, a Ca2+ channel blocker, signifying the importance of PfCRT’s large 
vacuolar loop in transport. We also provide evidence that the L272F mutation confers a 
significant fitness cost and methionine auxotrophy. Metabolomic analysis reveals an 
accumulation of short, hemoglobin-derived peptides in the L272F mutant, suggesting that PfCRT 
is involved in modulating hemoglobin catabolism. Finally, we monitored the movement of free 
Ca2+ upon ionophore stimulation to study the role PfCRT in digestive vacuole membrane 
permeability to cations.  Our data suggest that PfCRT is involved in maintaining the ionic 





The Plasmodium falciparum chloroquine resistance transporter (PfCRT) is a member of the 
Drug/Metabolite Transporter (DMT) superfamily that localizes to the digestive vacuole (DV) 
membrane of intra-erythrocytic asexual blood stage parasites (68, 332). Genetic studies have 
shown that mutant PfCRT is the key determinant in conferring resistance to the former first-line 
drug chloroquine (CQ), a 4-aminoquinoline that accumulates in the acidic DV in its di-
protonated form (CQH2+) and inhibits free heme detoxification (31, 67). PfCRT mutations can 
also modulate susceptibility to multiple other antimalarials, including artemisinin derivatives and 
various partner drugs in globally adopted artemisinin-based combination therapies (ACTs), 
notably amodiaquine, piperaquine, lumefantrine, and mefloquine (54, 57, 90, 316, 329). 
Consistent with its complex patterns of evolution in multiple geographic regions subject to 
varied selective pressures, there are currently 53 known PfCRT isoforms (54, 72, 333). 
 
Significant progress has been made in understanding the relationship between these isoforms and 
drug resistance, particularly in vitro where resistance is determined by measuring the half-
maximal inhibitory concentration (IC50) for a given drug or strain. CQ resistance, for instance, is 
exemplified by the significant increases in IC50 values of CQ resistant (CQR) strains relative to 
CQ sensitive (CQS) strains (57, 332). Relying on a high electrical membrane potential difference 
between the highly acidic DV and the parasite cytoplasm, CQR isoforms efficiently efflux 
CQH2+ out of the DV, the site of action of this weak-base drug (72, 89, 334, 335). The 
underlying native function of PfCRT, however, remains unclear. Studies in parasites and 
heterologous expression systems (e.g. yeast and Xenopus) have suggested that PfCRT transports 
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glutathione, Cl- ions, H+ ions, or a range of cationic substrates including Hemoglobin (Hb)-
derived amino acids and peptides (81, 84, 92-94, 336).  
 
Previously, we reported a novel PfCRT mutation at position 272 (L272F) that produces large, 
translucent DVs in both the CQS 3D7 strain that expresses wild-type pfcrt and the CQR Dd2 
strain that expresses a variant pfcrt containing 8 point mutations (Figure 5.1a) (56). L272 lies at 
the start of loop 7 (68) and sits adjacent to residue Q271, which when mutated (Q271E) 
contributes to increased PfCRT CQ transport activity and resistance (321). Using zinc-finger 
nucleases (ZFNs), we introduced the L272F mutation into a CQR Dd2 strain and showed that in 
addition to a ~2-fold increase in DV surface area when visualized on thin blood smears (Figure 
5.1b) (56), the L272F mutation nearly fully sensitized CQR parasites to 4-aminoquinoline 
compounds including CQ, monodesethyl-chloroquine (md-CQ), and monodesethyl-amodiaquine 
(md-ADQ). In Xenopus oocytes heterologously expressing PfCRT, CQ transport was 
significantly impaired by the L272F mutation (56). 
 
Given our initial findings, we sought to investigate the effect of the PfCRT L272F mutation on 
cellular processes. Mutations in PfCRT have been associated with Hb catabolism in the DV by 
metabolic quantitative trait locus (mQTL) mapping in the progeny of a genetic cross between 
CQR and CQS parental strains. Metabolomic analysis of these strains demonstrated that CQR 
PfCRT isoforms accumulated short, Hb-derived peptides in the DV and exhibited a subsequent 
fitness cost (94). This accumulation of short, Hb-derived peptides suggested that PfCRT might 
be involved in the transport of (A) peptides or amino acids out of the DV, (B) metal ions 
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Figure 5.1 The PfCRT L272F 
mutation in the large vacuolar 
loop creates an enlarged digestive 
vacuole phenotype 
A. Schematic of PfCRT predicted 
topology. The L272F mutation (blue 
dot) is predicted to localize to a large 
loop, extending into the DV, 
between transmembrane helices 7 
and 8. The other mutations listed are 
present in the Dd2 mutant protein 
that that mediates CQ resistance and 
differs from the wild-type sequence 
at 8 positions (orange dots: M74I, 
N75D, K76T, I220S, Q271E, 
N326S, I356T, and R371I). B. 
Representative images of Dd2, 
Dd2Dd2, Dd2Dd2 L272F, and GC03 
parasites at ring, trophozoite, and 
schizont stages. Parasites were 
Giemsa-stained and visualized by 
light microscopy. Dd2Dd2 L272F 
exhibited enlarged, translucent DVs 
in trophozoite and schizont stages 
when Hb catabolism is the most 
active. 
 
Hb is present at low millimolar concentrations in the red blood cell (RBC) cytoplasm and is 
imported into the DV via cytostomes or endocytic vesicles (9, 337). Hemoglobin is digested in 
the DV via a semi-ordered progression of aspartic and cysteine proteases oligopeptides (338). 
This process releases free Fe2+-heme, which rapidly oxidizes to Fe3+-heme that forms E-hematin 
dimers that are detoxified via their incorporation into chemically inert hemozoin crystals (30, 
31). Oligopeptides are further degraded by the Cl--dependent exopeptidase dipeptidyl 
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aminopeptidase 1 (PfDPAP1) and the metal ion-dependent peptidases falcilysin, aminopeptidase 
P (PfAPP), and aminopeptidase N (PfA-M1), whose in vivo metal co-factors are thought to be 
one Zn2+, two Mn2+, and one Zn2+, respectively. These peptidases produce short peptides and 
amino acids, which can be transported out of the DV (32, 34-37, 339). During one 48-hour 
intraerythrocytic development cycle, parasites will degrade up to 65 to 75% of an infected RBCs 
(iRBCs) Hb in the DV. Despite this abundance, it has been estimated that parasites only use 
~16% of the Hb-derived amino acids as a nutrient source (22), while a large portion of the 
remainder is released into the surrounding host plasma (279).  
 
Inhibition of Hb catabolism generates two enlarged DV phenotypes when visualized by light 
microscopy: (A) parasites treated with upstream Hb-protease complex inhibitors such as N-
acetyl-leucinyl-leucinyl-norleucinal (ALLN) or trans-Epoxysuccinyl-L-leucylamido(4-
guanidino)butane (E64) accumulate undigested Hb, producing “dark,” enlarged DVs in Giemsa-
stained thin blood smears (26, 340); or (B) inhibition of downstream peptidases such as PfA-M1 
produces translucent, enlarged DVs, where eosin no longer stains globular Hb, resulting in an 
accumulation of short peptides (23). Mutations in PfCRT or inhibition by drugs can also increase 
DV volume. For instance, the CQR Dd2 haplotype can produce parasites with larger DV 





Figure 5.2 The enlarged DV 
phenotype depends on the 
multiplicity of infection per red blood 
cell 
Each strain (Dd2, Dd2Dd2, Dd2Dd2 L272F, 
and GC03) was scored for the presence 
or absence of an enlarged phenotype 
and sorted based on the number of 
parasites in a single RBC, i.e. the 
multiplicity of infection. Thin blood 
smears of asynchronous, asexual blood 
stage parasites were fixed with 
methanol, stained for 20 minutes in 
10%  (v/v) Giemsa  (Invitrogen), 
washed, and air-dried. Trophozoites and 
schizonts with enlarged DVs phenotype 
were quantified by visual inspection of 
316 Dd2, 312 Dd2Dd2, 322 Dd2Dd2 L272F, 
and 211 GC03 iRBCs using an 
Olympus CX 41 light microscope with 
a 100× objective. Of note, enlarged 
DVs were never observed in CQS 
GC03 parasites.  
 
 
We hypothesized that the L272F mutation would disrupt Hb catabolism, thereby producing an 
enlarged DV phenotype.  To test this, we applied zinc-finger nucleases-mediated gene editing to 
introduce this mutation into Dd2 parasites (71). Comparison of isogenic lines expressing Dd2 
pfcrt or the Dd2+L272F variant revealed that the L272F mutation confers a fitness cost as well as 
methionine auxotrophy. By peptidomic analysis, we observed an altered profile of small Hb-
derived peptides in the DV and disruption of the efflux of free Ca2+ across the DV membrane 
when stimulated by ionophores.  We also further investigated the contribution of the L272F 
mutation to antimalarial drug susceptibility. Together, our data support the hypothesis that 
PfCRT is involved in ionic homeostasis in the DV, a key factor in maintaining the catalytic 




5.3.1 The PfCRT L272F mutation reverses 4-aminoquinoline drug resistance 
independently of verapamil  
A unique characteristic of CQR PfCRT is the partial sensitization of CQR parasites when CQ is 
supplemented with VP, an L-type Ca2+ channel blocker (86, 334). Analyses of PfCRT transport 
kinetics in Xenopus oocytes suggested that VP is a partial mixed-type inhibitor of CQR PfCRT-
mediated CQ transport (90). In this model, PfCRT harbors a poly-specific substrate-recognition 
cavity with various overlapping substrate binding sites. For instance, CQ-bound PfCRT 
predominantly blocks VP access to its binding site and transport, but occasionally permits CQ-
VP symport (90). VP-driven CQ sensitization, or VP reversibility, has been shown to require 
mutations in transmembrane domain 1 (C72S, K76T) or loop 9 (N326D, I356L) (86, 341). Three 
of these mutations overlap with the minimally required set of four mutations that confer CQ 
resistance in PfCRT (K76T, A220S, N326D, I356L) (75). We hypothesized that the position of 
the L272F mutation interferes with drug transport in a manner independent of VP.   
 
To determine how the L272F mutation impacts VP and 4-aminoquinoline transport, we 
examined four strains: Dd2 (a CQR parental control), Dd2Dd2 (a recombinant control), Dd2Dd2 
L272F, and GC03 (a CQS control) (See Figure 4.4 for a schematic of the gene-editing strategy of 
the recombinant strains Dd2Dd2 and Dd2Dd2 L272F).  Each strain was pressured with 0.8 μM VP in 
conjunction with the 4-aminoquinoline compounds CQ, md-CQ, or md-ADQ. Our data reveal 
that the L272F mutation and VP independently contribute to a 4.3 and 4.5 fold reduction in mean 
CQ IC50 values in the Dd2





Figure 5.3 In vitro susceptibility of pfcrt-modified lines to 4-aminoquinoline drugs tested  
± the resistance reversal agent verapamil 
Graphs show mean ± SEM IC50 values for Dd2, Dd2Dd2, Dd2Dd2 L272F, and GC03 in response to 
CQ, md-CQ, and md-ADQ ± 0.8 μM VP. a IC50 values without VP were previously published 
(56). VP results were obtained in parallel in the same sets of assays. * p < 0.05, ** p < 0.01, one-
tailed Student’s t-test relative to the no VP IC50 value in the same strain. # p < 0.05, ## p < 0.01, 
one-tailed Student’s t-test relative to Dd2Dd2. n = 3 independent assays performed in duplicate. 
 
Combined, the L272F mutation and VP reduce mean CQ IC50 values 8.6 fold, sensitizing 
Dd2Dd2 L272F to the level of CQS GC03. md-CQ and md-ADQ reflected similar fold reductions 
when VP was used in transgenic parasites expressing the Dd2+L272F variant. Of note, the md-
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CQ IC50 values for the L272F variant remained 4–fold higher than those observed with GC03, 
consistent with this mutation nearly fully countering the resistance-conferring properties of the 
Dd2 sequence (that carries the K76T molecular marker of CQR). 
 
In the poly-specific substrate-recognition cavity model of PfCRT, the bulky phenylalanine at 
residue 272 would be predicted to impair quinoline access to PfCRT, but not interfere with VP 
sensitization. In this scenario, CQ, md-CQ, or md-ADQ molecules that did manage to bypass the 
L272F mutation such that they could be effluxed by the variant transporter would be inhibited by 
the presence of VP occupying an overlapping binding site. These data reveal a novel mechanism 
by which the L272F mutation can sensitize CQR parasites to 4-aminoquinoline drugs in a way 
that preserves the resistance reversal properties of VP, heretofore thought to only be active in 
CQR parasites (86). 
 
5.3.2 The L272F mutation has little effect drugs not transported by PfCRT  
To determine whether the PfCRT L272F mutation might have a pleitropic effect on antimalarial 
potency, we examined this mutant’s response to three clinically relevant ACT partner drugs: 
lumefantrine, mefloquine, and pyronaridine. Lumefantrine and mefloquine can be modulated by 
PfCRT haplotypes (57), although stronger effects are observed with changes in the haplotype or 
copy number of the P. falciparum multidrug resistance 1 gene, pfmdr1 (51-53), which also 
encodes a DV-resident transporter. Experiments with genetically modified lines have shown that 
mutant PfCRT haplotypes can increase parasite susceptibility (as defined by lower IC50 values) 
by ≤ 2-fold (54). Pyronaridine acts on both CQR and CQS strains and is not thought to be 
impacted by common mutant forms of pfcrt (49). Our in vitro susceptibility tests found that 
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compared to Dd2Dd2, Dd2Dd2 L272F exhibited statistically non-significant 1.0, 1.1, and 1.3 fold 
changes in lumefantrine, mefloquine, and pyronaridine IC50 values, respectively (Figure 5.2). 
This suggests that despite the changes to 4-aminoquinoline response and DV morphology in the 




Figure 5.4 In vitro susceptibility of pyronaridine, lumefantrine, and mefloquine 
IC50 ± SEM values for Dd2, Dd2Dd2, Dd2Dd2 L272F, and GC03 in response to pyronaridine, 
lumefantrine, and mefloquine. All values were non-significant relative to Dd2Dd2 save for GC03 
in mefloquine. * p < 0.05, two-tailed Student’s t-test relative to Dd2Dd2, n = 3 independent assays 
performed in duplicate. 
 
5.3.3 The L272F mutation produces a fitness cost and confers methionine auxotrophy 
The reduction of 4-aminoquinoline susceptibility and the enlarged DV phenotype of the L272F 
mutant led to the recent suggestion that PfCRT was significantly impaired in its native function 
(56), which although undefined is known to be essential in the parasite (95, 342). Changes in the 
PfCRT haplotype are closely tied to growth rates in vitro, a proxy of parasite fitness (54, 94). For 
instance, parasites expressing the mutant pfcrt Dd2 allele are less fit than the isogenic line 
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expressing the wild-type (GC03) allele. This fitness cost is exacerbated when Dd2 is propagated 
in media lacking all amino acids except isoleucine, which is absent in Hb and must be supplied 
exogenously (94). In this minimal media, parasites must derive all amino acids (except 
isoleucine) from Hb. These findings suggest that PfCRT mutations can impair the availability of 
amino acids for cellular processes. 
 
 
Figure 5.5 The PfCRT L272F mutation 
exerts a fitness cost and requires 
methionine for growth 
A. Head-to-head in vitro competition 
assay between Dd2Dd2 (diamonds) and 
Dd2Dd2 L272F (circles). Dd2Dd2 and Dd2Dd2 
L272F were seeded at a 1:4 ratio and 
monitored every 48 hours for 20 
generations. After 4 generations, cultures 
were split into two replicates. Observed 
allele frequencies were fit using a 
computer model of the Plasmodium life 
cycle (solid lines), which indicated a 21% 
fitness difference and 1-hour life cycle 
length between strains (R2 = 0.986).  
Assays performed by Ian Lewis (U. of 
Calgary). B. Growth rates of Dd2Dd2 (blue 
bars) and Dd2Dd2 L272F (dark blue bars) in 
amino acid-rich media (RPMI-VI) and 
minimal media (absent of all amino acids 
save for supplementation with the ones 
denoted by single letter codes, e.g. IM: 
isoleucine and methionine). Unlike 
Dd2Dd2, Dd2Dd2 L272F cannot grow in 
medium containing only isoleucine, but 
can be rescued with the addition of 
methionine (IM and IMC). Mean doubling 
times were calculated from three 
independent experiments for each strain 
and media condition. Data are presented 
as means ± SEM. p < 0.05, ** p < 0.01; 
one-tailed Student’s t-test relative to 
Dd2Dd2. Assays performed by Seema 




To test for altered growth rates, we seeded Dd2Dd2 L272F and Dd2Dd2 in a 4:1 ratio in an in vitro 
head-to-head competition and monitored pfcrt allele frequency every 48 hours for 40 days (~20 
generation) by gDNA isolation and sequencing (Figure 5.5a). Over this time course, Dd2Dd2 
L272F exhibited a substantial fitness cost relative to Dd2Dd2, suggesting that the L272F mutation 
has a major adverse impact on native PfCRT function. Using a custom computer model of the 
Plasmodium life cycle, we found that the difference in growth curves between the lines could be 
explained by (R2 = 0.986) a one-hour delay in asexual cell cycle length and a % relative fitness 
cost per generation in Dd2Dd2 L272F compared with Dd2Dd2. 
 
It has been demonstrated that cultured P. falciparum can rely on hemoglobin catabolism to 
supply all amino acids required for growth except isoleucine, which is absent from human 
hemoglobin (19). To determine whether the L272F mutation impairs the ability of parasites to 
secure essential amino acids from vacuolar hemoglobin catabolism, we profiled the amino acid 
requirements in the L272F mutant. We focused our analysis on amino acids that are not effluxed 
from the parasite in substantial quantities, namely Met, Cys (provided as cystine), Asp, Asn, Glu, 
Gln, Lys and Arg (279).In amino acid-rich media (RPMI-VLA, which lacks valine, leucine, and 
alanine supplementation but does not affect parasite growth rate (279)), Dd2Dd2 L272F exhibited a 
growth defect relative to Dd2Dd2 (Figure 5.5b), reflecting our observations in regular medium 
described above. In minimal media (+I) where only isoleucine was supplemented, Dd2Dd2 L272F 
could not replicate, while the Dd2Dd2 growth rate remained unchanged relative to its rate in 
RPMI-VLA. Therefore the L272F mutation exacerbated the fitness cost already witnessed in 
parasites expressing the Dd2 allele (when compared with the wild-type allele). Dd2Dd2 L272F 
  
 120 
growth could not be returned to amino acid-rich media rates in media supplemented with +IC, 
+IKR, or +IDENQ, denoted by single letter amino acid codes. However, Dd2Dd2 L272F growth 
returned to RPMI-VLA levels in media supplemented with +IM or +IMC.  
 
These data provide compelling evidence that PfCRT is an important factor in the availability of 
amino acids, particularly methionine, for cellular processes and growth. However, this result 
does not prove that PfCRT is an amino acid or methionine transporter. Methionine is a low 
abundance amino acid in Hb (1.7%), and some strains have been found to require methionine in 
addition to isoleucine for efficient in vitro culture propagation (19). Therefore methionine 
auxotrophy is likely a consequence of the L272F mutation’s impact on PfCRT as opposed to the 
alternative inference that methionine is a primary physiological substrate. These data nonetheless 
highlight the close relationship between PfCRT and Hb catabolism.  
 
5.3.4 The L272F mutation produces a further accumulation of short peptides 
To investigate the link between the L272F mutation and Hb catabolism, we examined the 
accumulation of peptides in the L272F mutant. To determine peptide accumulation, we analyzed 
endogenous the metabolites of magnetically purified Dd2, Dd2Dd2, Dd2Dd2 L272F, and GC03 
parasites 38 hours post invasion, using high-resolution mass spectrometry (Figure 5.6), as 





Figure 5.6 PfCRT L272F mutants accumulate short peptides 
A. Total concentrations per parasite of short, Hb-derived peptides for Dd2 (light blue), Dd2Dd2 
(blue), Dd2Dd2 L272F (dark blue), and GC03 (light grey) as measured by LC-MS. Two independent 
experiments each with three experimental replicates. B. Metabolite category z-scores, relative to 
Dd2, of metabolites detected in LC-MS. Each z-score (bar) is the number of standard deviations 
of a metabolite category such that z = (x - μ)/σ, where x is the mean concentration of a 
metabolite (e.g. PEEK) in two independent experiments, μ is the mean of the metabolite category 
(e.g. Peptide), and σ is the standard deviation of the Dd2 metabolite category (e.g. Peptide). 
Metabolomic analyses performed by Ian Lewis (U. of Calgary). 
 
Consistent with previous work defining the peptide accumulation phenotype in CQR strains (94), 
we observed a 50 to 70 μM increase in Hb-derived total peptide concentration irrespective of the 
Hb subunit (α or β) in the CQR strains Dd2 and Dd2Dd2, relative to the CQS strain GC03. Dd2Dd2 
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L272F exhibited a similar total peptide concentration (Figure 5.6a) and mean z-scores for peptide 
species (Figure 5.6b) relative to its recombinant control Dd2Dd2. Both Dd2Dd2 and Dd2Dd2 L272F 
exhibited increased peptide concentrations relative to Dd2, which is likely attributable a 
reduction in expression caused by the absence of most introns in the pfcrt coding sequence, as 
previously described (57). 
 
Figure 5.7 PfCRT L272F mutants diverge in peptide accumulation profile 
Concentrations of short, Hb-derived peptides (denoted by single letter codes) for Dd2 (light 
blue), Dd2Dd2 (blue), Dd2Dd2 L272F (dark blue), and GC03 (light grey) as measured by LC-MS. 
Dd2Dd2 L272F preferentially accumulates a subset of peptides (e.g. PEE, PEEK, PVNF, and DLH) 
that are enriched in CQR strains. Source of peptide denoted with Hb subunit α or β. Peptidomics 
performed by Ian Lewis (U. of Calgary). 
 
While total peptide concentrations remain unchanged between Dd2Dd2 and Dd2Dd2 L272F, the 
profile of peptides differed (Figure 5.7, Figure 5.8). For instance, peptide concentrations of 
HVDD and PD were lower in the L272F mutant relative to the recombinant control. In contrast, 
two peptides—PEEK and PEE—were 3.6, 1.5, 1.6, and 1.4 fold preferentially more concentrated 






Metabolite z-scores, relative to Dd2, of 
metabolites detected in LC-MS. Each 
z-score (bar) is the number of standard 
deviations of a metabolite such that z = 
(x - μ)/σ, where x is the concentration 
of a metabolite (e.g. PEEK) in one 
experiment, μ is the mean of the 
metabolite, and σ is the standard 
deviation of the same metabolite in 
Dd2. Metabolomic analyses performed 
by Ian Lewis (U. of Calgary) 
Together, these data confirm that the PfCRT Dd2 isoform profoundly perturbs Hb catabolism, 
leading to the accumulation of globin peptides (94). These data also indicate that the effect of the 
L272F mutation modulates the peptide accumulation profile by increasing select species (PEEK 




5.3.5 The L272F mutation restricts free Ca2+ efflux upon ionophore stimulation 
Accumulation of short, Hb-derived peptides suggested the terminal peptidases—PfAPP, PfA-
M1, PfDPAP1, and falcilysin—are inhibited in CQR strains and the L272F mutant. To 
investigate the effects of PfCRT mutations on ionic balance and Hb catabolism, we examined 
free Ca2+ efflux from the DV upon ionophore stimulation. Falcilysin, PfAPP, PfA-M1, and 
PfDPAP1 are known to depend on catalytic ions: one Zn2+, two Mn2+, Cl-, and one Zn2+, 
respectively (32, 35, 37, 339). Therefore, we hypothesized that PfCRT might inhibit peptidase 
function by disrupting DV ionic balance. 
 
To determine the effect of PfCRT on ion maintenance, we examined the effect of the L272F 
mutant on free Ca2+ in the parasite. The DV is believed to be a secondary source of intracellular 
Ca2+, with the primary store located in the endoplasmic reticulum (343-345). Although Ca2+ is 
not a catalytic cation involved in resident DV peptidase activity, it is a well-studied, essential ion 
involved in cytoplasmic protease activity, host-cell invasion, and intra-erythrocytic development 
(343, 346-348). Furthermore, free Ca2+ release from the DV was reported in a recent study to be 
associated with the CQ susceptibility status (349). Therefore, we chose Ca2+ as a representative 
cation to study PfCRT and ionic balance in parasites. 
 
We hypothesized that if PfCRT could modulate the permeability of the DV membrane to cations, 
its haplotypes would affect the levels of free Ca2+ in the cytoplasm upon ionophore stimulation 
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(282, 347). Ca2+ release from the DV is triggered by the redistribution of the ionic balance and 
disruption of membrane potentials caused by ionophore treatment (282, 347).  
 
 
Figure 5.9 PfCRT L272F mutant digestive vacuoles are less permeable to Ca2+ upon 
ionophore treatment 
The efflux of free Ca2+ from the DV into the cytoplasm was measured in ionophore-treated 
parasites using the fluorescent dye Fluo-4 AM for 3D7 (light orange), GC03 (orange), Dd2GC03 
(dark orange), Dd2 (light blue), Dd2Dd2 (blue), Dd2Dd2 L272F (dark blue). Each strain was 
independently treated with the monensin, nigericin, or CQ.  (a) Mean free Ca2+ concentrations 
for ionophore treated parasites. All three CQS strains expressing wild-type pfcrt, namely 3D7, 
GC03 and the Dd2GC03, efflux significantly more free Ca2+ than the CQR line Dd2Dd2, whose 
Ca2+ efflux is very similar to non-recombinant Dd2.  The Dd2+L272F variant, which is nearly 
fully sensitive to CQ, shows the lowest rate of Ca2+ efflux. Data are presented as means ± SEM, 
calculated from nine independent experiments. ** p < 0.01, *** p < 0.001, **** p < 0.0001; 
two-tailed Mann-Whitney U test relative to Dd2Dd2.Assays performed by Maneesh Singh (U. of 
Sao Paolo). 
 
To stimulate a free Ca2+ response from the DV, we treated parasites with the Na+/H+ ionophore 
monensin or the K+/H+ ionophore nigericin. Monensin and nigericin are lysosomotropic 
carboxylic ionophores that reversibly form complexes with monovalent ions and act directly as 
Na+/H+ and K+/H+ exchangers to disrupt Na+ and K+ electrochemical gradients, respectively 
(350, 351). We also tested CQ, which has been shown previously to release Ca2+ from the DV 
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and also act as a Zn2+ ionophore in human lysosomes. It is unclear however how mechanistically 
CQ evokes an ion response (282, 349, 352). We monitored changes in free Ca2+ levels in the 
cytoplasm using the fluorescent Ca2+ indicator Fluo-4 AM combined with the organic anion 




Figure 5.10 PfCRT is not a factor in Ca2+ release from the endoplasmic reticulum 
Efflux of free Ca2+ into the cytoplasm treated with ionophores was measured using the 
fluorescent dye Fluo-4 AM for 3D7 (light orange), GC03 (orange), Dd2GC03 (dark orange), Dd2 
(light blue), Dd2Dd2 (blue), Dd2Dd2 L272F (dark blue). Each strain was independently treated with 
the ionophores (A) monensin and thapsigargin, (B) nigericin and thapsigargin, and (C) CQ and 
thapsigargin. Error bars indicate S.E.M. of nine independent experiments. *** p < 0.001, **** p 
< 0.0001; two-tailed Mann-Whitney U test relative to Dd2Dd2. Assays performed by Maneesh 
Singh (U. of Sao Paolo). 
 
Studies were conducted with six strains: Dd2, Dd2Dd2, Dd2Dd2 L272F, GC03, and two CQS strains: 
3D7 and Dd2GC03, a Dd2 parasite engineered to express GC03 pfcrt (71) (Figure 5.9). 3D7 served 
as an additional CQS control while Dd2GC03 served as an isogenic background control to 
distinguish between the effects of various PfCRT haplotypes expressed on a common genetic 
background (Dd2). The association of PfCRT haplotype with free Ca2+ release from the DV has 
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to the best of our knowledge been noted once before (349), but those experiments did not control 
for strain-dependent differences. 
 
In our assays, we first observed that upon stimulation with monensin, nigericin, or CQ, free Ca2+ 
release from the DV in Dd2Dd2 was reduced 1.4–fold for each ionophore compared to the CQS 
isogenic background control Dd2GC03 (Figure 5.9). Interestingly, the expression of the wild-type 
pfcrt allele in Dd2 resulted in elevated free Ca2+ concentrations that matched those observed 
with the other CQS parasites 3D7 and GC03. Relative to Dd2Dd2, the L272F mutant further 
reduced free Ca2+ release by 1.6, 1.2, and 1.3 fold, respectively. Indeed, this mutant showed the 
lowest free Ca2+ levels of all, despite the fact that this strain is close to fully CQS, showing that 
these two phenotypic consequences of this mutation are separate. PfCRT haplotype had little to 
no effect on Ca2+ release from endoplasmic reticulum Ca2+ stores using the SERCA-pump 
inhibitor thapsigargin in conjunction with the above ionophores (Figure 5.10). Our data therefore 




PfCRT is an essential factor for P. falciparum intra-erythrocytic development and a key protein 
for modulating resistance to the vast majority of antimalarials (316, 332). Therefore, exploring 
its biological function and the ramifications of its multiple isoforms is both of basic biological 
interest and also relevant in terms of understanding its ability to profoundly modulate parasite 
susceptibility to multiple first-line antimalarial drugs (353). Here, we have expanded our 
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understanding of the role of PfCRT by exploiting a L272F mutation, which we have previously 
shown to enlarge the DV and inhibit 4-aminoquinoline drug transport (56). Our analysis reveals 
that this mutation, introduced into a Dd2 PfCRT isoform that normally imparts CQR, is capable 
of nearly fully sensitizing parasites to both CQ, its metabolite md-CQ and the related drug ADQ, 
while retaining the resistance reversal properties of VP. We also document the profound growth 
defect caused by this mutation, which resulted in a 21% fitness cost per generation as well as a 
one-hour extension in the intra-erythrocytic developmental cycle. Growth in amino acid depleted 
medium was virtually eliminated unless exogenous methionine was reintroduced, consistent with 
this mutant being auxotrophic for methionine, a low abundance amino acid. We also document a 
PfCRT L272F-dependent pattern of accumulation of Hb-derived small peptides, and report a role 
of PfCRT haplotype on ionic balance in the DV. 
 
We observed a pattern of peptide accumulation in Dd2, Dd2Dd2, and Dd2Dd2 L272F that supports a 
model where PfCRT mutations lead to the attenuation of the terminal peptidase-mediated steps 
in Hb catabolism. Three metallopeptidases—falcilysin, PfAPP, PfA-M1—and the Cl- ion-
dependent PfDPAP1 are involved in this process (33, 34, 36, 37). Inhibition of one peptidase, 
PfA-M1, yields similar phenotypes as Dd2Dd2 L272F: enlarged, translucent DVs and an 
accumulation of Hb-derived peptides slightly longer than in Dd2Dd2 L272F (e.g. 
LTPEEKSAVTALW, compared to PEEK) (23). In our Dd2Dd2 L272F mutant, we observed a 
modulation of the profile of Hb-derived peptide accumulation relative to its recombinant control 
Dd2Dd2 (Figure 5.7, Figure 5.8). For instance, peptides PEE and PEEK, but not PE, are 
preferentially enriched in Dd2Dd2 L272F parasites. This suggested that a specific peptidase, which 
acts on PEE and PEEK, is inhibited in the L272F mutant. PfDPAP1 is a plausible candidate for 
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this activity, given that P2 proline is a preferred substrate (using the Schechter and Berger 
nomenclature where a substrate P-Xn is cleaved to form the products P-X + Xn-1) (33, 354). 
While PfDPAP1 readily accepts a P2 proline, a P1 glutamate exhibits yields low enzyme activity 
(33). Therefore, attenuated PfDPAP1 may cleave P-X substrates with higher specificity, but be 
inhibited from acting on substrates with lower specificity such as PEE, PEEK, and to a lesser 
extent PVNF (Figure 5.7) (33). The known P1 and P1’ specificities of PfAPP and PfA-M1 are 
not consistent with these exopeptidases having a role in the hydrolysis of PEEK and PEE (37, 
355). 
 
Attenuation of PfDPAP1 suggests that PfCRT plays a role in regulating ion flux across the DV 
membrane. Previously, Cl- has been associated with PfCRT-mediated maintenance of DV pH 
(93). DV volume can be rapidly decreased by the removal of Cl- from the DV, a process likely 
mediated by a countercation rather than Cl- itself. Interestingly, reducing DV volume by 
removing Cl- can be blocked with the addition of CQ (335). 
 
This relationship between peptidases and PfCRT is particularly intriguing given our observation 
that release of Ca2+ (a possible Cl- counteraction in the DV) upon ionophore stimulation is 
inhibited in Dd2, Dd2Dd2, and Dd2Dd2 L272F and not wildtype PfCRT strains (Figure 5.9). This 
trend of Ca2+ transport inhibition, which is consistent with previous work (349), also correlates 
with the accumulation of short, Hb-derived peptides (Figure 5.6) and the reduction of overall 
parasite fitness (Figure 5.5). Furthermore, studies in mammalian cells have shown that Ca2+ 
transport by voltage-dependent L-type Ca2+ channels (which are also inhibited by VP) and non-




Together, this suggests that PfCRT may be a H+-coupled poly-specific cationic nutrient 
transporter, as previously demonstrated in proteoliposomes (81). In this model, the PfCRT 
L272F mutant is inhibited in transporting Ca2+, short Hb-derived peptides, aminoquinoline drugs, 
and VP (Figure 5.3). We speculate that this broad substrate specificity is consistent with the 
polymorphic nature of PfCRT (72) and it’s the ability to transport multiple drugs (90). 
 
While our data fit this model, we cannot definitively conclude that PfCRT transports a variety of 
cationic substrates and acknowledge the possibility that PfCRT may transport another unknown 
substrate. Given the central role of PfCRT both in parasite development and in resistance to 
heme-binding antimalarials, there is a pressing need to elucidate its biological functions in the 
context of parasite physiology and leverage these insights into identifying novel approaches to 




CHAPTER 6. DICUSSION AND FUTURE DIRECTIONS 
6.1. OVERVIEW 
Recent estimates indicate about 3.2 billion people in 97 countries are at risk of malaria; 438,000 
of whom died in 2015 (359). However, malaria mortality has declined 47% from 2001 to 2013 as 
a result of a multifaceted approach that involves disease prevention, control, and treatment 
through three main pillars: (A) vector (mosquito) control, (B) chemoprevention, and (C) rapid 
diagnostic testing and antimalarial drug treatment (359). Antimalarial compounds underpin two 
of these three pillars, therefore highlighting the important role of chemotherapies in reducing the 
global malaria disease burden. 
 
Currently, artemisinin-based combination therapies (ACTs) serve as the first-line antimalarial 
chemotherapy. While ACTs have contributed significantly to improving disease outcomes, 
artemisinin resistance has threatened the efficacy of these therapies, prompting efforts to better 
monitor the spread of resistance, understand the genetic factors underlying resistance, and 
develop novel antimalarial compounds to circumvent resistance altogether (46, 58, 316, 317, 
360). Therefore, elucidating the multitude of genetic factors that contribute to drug resistance is 
important for malaria eradication. 
 
One major hypothesized contributor of the emergence of drug resistance has been the 
evolvability, or mutability, of malaria parasites. Resistance to multiple antimalarial compounds 
has intriguingly arisen in Southeast Asia, namely Cambodia (96-99). In contrast to the original 
hypothesis that Southeast Asian parasites are hypermutable (101), we have determined that the 
emergence of resistance to former first-line antimalarials, such as CQ, is not due to the a 
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markedly increased rate of evolution of the parasite. Some contemporary Cambodian isolates do 
however exhibit a mild mutator phenotype, akin to that seen in drug resistant bacteria (287, 289-
291), suggesting it is possible that changes in mutability in Southeast Asian parasites is a 
contributing force in driving the emergence of drug resistance in the Great Mekong Subregion. 
Other factors include a lower host immunity in Southeast Asia, a more frequent occurrence of 
monoclonal infections that reduces negative impacts of fitness costs that can arise as a result of 
multidrug resistance, and an overall greater exposure of parasites to drug treatment as a selective 
force. 
 
The ability to dissect the underpinnings of not only the rate at which parasites evolve drug 
resistance, but also what specific genetic changes confer drug resistance, requires rapid and 
efficient gene engineering technologies. Here, we demonstrated the first use of ZFNs to generate 
a single DSB in pfcrt to increase the rate of recombination and permit allelic replacement (71). 
This technology enables a researcher to introduce nearly any desired pfcrt haplotype into any 
parasite strain in order to study the relationship between haplotype and resistance to antimalarial 
compounds and parasite biology.  
 
While this type of genome engineering strategy can be applied to any parasite gene, investigating 
specifically how PfCRT functions in the parasite provides insight into the basic biology of the 
parasite with important ramifications on how it modulates resistance to numerous antimalarial 
compounds. Using the ZFN-mediated allelic replacement of pfcrt strategy, we generated a 
unique PfCRT mutant (Dd2Dd2 L272F) (56), which enabled us to link PfCRT with the terminal 




6.2. CHAPTER 3 Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium 
falciparum Malaria Parasites 
 
The Accelerated Resistance to Multiple Drugs (ARMD) phenotype was the first hypothesis to 
provide some explanation of the phenomena of the repeated emergence of antimalarial drug 
resistance from Southeast Asia (101). According to the ARMD phenotype, Southeast Asian 
parasites (e.g. W2) can acquire drug resistance to compounds such as CQ, 
sulfadoxine/pyrimethamine, atovaquone, and now artemisinin because of their ability to evolve 
at a much higher rate, up to 1000-fold. 
 
However, it has been recently shown in in vitro culture and in silico studies that non-Southeast 
Asian laboratory strains 3D7 and HB3 are no less mutable than Southeast Asian W2 and Dd2 
(102, 103, 285). Our data herein support the growing evidence that the ARMD phenotype, as 
originally defined, is not a true characteristic of Southeast Asian parasites. We developed a 
fluctuation assay for P. falciparum using the spiroindolone compound KAE609 to measure 
mutation rates between a diverse set of strains (Figure 3.1). We observed no difference in 
relative mutation rates amongst 3D7, W2, and Dd2, therefore providing further evidence that the 
ARMD phenotype cannot be recapitulated. 
 
Intriguingly, we identified a novel mild mutator phenotype preferentially associated with 
artemisinin-resistant recently derived Cambodian isolates. Strains PH0212-C and PH0482-C 
exhibited a respective 3.4- and 2.3-fold increase in mutability relative to 3D7. This was 
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consistent with the increase in the benchmark mild mutator Dd2 exo1Δ strain, which was 2.5-
fold more mutable than its isogenic parent Dd2. We hypothesized that mutations found in the 
MMR pathway recently found to be associated with the artemisinin resistance (45) were the 
causative factors in producing the mild mutator phenotype. 
 
By modeling the mlh1-P203S mutation into an episomal copy of the essential MMR factor Mlh1 
in yeast, we were able to observe a 1.6-fold increase in mutation rate relative to wild-type in a 
lys2ΔBgl fluctuation assay (Figure 3.3), indicating the mild mutator phenotype in P. falciparum 
associates with artemisinin resistance. These data are consistent with recent studies (102, 103, 
285), but are in stark contrast to the original report describing the ARMD phenotype (101). For 
two major reasons, we hypothesize that the original study mischaracterized the mutability of 
Southeast Asian parasites. 
 
First, we believe the original study lacked experimental stringency in determining variations in 
mutability, which our KAE609 fluctuation assays overcome (see 3.3.3). In the original study, 
parasites propagated to 109 parasites, split into three experimental replicates in flasks at various 
inocula (108, 107, 106, and 105), and each was subjected to 100 nM 5-FOA. It is unclear from 
this study whether each strain was cloned prior to starting the experiment. Non-clonal starting 
cultures are inherently inaccurate as a given strain may have been cultured in vitro for longer and 
may therefore have greater genomic heterogeneity. Resistance was observed in only W2 cultures 
(108, 107, and 106), but never in non-Southeast Asian parasites. This measure of mutability, 
termed the frequency of resistance or mutant frequency, is often inaccurate and subject to 
stochastic “jackpot” events which distort the calculation of true mutation rates (295). It is 
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plausible that W2 resistance to 5-FOA was a result of a jackpot event thereby mischaracterizing 
Southeast Asian parasites as ARMD. This would be consistent with our inability to yield 5-FOA 
resistant parasites in fluctuation assays in W2 and V1/S (3.3.2). Our fluctuation assay controls 
for the possibility of jackpot events by utilizing independent repeats of parasite clones. 
 
Second, the ARMD phenotype focuses on large variations in mutation rates between multidrug-
resistant and sensitive parasites. Studies in natural bacterial populations present an alternative 
perspective. Hypermutators can and do acquire resistance to drugs quickly in vitro, but when 
propagated longer are outcompeted by mild mutators due to an accumulation of detrimental 
mutations (290, 291). Mild mutators more readily provide an appropriate balance between the 
ability to adapt to drug pressure via the acquisition of resistance-conferring mutations and the 
need to maintain overall fitness (287, 289, 291). This may be important for the acquisition of 
resistance to first-line antimalarial therapies such as CQ or ACTs that require the gradual 
acquisition of multiple mutations to build full resistance (75, 316).  
 
To confirm the genetic link between MMR and the mild mutator phenotype, we suggest three 
possible experimental routes: 
a. Introduce or remove DNA repair gene mutations associated with artemisinin-resistance 
(Table 3.1) into wild-type strains and calculate KAE609 mutation rates. We have previously 
attempted to introduce the mlh1-P203S and pms1-S506I mutations into various strains (3D7, 
Dd2, V1/S, PH0167-C, and PH0212-C) using either ZFN (targeting pfmlh1) or CRISPR/Cas9 
(both T7 and U6 systems targeting pfmlh1 or pfpms1; M. Lee, unpublished and (125, 126)) 
gene editing systems, but were unsuccessful (See APPENDIX 5). Engineering these 
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mutations would provide clarity on the degree to which each mutation contributes to the mild 
mutator phenotype and the molecular pathways involved. Using these data, we would then be 
able to better determine how these mutations might contribute to the spread of artemisinin 
resistance. For instance, if the mlh1-P203S mutation is the predominant driver of the mild 
mutator phenotype, we can use the spatiotemporal genomic data (292) to see that pfmlh1-
P203S clusters with specific k13 mutations (e.g. k13-C580Y) in Southeast Asia (Figure 6.1). 
Therefore if it drives the mild mutator phenotype in vivo, it might contribute to the 
emergence of artemisinin resistance in Southeast Asia. 
b. Obtain KAE609 mutation rates of additional isolates from different countries and genetic 
backgrounds. To determine if the mild mutator phenotype is a common phenomenon in not 
just Cambodian or k13-C580Y parasites, it will be necessary to expand the strains included in 
this study. For example, the inclusion of Thai isolates harboring the k13-R539T and mlh1-
P203S mutations would bring clarity to the contribution of Mlh1 mutations in the mild 
mutator phenotype. Furthermore, including African isolates would address the hypothesis 
that the mild mutator phenotype is found solely in contemporaneous Southeast Asian 
isolates. 
c. Select for artemisinin resistance in engineered mild mutators. An engineered strain that 
encodes mlh1-P203S and pms1-S506I and replicates the KAE609 mutation rate of PH0212-C 
(which also encodes mlh1-P203S and pms1-S506I and exhibits a 3.4-fold higher mutation 
rate than 3D7, Figure 3.1) would likely generate a 3.4-fold increase in the probability of 
acquiring a single SNP in k13. Stepwise selection for artemisinin resistance in the African 
F32 strain required a duration of 30 drug-pressure cycles, or roughly 1 year, to yield an 
artemisinin-resistant k13-M476I mutant (F32-ART) (361). This engineered double mutant 
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may then be able to acquire an artemisinin resistance-conferring SNP in k13 in roughly 100 
days. This assay can be done in parallel with the strain Dd2 exo1Δ, which can serve as a mild 
mutator experimental control. This experiment would provide firm proof that the mild 
mutator can significantly contribute to the appearance of artemisinin resistance. 
d. It will also be beneficial to generate a mlh1Δ P. falciparum strain. As stated above, Mlh1 is 
an essential component of MMR and the key factor in the MutLα (Mlh1-Pms1) and MutLγ 
(Mlh1-Mlh3) complexes. In yeast, mlh1Δ strains have been shown to be hypermutable with a 
1,253-fold increase compared wild-type (9.90 × 10−9 mutations/generation) in a hom3-10 
fluctuation assay and a 29-fold increase compared to wild-type (3.01 × 10−7 
mutations/generation) in a CanR fluctuation assay (315). Yeast pms1Δ strains exhibit similar 
changes in mutation rate in these assays. Either a mlh1Δ or pms1Δ strain would serve as a 
hypermutable control in KAE609 fluctuation assays. Additionally, these strains could 
improve the efficiency of antimalarial drug selection experiments where parasites are 
pressured with novel compounds to select for resistant progeny. These experiments often 
require large numbers of parasites (e.g. 109) to yield drug resistant mutants. A hypermutator 




Figure 6.1 Geographic distribution of pfmlh1-P203S and k13-C580Y 
A. The allele frequency of mlh1-P203S and k13-C580Y in whole-genome sequences of isolates 
in the Pf3k – release 3 database (292). Number of isolates that encode mlh1-P203S: Cambodia: 
114, Myanmar: 5, Thailand: 5, Vietnam: 1. No isolate from the remaining countries exhibit 
mlh1-P203S. Number of isolates that encode k13-C580Y: Cambodia: 186, Thailand: 21, 
Vietnam: 5. No isolate from the remaining countries exhibit k13-C580Y. B. Total number of 
isolates sequenced at mlh1 or k13 in each country. mlh1: DR Congo: 113, The Gambia: 65, 
Ghana: 517, Malawi: 369, Mali: 96, Nigeria: 5, Senegal: 137, Bangladesh: 50, Cambodia: 563, 
Myanmar: 60, Laos: 84, Thailand: 140, Vietnam: 94. k13: DR Congo: 112, The Gambia: 64, 
Ghana: 513, Malawi: 367, Mali: 96, Nigeria: 5, Senegal: 136, Bangladesh: 50, Cambodia: 512, 




Additionally, the effects of MMR mutations, given their potential role in crossing over (161, 
362), can be explored in the meiotic phase of the Plasmodium lifecycle. Meiosis in P. falciparum 
is an understudied area of research due to justified concerns over safety. Though, greater insight 
into the mechanistic properties of meiosis specific to P. falciparum could benefit research into 
how drug resistance loci are maintained within an interbreeding population, how populations are 
structured in various global regions, and how sexual reproduction contributes to malaria 
evolution. Currently, experiments are often performed in the rodent malaria P. berghei or limited 
to studying the progeny of three P. falciparum genetic crosses: 3D7 × HB3 (177), HB3 × Dd2 
(173, 174, 178-180), and 7G8 × GB4 (175, 181, 182). We have designed a system to monitor 
meiotic crossing over in P. falciparum using fluorescent chromosomal tags (detailed in 
APPENDIX 6). This strategy, combined with a rapid and efficient approach to gene engineering, 
would provide a scaffold for better understanding sexual reproduction in P. falciparum. 
Experiments investigating meiosis in P. falciparum would be able to determine which molecular 
factors, such as Mlh1, are important in controlling crossover resolution, chromosome 
segregation, and linkage disequilibrium. 
 
Our data also yielded useful insights into KAE609. As stated above, we observed 13 novel 
pfatp4 mutations in KAE609-resistant clones (Figure 3.2). Prior studies using KAE609 or other 
PfATP4 inhibitors have to date reported 24 mutations in this gene (272, 301, 302, 308, 309). The 
polymorphic nature of pfatp4 in response to low drug concentrations exemplifies its ideal use for 
fluctuation analyses in P. falciparum. In vitro KAE609 susceptibility experiments, however, 
cannot recapitulate the pharmacokinetic and pharmacodynamic properties of this compound in 
vivo. Indeed, efficacy studies in humans will be required to assess the parasitological and clinical 
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risk associated with the polymorphic nature of pfatp4. Pharmacokinetic studies in humans show 
that a 300 mg dose of KAE609 can produce a maximum plasma concentration of around 2 μg/ml 
in 3 to 8 hours (363). This equates to roughly 5 μM KAE609, which is 2,000-fold higher than the 
2.5 nM concentration used in our drug pressure experiments. Also, the largest changes in IC50 
values attributed to single or double mutations in response to 2.5 nM KAE609 so far have been 
only 20 to 30–fold ((272) and Table 3.6). Therefore, to avoid the rapid selection of KAE609-
resistant parasites in patients, it will be important to determine whether resistance can be easily 
obtained even at very high doses. 
 
Together, our results suggest that the MMR machinery is involved in shaping parasite evolution. 
Further research will be necessary to determine to what extent a mild mutator phenotype in P. 
falciparum facilitates the acquisition of multidrug resistance in parasite populations and to define 
how parasite sexual reproduction contributes to the maintenance of resistance-associated loci.   
 
6.3. CHAPTER 4 Site-specific genome editing in Plasmodium falciparum using engineered 
zinc-finger nucleases. 
 
The ability to rapidly and efficiently genetically engineer pfcrt is an important step in elucidating 
how the gene contributes to basic cellular processes and modulates susceptibility to numerous 
antimalarial compounds. We have designed and implemented a ZFN-mediated strategy to 
quickly and consistently generate unique pfcrt-modified strains (Figure 4.5) that has already been 





One of the key conclusions to be drawn from this system is the importance of the rate-limiting 
step of generating a DSB in the parasite genome, a well understand factor in other model 
organisms (128, 364). The genomic break is the predominant reason engineered nucleases are 
less time and resource intensive compared to established technologies such as SSC. In P. 
falciparum, evidence indicates that a genomic break is currently the only way to induce HR to 
engineer the endogenous genes. DSBs generated on episomally maintained plasmids using the 
homing endonuclease I-SceI (S. Adjalley, doctoral thesis) and pfcrt-targeting ZFNs (detailed in 
APPENDIX 8) to create linearized DNA do not catalyze genome editing. To date, genome 
modification using linearized DNA in P. falciparum has only been successful in conjunction 
with a Cas9-mediated genomic break (126). 
 
The relative efficiency in introducing novel pfcrt haplotypes into the genome additionally 
benefits from the absence of robust NHEJ or A-EJ pathways (12, 365). For instance, gene 
engineering in mammalian cells often requires thorough screening for NHEJ or A-EJ outcomes 
(252). This absence also benefits the parasite in the assurance that genomic changes due to off-
target effects are likely to be rare, unlike in other organisms (366). For instance, whole-genome 
sequencing of ZFN-edited parasites has shown no evidence of off-target modifications (71). 
 
Despite its efficiency, ZFN-mediated allelic replacement of pfcrt does have some detriments. For 
one, it generates a novel recombinant locus that encodes all 13 exons, but only 1 intron (intron 
1). Previously, recombinant pfcrt strains generated using single-site crossover in which all 
introns except intron 1 were removed, showed that loss of intronic sequence inhibits full pfcrt 
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expression (57), which can ultimately modulate susceptibility to CQ (95). Removal of all pfcrt 
introns significantly reduces pfcrt expression further ((124) and our published observations). 
 
Furthermore, ZFN design is prohibitively expensive for widespread use. Therefore, investment in 
designing a ZFN pair for a single gene requires careful cost-benefit analysis. Currently, the 
CRISPR/Cas9-mediated gene engineering systems largely circumvent this issue. Therefore, gene 
modification in P. falciparum is shifting significantly towards the use of CRISPR/Cas9. The 
CRISPR/Cas9 systems utilizing either the T7 or the U6 RNA polymerases provide a simple, 
rapid, and cost-effective platform for editing any parasite locus (367). Furthermore, nuclease-
deactivated Cas9 can be used to activate or repress genes (368). As such, interest in 
CRISPR/Cas9 is high in the malaria research community. Despite this, successful gene editing 
has only been published once for P. berghei (127) and twice for P. falciparum (125, 126) in the 
past two years. Anecdotal evidence suggests that CRISPR/Cas9-mediated gene engineering is a 
largely inefficient process in P. falciparum. In contrast, ZFN-mediated gene engineering has had 
a much higher success rate. 
 
The difference in success rate between ZFNs and CRISPR/Cas9 is still unclear. It is possible that 
the Cas9 enzyme functions poorly when expressed in the parasite relative to other engineered 
nucleases. Other nucleases and recombinases have exhibited mixed success when expressed in P. 
falciparum. For instance, mycobacteriophage Che9c and Halo recombineering systems (369) 
have not worked in P. falciparum (S. Adjalley, doctoral thesis), while the mycobacteriophage 
Bxb1 integrase (330, 370) and the S. cerevisiae homing endonuclease I-SceI have ((365), S. 
Adjalley, doctoral thesis, and A. Lee, unpublished observations). Cas9 itself has also been shown 
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to vary in efficiency if derived from S. pyogenes or S. aureus (371) and can be engineered for 
improved specificity (262, 372). Therefore, currently the relative efficiency of ZFNs ((Table 4.2) 
and (71)) compared to CRISPR/Cas9 should continue to be leveraged for genetic analyses. 
However, going forward, the underlying mechanistic differences between ZFNs and 
CRISPR/Cas9 should be elucidated to overcome this efficiency bias. The implementation of a 
truly efficient CRISPR/Cas9 system in P. falciparum would greatly benefit the malaria research 
community. 
 
6.4. CHAPTER 5 Evidence for Regulation of Hemoglobin Metabolism and Intracellular 
Ionic Flux by the Plasmodium falciparum Chloroquine Resistance Transporter 
Our data showed that the pfcrt-L272F mutation generates a unique mutant and provides insight 
into the role of PfCRT in parasite biology and drug resistance. First, we genetically validated that 
the L272F mutation by introducing it into a recombinant Dd2 parasite background (Dd2Dd2 
L272F). We observed that the mutation alone causes a 2-fold increase in DV surface area (which 
extrapolates to a 3-fold increase in DV volume) (56). Importantly, we determined that the L272F 
mutation blocks transport of 4-aminoquinoline drugs and VP. Inhibition of drug transport 
indicated the L272F mutation blocked transport of the native substrate(s) of PfCRT. We 
observed in this mutant an accumulation of short, Hb-derived peptides and retention of Ca2+ ions 
upon ionophore stimulation. This indicated that PfCRT fits the H+-coupled poly-specific nutrient 
transporter model where PfCRT transports a variety of cationic substrates from H+ ions, to metal 




Despite the growing portfolio of non-DV targeting antimalarial compounds, such as artemisinin 
and KAE609, elucidating the function of PfCRT is an important goal for malaria research. The 
L272F mutant is well suited for this challenge given its significant inhibition of native PfCRT 
function in the absence of exogenous small molecules (e.g. VP) while still maintaining viable 
parasites. 
 
The importance of comprehensively elucidating PfCRT function, evolution, and susceptibility to 
antimalarials is highlighted by four major reasons: 
a. Widespread use of CQ and related antimalarials has dramatically altered the global pfcrt 
haplotype landscape, such that there are currently 53 known isoforms (72). Therefore, any 
future antimalarial therapies will be applied to parasites encoding varying pfcrt loci, which 
may affect drug efficacy. The relevance of pfcrt is particularly notable in Southeast Asia, the 
epicenter of CQ resistance, where the recent emergence of resistance to ACTs has been 
shown to be associated with a pfcrt-I356T mutation (316).  
b. CQ and related antimalarials are still used today. CQ is still one of the predominant 
treatments for P. vivax infections (359), but the intriguingly, the relationship between CQ 
susceptibility and P. vivax crt is still unclear (373). In P. falciparum, pfcrt-associated drugs 
continue to be used in ACTs: artesunate-amodiaquine, artesunate-mefloquine, and 
dihydroartemisinin-piperaquine (374).  
c. Cessation of widespread CQ usage has led to the re-emergence of CQS, wild-type parasites 
(375), likely due the fitness cost associated with CQ resistance (54, 75). Additionally, anti-
correlated antimalarials acting on the pfcrt locus can be used to pressure parasites into an 
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evolutionary loop (See 4.3.5). Therefore, the usefulness of pfcrt-associated compounds could 
be extended if carefully administered and monitored.  
d. As we have shown, pfcrt mutations have significant effects that extend beyond just the 
transport of CQ away from its site of action and into DV homeostasis, morphology, and 
function. For instance, PfCRT haplotype is associated with altering an autophagy-like 
process in the presence of cytocidal concentrations of CQ (65). Attempts to disrupt or 
knockout pfcrt have been unsuccessful, indicating it is an essential gene (95). Therefore, 
dissecting PfCRT function will likely provide a deeper insight the basic biology underlying 
additional parasite functions and molecular pathways. 
 
Currently, most investigations into PfCRT function typically involve the expressing recombinant 
PfCRT in proteoliposomes, Xenopus oocytes, S. cerevisiae plasma membranes, or purified 
parasite DVs (56, 72, 81, 335, 376). Studies in whole parasite cells benefit from the endogenous 
pH and electrochemical gradients across the DV, which are closely tied to PfCRT CQ transport 
function (72). However, these studies contend with the influence of additional factors, such as 
PfMDR1 (343). 
 
Our data, obtained from whole parasite cells, suggest PfCRT may be involved in the transport of 
a diverse profile of cationic substrates. However, assays performed in whole cells are often 
limited in that directly attributing a substrate to transporter is difficult. Elucidating the native 
function and substrates of PfCRT would therefore benefit from a number of experimental paths. 
First, the crystal structure of PfCRT would greatly support the understanding of where drugs and 
candidate substrates can bind and how PfCRT polymorphisms alter their affinity. Structural data 
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would not only clarify PfCRT’s role in the modulation of susceptibility to established 
antimalarials, but could also be used to screen novel compounds for potential cross-resistance or 
synergy. 
 
Second, ZFN-mediated allelic replacement of pfcrt can and have generated a large number of 
mutant PfCRT strains and corresponding isogenic background controls, thereby isolating 
experimental outcomes to PfCRT mutations by reducing background effects (e.g. PfMDR1). To 
date, these strains have been utilized to understand how pfcrt haplotype affects drug 
susceptibility, overall fitness, and evolution (75, 329). To test the hypothesis that PfCRT is a 
poly-specific nutrient transporter (81), experiments in ZFN-edited strains could examine if 
radiolabeled Hb-derived peptides are differentially exported from the DV (377), if DV metal ion 
distribution is altered in mutant strains (e.g. Dd2Dd2 L272F) through X-ray microanalysis (16), or 
if hemozoin formation is disrupted due to an altered DV osmolyte balance (31). 
 
PfCRT is not only an essential parasite protein, but it is also one that has been one of the central 
factors in much of our understanding of malaria as a disease and as an organism. CQ and PfCRT 
have played important roles in efforts to treat malaria in the latter half of the 20th century. 
Therefore, elucidating all aspects of PfCRT function will be instrumental in the future of 
antimalarial drug development and will likely be a key part of many of the answers to the 
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Abstract
Malaria control efforts have been continuously stymied by drug-resistant strains of Plasmo-
dium falciparum, which typically originate in Southeast Asia prior to spreading into high-
transmission settings in Africa. One earlier proposed explanation for Southeast Asia being
a hotbed of resistance has been the hypermutability or “Accelerated Resistance to Multiple
Drugs” (ARMD) phenotype, whereby multidrug-resistant Southeast Asian parasites were
reported to exhibit 1,000-fold higher rates of resistance to unrelated antimalarial agents
when compared to drug-sensitive parasites. However, three recent studies do not recapitu-
late this hypermutability phenotype. Intriguingly, genome sequencing of recently derived
multidrug-resistant Cambodian isolates has identified a high proportion of DNA repair gene
mutations in multidrug-resistant parasites, suggesting their potential role in shaping local
parasite evolution. By adapting fluctuation assays for use in P. falciparum, we have exam-
ined the in vitromutation rates of five recent Cambodian isolates and three reference labo-
ratory strains. For these studies we also generated a knockout parasite line lacking the
DNA repair factor Exonuclease I. In these assays, parasites were typed for their ability to
acquire resistance to KAE609, currently in advanced clinical trials, yielding 13 novel muta-
tions in the Na+/H+-ATPase PfATP4, the primary resistance determinant. We observed no
evidence of hypermutability. Instead, we found evidence of a mild mutator (up to a 3.4-fold
increase in mutation rate) phenotype in two artemisinin-resistant Cambodian isolates,
which carry DNA repair gene mutations. We observed that one such mutation in the Mis-
match Repair protein Mlh1 contributes to the mild mutator phenotype when modeled in
yeast (scmlh1-P157S). Compared to basal rates of mutation, a mild mutator phenotype
may provide a greater overall benefit for parasites in Southeast Asia in terms of generating
drug resistance without incurring detrimental fitness costs.
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Introduction
Malaria infections caused by the eukaryotic pathogen Plasmodium falciparum place an
immense burden on many under-resourced nations around the world, particularly in sub-
Saharan Africa. Over the past 15 years, considerable progress towards reducing the global bur-
den of malaria has been achieved through the widespread adoption of highly effective artemisi-
nin-based combination therapies (ACTs) and mosquito control [1]. These gains, however, are
threatened by the emergence of ACT resistance in Western Cambodia [2], which has now
spread across Southeast Asia [3].
The emergence of artemisinin resistance in Southeast Asia recalls that of resistance to earlier
first-line antimalarials, notably chloroquine (CQ) and sulfadoxine-pyrimethamine [4–7]. CQ
resistance spread from Southeast Asia to the far higher endemicity regions of Africa in the
1980s, where CQ resistance still persists [5]. It was earlier hypothesized that CQ-resistant
Southeast Asian strains exhibited a hypermutability phenotype compared to non-Southeast
Asian counterparts [8, 9], enabling the former to acquire single nucleotide polymorphisms
(SNPs) and new drug resistance traits at an accelerated rate.
Evidence supporting this hypermutability phenotype, termed “Accelerated Resistance to
Multiple Drugs” (ARMD), came from resistance selection studies with the antimalarial com-
pounds 5-fluoroorotic acid (5-FOA) and atovaquone. Those data reported that the Southeast
Asian multidrug-resistant W2 strain was much more mutable (by 10 to 1,000-fold) as com-
pared to non-Southeast Asian strains [8]. However, detailed analyses of the mutation rates of
the W2 strain or its clone Dd2, propagated in long-term in vitro culture, in comparison with
reference strains, have since shown no evidence in favor of an ARMD phenotype [10, 11]. Fur-
thermore, in silico analysis of contemporary P. falciparum genomes fromMali and Southeast
Asia also found no evidence of an ARMD phenotype [12].
These studies provide compelling evidence that the ARMD phenotype is not characteristic
of Southeast Asian multidrug-resistant parasites. Nevertheless, recent whole-genome sequenc-
ing of Asian and African patient-derived isolates (obtained between 2007 and 2011) has
revealed mutations in a number of DNA repair genes that are overrepresented in parasites
from Cambodia, where artemisinin resistance first emerged [9]. These mutations occurred pri-
marily in the Mismatch Repair (MMR) factors Mlh1, Pms1, and Exo1. In bacteria found in nat-
ural environments, such as the human gastrointestinal system, mild mutator strains encoding
MMRmutations have been shown to account for a larger percentage of total cells (25%) com-
pared to hypermutators (1%), and the former associate with a higher degree of antibiotic resis-
tance [13–15]. Furthermore, mild mutators can acquire drug resistance that requires multiple
SNPs more efficiently than hypermutators [16]. Long-term in vitro propagation has shown
that bacterial hypermutators frequently display fitness costs associated with the accumulation
of detrimental mutations, whereas mild mutators provide sufficient genetic diversity with min-
imal fitness costs [17, 18].
Based on these observations, we hypothesized that Cambodian isolates encoding mutations
in DNA repair genes could drive a mild mutator phenotype. To investigate this possibility, we
have adapted a fluctuation assay for P. falciparum using the spiroindolone compound KAE609
[3, 19], which scores for resistance-conferring SNPs in pfatp4 and enables the comparison of
mutation rates for a diverse collection of parasite strains. Using this method, we observed two
artemisinin-resistant Cambodian isolates that exhibit a mild mutator phenotype and 13 novel,
resistance-conferring mutations in pfatp4. By modeling the MMR gene mutation (pfmlh1-
P203S) in yeast, we observed that this alone can drive a mild mutator phenotype.
Evidence of a Mild Mutator Phenotype in Cambodian Malaria Parasites




Laboratory strains (3D7, W2, Dd2, and V1/S) were obtained from the Malaria Research and
Reference Reagent Resource Center (MR4). All Cambodian clones (PH0167-C, PH0164-C,
PH0306-C, PH0482-C, and PH0212-C) were isolated by Dr. Rick Fairhurst (NIAID/NIH) in
Pursat, western Cambodia in 2010 [20, 21]. The Exonuclease I-deficient Dd2 exo1Δ line was
generated from Dd2, as described below. A description of parasite origins is provided in S1
Table.
Parasite culturing and DNA analysis
Asexual blood stage parasites were maintained in human red blood cells in RPMI-1640 malaria
culture media containing 0.5% (w/v) Albumax II (Invitrogen) under 5% O2, 5% CO2, 90% N2
as described [22].
Parasite trophozoite-infected erythrocytes were harvested and saponin-lysed. Parasite geno-
mic DNA (gDNA) was extracted and purified with QIAGEN DNeasy Blood Kits. KAE609-
resistant gDNA was extracted, and pfatp4 (PF3D7_1211900) was amplified by PCR using
primers 5’-GTAGAAGAATCACCTAAATCTATAGG-3’ and 5’-CAAGCAAAATTTTTACCA
CATG-3’. PCR products were Sanger sequenced.
Construction of the P. falciparum exo1Δmutant
To generate a P. falciparum exo1Δ knockout strain, we generated the pcamBSD-exo1 plasmid
that was used to genetically disrupt the pfexo1 (PF3D7_0725000) open reading frame. First, a
1187 bp fragment of pfexo1 encoding NotI and PstI restriction sites was PCR amplified from
Dd2 gDNA using primers 5’-CTTGCGGCCGCGTAATGATTTTCATATAACTGGTATGGG-3’
and 5’-CTTCTGCAGCATCGAAAGTATGTTCACACGTTCCG-3’. This NotI and PstI digested
fragment was cloned into pcamBSD [23], which encodes the blasticidin-S-deaminase (bsd)
selectable marker, yielding pcamBSD-exo1. Dd2 parasites were transfected with purified circu-
lar pcamBSD-exo1 plasmid as described [22]. One day post-electroporation, parasites were
exposed to 2 μg/ml of blasticidin (Invitrogen). Blasticidin media was replaced daily until day 7
post-electroporation and every 2 days thereafter. Transformed parasites were detected by light
microscopy 11 days post-electroporation, maintained in blasticidin-containing media, and
periodically checked by PCR for single site crossover-based plasmid integration into the pfexo1
locus. This PCR screen used the primers 5’-TCACTAAAGGGAACAAAAGCTGG-3’ and
5’-AAGGTCATCCTTCTTTTCCCAC-3’. Plasmid integration was detected on day 31 post-
electroporation. The mixed culture was then cloned by limiting dilution in a 96-well plate [24].
To detect clones, plates were screened by flow cytometry on an Accuri C6 flow cytometer cou-
pled to a HyperCyt autosampler, with infected red blood cells (iRBCs) labeled using 1.6 μM
Mito Tracker Deep Red and 2× SYBR Green (Invitrogen) [25]. Integration-positive clones
were confirmed by PCR.
KAE609 fluctuation assays
For a schematic representation of the fluctuation assay, see Fig 1A. On day 0, each parental par-
asite strain was first cloned by limiting dilution. Single clones were expanded to ~5×108 total
iRBCs and then seeded into two 96-well plates. Stocks were also cryopreserved at this time. The
first plate was inoculated with 2.5×108 total iRBCs of a parental clone at ~3% hematocrit in
selective media containing 2.5 nM KAE609 (kindly provided by Dr. Thierry Diagana, Novartis
Institute of Tropical Diseases) [19]. The second plate (0.8 parasites/well) was a control in
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which a parental clone was cloned again by limiting dilution in a 96-well plate (without drug
pressure) to calculate an accurate starting culture density (number of iRBCs/ml).
KAE609-containing selective media (with 0.9% hematocrit) was added to drug-pressured
96-well plates daily for 4 days, followed by the addition of fresh selective media (without RBCs)
every 48 hours. Fresh RBCs were added on days 14, 17, and 20. Drug-resistant clones were
detectable by flow cytometry generally around day 20 post-inoculation (matching the growth
rate for unpressured clones).
Fluctuation assay mutation rate calculation
Mutation rates were calculated for both parasite and yeast fluctuation assays using the Ma-
Sandri-Sarkar Maximum Likelihood Estimator (MSS-MLE) Method via the online Fluctuation
Analysis Calculator (FALCOR) [26]. In this analysis, r is the total count of KAE609-resistant
clones per parental clone tested, and Nt is the corrected starting number of parasites deter-
mined from each clone’s control plate. MSS-MLE is considered to be a more accurate method
of calculating mutation rates as compared to the Lea-Coulson or other methods [27]. Statistical
analysis was performed using Prism 6 (GraphPad Software, Inc.).
In vitro susceptibility assays
In vitro IC50 values were measured by incubating parasites for 72 hours across a range of
KAE609 concentrations (0.2–100 nM). Final parasitemia were measured by flow cytometry
and IC50 values were calculated by non-linear regression analysis [25].
Fig 1. Determination of mutation rates in a KAE609 fluctuation assay. (A) Schematic of fluctuation assay protocol. (B) KAE609 fluctuation assay
mutation rates (light blue bars and bolded text) calculated by MSS-MLE for n independent clones. Two-tailed Student’s t-tests were performed for each strain
relative to 3D7 with the exception of Dd2 exo1Δ, which was compared to Dd2, its isogenic background parent (#). 95% confidence intervals (lower and upper
limits) are denoted in brackets. Fold changes (fc) are listed relative to 3D7. Dd2 exo1Δ is compared to Dd2. * p = 0.02, ** p < 0.01.
doi:10.1371/journal.pone.0154166.g001
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Yeast plasmid and strain construction
Themlh1Δ strain SJR0538 (MATa ade2-101oc his3Δ200 ura3ΔNco lys2ΔBgl mlh1Δ::URA3) has
been previously reported [28]. This strain was transformed by heat shock with three separate
plasmids, namely pEAA213 [29], pEAA213-P157S, and pEAA213-K30A-E31A. pEAA213
encodes the full-length S288cMLH1 gene inserted in pRS415 (ARSH4 CEN6 LEU2 KANMX).
TheMLH1 gene in pEAA213 was mutated by site-directed mutagenesis to generate the
mlh1-P157S andmlh1-K30A-E31A expressing plasmids pEAA213-P157S and pEAA213--
K30A-E31A, respectively. These transformations yielded SJR0538-WT, SJR0538-P157S, and
SJR0538-K30A-E31A.
Yeast media and growth conditions
SJR0538-WT, SJR0538-P157S, and SJR0538-K30A-E31A were all grown in YEP medium (1%
yeast extract, 2% Bacto Peptone; 2.5% agar for plates) supplemented with 2% glycerol and 2%
ethanol (YEPGE) and 200 μg/ml G418 (Geneticin). Synthetic complete (SC) medium contain-
ing 2% dextrose and lacking lysine (SC-Lys) was used for selective growth.
lys2ΔBgl fluctuation assays
All yeast strains were propagated for three days on YEPD+G418 plates. Single clones were
inoculated in 10 ml of YEPGE+G418 liquid medium and propagated for 2 days at 30°C with
constant shaking. Cells were harvested by centrifugation, washed once with ddH2O, and resus-
pended in 1 ml of ddH2O. Dilutions were plated onto SC-Lys plates for 3 days at 30°C to select
for Lys+ revertants, or control YEPD plates to calculate an accurate starting inoculum. Nine
clones were tested for SJR0538-WT and SJR0538-P157S, and eleven for SJR0538-K30A-E31A.
Results and Discussion
Some Cambodian isolates exhibit a mild mutator phenotype
To determine mutation rates for a diverse selection of P. falciparum strains, we adapted the
fluctuation assay, a common microbiological method to measure and compare mutation rates
[30–32], to P. falciparum. Fluctuation assays estimate mutation rates based on the distribution
of mutant clones that arise in parallel cultures subjected to selective pressure.
In our P. falciparum-adapted fluctuation assay (Fig 1), we pressured parasites with the spir-
oindolone compound KAE609 (also known as NITD609 or cipargamin) [33]. We chose
KAE609 for three major reasons: (1) Resistance to low-level (2.5 nM) KAE609 can be readily
conferred by a number of unique SNPs in pfatp4 [19, 34–36]. Given more than one indepen-
dent SNP in pfatp4 can yield resistant clones, we were therefore able to capture a broad range
of mutation rates, including for low or basal rates (e.g. that of the drug-sensitive reference 3D7
strain). In the original ARMD report, only one of five strains pressured with 5-FOA yielded a
frequency of resistance measurement [8]. (2) Using KAE609 is much less time and resource
intensive than using drugs that select for resistance at much lower frequencies (3). KAE609 is
also fast acting [37]. Mutations that impart resistance would therefore have to be present at the
time of drug exposure in order for parasites to survive. This speed of action was preferred to
slower acting agents that might allow resistance-conferring SNPs to be encoded beyond the
first generation of selective pressure, which would yield inflated mutation rates.
In our KAE609 fluctuation assays (Fig 1), we assayed 3D7, W2, and Dd2, which have been
shown to have similar basal mutation rates [10, 11], and therefore served as wild-type controls.
As a benchmark for a mild mutator phenotype, we generated and assayed a P. falciparum Exo-
nuclease I knockout strain (Dd2 exo1Δ). exo1Δ strains exhibit mild mutator phenotypes in
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other organisms, as Exonuclease I often mediates the fastest, although non-essential, mecha-
nism for many DNA repair pathways [30, 38]. We also tested V1/S, a multidrug-resistant Viet-
namese strain [39, 40] that carries two DNA repair gene mutations (Table 1) found in
contemporary artemisinin-resistant Cambodian isolates, suggesting that it too may exhibit a
mild mutator phenotype. Finally, we tested five recently derived Cambodian isolates that
encode various DNA repair mutations [9]. These isolates were chosen to encompass the poten-
tial contributions of DNA repair mutations in Cambodian isolates. For instance, PH0167-C is
artemisinin-sensitive and encodes no mutations overrepresented in artemisinin-resistant iso-
lates (Table 1). PH0167-C nonetheless harbors two unique DNA repair gene mutations, not
associated with artemisinin resistance. In contrast, PH0212-C encodes four mutations associ-
ated with artemisinin resistance, in particular for the two factors Mlh1 and Pms1 that are both
essential for MMR.
Parallel cultures of each strain were pressured and maintained in 2.5 nM KAE609 in 96-well
plates until resistant clones were detectable by flow cytometry (See Materials and Methods).
To confirm that our fluctuation assays yielded KAE609-resistant clones, we determined half-
maximal inhibitory concentration (IC50) values using 72 hour in vitro susceptibility assays for
each parent and two randomly selected drug-pressured clones. Sanger sequencing of the pfatp4
gene from resistant clones yielded 16 total mutations, 13 of which have not been previously
reported (Table 2).
As mentioned above, the polymorphic nature of pfatp4 in response to KAE609 allowed us
to calculate mutation rates for all strains, including wild-type strains, which was previously not
possible for 5-FOA [8]. It is important to note that these mutation rates are specific to
KAE609, for which resistance in vitro can be mediated by single SNPs, and are useful for calcu-
lating relative differences between strains. However, the absolute KAE609 mutation rates
should not be directly compared with those calculated using other drugs or methods of calcula-
tion unless the studies are conducted in parallel. As examples, selection for mefloquine resis-
tance typically results in pfmdr1 gene amplification [41], for chloroquine multiple mutations in
pfcrt are required [42], and for atovaquone mutations involve single SNPs in the genome of
mitochondria, which are present as multiple copies per parasite [43].
With all strains, mutation rates were compared to 3D7, except for Dd2 exo1Δ that was com-
pared to its parental Dd2 strain. These data revealed no significant differences between 3D7,
W2, and Dd2 in their KAE609 mutation rates. This result was not consistent with the original
ARMD study, which reported that W2 was hypermutable relative to 3D7 [8]. We also observed
no significant differences in mutation rates amongst the three Cambodian isolates PH0167-C,
PH0306-C, and PH0164-C that carried fewer DNA repair gene mutations compared to the two
other isolates (Table 1, Fig 1B). These observations provide additional evidence against an
ARMD phenotype being present in the W2 strain.
Results with our Dd2 exo1Δ line showed a statistically significant 2.5-fold increase in muta-
tion rate relative to its isogenic background parent Dd2. This is similar to yeast exo1Δ strains,
which exhibit a 3-fold increase in mutation rate in lys2ΔBgl fluctuation assays [44], and con-
firms the usefulness of Dd2 exo1Δ as a benchmark mild mutator in P. falciparum fluctuation
assays.
We observed mild mutator phenotypes in three additional strains. V1/S exhibited a non-
statistically significant 1.7-fold increase in mutation rate relative to 3D7. However, its mutation
rate was very similar to Dd2 exo1Δ. PH0482-C and PH0212-C exhibited statistically significant
2.3- and 3.4-fold increases relative to 3D7, respectively (Fig 1B). As stated above, PH0482-C
and PH0212-C encode the most DNA repair gene mutations that cluster with artemisinin
resistance. These data suggest some correlation between DNA repair gene mutations and the
mild mutator phenotype, which merits further investigation.
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Our data also yielded useful insights into KAE609. As stated above, we observed 13 novel
pfatp4mutations in KAE609-resistant clones (S1 Fig). Prior studies using KAE609 or other
PfATP4 inhibitors have to date reported 24 mutations in this gene [19, 35, 36, 45, 46]. The
polymorphic nature of pfatp4 in response to low drug concentrations exemplifies its ideal use
for fluctuation analyses in P. falciparum. In vitro KAE609 susceptibility experiments, however,
cannot recapitulate the pharmacokinetic and pharmacodynamic properties of this compound
in vivo. Indeed, efficacy studies in humans will be required to assess the parasitological and
clinical risk associated with the polymorphic nature of pfatp4. Pharmacokinetic studies in
Table 2. pfatp4mutations and IC50 values for parasites used in KAE609 fluctuation assay.
Strain Clone Pressured Mutations IC50 ± SEM (nM)e Fold Changef p valuef
3D7 B2 No WT 0.79 ± 0.01 1.0 −
B3 Yes S312P 3.61 ± 0.47 4.6 0.01
E6 Yes T416N 8.00 ± 0.18 10.2 0.0003
W2a D2 No WT 0.78 ± 0.06 1.0 −
H6 Yes V414D 3.52 ± 0.09 4.5 0.0009
E12 Yes S312P 2.78 ± 0.22 3.6 0.003
Dd2a A7 No WT 0.58 ± 0.10 1.0 −
D9 Yes Q172Hb 3.52 ± 0.14 6.1 0.001
Dd2 exo1Δa C11 No WT 0.49 ± 0.05 1.0 −
D7 Yes I379N 2.88 ± 0.27 5.8 0.006
E2 Yes I379N 2.70 ± 0.26 5.5 0.006
V1/Sa B6 No WT 1.10 ± 0.13 1.0 −
B2 Yes V204L/L350Vc 7.34 ± 0.22 6.7 0.001
E4 Yes L938I 4.27 ± 0.23 3.9 0.003
PH0167-Ca A2 No WT 0.41 ± 0.03 1.0 −
D9 Yes Q172Hb 4.66 ± 0.59 11.4 0.01
PH0306-Ca A3 No WT 0.60 ± 0.07 1.0 −
D6 Yes V400A 5.42 ± 0.32 2.5 0.003
B9 Yes A421E 1.51 ± 0.13 9.0 0.02
PH0164-C E8 No WT 0.55 ± 0.03 1.0 −
D1 Yes P966Ad 4.06 ± 0.22 7.4 0.002
F1 Yes E895K 1.91 ± 0.17 3.5 0.006
PH0482-Ca F4 No WT 0.98 ± 0.11 1.0 −
C1 Yes A1207V 2.17 ± 0.07 2.2 0.006
A6 Yes A1158V 1.63 ± 0.13 1.7 0.002
PH0212-Ca G2 No WT 0.73 ± 0.09 1.0 −
A6 Yes A1158V 3.50 ± 0.17 4.8 0.003
A1 Yes A967G 24.3 ± 0.76 33.4 0.0005
B12 Yes A967G 20.9 ± 2.23 28.7 0.006
D3 Yes L350Hc 15.2 ± 2.58 21.0 0.01
C7 Yes V400A 9.61 ± 0.32 13.2 0.0004
a Harbors the additional pfatp4 polymorphism G1128R.
b Previously observed in [36], pressured with MMV007275.
c Previously observed in [35], pressured with (+)-SJ733.
d Previously observed in [35], pressured with KAE609.
e n = 3 independent assays in duplicate for each IC50 value.
f Relative to isogenic parent. p values were determined using the Student’s t test. WT = wild-type.
doi:10.1371/journal.pone.0154166.t002
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humans show that a 300 mg dose of KAE609 can produce a maximum plasma concentration
of around 2 μg/ml in 3 to 8 hours [47]. This equates to roughly 5 μMKAE609, which is
2,000-fold higher than the 2.5 nM concentration used in our drug pressure experiments. Also,
the largest changes in IC50 values attributed to single or double mutations in response to 2.5
nM KAE609 so far have been only 20 to 30–fold ([19] and Table 2).
The Cambodian mutant Mlh1 allele exhibits a minor mutator phenotype
in yeast
We sought to model the DNA repair gene mutations found in artemisinin-resistant parasites
in a yeast system to test for a possible association between these mutations and mutator pheno-
types. Among these mutations, only one gene, the MMR factor Mlh1, had a mutation (pfmlh1-
P203S) that could be mapped to a yeast ortholog [48], in this case Mlh1 (scmlh1-P157S) (Fig
2A). The ability to map the Mlh1 mutation is serendipitous for a number of reasons. First,
Mlh1 is an essential MMR protein that plays a major role in the generation of SNPs [18, 49].
Second, the pfmlh1-P203S mutation is found in the mild mutator P. falciparum strains
PH0212-C and PH0482-C. Third, the homologous residue in yeast, scmlh1-P157, is located in
a conserved region near motif IV of the essential N-terminal ATPase domain (Fig 2A). Fourth,
in yeast the mutation to lysine at residue P157 produces a strong mutator phenotype in an
exo1Δ background, which amplifies the mutator effect [30]. A mutation at the homologous res-
idue in human MLH1 has also been associated with hereditary nonpolyposis colorectal cancer
[50], a cancer mediated by mutations in MMR genes. Finally, among the 3,000 P. falciparum
isolates sequenced in the Pf3k database, the pfmlh1-P203S mutation has only been found in
Fig 2. Determination of mutation rates for a clinically relevantmlh1 allele in yeast. (A) Schematic of the yeast Mlh1 (ScMlh1) amino acid sequence.
Yellow domains represent the N-terminal region containing the GHL superfamily ATPase, ATPase motifs, and the essential residues K30 and E31. The
ScMlh1-P157 (and homologous PfMlh1-P203) residue is denoted in the conserved N-terminal domain. Blue domains representing the conserved C-terminal
domain are also shown. “Dimerization” domains are important for dimerization with Pms1. The “Regulatory” region is important for Mlh1 regulation. The MIP
binding sites are important for interactions with factors such as Exo1 [48]. (B) Yeast lys2ΔBgl fluctuation assay mutation rates (yellow bars and bolded text)
comparing wild-type (WT), scmlh1-P157S, and scmlh1-K30A E31A. Two-tailed Student’s t-test compared to wild-type. 95% confidence intervals (lower and
upper limits) are denoted in brackets. Fold changes (fc) are listed relative to scmlh1-WT. *** p < 0.0001.
doi:10.1371/journal.pone.0154166.g002
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Southeast Asia (in Cambodia, Myanmar, Thailand, and Vietnam), and never in Africa or Ban-
gladesh [51].
To test the effect of scmlh1-P157S, we transformed a Mlh1 knockout yeast strain (SJR0538:
lys2ΔBgl mlh1Δ) with plasmids encoding either wild-type scmlh1-WT, or scmlh1-P157S, or
scmlh1-K30A E31A. In yeast, scmlh1-WT was shown to fully rescue MMR functionality,
whereas the ATPase-dead scmlh1-K30A E31A plasmid phenocopied a full Mlh1 knockout
[52]. To test for mutability differences, each yeast strain also encoded an internal frameshift in
LYS2 (lys2ΔBgl), which rendered the strain auxotrophic for lysine. Reversion to lysine prototro-
phy requires a return to wild-type functionality, but not necessarily wild-type sequence, as a
number of different reversion events in lys2ΔBgl can restore function. Therefore, the lys2ΔBgl
fluctuation assay measures an artificially increased mutation rate [28], similar in concept to
our KAE609 assay, as in both assays several distinct genetic changes can produce the selected
phenotype. For each of the three scmlh1 strains, we measured mutation rates by measuring the
return to growth on media lacking lysine (Fig 2B).
Our wild-type and K30A E31A strains provided the lower and upper limits of our assay,
respectively. K30A E31A had a mutation rate of 5.29×10−7 mutations per generation (95% con-
fidence intervals (CI) [4.4×10−7, 6.2×10−7], n = 11), which was 23.3-fold higher (p<0.0001,
two-tailed Student’s t-test) than the wild-type, whose rate was calculated at 0.23×10−7 (95% CI
[0.14×10−7, 0.33×10−7], n = 9). Our scmlh1 P157S strain exhibited an elevated mutation rate of
0.37×10−7 (95% CI [0.24×10−7, 0.52×10−7], n = 9), a 1.6-fold increase compared to wild-type
(p<0.0001, two-tailed Student’s t-test). These data provide evidence that the scmlh1-P157S
mutation can confer a mild mutator phenotype.
Given the conservation of the region in which it lies, themlh1-P203S mutation in P. falcipa-
rum likely also mediates a mild mutator phenotype, particularly if compounded with additional
DNA repair mutations (e.g. Pms1). Gene editing experiments are currently ongoing to examine
the contributions of MMRmutations to mild mutator phenotypes in P. falciparum.
In our study, we have focused on the effects of DNA repair gene mutations in the intraery-
throcytic, asexual cycle. It is tempting to consider that the effects of these mutations might also
extend to the sexual stages that genetically recombine in the Anophelesmosquito host. In meio-
sis, for instance, the complex of Mlh1-Mlh3 (MutLγ) and Exo1 has been shown to resolve mei-
otic crossovers [53]. Additionally, the Mlh1-Pms1 complex (MutLα) prevents post-meiotic
segregation and divergence from Mendelian inheritance [54]. We posit that P. falciparum
DNA repair mutations might reduce meiotic recombination and thereby contribute to the
maintenance of multigenic drug-resistant traits in Southeast Asian strains. Such a mechanism
would be consistent with the over-representation of these DNA repair genes in artemisinin-
resistant parasites in Cambodia, which comprise genetically distinct parasite subpopulations
whose primary resistance determinant K13 appears to be in linkage disequilibrium with multi-
ple genetic traits on distinct chromosomes [9]. Dissecting the role of these DNA repair genes in
meiosis will require the investigation of rates of chromosomal crossovers in gene-edited P. fal-
ciparum parasites examined in Anophelesmosquitoes, a complex but exciting undertaking.
Since the ARMD phenotype was initially described [8], examining whether this is a consis-
tent characteristic of multidrug-resistant parasites has focused on finding hypermutators with
very large variations in mutability rates compared to drug-sensitive parasites. Studies in natural
bacterial populations present an alternative perspective. Hypermutator strains can and do
acquire resistance to drugs quickly in vitro, but when propagated longer become outcompeted
by mild mutators due to an accumulation of additional detrimental mutations [17, 18]. Mild
mutators can more readily provide an appropriate balance between the ability to adapt to drug
pressure via the acquisition of resistance-conferring mutations and the need to maintain over-
all fitness [14, 16, 18]. This may have been important for the acquisition of resistance to earlier
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first-line antimalarial therapies such as CQ or pyrimethamine+sulfadoxine, or current first-
line artemisinin-based therapies, which require multiple mutations in one or more genes to
build full resistance [6, 42, 55]. Further research will be necessary to determine to what extent a
mild mutator phenotype in P. falciparum facilitates the acquisition of multidrug resistance in
parasite populations, as has been observed in bacteria.
Conclusion
We provide evidence of a mild mutator phenotype in some contemporary Cambodian isolates,
using a fluctuation assay adapted for use in P. falciparum. These strains are artemisinin-resis-
tant and carry multiple DNA repair gene mutations. One such mutation, pfmlh1-P203S, drives
a mild mutator phenotype when modeled in yeast. In describing this phenotype, we provide
further evidence that the ARMD phenotype cannot be recapitulated, under the drug selection
conditions adopted herein. As such, we posit that the focus in P. falciparum should be shifted
from the ARMD phenotype to a more detailed examination of mild mutator phenotypes,
which have been shown to be more relevant than hypermutators for antibiotic resistance and
evolution of natural bacterial populations [13–16].
Supporting Information
S1 Fig. pfatp4mutations that confer resistance to KAE609. (A) Amino acid changes in
PfATP4 determined from KAE609-resistant parasites in our study (denoted in red) and
PfATP4 mutations from previously published studies. Previously reported mutations were
identified when pressuring parasites with a GNF-Pf4492 [45], b MMV011567 [36], c
MMV007275 [36], d C2-1 [46], e KAE609 [19], f NITD678 [19], g KAE609 [35], h SJ733 [35], i
SJ311 [35], j NITD678 [35], or k MMV772 [35]. l The variant residue G1128R was found in
some parental lines not pressured with KAE609 and was also reported in [36]. PfATP4
domains were determined using the Pfam database of protein families, version 28.0 [56]. (B) A
PfATP4 homology model (C-score: -1.68, estimated TM-score 0.51±0.15, estimated RMSD
13.7±4.0Å) showing the 3D locations of the mutations found in this study (red spheres).
Homology modeling was performed via the I-TASSER online server [57, 58] and visualized
with Protean 3D (DNASTAR Lasergene version 12) and Adobe Illustrator CS4.
(PDF)
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Malaria afflicts over 200 million people worldwide, and its most 
lethal etiologic agent, Plasmodium falciparum, is evolving to 
resist even the latest-generation therapeutics. Efficient tools 
for genome-directed investigations of P. falciparum-induced 
pathogenesis, including drug-resistance mechanisms, are clearly 
required. Here we report rapid and targeted genetic engineering 
of this parasite using zinc-finger nucleases (ZFNs) that produce 
a double-strand break in a user-defined locus and trigger 
homology-directed repair. Targeting an integrated egfp locus,  
we obtained gene-deletion parasites with unprecedented  
speed (2 weeks), both with and without direct selection.  
ZFNs engineered against the parasite gene pfcrt, responsible for 
escape under chloroquine treatment, rapidly produced parasites 
that carried either an allelic replacement or a panel of specified 
point mutations. This method will enable a diverse array of 
genome-editing approaches to interrogate this human pathogen.
By current estimates, 655,000 individuals die each year from 
severe malaria caused by the protozoan parasite P. falciparum. 
Recent reductions in the global disease burden, brought about 
by artemisinin-based combination therapies and anti-mosquito 
measures, are at risk of being overturned by mutation-driven 
resistance1. Defining molecular pathways of malaria patho-
genesis and identifying mechanisms of treatment failure require 
precise manipulation of the parasite genome. Existing methods, 
despite having yielded important insights, do not adequately meet 
these challenges2,3.
Genome editing with customized ZFNs has been successfully 
applied to a range of multicellular organisms4,5. To achieve edit-
ing, pairs of zinc-finger proteins with unique specificity for adja-
cent sequences on either strand of the DNA helix are linked to an 
endonuclease (FokI) that functions as an obligate heterodimer6,7. 
ZFNs induce a double-strand break (DSB) that can alter the 
target, either by activating the error-prone nonhomologous end-
joining pathway or by stimulating homologous recombination 
when a donor template is provided. In metazoans, nonhomologous 
end joining can produce nuclease-mediated gene disruption8. 
Site-specific genome editing in Plasmodium 
falciparum using engineered zinc-finger nucleases
Judith Straimer1, Marcus C S Lee1, Andrew H Lee1, Bryan Zeitler2, April E Williams3,4, Jocelynn R Pearl2,  
Lei Zhang2, Edward J Rebar2, Philip D Gregory2, Manuel Llinás3,4, Fyodor D Urnov2 & David A Fidock1,5
However, P. falciparum lacks several critical components of this 
pathway (Ku70, Ku80 and DNA ligase IV9; unpublished observa-
tions). Thus, homologous recombination is likely the primary path-
way of DSB repair in this parasite10, and gene-targeting approaches 
using this process have been successful, albeit highly inefficient3. 
We hypothesized that ZFNs could improve efficiency by introduc-
ing DSBs in a specified target site at a much higher frequency than 
occurs stochastically. Here we establish methods of genome editing 
in P. falciparum.
RESULTS
2A peptide permits dual protein synthesis in P. falciparum
Directed genome editing requires the coordinated expres-
sion of two ZFNs that heterodimerize to cleave a unique site. 
Given the paucity of selectable markers for P. falciparum and 
the instability of propagating large plasmids containing AT-rich 
P. falciparum DNA in Escherichia coli3, we first tested whether a 
plasmid-encoded ZFN pair could be coexpressed from a single 
promoter using a viral 2A ‘ribosome skip’ peptide. This short 
self-processing sequence permits polycistronic expression of 
individual polypeptides11. We generated transgenic parasites 
expressing a mrfp-2A-gfp fusion driven by the calmodulin 
promoter (Fig. 1a). Both protein products were detected in para-
sites by fluorescence microscopy, and immunoblotting for the 
downstream GFP reporter revealed its expression as the 27-kDa 
monomer (Fig. 1a). Deletion of a key proline residue in the 2A 
peptide crippled cotranslational release, resulting in a mRFP-
2A P-GFP fusion protein with a molecular mass slightly greater 
than the conventional fusion of these two proteins (Fig. 1a). These 
findings confirm efficient ribosomal skipping across the 2A site 
and illustrate its utility for dual protein expression from a single 
promoter in P. falciparum.
ZFNs mediate gene ablation in P. falciparum parasites
We set out to achieve ZFN-mediated gene disruption in 
P. falciparum by targeting a chromosomal egfp locus. First we 
integrated the target egfp gene into the cg6 locus of NF54 parasites 
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Princeton University, Princeton, New Jersey, USA. 5Division of Infectious Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, 
New York, New York, USA. Correspondence should be addressed to D.A.F. (df2260@columbia.edu).
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using attB × attP integrase–mediated recombination12, generat-
ing the NF54EGFP line that was uniformly EGFP positive (Fig. 
1b–d). We then designed a composite pZFNegfp-egfp–human 
dihydrofolate reductase (hdhfr) donor plasmid comprising our 
2A-linked egfp-specific ZFN expression cassette as well as two 
homology regions (egfp 5  and 3 ) that flanked the ZFN cleav-
age site. To select for egfp-disrupted parasites, the 5  homology 
region was fused in frame with hdhfr13 such that resistance to the 
antifolate drug WR99210 would be contingent on the egfp-hdhfr 
fusion integrating downstream of the genomic calmodulin pro-
moter (Fig. 1b). Targeted integration of hdhfr into the egfp locus 
should produce a GFP-negative parasite.
After electroporation of the ZFN donor plasmid into the 
NF54EGFP line, parasites were selected directly with WR99210 
(yielding the NF54 egfpA line) or first supplemented with red blood 
cells preloaded with plasmid DNA (reported to increase transfor-
mation efficiency14 and yielding the three lines NF54 egfp-B1/B2/B3). 
With all four lines, WR99210-resistant parasites were detected 
15 d after electroporation. We confirmed ZFN-driven disruption 
of the egfp gene by fluorescence microscopy, PCR and Southern 
blotting (Fig. 1c–e). Flow cytometry of the bulk cultures revealed 
the complete loss of fluorescence in all NF54 egfp lines (Fig. 1f). 
Three independent transfections with a ZFN-deficient control 
pegfp-hdhfr plasmid failed to yield parasites after 60 d.
To assess potential off-target activity of the ZFNs, we sequenced 
the genomes of two edited lines (NF54 egfpA and NF54 egpfB1) 
as well as the parent (NF54EGFP). Sequence analysis revealed 
a depth of coverage of hdhfr (56× and 42× for NF54 egfpA and 
NF54 egfpB1, respectively) that mirrored the average coverage 
across the entire genome (54× and 69×), consistent with the pres-
ence of a single genomic copy of hdhfr (Supplementary Table 1). 
Furthermore, flanking sequence reads that partially overlapped 
hdhfr could only be mapped to the egfp-hdhfr locus, consistent 
with the specific disruption of egfp (Supplementary Fig. 1a,b).
Gene replacement in the absence of a selectable phenotype
Gene disruption by in-frame integration of a selectable marker is 
limited to targets that are expressed during the asexual blood stage. 
We sought to develop a broader strategy for gene manipulation, 
irrespective of expression pattern during the parasite life cycle and 
independent of a selection event. We first aimed to replace the egfp 
reporter with monomeric rfp (mrfp) fused to the cytosolic ATPase 
pfvps4. This fusion was placed on a donor plasmid (pmrfp-vps4) 
flanked by egfp UTRs and plasmid backbone sequences (3.5 kb 
and 2.8 kb on the 5  and 3  ends, respectively) that provided 
templates for homologous recombination (Fig. 2a). ZFNs were 
expressed from a separate plasmid (pZFNegfp-hdhfr) containing 
the hdhfr selectable marker. The plasmids were coelectroporated, 
and WR99210 pressure was applied for 6 d to transiently enrich 
for parasites that expressed the ZFNs. Parasite proliferation was 
detected microscopically 12 d after electroporation.
Imaging and quantification of parasite fluorescence from the bulk 
cultures was consistent with a gene replacement efficiency of 88% 
and 62% in two independent experiments (Fig. 2b,c). This level of 
efficiency was confirmed by analysis of clonal lines, which expressed 
mRFP and not EGFP in 19 of 27 (70%) and 21 of 39 (54%) cloned 
parasites from the two experiments. This recombination event 
involves DNA end resection of greater than 260 bp from at least one 
side of the DSB, leading to invasion of the mrfp flanking sequences 
common to both the donor plasmid and the chromosomal egfp 
locus (Fig. 2a). These flanking sequences were shared with the ZFN 
expression vector, which could compete with the pmrfp-vps4 plas-
mid as a template for homology-directed repair and could account 
for the minority of nonfluorescent parasites observed in the bulk 
cultures (Fig. 2c). PCR and Southern blot analyses nonetheless 
confirmed replacement of egfp with the mrfp fusion in the majority 
of parasites, shown in two representative clones (Fig. 2d,e).
Allelic replacement of an endogenous parasite gene
An important drug-resistance determinant in P. falciparum is the 
chloroquine (CQ) resistance transporter PfCRT15,16. The exten-
sive worldwide use of CQ in malaria treatment has led to the 
selection of multiple mutations in pfcrt17. Genetic engineering 
of isogenic parasites expressing various pfcrt alleles is required to 
fully analyze their phenotypic impact on drug response, but this 
has proven exceptionally time and labor intensive18,19.
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Figure 1 | 2A-linked ZFNs drive efficient disruption of egfp in P. falciparum. (a) Coexpression of 2A-linked mRFP and GFP  
monomers from a single calmodulin promoter (cam) is demonstrated by fluorescence microscopy and immunoblotting  
for GFP. The red arrow indicates the ribosome skip site. C, control untransfected parasites; DIC, differential interference  
contrast. (b) Strategy to disrupt egfp integrated at the genomic cg6 locus. The donor plasmid encodes 2A-linked left (L)  
and right (R) ZFNs as well as egfp homologous regions flanking the ZFN target site (thunderbolt). Repair of the ZFN-induced  
DSB, via homology-directed repair using the donor as template, yielded an in-frame integration of hdhfr into the egfp locus. (c) Micrographs showing 
EGFP expression in the parental line NF54EGFP but not in the recombinant line NF54 egfpA. Nuclei were stained with Hoechst 33342. (d) PCR analysis of 
the ZFN-transfected lines NF54 egfpA/B1/B2/B3 and the parental line NF54EGFP using the primer (p) positions indicated in b. (e) Southern blot hybridization 
of genomic DNA digested with ClaI and BamHI (see b) demonstrates integration of hdhfr in the ZFN-transfected lines (bottom) and the expected 2-kb 
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We designed ZFNs against pfcrt using an 
archive of prevalidated modules, each con-
sisting of two zinc fingers8,20. On the basis 
of results from yeast proxy cleavage assays21 (data not shown), 
we selected the two most active nuclease pairs (13/15 and 14/15; 
Supplementary Table 2). These pairs, which target the boundary 
of intron 1 and exon 2, were cloned into a plasmid expressing a 
blasticidin S-deaminase (bsd) selectable marker, thereby yielding 
pZFNcrt-bsd (Fig. 3a). The pfcrt donor sequence was inserted on 
a second plasmid (pcrtDd2-hdhfr), consisting of the pfcrt cDNA 
from the CQ-resistant (CQR) strain Dd2 and the 3  UTR from 
the P. berghei crt ortholog, followed by an hdhfr expression 
cassette that served as an independent selectable marker. 
Upstream and downstream regions of homology flanked these 
elements to promote ZFN-mediated replacement of the entire 
3.1-kb gene with the donor-provided pfcrt 1.2 kb-cDNA and the 
downstream hdhfr selectable marker (Fig. 3a).
We chose to modify the CQ-sensitive (CQS) strains 106/1 and 
GC03, which harbor distinct alleles and exhibit characteristic 
drug-response phenotypes15. We first electroporated the donor 
plasmid pcrtDd2-hdhfr and applied WR99210 to select for episo-
mally transformed parasites (Fig. 3a). These parasites were then 
electroporated with pZFNcrt-bsd, and blasticidin was applied for 
6 d to enable transient ZFN expression and consequent homology-
directed repair. Prolonged selection for the ZFN plasmid (12 d) 
caused a delay in parasite re-emergence after electroporation 
(data not shown), potentially due to repeated chromosome cleav-
age. After removal of blasticidin, but not WR99210, parasite pro-
liferation was detected microscopically after 13–16 d. In a clonal 
analysis, we observed replacement events in 13 of 82 (15.9%) 
106/1 clones and 4 of 83 (4.8%) GC03 clones by PCR (Fig. 3b). 
Southern blotting of two representative clones (GC03crt-Dd2 G9 and 
GC03crt-Dd2 H6) demonstrated acquisition of the donor-provided 
CQR pfcrt allele (Fig. 3c). We confirmed the CQ resistance pheno-
type of these two clones, which both displayed a four- to fivefold 
shift in CQ half-maximal inhibitory concentration (IC50) values 
compared to the GC03 parent (Fig. 3d). Notably, in three inde-
pendent transfections, 106/1 and GC03 parasites that only 
received the pfcrt donor plasmid but not the ZFN plasmid failed 
to yield allelic replacement parasites after more than 6 months.
Site-specific editing of a parasite drug-resistance locus
We next assessed whether our engineered pfcrt-targeted ZFNs 
could drive a subtle gene-editing event that delivers a single point 
mutation to the targeted site from an episomal donor template. In 
contrast, conventional allelic exchange strategies for P. falciparum 
typically result in significant modification of the endogenous 
locus by crossover-mediated incorporation of the entire plasmid 
(often as a concatamer), including a selectable marker and other 
sequence elements3.
To achieve gene editing in P. falciparum, we exploited the CQ 
resistance–conferring properties of mutant pfcrt. PfCRT medi-
ates resistance by transporting CQ from the digestive vacuole 
when residue Lys76 has mutated to threonine (in the case of 
field isolates) or isoleucine (observed in CQ-pressured 106/1 
parasites15,22,23). pfcrt alleles from CQR parasite strains also pos-
sess at least three additional, potentially compensatory muta-
tions24. For this experiment, we chose the CQS 106/1 strain, 
whose pfcrt allele encodes six out of seven CQR mutations 
observed in Asian and African strains while retaining the CQS 
Lys76 codon (Fig. 4a). On the basis of prior studies15,22, muta-
tion of pfcrt codon 76 from lysine to isoleucine in this isolate 
was predicted to confer resistance.
We generated the ZFN expression plasmid pZFNcrt-bsd with a 
1-kb pfcrt donor sequence that spans the ZFN cleavage site and 
encodes the K76I mutation (yielding the plasmid pZFNcrt-76I) 
(Fig. 4a). We tested two versions of the donor sequence: one with 
an intact ZFN binding site (‘mut1’) and another with four silent 
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Figure 2 | ZFNs mediate efficient gene 
replacement of egfp. (a) Schematic of the  
egfp replacement strategy. ZFNs were expressed 
from the calmodulin promoter (cam) on the 
pZFNegfp-hdhfr plasmid and were cotransfected 
with the mrfp-vps4 donor sequence. Homology-
directed repair of the ZFN-induced DSB, using 
the flanking regions on the donor as template, 
resulted in replacement of egfp with the mrfp-
vps4 fusion construct. (b) The parental line 
NF54EGFP, a post-ZFN bulk culture and a clonal 
line were imaged for EGFP and mRFP expression. 
Nuclei were stained with Hoechst 33342.  
(c) Quantification of parasite fluorescence in the  
bulk culture in two independent experiments 
(n = 1,042 and n = 1,032). (d) PCR analysis 
of parental NF54EGFP and ZFN-transfected bulk 
cultures and individual parasite clones. Primer (p) 
positions are shown in a. (e) Southern blot 
hybridization of genomic DNA from the 
indicated parasite lines digested with ClaI and 
BamHI (see a) using an egfp probe (left) and 
a mrfp probe (right). Linearized transfection 
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and cleavage of a successfully modified chromosomal target, thereby 
potentially enhancing editing efficiency. We placed 106/1 parasites 
under 33 nM CQ 1 d after electroporation to eliminate unmodified 
CQS parasites. Parasite proliferation was detected microscopically 
16–33 d after electroporation. In contrast, similar CQ exposure of 
six independent nontransfected 106/1 cultures yielded no para-
sites after 90 d.
In five independent parasite transfections, we observed 100% 
K76I conversion rates by sequence analysis of the pfcrt locus 
(Fig. 4a and Table 1). No alternate mutations were detected at 
this position. Editing of the Lys76 codon was equally successful 
using either ZFN pair (13/15 or 14/15; Supplementary Table 2), 
irrespective of whether the ZFN binding site was mutated in the 
donor construct (Table 1). Of note, the additional four silent 
mutations in the mut2 template were always incorporated at the 
pfcrt locus. In addition, both the mut1 and mut2 donor templates 
contained a pfcrt 5  UTR sequence harboring a single-base-pair 
deletion (a string of seven thymidines (T7), compared to eight 
(T8) in the endogenous locus). This deletion, located ~300 bp 
upstream of the ZFN cut site, was transferred into the edited gene 
sequence with a mean efficiency of 51% (Table 1). By comparison, 
mutations located an equivalent distance from the nuclease cleav-
age site have been captured with considerably lower frequency 
in mammalian cells (for example, 5% in mouse embryonic stems 
cells25). Importantly, the T7 deletion was captured despite its pres-
ence on the side opposite the DSB relative to the selected K76I 
mutation (located 140 bp downstream of the ZFN cleavage site). 
The incorporation into the chromosomal target of all mutations 
on the donor plasmid could be explained by gene editing proceed-
ing via synthesis-dependent strand annealing or other noncross-
over events (Fig. 4a and Supplementary Fig. 2)10.
We confirmed the CQ-resistance phenotype of two gene-edited 
lines, 106/113/15mut2 and 106/114/15mut1 (Fig. 4b). Both lines dis-
played a five- to sixfold shift in CQ IC50 values relative to the 
106/1 parental strain. This shift in drug response was comparable 
to a CQR mutant of 106/1 (termed 106/1I76) bearing the K76I 
mutation derived by CQ pressure15,22.
Whole-genome sequencing revealed no detectable off-target 
activity of the pfcrt-targeting ZFN pairs in two representative 
recombinant lines (106/113/15mut1 and 106/114/15mut1). Illumina 
next-generation sequencing yielded a 15× coverage for >97% 
of all three genomes (Supplementary Table 1). We found no 
evidence of any rearrangement of the pfcrt locus in these edited 
lines, and we confirmed 100% incorporation of the K76I mutation 
(Supplementary Fig. 1c).
To demonstrate the applicability of ZFNs for generating 
single-nucleotide polymorphisms (SNPs) that may not confer a 
selectable phenotype, we repeated the ZFN-mediated pfcrt K76I edit-
ing event described above without applying CQ pressure. To select 
for transfected parasites and ensure ZFN expression, we added the 
hdhfr selection cassette to the mut2 version of the pZFNcrt-76I plas-
mid (yielding pZFNcrt-76I-hdhfr) (Fig. 4a). Transfected Dd2 para-
sites were selected with WR99210 for 6 d, and parasite proliferation 
was observed 11 d after removal of drug. From two independent 
experiments, we generated a total of 76 clones and used these to PCR-
amplify the pfcrt genomic locus (Table 1). This analysis identified 
the ZFN binding-site mutations in 18.4% and the K76I mutation 
in 15.8% of clones. The upstream T7 deletion was also found in all 
edited clones. These data suggest that nonselected gene-editing events 
can be generated efficiently enough to readily permit the isolation 
of modified parasite clones by limiting dilution, thus expanding the 
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Figure 3 | ZFN-driven allelic replacement of pfcrt. 
(a) Schematic of the pfcrt allelic replacement 
strategy. The pZFNcrt-bsd plasmid encodes pfcrt-
specific ZFNs, with expression driven by the 
calmodulin promoter (cam). The pcrtDd2-hdhfr 
donor plasmid contains the 1.2-kb coding sequence 
of the Dd2 pfcrt allele (comprising exon 1,  
intron 1 and exons 2–13) followed by 0.7 kb of 
the pbcrt 3  UTR and the hdhfr selectable marker 
(gray). These cassettes are flanked by homology 
regions comprising 1 kb of the pfcrt 3  UTR and 
0.4 kb upstream of the DSB. ZFN-driven homology-
directed repair yielded the pfcrt-modified GC03crt-Dd2 
locus. (b) PCR analysis of two independent clones. 
Primer (p) positions are shown in a. (c) Southern 
blotting of genomic DNA from the indicated 
parasite lines digested with SalI and BstBI and 
probed for hdhfr (black bar in a). The band size 
(6.7 kb) observed with clones G9 and H6 is 
consistent with pfcrt replacement. The pcrtDd2-
hdhfr plasmid was linearized with SpeI (8.1 kb) 
and is present as episomes in clones G7 and C6 
as well as in the ZFN-negative control line, GC03 
+ pcrtDd2-hdhfr. (d) Plot showing half-maximal 
inhibitory concentration (IC50  s.e.m.) values for 
the indicated parasite lines. Asterisks indicate 
significant differences between the GC03 parental 
line and each of the two representative pfcrt allelic 
replacement clones GC03crt-Dd2 G9 and GC03crt-Dd2 H6 
and the CQ-resistant Dd2 line (*P = 0.0286, Mann-
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DISCUSSION
Here we have established diverse ZFN-driven strategies with 
broad utility for interrogating the P. falciparum genome. These 
include gene disruption and replacement approaches that can be 
used to verify the essentiality of parasite genes as well as site- 
specific editing approaches to probe gene function. ZFN-mediated 
genome editing of P. falciparum differs fundamentally from prior 
methods of genetic manipulation, which have typically relied on 
stochastic integration of plasmids designed for gene disruption or 
allelic exchange via homologous recombination (Supplementary 
Fig. 2)26. In these cases, integration likely takes place after a rare 
and random DSB occurs in the gene of interest. Plasmid integra-
tion is typically observed after 2–4 months, and any fitness costs 
resulting from genome manipulation jeopardize the acquisition 
of the recombinant line. Extreme cases include the engineering 
of the pfcrt CQ-resistance locus, which required two rounds of 
genetic manipulation and over 18 months of continuous culture 
to obtain the desired clones18. Furthermore, the nondirected 
nature of this earlier method of allelic exchange meant that inte-
gration could take place at any genomic site with homology to the 
transfection plasmid, often yielding undesired outcomes. Even 
if integration occurs in the desired locus, single-site crossovers 
could result in a recombinant locus that harbors the plasmid-
borne mutations in a nonfunctional duplicated fragment and not 
the functional gene27.
With the approaches we describe, parasites carrying the desired 
specific editing event can be obtained rapidly and with an efficiency 
that approaches 100% in cases when the outcome yields a select-
able phenotype. Notably, we could readily obtain parasites with 
gene-deletion, allelic-exchange or single-nucleotide editing events 
even in the absence of a selectable phenotype. The efficiencies of 
these editing events ranged from relatively high in the case of the 
egfp-mrfp replacement (88%), when ~3-kb homology arms were 
provided on either side of the target locus, to more modest levels 
(~18% efficiency) for the pfcrt K76I editing, when a 1-kb sequence 
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Figure 4 | ZFN editing of pfcrt with and 
without CQ selection. (a) Schematic of the 
pfcrt editing strategy. The calmodulin promoter 
drives expression of the pfcrt-specific ZFN 
pairs from plasmids with (pZFNcrt-76I-hdhfr) 
or without (pZFNcrt-76I) the selectable marker 
hdhfr. The homologous donor sequence for DSB 
repair comprises a fragment of pfcrt stretching 
0.4 kb upstream and 0.6 kb downstream of the 
ZFN target site (thunderbolt). One version of 
the donor (termed mut1) is identical to the 
genomic locus but contains the mutant I76 
codon (starred) that confers CQ resistance 
as well as a single-nucleotide deletion, 
T7 (versus T8), in the endogenous 5  UTR. 
An alternate donor construct (mut2, not 
shown) is mutated at the ZFN binding site. 
Homology-dependent repair of a ZFN-induced 
DSB leads to incorporation of donor-provided 
SNPs. The chromatograms show sequence 
analysis of genomic and mut2 recombinant 
DNA. The 5  UTR deletion as well as the 
mutations at the ZFN binding site and the CQ 
resistance–conferring I76 codon are indicated. 
(b) Plot showing half-maximal inhibitory concentration (IC50  s.e.m.) values for the indicated parasite lines. The asterisk indicates that the 106/1 
parental line is significantly different (*P < 0.0286, Mann-Whitney U test, n = 4, two-tailed) from the gene-edited parasites as well as the previously 
established CQR line 106/1I76.
Table 1 | Efficiency of ZFN-mediated gene editing of pfcrt either with or without selection
Proportion of editing events across sites
Strain ZFN pair Donor Sequences analyzed ZFN binding site K76I T (deletion)
CQ
106/1 13/15 pfcrt-76I-mut1 29 pGEM-T N/A 29 of 29 0 of 29
106/1 13/15 pfcrt-76I-mut2 25 pGEM-T 25 of 25 25 of 25 9 of 25
106/1 14/15 pfcrt-76I-mut1 38 pGEM-T N/A 38 of 38 38 of 38
106/1 14/15 pfcrt-76I-mut1 28 pGEM-T N/A 28 of 28 28 of 28
106/1 14/15 pfcrt-76I-mut2 31 pGEM-T 31 of 31 31 of 31 6 of 31
Targeting efficiency with CQ selection 100% 100% 51%
No CQ
Dd2 13/15 pcrt-76I-mut2 36 parasite clones 4 of 36 2 of 36 4 of 4a
Dd2 14/15 pcrt-76I-mut2 40 parasite clones 10 of 40 10 of 40 10 of 10a
Targeting efficiency without CQ selection 18.4% 15.8% (18.4%)
Distance from ZFN cut site 3–6 bp 140 bp 296 bp
The table shows ZFN-mediated pfcrt gene-targeting efficiency in the presence or absence of CQ pressure. The site of cleavage of the ZFN pairs and constructs are described in Figure 4.
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were sufficient to readily isolate parasite clones bearing the 
desired modifications. Furthermore, the capture of mutations 
several hundred base pairs from the DSB site provides some flex-
ibility when selecting ZFN pairs. The shortest region of homology 
was 0.5 kb (for the egfp disruption strategy), and the potential 
increase in editing efficiency by using longer regions must be bal-
anced by constraints on the size and stability in E. coli of AT-rich 
P. falciparum transfection plasmids.
ZFN-mediated editing can now be leveraged to generate 
knockouts or more subtle modifications (including fusions with 
fluorescent reporters20 or affinity tags) that probe parasite gene 
function across a broad range of biological contexts. This includes 
the ability to inactivate genes without integrating a selectable 
marker, thus fulfilling an important requirement for genetically 
attenuated vaccines. ZFNs can also be deployed for sequence-
specific editing28—for example, to assess the involvement of 
candidate loci and identify causal polymorphisms in order to sur-
vey the spread of antimalarial drug resistance in endemic areas. 
ZFN-mediated genome editing now adds a powerful reverse-
genomic methodology for dissecting the etiologic agent of a major 
human infectious disease.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Requests for materials. Requests for ZFNs should be directed 
to furnov@sangamo.com.
Note: Supplementary information is available in the online version of the paper.
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Zinc-finger nuclease engineering. ZFNs specific for egfp have 
been described previously29. ZFNs targeting pfcrt (MAL7P1.27) 
were designed and assembled using an archive of validated mod-
ules8 and screened for activity using a yeast proxy system21.
Plasmid construction. To test whether the Thosea asigna virus 2A 
peptide11 could mediate cotranslational polypeptide separation 
in P. falciparum, we generated the pDC2-cam-mrfp-2A-gfp-attP 
plasmid (whose expression cassette is illustrated in Fig. 1a). The 
2A and mrfp fragments were first amplified separately and linked 
by ‘splicing by overlap extension’ (SOE) PCR. The 2A sequence 
was amplified from the plasmid pVAX-ZFN-L-2A-ZFN-R21 using 
primers p18 + p19 (Supplementary Table 3), and mrfp was ampli-
fied from pML2 (ref. 30) using primers p21 + p22. The linked 
mrfp-2A sequence was amplified using primer p21 and either 
p19 (full 2A sequence) or p20 (2A P21). Finally, the mrfp-2A 
fusions were digested with AvrII and BglII and inserted into a 
pDC2-based expression vector30 following excision of the 5  gfp 
full-length sequence in the tandem gfp-gfp plasmid pDC2-cam-
gfp(N-C)-attP. To generate the construct used to produce the 
NF54EGFP line, the egfp coding sequence was amplified from an 
EGFP-FokI plasmid using primers p23 + p24 and was cloned into 
the AvrII and XhoI restriction sites of pDC2-cam-gfp(N-C)-attP. 
This cloning yielded the egfp integration plasmid pDC2-cam-
egfp-attP used to generate the NF54EGFP line.
Expression of ZFNs in P. falciparum was achieved by cloning 
these downstream of a calmodulin (PF14_0323) promoter and 
upstream of an hsp86 (PF07_0030) 3  UTR in a pDC2 vector with 
or without the hdhfr or bsd selectable marker. ZFNs linked with 
the 2A peptide were digested with NheI and XhoI and were cloned 
into the compatible restriction sites AvrII and XhoI, thereby 
yielding the intermediate plasmids pZFNegfp and pZFNcrt and 
the final transfection plasmids pZFNegfp-hdhfr and pZFNcrt-bsd. 
The donor templates provided for the ZFN-induced DSB repair 
were either placed on the same plasmid as the ZFN expression 
cassette or on a separate plasmid, as indicated below.
To generate the egfp-hdhfr donor template (Fig. 1b), we first 
amplified 5  and 3  regions of homology flanking the ZFN cleavage 
site in the integrated egfp locus. The 5  region was PCR-amplified 
from pDC2-cam-egfp-attP using primers p3 + p25 (yielding 
a 543-bp product), whereas the 3  region (denoted egfp 3 ) 
was amplified using primers p27 + p28 (yielding a 795-bp prod-
uct). A promoterless hdhfr selection cassette was then ampli-
fied with primers p26 + p4 and fused in frame to egfp 5  using 
primers p3 + p4 in a SOE PCR reaction. The egfp-hdhfr template 
was then cloned into pZFNegfp using ApaI and SacII restriction 
sites. The second homologous region egfp 3  was then inserted 
using the restriction sites BstAPI and ZraI, thereby yielding the 
transfection plasmid pZFNegfp-egfp-hdhfr (Fig. 1b). To produce 
the pegfp-hdhfr control plasmid, we excised the egfp-specific 
ZFN segment following HindIII digestion of pZFNegfp-egfp-
hdhfr and agarose gel electrophoresis, and then we religated 
the plasmid.
To assemble the mrfp-vps4 donor template (Fig. 2a), we ampli-
fied mrfp and vps4 separately and then linked the two products by 
SOE PCR. The mrfp sequence was amplified from pML2 (ref. 30) 
using primers p29 + p30, and vps4 was amplified from NF54 
genomic DNA using primers p31 + p32. The linked mrfp-vps4 
sequence was amplified with p29 + p32 and cloned into the AvrII 
and XhoI restriction sites of pDC2, thereby yielding the replace-
ment plasmid pmrfp-vps4.
To generate the pcrtDd2-hdhfr donor plasmid for pfcrt allelic 
replacement (Fig. 3a), we first amplified intron 1 through exon 13 
of pfcrt Dd2 cDNA and pbcrt 3  UTR from an expression plas-
mid31 using p33 + p34. The PCR product was cloned into the 
restriction sites NotI and SpeI of the pCC1 plasmid (containing 
an hdhfr cassette). The left homology region, comprising the pfcrt 
5  UTR to intron 1 sequence (431 bp), was subcloned from the 
pZFNcrt-76I plasmid with ApaI and SalI (see below). The pfcrt 3  
UTR served as the right region of homology and was amplified 
from 106/1 gDNA using primers p35 + p36 (yielding a 1,050-bp 
product) and then inserted into EcoRI and ClaI to generate the 
allelic replacement plasmid pcrtDd2-hdhfr (Fig. 3a).
We generated two donor constructs to introduce a single point 
mutation (K76I) in pfcrt, located 140 bp downstream of the ZFN 
cut site. A 1-kb donor fragment without additional mutations 
at the ZFN target site (mut1) was PCR-amplified from genomic 
DNA isolated from 106/1I76 parasites15 using primers p37 + p38 
and was cloned into the ApaI and SacI restriction sites in pZFNcrt. 
We also generated a second donor template with four silent muta-
tions at the ZFN binding site (mut2) via SOE PCR using primers 
p37 + p39 and p38 + p40 for the first round of PCR and p37 + p38 
for the second round (Supplementary Table 3). The same restric-
tions sites ApaI and SacI were used to clone donor fragment mut2. 
Both donor constructs contained a single-nucleotide (T) deletion 
in the 5  UTR of pfcrt located 0.3 kb upstream of the ZFN cut site. 
The two ZFN pairs (13/15 and 14/15; Supplementary Table 2) 
were expressed from a plasmid (pZFNcrt-76I) containing either 
the mut1 or mut2 donor.
Parasite cultures and transfections. Asexual blood-stage 
parasites were propagated in human red blood cells in RPMI-
1640 malaria culture medium13 with 0.5% (w/v) Albumax II 
(Invitrogen) under 5% O2/5% CO2/90% N2. Parasites were 
electroporated with purified circular plasmid DNA as 
described13. The 2A test line expressing mRFP-2A-GFP (Fig. 1a) 
was generated by attB × attP crossover-mediated integration32 
of the pDC2-cam-mrfp-2A-gfp-attP plasmid into the cg6 locus 
of the recipient line Dd2attB. The NF54EGFP target line (Fig. 1b) 
was similarly generated by attB × attP–mediated integration of 
the EGFP expression plasmid (pDC2-cam-egfp-attP) into the 
NF54attB line12. attB × attP crossover events were mediated by 
Bxb serine integrase, which was supplied by cotransfection with 
the plasmid pINT32.
To test for ZFN-mediated cleavage of our integrated egfp 
sequence, we electroporated NF54EGFP parasites with the plas-
mid pZFNegfpegfp-hdhfr. This plasmid was designed to inte-
grate a functional egfp-hdhfr fusion (Fig. 1b) expressed from 
the upstream calmodulin promoter and conferring resistance to 
WR99210 (Jacobus Pharmaceuticals). Parasites were selected 
with 2.5 nM WR99210 for 24 (line A), 48 (line B1), 96 (line B2) 
or 120 h (line B3) after electroporation. To potentially increase 
the efficiency of plasmid delivery and gene disruption, lines 
B1–B3 were supplemented (1:1) with red blood cells preloaded 
with additional plasmid (50 g) 24 h after electroporation14. 
In a control experiment, we electroporated the donor plasmid 






























with 2.5 nM WR99210 the following day. All phenotypic and 
genotypic analyses of this set of parasite lines were performed 
on bulk cultures.
To perform our ZFN-driven egfp replacement with mrfp, we 
coelectroporated NF54EGFP parasites with the plasmids pZFNegfp-
hdhfr and pmrfp-vps4 (Fig. 2a). The pZFNegfp-hdhfr plasmid con-
tained the 2A-linked egfp-specific ZFNs that were expressed from 
a calmodulin promoter. Selection for this plasmid was applied with 
2.5 nM WR99210, which was applied 1 d post-electroporation and 
was maintained for 6 d. The pmrfp-vps4 plasmid provided the 
mrfp donor sequence flanked by homologous regions. No selec-
tion was applied for this plasmid. Parasite clones illustrated in 
Figure 2 were generated by limiting dilution.
To replace the endogenous pfcrt allele, GC03 and 106/1 para-
sites were first electroporated with the donor plasmid pcrtDd2-
hdhfr and selected with 2.5 nM WR99210 to enrich for episomally 
transformed parasites. These parasites (GCO3 + pcrtDd2-hdhfr or 
106/1 + pcrtDd2-hdhfr) were then electroporated with pZFNcrt-bsd 
(Fig. 3a). One day after electroporation, parasites were selected 
with 2 g/ml blasticidin (Invitrogen) and 2.5 nM WR99210 for 
6 d and then selected with only WR99210. Parasite clones were 
generated by limiting dilution where indicated.
To edit pfcrt using CQ selection, 106/1 parasites were electro-
porated with pZFNcrt-76I plasmids harboring either the mut1 or 
mut2 sequence template (the latter harbored four ZFN binding 
site mutations). Transformed parasites were treated with 33 nM 
CQ phosphate (Sigma-Aldrich) to select for acquisition of the 
K76I mutation (Fig. 4a). To edit pfcrt without CQ selection, Dd2 
parasites were electroporated with pZFNcrt-76I-hdhfr. One day 
after electroporation, parasites were exposed to 2.5 nM WR99210 
for 6 d to select for plasmid transformation (Fig. 4a). Analysis of 
parasite lines was performed on bulk cultures.
DNA analysis. P. falciparum trophozoite-infected erythro-
cytes were harvested and saponin-lysed. Parasite genomic DNA 
was extracted and purified using DNeasy Blood kits (Qiagen). 
Integration of the hdhfr cassette into the cg6-egfp locus of 
NF54EGFP parasites was confirmed by PCR amplification of the 
target locus using primers p1 + p2 (yielding a 1.8-kb fragment), 
p1 + p4 (3.9 kb), p5 + p7 (4.2 kb) and p3 + p6 (1.5 kb in NF54EGFP 
and 3.4 kb in ZFN-transfected parasites) (Fig. 1b,d). Replacement 
of the integrated egfp with mrfp at the chromosomal cg6 locus was 
shown by PCR amplification of the target locus using primers p10 + 
p7 (yielding a 5.7-kb fragment), p1 + p9 (yielding a 4.8-kb frag-
ment) and p8 + p6 (yielding a 2.8-kb fragment for the mrfp-vps4 
replacement, compared with 1.6 kb for the original egfp locus and 
3.3 kb for the zfn cassette) (Fig. 2a,d).
Allelic replacement of the endogenous GC03 pfcrt locus by the 
pcrtDd2-hdhfr donor sequence was confirmed by PCR of the target 
locus with primers p11 + p13 (GC03 parent: 1.4 kb, GC03crt-Dd2 
recombinant: 1.2 kb, GC03 + pcrtDd2-hdhfr: 1.4 kb, pcrtDd2-hdhfr: 
no product); p12 + p13 (GC03: 0.6 kb, GC03crt-Dd2: 0.4 kb, GC03 + 
pcrtDd2-hdhfr: 0.4 and 0.6 kb, pcrtDd2-hdhfr: 0.4 kb); and p14 + 
p15 (GC03: no product, GC03crt-Dd2: 2.5 kb, GC03 + pcrtDd2-
hdhfr: no product, pcrtDd2-hdhfr: no product) (Fig. 3a,c).
Editing of pfcrt codon 76 (Fig. 4) was confirmed by PCR-
amplifying the genomic locus with primers p23 + p27 that flank 
the pfcrt donor sequence. These products were amplified either 
from bulk cultures (and afterward cloned into pGEM-T), or from 
parasite clones (Table 1). Sequencing was performed with primers 
p24, p25, p26, p18 and p20 (Supplementary Table 3).
Whole-genome sequencing and data processing. Genomic DNA 
was prepared from the parental line NF54EGFP and the two ZFN-
transfected lines NF54 egfpA and NF54 egfpB1 as well as from 106/1 
and 106/113/15mut1 and 106/114/15 mut1. These DNAs were sheared 
(10 g per line) to obtain a fragment size of ~200–400 bp using an 
E220 focused-ultrasonicator (Covaris Inc.) and the following set-
tings: 10% duty cycle, intensity 5, 200 cycles per burst, 180 s treat-
ment time. Sheared gDNA was size selected on a 2% low-melting 
agarose gel and then purified. Barcoded libraries for Illumina 
TruSeq single-end sequencing were then constructed from the 
size-selected, sheared material using NEBNext DNA Library 
Preparation reagents (NEB) by following the standard Illumina 
library preparation protocol but omitting the final size-selection 
step. To assess the quality and percentage of adaptor-ligated 
material, the final sequencing libraries were tested on an Agilent 
2100 Bioanalyzer (Agilent Technologies) along with the original 
size-selected fragmented gDNA from the same preparation. The 
concentration of each library was determined using a Quant-iT 
dsDNA Broad-Range Assay Kit (Invitrogen). For the NF54 egfpB1 
line, the sequencing adaptor ligation was determined to be less 
than 50% efficient. We therefore PCR-amplified the sequencing 
library as described33 to minimize GC bias. PCR conditions for 
50- l reactions were: 1× Kapa HiFi Buffer, 60 nM tetramethyl-
ammonium chloride, 0.3 mM each dNTP, 0.4 M each primer and 1 U 
Kapa HiFi DNA polymerase, with thermocycling conditions of 
1 min at 98 °C followed by 12 cycles of 10 s at 98 °C, 1 min at 55 °C 
and finally 5 min at 55 °C. The final libraries were multiplexed 
with three barcoded samples and 20% PhiX control DNA per lane 
and were sequenced using an Illumina HiSeq 2000 system.
Sequencing outputs were uploaded into Galaxy34, which is 
hosted locally at the Lewis-Sigler Institute for Integrative Genomics 
at Princeton University. Sequence reads were mapped to the 
P. falciparum 3D7 reference genome v. 8.0 (http://plasmodb.org/
common/downloads/release-8.0/Pfalciparum/) using the Burrows-
Wheeler alignment tool35, and files were formatted using Sequence 
Alignment/Maptools36. GATK tools were applied to assess depths 
of coverage for the overall genomes and specific regions of interest 
and to perform SNP discovery and filtering using standard hard-
filtering parameters37. Alignments and variants were visualized 
using the Integrative Genomics Viewer38.
Southern blot hybridizations. Edited lines obtained from the 
egfp disruption and the egfp/mrfp replacement experiments and 
the parental control were analyzed using pairs of Southern blots, 
as follows. For each blot, 2 g of genomic DNA was digested with 
ClaI + BamHI, separated by electrophoresis on a 0.7% agarose gel 
and transferred onto a Nytran nylon membrane. Hybridization 
of the first blot was performed at 54 °C with a 710-bp 32P-labeled 
egfp probe that was PCR-amplified from pDC2-cam-egfp-attP 
using primers p3 + p26. The second blot was either hybridized 
with a 560-bp 32P-labeled hdhfr probe or a 670-bp 32P-labeled 
mrfp probe amplified by PCR with primers p10 + p17 (mrfp) 
or p28 + p4 (hdhfr) from the respective plasmids pmrfp-vps4 or 
pZFNegfp-hdhfr. Linearized transfection plasmids served as posi-
tive controls (8.4 kb, 8.3 kb and 9.9 kb for the egfp, mrfp and hdhfr 






























Parasite lines obtained following pfcrt allelic replacement were 
analyzed on pairs of Southern blots, for which 2 g of genomic 
DNA was digested with SalI + BstBI. Digests were separated by 
electrophoresis on a 0.7% agarose gel and transferred onto a 
Nytran nylon membrane. Hybridization was performed at 55 °C 
with a 600-bp 32P-labeled hdhfr probe amplified from pcrtDd2-
hdhfr by PCR with primers p26 + p4.
In vitro susceptibility assays. In vitro IC50 values were determined 
by incubating parasites for 72 h across a range of concentrations of 
CQ (2,000 nM −2.5 nM). After 72 h of incubation, parasite growth 
was determined by measuring parasitemia using flow cytometry. 
Cells were stained with 1.6 M Mito Tracker Deep Red and 2× 
SYBR Green (Invitrogen) in 1× PBS supplemented with 5% FBS39. 
In vitro IC50 values were calculated by nonlinear regression analy-
sis and Mann-Whitney U tests were used for statistical analysis. 
A nonparametric statistical analysis was appropriate as experiments 
were independent and no normal distribution was assumed.
For the pfcrt gene-replacement experiment (Fig. 3d), the IC50 
value for the GC03 parental line (mean  s.e.m. 18.4  5.3 nM, 
n = 4) was significantly different from the two pfcrt allelic replace-
ment clones GC03crt-Dd2 G9 (91.8  10.7 nM, n = 4, P = 0.028, 
two-tailed) and GC03crt-Dd2 H6 (100.3  15.5 nM, n = 4, P = 0.028, 
two-tailed). No significant difference in IC50 values was observed 
between the parental GCO3 line and the control GC03 + pcrtDd2-
hdhfr line that episomally replicated the donor plasmid (18.6  
6.8 nM, n = 4, P = 1.0, two-tailed).
For the pfcrt gene-editing experiment (Fig. 4b), the IC50 value for 
the 106/1 parental line (mean  s.e.m. 27.4  1.2 nM, n = 4) was sig-
nificantly different (*P = 0.028, two-tailed, Mann-Whitney U test) 
from the gene-edited parasites 106/113/15mut2 (153.6  18.3 nM) 
and 106/114/15mut1 (145.1  17.8 nM) as well as the previously 
established CQR line 106/1I76 (177.9  16.8 nM).
Fluorescence analysis of recombinant parasites. For live-cell 
imaging, resuspended cultures were washed once with RPMI-
1640 media lacking Albumax II, and the cells were applied to 
poly(l-lysine)-coated glass-bottom culture dishes (MatTek) and 
overlaid with 1 ml of RPMI media containing 2 g/ml Hoechst 
33342 (Sigma) to stain the nuclei. Images were acquired on a Nikon 
Ti-E inverted microscope with 100× N.A. 1.4 PlanApo optics and 
a CoolSnap HQ2 camera. Images were collected with Nikon NIS 
Elements software and assembled using Adobe Photoshop.
To quantify the proportion of EGFP-positive parasites in the 
NF54EGFP and ZFN-modified lines, parasite cultures were ana-
lyzed by flow cytometry. Cells were stained for 10 min with 250 nM 
SYTO 61 dye (Invitrogen) in aqueous solution containing 0.2% 
dextrose and 0.9% sodium chloride. After a single wash, 50,000 
cells were counted on an Accuri C6 Flow Cytometer. Data were 
analyzed with FlowJo 7.6.3 with gating for nuclear stain SYTO 61 
(FL4) and for green fluorescence (FL1).
29. Geurts, A.M. et al. Knockout rats via embryo microinjection of zinc-finger 
nucleases. Science 325, 433 (2009).
30. Lee, M.C., Moura, P.A., Miller, E.A. & Fidock, D.A. Plasmodium falciparum 
Sec24 marks transitional ER that exports a model cargo via a diacidic 
motif. Mol. Microbiol. 68, 1535–1546 (2008).
31. Ecker, A. et al. Evidence that mutant PfCRT facilitates the transmission to 
mosquitoes of chloroquine-treated Plasmodium gametocytes. J. Infect. Dis. 203, 
228–236 (2011).
32. Nkrumah, L.J. et al. Efficient site-specific integration in Plasmodium 
falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. 
Nat. Methods 3, 615–621 (2006).
33. Oyola, S.O. et al. Optimizing Illumina next-generation sequencing library 
preparation for extremely AT-biased genomes. BMC Genomics 13, 1 (2012).
34. Goecks, J., Nekrutenko, A. & Taylor, J. Galaxy: a comprehensive approach 
for supporting accessible, reproducible, and transparent computational 
research in the life sciences. Genome Biol. 11, R86 (2010).
35. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
36. Li, H. et al. The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 25, 2078–2079 (2009).
37. DePristo, M.A. et al. A framework for variation discovery and genotyping 
using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
38. Robinson, J.T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 
24–26 (2011).
39. Ekland, E.H., Schneider, J. & Fidock, D.A. Identifying apicoplast-targeting 






























Supplementary Information  
 
Site-Specific Editing of the Plasmodium falciparum Genome Using 
Engineered Zinc-Finger Nucleases 
 
Judith Straimer1, Marcus CS Lee1, Andrew H Lee1, Bryan Zeitler2, April E Williams3,4, 
Jocelynn R Pearl2, Lei Zhang2, Edward J Rebar2, Philip D Gregory2, Manuel Llinás3,f4, 
Fyodor D Urnov2 & David A Fidock1,5* 
 
1Department of Microbiology & Immunology, and 5Division of Infectious Diseases, 
Department of Medicine, Columbia University College of Physicians and Surgeons, New 
York, New York, USA; 2Sangamo BioSciences, Inc., Richmond, California, USA; 
3Department of Molecular Biology and 4Lewis-Sigler Institute for Integrative Genomics, 
Princeton University, Princeton, New Jersey, USA 
 
Table of Contents 
Supplementary Figure 1 | Whole-genome sequence analysis of parental and ZFN-edited 
parasite lines. 
Supplementary Figure 2 | A canonical model for homology-directed repair. 
 
Supplementary Table 1 | Whole-genome and recombinant locus sequence coverage of 
parental and ZFN-edited Plasmodium falciparum lines. 
Supplementary Table 2 | Sequence of pfcrt ZFN-binding sites and amino acid sequences 
of zinc-finger proteins. 


















3’hdhfr2A ZFN LZFN R cam 5’
pfcrt gene













































Supplementary Figure 1 | Whole-genome sequence analysis of parental and 
recombinant parasite lines. a) Whole-genome sequencing tracks of NF54EGFP (upper 
panel) and the ZFN-transfected lines NF54∆egfpA (middle panel) and NF54∆egfpB1 (lower 
panel) were aligned to elements of the linearized plasmid pZFNegfp-egfp-hdhfr. The read 
assemblies demonstrate the presence of hdhfr in the ZFN-transfected lines but not in the 
parental line. The absence of ZFNs in all three lines indicates the lack of residual 
episomes, and is consistent with all the edited parasites harboring an integrated copy of 
hdhfr. b) Sequence tracks were aligned to the egfp locus including 5’ and 3’ UTRs (cam 
and hsp86 respectively). The parental line NF54EGFP shows an intact locus compared to 
the ZFN-transfected parasites, which demonstrate a gap at the ZFN cleavage site (red box 
and yellow thunderbolt) that incorporated the hdhfr cassette. ZFNs are illustrated in blue. 
c) Sequence alignment of the parental line 106/1 (upper panel) and the pfcrt-edited lines 
106/113/15mut1 (middle panel) and 106/114/15mut1 (lower panel), showing that the pfcrt 
locus remains intact with no evidence of any rearrangements. The ZFNs are illustrated in 
blue and a red box and the yellow thunderbolt highlight the cleavage site. The lettering 
refers to the wild-type A nucleotide in green and the mutant T nucleotide in red present at 




























































Supplementary Figure 2 
ZFN-mediated gene editing
Recombinant line in ~2 to 4 weeks
High efficiency of modification
Site-specific
Conventional allelic exchange 
Recombinant line in ~3 to > 6 months
Low efficiency of modification
Undefined, stochastic site of crossover
3’
Transfected parasite




Supplementary Figure 2 | The canonical model for homologous recombination. 
Conventional genome modification strategies in P. falciparum rely on prolonged selection 
regimes to enrich for rare and stochastic double strand break (DSB)-mediated integration events 
that, due to the undefined site of crossover, may not always capture the mutation of interest. In 
contrast, ZFNs targeting a precise site induce DSBs that efficiently trigger homology-directed 
repair from a donor template. a) Stochastic or ZFN-mediated DSBs in the genome stimulate 
homology-directed repair. DNA ends are resected from 5’ to 3’, generating 3’ single-stranded 
DNA (ssDNA) tails and committing repair to homologous recombination. b) One tail invades the 
donor template (Strand Invasion), forming a D-loop, and acts as a primer to initiate DNA 
synthesis from the donor template, thereby incorporating potential SNPs (green squares). c) In 
the Synthesis Dependent Strand Annealing (SDSA) pathway, the ssDNA tail is then actively 
displaced and bridges the DSB, fixing the DNA lesion and incorporating the donor mutation. 
During mitosis, a majority of D-loops form Non-Crossovers (NCOs) via SDSA. The resulting 
mismatch generated by the incorporation of the mutated nucleotide is repaired primarily in favor 
of the donor sequence by the mismatch repair machinery. If SDSA is not used, d) the second 
DSB-generated ssDNA end is captured and e) forms a double Holliday Junction. f) The two 
Holliday Junctions can be pushed together (Dissolution) by helicases (grey arrows) to form a 
NCO product. Alternatively these junctions can be resolved by structure-specific endonucleases 
(resolvases, red and purple triangles). Depending on the pattern of cleavage, resolution can form 
either a g) NCO or h) Crossover (CO) product. Previous P. falciparum genome modification 
strategies relied on solely on the CO pathway. COs are suppressed in mitotically dividing cells, 
making this a low frequency event. In contrast, ZFN-based strategies exploit NCO repair 
pathways to yield a much higher frequency of gene editing. Parasites carrying modifications 
ranging from single point mutations to insertion of an entire transgene can be generated in a short 
time frame, reflecting the 100–1,000 fold increase in homologous recombination frequency 





Supplementary Table 1. Whole-genome and recombinant locus 




a Genome data were generated on a Illumina HiSeq 2000 system. 





Supplementary Table 2. Sequence of pfcrt-specific ZFN binding sites 
and amino acid sequences of zinc-finger proteins. 
 
a The right ZFN (30415-KKR) is specific to a sequence on the + strand.  
b The two left ZFN (30413-ELD and 30414-ELD) bind to the complementary (-) strand of pfcrt.  


















Supplementary Table 1. Whole-genome and recombinant locus sequence coverage of 
parental and ZFN-edited Plasmodium falciparum lines. 
 Coverage of Whole Genomea Coverage of Recombinant Locusb 
Parasite Line 










% > 15 x 
Coverage 
NF54EGFP 3,305,342,890 144.5 88.1 101 0.2 0 
NF54!egfpA  1,230,610,575 53.8 93.2 31,613 56.1 92 
NF54!egfp B1  1,583,172,847 69.2 94.1 23,735 42.1 85.3 
106/1 1,144,034,688 50.0 99.5 123,672 40.6 87.6 
106/113-15mut1 3,605,540,604 157.6 96.8 403,058 132.4 96.7 
106/114-15mut1 2,572,409,833 112.5 98.7 293,672 95.7 93.4 
a Genome data were e erate  on a Illumina HiSeq 2000 system. 
b The recombinant locus in the case of the NF54 and the 106/1 lines was dhfr and pfcrt respectively.  
Supplementary Table 2. Sequence of pfcrt-specific ZFN binding sites and amino acid sequences of zinc-finger proteins. 
pfcrt ZFN Binding Sequence (underlined) ZFN Finger 1 Finger 2 Finger 3 Finger 4 Finger 5 Finger 6c 
TTCCCTtGTCGACCTTAACagatgGCTCACGTTTAGGTG 30415-KKR
a
 RQDCLSL RNDNRKT TSGSLSR DRSNLSS QSSDLSR  
AAGGGAaCAGCTGGAATTGtctacCGAGTGCAAATCCAC 30413-ELD
b QSGNLAR RQEHRVA DRSNLSR DSSARNT RSDNLSV TSGSLTR 
        
CTTGTCGACCTTAACagatgGCTCACGTTTAGGTG 30415-KKR
a
 RQDCLSL RNDNRKT TSGSLSR DRSNLSS QSSDLSR  
GAACAGCTGGAATTGtctacCGAGTGCAAATCCAC 30414-ELD
b
 RSDNLSV  DRSNLSR DSSARNT RSDNLSV TSGSLTR  
 
a The right ZFN (30415-KKR) is specific to a sequence on the + strand.  
b The two left ZFN (30413-ELD and 30414-ELD) bind to the complementary (-) strand of pfcrt.  
c ZFN 30415-KKR and 30414-ELD consist of five zinc fingers and 30413-ELD of six. 
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Supplementary Table 3. List of oligonucleotides used in this study. 
 
Name Nucleotide Sequence (5’-3’) Description Lab Name 
p1 GAAAATATTATTACAAAGGGTGAGG cg6 5’ fwd p1969 
p2 ACGAATTCTTAGCTAATTCGCTTGTAAGA bsd rev p836 
p3 CTGGGCCCATGGTGAGCAAGGGCGAGGAGC egfp Homologous region I ApaI fwd p3088 
p4 ACCCCGCGGTTAATCATTCTTCTCATATAC hdhfr Homologous region I SacII rev p3078 
p5 GAGTCGTATTACAATTCACTGG pDC2 plasmid backbone Rep20 p3235 
p6 CTTAATCATTTGTATTTGGGAGG hsp86-3’ rev p3202 
p7 CTCTTCTACTCTTTCGAATTC cg6 rev p1970 
p8  CGGATCCTTTTAAACTAGAAAAGGAATAAC 1 kb Cam promoter (~75bp upstream) fwd p1170 
p9 CCCTCGAGTTATGTACCGTTCATTCCATATTG PF14_0548 stop XhoI rev p1143 
p10 ATGGCCTCCTCCGAGGACGTCATC mrfp fwd p1136 
p11 CTTGGGCCCAAGTTGTACTGCTTCTAAGC pfcrt 5'UTR (-494-517) ApaI fwd p3404 
p12 CTTGAATTCATGGCTCACGTTTAGGTGGAG pfcrt exon 2 EcoRI fwd p3312 
p13 CTTATCGATAAGCAGAAGAACATATTAATAGGAATACTTAATTG pfcrt exon 3 ClaI rev p3265 
p14 CTCGAGATGGTTGGTTCGCTAAACTGC hdhfr (+1-21) XhoI fwd p3315 
p15 TTGACCCTTATATATTCCACCCA pfcrt 3' UTR (+1285-1308) rev p3403 
p16 CCAAGTTGTACTGCTTCTAAG pfcrt 5' UTR (-495-516) fwd 105’F2 
p17 TACAACAATAATAACTGCTCCGAG pfcrt exon 4 rev AB17B 
p18 CTCCACCGGCGCCAGTAGTAGATCTGGCGGCGGAGAGGG T2A peptide/mrfp overlap BglII fwd p3361 
p19 CGCGGATCCGCTAGCAGGGCCGGGATTCTCCTCC T2A peptide NheI BamHI rev p3362 
p20 CGCGGATCCGCTAGCGCCGGGATTCTCCTCC T2A peptide ΔP21 NheI BamHI rev p3363 
p21 CGCCTAGGATGGCCTCCTCCGAGGACGTCATC mrfp AvrII fwd p1140 
p22 GGCGCCGGTGGAGTGGC mrfp rev p1141 
p23 TTCCTAGGATGGTGAGCAAGGGCG egfp AvrII fwd p3006 
p24 CCCTCGAGTTACTTGTACAGCTCGTCC egfp stop XhoI rev p3007 
p25 CGAACCAACCATTCCGCTAGCACCGACGTTGTGGCTGTTGTAGTTGTAC egfp/hdhfr overlap Homologous Region I rev p3089 
p26 CAGCCACAACGTCGGTGCTAGCGGAATGGTTGGTTCGCTAAACTGC hdhfr/egfp overlap Homologous Region I fwd p3090 
p27 CCGCATATGGTGCTATATCATGGCCGACAAGCAGAAG egfp Homologous Region II BstAPI fwd p3091 
p28 CTGACGTCGAATTTATAAACGTTTGGTTATTAG hsp86-3’ Homologous region II ZraI rev p3080 
p29 CG CCTAGG ATGGCCTCCTCCGAGGACGTCATC AvrII ATG mrfp fwd p1140 
p30 GGCGCCGGTGGAGTGGC mrfp no stop rev p1141 
p31 GGGCCGCCACTCCACCGGCGCCACCGGTGGA ATGGACTCTGAAGAAACAATAAATTTG mrfp overlap ThrGlyGly ATG PF14_0548 fwd p1142 
p32 CCCTCGAGTTATGTACCGTTCATTCCATATTG PF14_0548 stop XhoI rev p1143 
p33 CTTGCGGCCGCGGGCCCCTTGTCGACCTTAACAGATGGC pfcrt intron 1 exon 2 NotI ApaI fwd p3262 
p34 CTTACTAGTTATTTCAAAAATCTTAGCATAAGGATTC pbcrt 3' UTR (+1-28) SpeI rev p3263 
p35 CTTGAATTCAATTATATCATTTATTTTTTTATATTTTTTATATTTTTTTTATTTTTCATG pfcrt 3' UTR (+1-51) EcoRI fwd p3310 
p36 CTTATCGATAACTGAAACTTGAAATAAGTGGCG pfcrt 3' UTR (+1025-1050) ClaI rev p3311 
p37 GGGCCCCTATAGATTATTTTCATTGTCTTCC pfcrt 5’ UTR (-150-175bp) ApaI fwd p3128 
p38 CGAGCTCAAGCAGAAGAACATATTAATAGG pfcrt exon 3 SacI rev p3131 
p39 CGAGATCCATCTATTAGGGTCGAC pfcrt intron 1 ZFN 30413/14/15 mut2 rev p3132 
p40 CCCTAATAGATGGATCTCGTTTAGG pfcrt intron 1 ZFN 30413/14/15 mut2 fwd p3133 
p41 AGATGGCTCACGTTTAGGTGGAGG pfcrt exon 2 fwd AF12 
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SUMMARY
Research into the complex genetic underpinnings of the malaria
parasite Plasmodium falciparum is entering a new era with the
arrival of site-specific genome engineering. Previously restricted
only to model systems but now expanded to most laboratory or-
ganisms, and even to humans for experimental gene therapy stud-
ies, this technology allows researchers to rapidly generate previ-
ously unattainable genetic modifications. This technological
advance is dependent on DNA double-strand break repair
(DSBR), specifically homologous recombination in the case of
Plasmodium. Our understanding of DSBR in malaria parasites,
however, is based largely on assumptions and knowledge taken
from other model systems, which do not always hold true in Plas-
modium. Here we describe the causes of double-strand breaks, the
mechanisms of DSBR, and the differences between model systems
and P. falciparum. These mechanisms drive basic parasite func-
tions, such as meiosis, antigen diversification, and copy number
variation, and allow the parasite to continually evolve in the con-
texts of host immune pressure and drug selection. Finally, we dis-
cuss the new technologies that leverage DSBR mechanisms to ac-
celerate genetic investigations into this global infectious pathogen.
INTRODUCTION
DNA double-strand breaks (DSBs) are one of the most deleteriousforms of damage that a cell can encounter. A single DSB can
potentially lead to loss of heterozygosity (in diploids), chromosome
translocations, chromosome loss, cell cycle stalling, overall genome
instability, and, ultimately, cell death (1, 2). The repair of DNA dam-
age is closely tied with DNA replication to ensure accurate copying of
the genome (3). The DNA repair machinery requires a significant
amount of energy to function, a sign of its importance to cell viability.
DNA double-strand break repair (DSBR) has been studied exten-
sively over the past 30 years, primarily in the budding yeast Saccha-
romyces cerevisiae (4, 5) as well as in humans (2, 6), in particular
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because maintaining genome stability is important for preventing
cancer.
Despite the destructive potential of DSBs, their role in the cell can
also be beneficial. The fidelity of DSBR must be lax enough to allow
for sufficient genetic variation. DSBs are created in certain cell types
to initiate programmed genome rearrangements, such as meiotic
crossing over (5, 7), immune response diversification (8), the mating-
type switch of budding yeast (5), and antigenic variation (e.g., in
Trypanosoma brucei [9]). Genetic manipulation relies on the gener-
ation of DSBs by use of site-specific endonucleases. Broken DNA
ends are highly recombinogenic (10), and the generation of DSBs is a
major rate-limiting factor in recombination (11, 12). Current tech-
nologies and strategies rely on the opportunistic use of the DSBR
pathways for accurate, efficient, and predictable gene editing (13, 14).
Here we first provide a brief overview of DSBR, including key find-
ings established in yeast, and describe the current research on Plas-
modium orthologs, functions, and unique attributes. We then delve
into the use of DSBR in basic parasite processes and the leveraging of
DSBR to genetically modify Plasmodium falciparum.
THE PLASMODIUM LIFE CYCLE
An infected female Anopheles mosquito taking a blood meal will
secrete its saliva along with Plasmodium sporozoites into the dermis
of its new host (15) (Fig. 1). Within an hour, these sporozoites mi-
grate to the host’s liver and invade hepatocytes. The sporozoites then
replicate, forming up to tens of thousands of merozoites, which burst
from the hepatocytes to enter the peripheral circulation. Merozoites
quickly invade erythrocytes, starting the asexual cycle (16) (Fig. 2).
Over the next 48 h, an intraerythrocytic P. falciparum parasite pro-
duces as many as 24 daughter merozoites, which burst from the host
cell to reinitiate a new round of asexual replication. Intraerythrocytic
parasites can also adopt an alternative, sexual-stage developmental
pathway, in which they form male or female gametocytes. Over a
2-week period, these stages mature and become infectious for mos-
quitoes (17). Upon transmission, gametocytes convert into gametes
that can then mate to form a zygote (15). Following meiosis, zygotes
convert into motile ookinetes that exit the blood meal confines and
traverse the midgut epithelium, after which they lodge under the
basal lamina and form oocysts. During the process of sporogony in-
side an oocyst, the parasite undergoes multiple rounds of replication
to generate thousands of haploid sporozoites, which migrate to the
mosquito salivary glands to await the next blood meal.
OVERVIEW OF DNA DOUBLE-STRAND BREAK REPAIR
Causes of Double-Strand Breaks
DSBs can be generated experimentally; others are inherent to cel-
lular processes (5). DSBs are used in many model organisms, and
FIG 1 The Plasmodium life cycle. A malaria infection begins with the transmission of a Plasmodium parasite via a female Anopheles mosquito host (left) to a
human host (right). After the initial liver stage, the parasite begins its asexual intraerythrocytic cycle. Sexual forms, which develop from the intraerythrocytic
parasites, can be transmitted to another mosquito. In the mosquito, parasites undergo meiotic and mitotic replication to form sporozoites, which can infect
another human host. RBCs, red blood cells.
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experimental sources include ionizing radiation (IR) (e.g., !- and
X-rays) (18), UV irradiation, chemical mutagens (e.g., hy-
droxyurea, camptothecin [CPT], and methyl methanesulfonate),
and DNA nucleases (e.g., zinc finger nucleases, Tal effector-like
nucleases, and the clustered regularly interspaced short palin-
dromic repeats-Cas [CRISPR/Cas] system). Inherent sources can
stem from cellular processes, such as the generation of reactive
oxygen species by aerobic metabolism (19), transcription (20),
and replication fork collapse (21).
Generating double-strand breaks in Plasmodium. In compar-
ison to DNA repair research done in model organisms such as
yeast, the use of DSB sources to interrogate Plasmodium biology
has been limited. For example, in Plasmodium, irradiation has
been used primarily in efforts to create attenuated sporozoite vac-
cines (22–24), such that parasites are compromised in their intra-
cellular replicative ability. Some chemical mutagens have been
used to study nucleotide or base excision repair (NER or BER,
respectively) (25–27). CPT, which generates DSBs by trapping the
topoisomerase I (TopI) reaction intermediate during relaxation of
supercoiled DNA and blocks the progression of the replisome, has
been shown to inhibit P. falciparum TOP1 (PlasmoDB gene iden-
tifier PF3D7_0510500) function in vitro (28) and is active against
parasite cultures, with a half-maximal inhibitory concentration
(IC50) of "1 #M in a 72-h drug assay (our unpublished results).
Several studies using the first-line antimalarial drug artesunate
as a chemical mutagen have emerged in the past decade. The ef-
fects of artesunate on mammalian cell lines show that it can pro-
mote oxidative DNA damage (29) and also induce a DSBR re-
sponse (29, 30). However, the far more potent activity of
artesunate against Plasmodium asexual blood-stage parasites (in
the low nanomolar range in vitro) and the recent identification of
a variant kelch protein (PF3D7_1343700) as a candidate molecu-
lar marker of artemisinin resistance (31) suggest a primary mode
of antimalarial action distinct from DNA damage.
DNA nucleases, specifically engineered endonucleases, are be-
coming more commonplace as tools for genetic modification in
many organisms, due to their ability to bind and generate DSBs in
most investigator-defined DNA sequences (14). These nucleases
and their use in Plasmodium are described in further detail below.
DNA damage arising from transcription, replication fork col-
lapse, or by-products of normal cellular processes, such as aerobic
respiration or hemoglobin degradation, has been studied even less
in Plasmodium. Replisome collisions with transcription bubbles
or single-stranded DNA (ssDNA) generated by oxidative damage
can lead to DSBs (20, 32). As an intraerythrocytic parasite grows, it
degrades copious amounts of hemoglobin in the digestive vacuole,
releasing heme. Heme is oxidized from ferrous (Fe2$) to ferric
(Fe3$) iron, producing hydroxyl radicals, a potent DNA-damag-
ing agent (33). Therefore, it is possible that in Plasmodium, cellu-
lar processes such as hemoglobin degradation and the release of
free radicals, coupled with the many rounds of DNA replication,
may result in the production of DSBs that the parasite must repair
to maintain viability.
DNA DOUBLE-STRAND BREAK REPAIR
In most eukaryotes, the DSBR response can be split into two main
branches: the “error-free” homologous recombination (HR)
pathway and the potentially “error-prone” end-joining (EJ) path-
ways. During HR, a broken DNA duplex utilizes a homologous
template (a sister chromatid, a homologous chromosome in dip-
loids, a donor plasmid, or an ectopic donor if the DSB forms
within a repeated sequence) for highly accurate repair. The EJ
pathways do not use a homologous template and instead ligate
broken DNA ends together, resulting in a higher possibility of
insertions or deletions (indels). Below, we outline DSBR and de-
scribe P. falciparum orthologs and experimental evidence where
possible. We use S. cerevisiae nomenclature in reference to or-
thologs, omitting Homo sapiens nomenclature for clarity unless
FIG 2 The Plasmodium asexual intraerythrocytic cycle. A haploid (1n) merozoite invades a red blood cell (RBC) and develops as the “ring” form from 0 h to
about 24 h postinvasion, corresponding to the G1 phase of the cell cycle. As the parasite transitions from rings to trophozoites, its metabolic activity increases in
preparation for DNA replication. Prior to S phase and DNA replication, the parasite is still haploid, allowing for possible alternative EJ pathways. DNA replication
produces multiple copies of the genome in an intact nucleus that does not undergo membrane degradation, providing homologous templates for HR. Plasmo-
dium DNA replication is asynchronous and can produce a range of sister chromatids, up to about 24n. Nearing the end of the 48-h cycle, each genome is packaged
into separate daughter merozoites, which then egress and invade another RBC.
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otherwise stated. P. falciparum, S. cerevisiae, and H. sapiens or-
thologs can be found in Table 1. For more in-depth reviews of
DSBR, we refer the reader to several excellent publications (1, 2, 4,
5, 34).
Mitotic Recombination: Mechanisms and Evidence in
Plasmodium
Initial double-strand break sensing and resection. A DSB is first
sensed by the Mre11-Rad50-Xrs2 (MRX) complex (Fig. 3A) (35).
TABLE 1 Bioinformatic comparison of genes involved in homologous recombination, nonhomologous end joining, and microhomology-mediated
end joining among S. cerevisiae, H. sapiens, and P. falciparum
Repair mechanism
Gene product or PlasmoDB ID
S. cerevisiae H. sapiens P. falciparumd


















DNA polymerase " DNA polymerase " PF3D7_1017000









Nonhomologous end joining Ku70 Ku70
Ku80 Ku80













Cdc9 DNA ligase I PF3D7_1304100
Rev3 DNA Pol # catalytic subunit PF3D7_1037000
Pol4 DNA Pol $
Rad30 DNA Pol %
a Lacks 5=-to-3= exonuclease indicative of WRN.
b Low homology.
c Possible UvrD helicase.
d P. falciparum orthologs were determined from previous publications or were confirmed by BLAST and identification of unique domains with Pfam, version 27.0.
Lee et al.
472 mmbr.asm.org Microbiology and Molecular Biology Reviews
228
FIG 3 Canonical models of homologous recombination, synthesis-dependent strand annealing, and break-induced replication. A double-strand break (DSB)
in a chromosome (A) is first sensed and tethered together by the MRX-Sae2 complex (B). (C) Resection by Exo1 (gray “Pac-man”) or the STR-Dna2 complex
(yellow and red triangles, respectively) exposes 3= ssDNA tails, which are then bound by RPA (green dots). RPA is replaced by Rad51 (gray helices) (D), which
forms a nucleoprotein filament that invades homologous templates (E). (F) Synthesis-dependent strand annealing (SDSA) uses the invading 3= tail as a primer
for DNA synthesis. Once sufficient homology is synthesized, the invading strand can bridge the DSB to restore chromosome integrity. (L) If the distal
chromosome arm is lost, then break-induced replication can occur, with DNA synthesis continuing conservatively until it reaches the end of the chromosome
arm. If both broken DNA ends are captured by a homologous template (G), then a double Holliday junction (dHJ) can be formed (H). This structure can be
resolved in a number of ways. (I) Merging of both Holliday junctions by the STR complex (yellow triangles) dissolves the dHJ in a hemicatenane structure, which
is unlinked by the Top3 topoisomerase. Cleavage of both Holliday junctions by structure-specific resolvases (purple triangles) can unlink the dHJ to produce
either noncrossover (J) or crossover (K) products.
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The MRX complex binds to double-stranded DNA (dsDNA) ends
formed by a DSB, positions both ends in close proximity, and, in
collaboration with Sae2, initiates 5=-to-3= resection, creating short
3=-terminated ssDNA tails (Fig. 3B). Initial resection is a rate-
limiting step in HR, as it provides the substrates for further, ex-
tensive resection (36, 37). Mre11 and Rad50 show high homology
with their Plasmodium orthologs, but Xrs2 and Sae2 do not, likely
due to low sequence conservation among all species.
Extensive resection. Initial resection is followed by 5=-to-3= ex-
tensive resection by functionally redundant factors (exonuclease 1
[Exo1] and the Sgs1-Top3-Rmi1-Dna2 [STR-Dna2] complex)
(36, 37), which commits DSBR to HR and generates long 3=
ssDNA tails (Fig. 3C). Exo1 degrades DNA from the 5= to the 3=
end and is a member of the 5=-structure-specific Rad2/XPG family
of nucleases, which are involved in most DNA repair pathways
(e.g., mismatch repair [MMR] and NER). Sgs1 is a RecQ helicase
that unwinds linear dsDNA, creating a Y-shaped structure that is
then cleaved by the flap endonuclease Dna2 (Fig. 3C) (38). Sgs1
has two human homologs, BLM and WRN (mutated in Bloom’s
and Werner’s syndromes, respectively). BLM has been shown to
be the primary resection protein in mammalian cells (39, 40),
although Xenopus WRN-DNA2 can also resect linear DNA sub-
strates in vitro (41). Both BLM and WRN have P. falciparum ho-
mologs (PF3D7_0918600 and PF3D7_1429900, respectively),
though the P. falciparum WRN homolog lacks the 5=-to-3= exonu-
clease domain that is characteristic of WRN proteins in other eu-
karyotes. It is therefore possible that PF3D7_1429900 is in fact a
different RecQ helicase.
The extent of resection varies between species. Yeast can ex-
hibit ssDNA tract lengths of up to 2 to 4 kb during mitotic HR and
up to 850 bases during meiotic HR (34). Detailed analyses of re-
section have not been performed in Plasmodium. Extensive
ssDNA resection tracts are likely to signal cell cycle arrest and
prevent unwanted recombination by exposing more unique se-
quence to search for a homologous template (34). In an A/T-rich
organism with extensive regions of low complexity, such as P.
falciparum, long resection tracts may be beneficial for ensuring
that a resected sequence is unique enough to undergo HR with the
correct template.
Rad51 nucleoprotein filament formation and strand inva-
sion. 3= ssDNA tails generated by resection are first coated by the
heterotrimeric replication protein A (RPA) complex (Fig. 3C),
protecting them from degradation and secondary structure for-
mation (42). P. falciparum encodes all three subunits of RPA and
an additional truncated version of the RPA1 subunit (RPA1S),
which antagonizes the long form (RPA1L) during in vitro recom-
bination (43). Yeast Rad52 (or the human breast cancer type II
susceptibility protein [BRCA2]) then displaces RPA and simulta-
neously delivers ATP-bound Rad51, the central HR recombinase,
onto ssDNA, allowing it to form a nucleoprotein filament (Fig.
3D). Rad51 catalyzes invasion and pairing between the ssDNA to
which it is bound and the complementary sequence to form a
displacement loop (D loop) (Fig. 3E).
Rad52 homologs have not been found in Plasmodium (44), and
the P. falciparum RPA1 homologs lack similarity to the N-termi-
nal domains of other eukaryotic RPA1 orthologs (45) that are
necessary for Rad52 interactions (46). Caenorhabditis elegans,
Drosophila melanogaster, and Arabidopsis thaliana all lack Rad52,
which may also be the case for P. falciparum. Mammals use
BRCA2 in addition to Rad52, and BRCA2 sequence similarity
even among mammals is relatively low. Nevertheless, BRCA2
homologs have been briefly mentioned for P. falciparum
(PF3D7_1328200) and Plasmodium yoelii (PY17X_1348100),
where homology is found in only 6 BRC repeats. These repeats are
known to stimulate Rad51-ssDNA binding and to prevent non-
specific Rad51-dsDNA binding (47). Trypanosoma cruzi, T. bru-
cei, and Leishmania major also have BRCA2 homologs with vari-
ous numbers of BRC repeats (48). Other BRCA2 regions (the
oligonucleotide-binding [OB] fold that binds ssDNA and the
Tower domain, which binds dsDNA), however, have not been
identified in these homologs. These regions also cannot be iden-
tified in the D. melanogaster BRCA2 homolog (47) and may be too
divergent to detect bioinformatically, as they can have low se-
quence conservation (49). Nevertheless, D. melanogaster BRCA2
remains proficient in homologous recombination (50), as is ex-
pected to be the case with Plasmodium parasites. In stark contrast
to Rad52 and BRCA2, P. falciparum Rad51 shows high homology
to Rad51 proteins of many species. Predictably, it is upregulated in
response to the DNA-damaging agent MMS, performs strand ex-
change on DNA substrates in vitro, and hydrolyzes ATP (44, 51).
Efficient Rad51-mediated D-loop formation is enhanced by
the Rad55-Rad57 heterodimer and the Rad54 motor protein.
Rad55-Rad57 stabilizes the Rad51 nucleoprotein filament by pre-
venting Rad51 displacement from ssDNA (52). Rad54 is a
dsDNA-dependent ATPase that translocates along dsDNA, en-
hances Rad51-dependent strand exchange, and stabilizes Rad51
filament formation on both ssDNA and dsDNA (53–55). Rad54,
however, only dissociates Rad51 from dsDNA. The synergistic
effects of Rad54 on Rad51-mediated strand exchange are mir-
rored in in vitro assays using purified P. falciparum Rad51
(PfRad51) and PfRad54 (PF3D7_0803400) (43).
D-loop formation is followed by polymerase !-dependent
DNA synthesis primed from the 3= OH group of the invading 3=
ssDNA tail (Fig. 3E). Synthesis extends for "250 bp in yeast (56),
expanding the D loop and incorporating any single nucleotide
polymorphisms (SNPs). So far, extension of the invading arm has
been found to incorporate SNPs 150 bases distal to the DSB with a
high frequency (13), and up to 900 bp distal at a lower but sub-
stantial level, during gene editing in P. falciparum (57). More de-
tailed frequencies and tract lengths have yet to be delineated thor-
oughly.
Noncrossovers (NCOs) and crossovers (COs). Two basic op-
tions exist after D-loop formation: synthesis-dependent strand
annealing (SDSA) (Fig. 3F) and formation of double Holliday
junctions (dHJs) (Fig. 3H). During SDSA, the invading strand is
extended to traverse the DSB, the D loop is collapsed, and the
extended strand bridges the DSB. The homologous template is left
unchanged. Possible SNPs copied from the homologous template
will generate heteroduplex DNA and be corrected by the MMR
machinery. MMR tends to favor the donor as the “correct” tem-
plate, but the mechanism of this proclivity has yet to be deter-
mined (56).
If the D loop captures the second 3= ssDNA tail (Fig. 3G), then
the D-loop intermediate can form a dHJ (Fig. 3H). dHJs are then
processed by two distinct, canonical pathways. dHJs can be “dis-
solved,” whereby they are merged together by the Sgs1-Top3-
Rmi1 (STR) complex into a hemicatenane structure, which is un-
linked by the topoisomerase Top3 to generate an NCO product
(Fig. 3I). Alternatively, dHJs can be resolved by Mus81-Mms4,
Yen1, or Slx1-Slx4 (58). Depending on the cleavage pattern of the
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dHJs, resolution will form NCO or CO products (Fig. 3J and K,
respectively). Currently, more intricate pathways branching from
the canonical model of dHJ resolution are being elucidated (58,
59). Some of the nucleases, such as Mus81, Yen1, Rad1, and
Rad10, have orthologs in P. falciparum and are listed in Table 1.
Orthologs could not be found for Mms4, Slx1, and Slx4.
By definition, HR by any of these mechanisms is highly accu-
rate, but errors can arise. For example, mitotic crossovers in dip-
loids can lead to loss of heterozygosity. Nonallelic HR (NAHR)
between repeated sequences can generate copy number variants
(CNVs) (discussed below) or translocations. Furthermore, if a
chromosome arm is lost during repair, the invading strand inter-
mediate can copy the homologous template until the site of its
telomere, using a process termed break-induced replication (BIR)
(Fig. 3L). BIR can cause extensive loss of heterozygosity in diploids
(60). In Plasmodium, BIR is one mechanism that is believed to
generate novel var sequences (see below).
Meiotic Recombination: Mechanisms and Evidence in P.
falciparum
Meiotic recombination is important for the efficient production
of sporozoites in Plasmodium (61), spores in budding yeast (62,
63), and gametes in mammals (7, 64). The basic mechanistic out-
comes of meiotic recombination are largely similar to those of
mitotic recombination, but they involve a larger set of meiosis-
specific proteins for the programmed generation of genetic diver-
sity (7, 63). Here we briefly discuss meiosis in Plasmodium and
focus on the meiotic factors involved in recombination.
The mosquito stage of the Plasmodium life cycle begins with
transmission of male and female gametocytes via a blood meal
(Fig. 1). Almost immediately, the male microgametocyte under-
goes three rapid rounds of DNA replication, producing eight hap-
loid genomes (65). Exflagellation produces eight single microg-
ametes (1n) (66). A microgamete can subsequently fertilize a
female macrogamete (1n), producing a zygote (2n). A subsequent
round of DNA replication (2n, 4c) is then followed by meiosis (67,
68) to form a tetraploid ookinete (2n, 4c). During meiosis, cross-
ing over via HR is known to be important for the formation of
yeast spores (62) and begins with the production of programmed
DSBs by the meiosis-specific topoisomerase-like protein Spo11
(69). Note that Plasmodium orthologs of Spo11 exist, suggesting a
conserved mechanism (70). In yeast, meiotic HR utilizes the
Rad51 homolog Dmc1 to catalyze strand exchange, with Rad51
playing a supporting role (71). In Plasmodium berghei, a Dmc1
knockout produces fewer and smaller oocysts and substantially
smaller numbers of sporozoites (61), implicating marked defects
in meiotic recombination. While a similar knockout has not been
studied in P. falciparum, Dmc1 is expressed in gametocytes prior
to meiotic recombination, implicating a similar role (72).
As with mitotic HR, successful strand invasion (Fig. 3E) pro-
vides the choice between forming NCOs and COs by various path-
ways (Fig. 3F and H). Spo11-induced DSBs are predominately
repaired as NCOs (likely by SDSA) and COs at a 10:1 ratio in
mammals (7). This relative excess of NCOs has also been seen in P.
falciparum (73, 74). However, these reports may still underrepre-
sent the number of NCOs, due to a lack of resolution or to NCO
products that are indistinguishable from either parental chromo-
some.
In contrast to the case for mitotic HR, resolution of meiotic dHJ
intermediates in S. cerevisiae requires the MutL homologs Mlh1
and Mlh3 along with Exo1 (7, 62). In the case of P. falciparum,
whole-genome sequence analysis of artemisinin-resistant Cambo-
dian parasite populations showed a high frequency of an Mlh1
(PF3D7_1117800) mutation (75), possibly implicating a defect in
meiotic crossing over. In a yeast exo1! strain, the homologous
Mlh1 mutation showed a moderate mutator phenotype (76), con-
sistent with a loss of function. To date, no Mlh3 ortholog has been
identified in P. falciparum. During meiotic recombination, each
chromosome averages one crossover (73, 74, 77) and has a genetic
map unit distance of "10 kb (77) to "15 kb (73) per centimorgan.
Meiosis is followed by many rounds of DNA replication inside
oocysts to form thousands of genomes that segregate into individ-
ual haploid sporozoites (66, 78).
Investigations into the process of meiotic recombination in
Plasmodium have been limited to analyzing P. berghei DNA con-
tent during sexual reproduction (65, 67). Several other studies,
nonetheless, have explored outcomes of meiotic recombination.
P. falciparum genetic cross studies have analyzed the segregation
of chromosomal markers (SNPs and microsatellites) spread out
over the genome between geographically distinct parasite clones:
3D7 # HB3 (79), HB3 # Dd2 (73, 74, 80–82), and 7G8 # GB4
(77, 83, 84). These were instrumental in mapping the dihydro-
folate reductase gene (dhfr) (85) and P. falciparum chloroquine
resistance transporter gene (pfcrt) (86) that are key drug resistance
loci and identifying key determinants of host cell tropism (77,
83, 84).
End Joining
Basic mechanisms of end joining. Parallel to HR, the EJ pathways
are comprised of the classical and alternative EJ pathways, by
which broken DNA ends are religated without a homologous tem-
plate for repair. The classical nonhomologous end-joining
(NHEJ) pathway (Fig. 4A) has commonly been referred to as the
“error-prone” pathway, though it is likely rather error-free but
accommodating of promoting genetic variability (87).
In yeast, NHEJ can be performed with just the Ku70/80 (Ku)
heterodimer and the DNA ligase IV-Lif1-Nej1 complex (88). The
Ku heterodimer binds broken DNA ends, which can protect them
from end resection and commitment to HR (89) and act as a
platform for NHEJ factor recruitment (88). Ku promotes EJ of a
variety of substrates by sterically fitting in the grooves of the DNA
double helix, as opposed to forming specific base interactions
(90). In vertebrates, the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) and the endonuclease Artemis are essential
NHEJ factors. DNA-PKcs and Artemis bind Ku-bound ends, and
phosphorylation of Artemis by DNA-PKcs activates its endonu-
clease activity (91). Either nucleolytic degradation or polymerase
nucleotide addition generates DNA ends compatible for EJ.
Absence of nonhomologous end joining in Plasmodium. To
date, bioinformatic analyses have failed to identify any Plasmo-
dium homologs of NHEJ proteins (Table 1) (92). In contrast, an-
other apicomplexan parasite, Toxoplasma gondii, carries a func-
tional Ku-dependent NHEJ pathway (93), suggesting that despite
relative evolutionary proximity to T. gondii, Plasmodium has lost
its NHEJ machinery. In support of this hypothesis, a recent study
showed the absence of any NHEJ products recovered from in vivo
endonuclease-generated DSBs in Plasmodium (13). Furthermore,
other eukaryotic pathogens, such as Giardia lamblia (94), Enceph-
alitozoon cuniculi (95), and Trichomonas vaginalis (96), also lack
NHEJ components.
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Possible alternative end-joining mechanisms in Plasmodium.
If NHEJ was indeed lost during Plasmodium evolution, then alter-
native EJ pathways may still be active. In yeast, ku! mutants re-
vealed pathways that occur at lower frequencies than that of NHEJ
(97). These Ku-independent processes include microhomology-
mediated end joining (MMEJ) (Fig. 4B) and single-strand anneal-
ing (SSA) (98) (Fig. 4C). Both pathways require resection to ex-
pose homologies internal to the DSB ends. MMEJ refers to joining
between microhomologies (up to 25 bp), whereas SSA occurs be-
tween more extensive homologies. Yeast Rad52 promotes anneal-
ing of the complementary ssDNA during SSA (99), by displacing
RPA coating ssDNA (100), but plays little or no role in MMEJ. As
discussed above, BRCA2, but not Rad52, is homologous to P. fal-
ciparum PF3D7_1328200. The Ustilago maydis BRCA2 homolog,
Brh2, is reported to promote strand annealing similar to the reac-
tion catalyzed by Rad52 (101), suggesting that the Plasmodium
BRCA2 homolog may fulfill a similar role. Nonetheless, current
evidence suggests that SSA is not a major mechanism of DNA
repair in Plasmodium (13). For another eukaryotic pathogen, T.
brucei, chromosomal and in vitro plasmid EJ assays produce only
MMEJ-generated repair products (102–104). NHEJ is not used,
and T. brucei Ku functions only in telomere maintenance (105).
A recent report (106) suggests that P. falciparum may be able to
repair a DSB by an alternative EJ mechanism whereby a few bases
are added to the broken ends, thereby providing microhomolo-
gies. The frequency of these events is very low, and larger deletions
(e.g., possible SSA products) beyond the locus analyzed were not
examined. Nevertheless, Plasmodium species carry all necessary
components of the MMEJ machinery, many of which overlap
those for HR (Table 1). However, given the general lack of NHEJ,
MMEJ, and SSA products observed in Plasmodium, it seems un-
likely that EJ processes occur to any significant extent in malaria
parasites.
Potential implications of the absence of end joining in Plas-
modium. The absence, or at least highly infrequent use, of EJ path-
ways in P. falciparum may be an important factor in the produc-
tion of a live, radiation-attenuated sporozoite vaccine. Haploid
sporozoites in the Sanaria PfSPZ vaccine are metabolically active
yet nonreplicating (23, 24, 107). PfSPZ is generated with sporozo-
ites dissected from infected mosquitoes exposed to 15 krad of
"-irradiation. Sufficient irradiation introduces DNA damage
(108) without compromising hepatocyte invasion, gene expres-
sion, and initial trophozoite development, but it prevents nuclear
division (109). Estimations from yeast data suggest that the 15-
krad dose is sufficient to generate small but sufficient numbers of
DSBs (110). Therefore, the crucial replication defect of irradiated
sporozoites may result from the parasite’s lack of an efficient EJ
pathway during this strictly haploid stage and may manifest itself
only when DNA replication occurs during liver-stage prolifera-
tion.
Studies of irradiated blood-stage P. falciparum support this
notion. Experimental analyses showed that cellular distress is dose
(111) and cell cycle (112) dependent. Studies with parasites sub-
jected to various IR doses throughout the asexual blood stage (Fig.
2) showed that ring-stage parasites and multinuclear schizonts
with a 1c chromosome content cannot reconstitute an in vitro
culture after IR exposure as efficiently as the case with trophozo-
ites, which have a chromosome content of #2c (112, 113). Given
that the trophozoite stage has numerous sister chromatids as tem-
plates for repair in a syncytium, the IR-induced DNA damage is
FIG 4 EJ pathways. (A) Nonhomologous end joining (NHEJ) involves the joining of broken DNA ends with little to no homology. A simplified model of NHEJ
depicts the restoration of the original DNA sequence and introduction of small insertions (blue strands) or small deletions. (B) Microhomology-mediated end
joining (MMEJ) relies on minimal resection by proteins shared with HR to expose short homologies of up to 25 bp, which can anneal, deleting any intervening
sequence. (C) Single-strand annealing (SSA) involves longer stretches of resection. Rad52 (not shown) in yeast displaces RPA and anneals longer homologies,
generating larger deletions.
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likely readily repaired by HR. Further studies are required to dis-
cern whether the segregation of chromosomes after DNA replica-
tion (78) inhibits efficient HR. Altogether, without a robust EJ
pathway, the data show that it is possible that Plasmodium is more
sensitive to DNA damage than other model organisms, such as
yeast and humans.
HOMOLOGOUS RECOMBINATION IN P. FALCIPARUM
Barring a few exceptions, DSBR in Plasmodium is rarely studied
solely at a mechanistic level. Most published studies examine the
products of such processes in the context of drug resistance, anti-
genic diversification, population structure, or genetic manipula-
tion. Together, these studies each contribute to a larger picture of
the consequences of Plasmodium DSBR, but few provide direct
experimental evidence of its underlying molecular intricacies.
Nevertheless, the compiled picture shows a unique organism in
which DSBR dictates a broad spectrum of phenotypes.
Subtelomeric Regions and Antigenic Diversification
Unlike the case in T. brucei, antigenic variation in the Plasmodium
parasite does not occur by HR. Whereas T. brucei undergoes
Rad51-dependent gene conversion to replace the active antigen-
encoding gene (the variant surface glycoprotein gene [VSG]) with
one of the many inactive pseudogenes (114) in order to evade host
defenses, P. falciparum antigenic variation is mediated at the epi-
genetic level (115). P. falciparum erythrocyte membrane protein 1
(PfEMP1), which is presented on the host’s infected erythrocyte
and exposed to the immune system, is encoded by the clonally
variant var gene family. var does not require a DSB to switch
between its family members and instead epigenetically silences all
but one var cassette among the !60 total per parasite (115).
Though recombination plays no role in antigenic variation, it
does mediate var gene antigen sequence diversification and var
gene family composition during mitotic (116–118) as well as mei-
otic (77, 119) cell cycles. var genes are located primarily in subte-
lomeric regions of chromosomes (120, 121), although some are
also found clustered in central chromosomal regions (92, 121,
122). The subtelomeric regions are also home to the rifin and
stevor multicopy gene families, which also interact with host fac-
tors. Spatial positioning studies show that chromosome ends are
clustered together at the nuclear periphery (121–123). In yeast,
spatial proximity of a DSB to a donor template greatly enhances
HR (124). Therefore, in addition to providing a mechanism for
selective var expression, clustering of subtelomeric ends may pro-
vide the close proximity between heterologous chromosomes for
recombination to generate novel var sequences (122).
The rate of recombination in these subtelomeric regions has been
shown to be much higher than in the core chromosome: for in vitro
3D7 cultures, the mitotic recombination rate is about 4.7 " 10#6
events per base pair per generation, with over 80% of events occur-
ring in the subtelomere (117). Parasite populations from different
global regions reaffirm this notion (119). It is possible, nevertheless,
that both mitotic and meiotic recombination contribute to recombi-
nation in subtelomeric regions, as both can occur during the mos-
quito stages. This may provide parasites with the ability to persist
longer in a single blood-stage infection by forming novel var se-
quences and, thus, distinct PfEMP1 antigens (116).
Mechanistically, the diversification of var sequences and var
gene family composition can be driven by a number of recombi-
nation pathways. Reports pinpointing the precise mechanisms
driving these events have not been published, although insights
can be gleaned by analyzing the recombination products. For ex-
ample, a var allele can copy a portion of a donor allele to produce
a novel, chimeric allele. In mitotically dividing P. falciparum cells,
studies suggest that this process is mediated by an SDSA-mediated
gene conversion event (116, 117) (Fig. 3F) and by BIR (Fig. 3L)
(117). Intragenic COs between two rif genes can create two novel
sequences (116). NAHR (discussed below) (Fig. 5A) may also de-
lete or amplify large swaths of sequence in subtelomeric regions,
thereby altering var gene family composition for a given parasite
(117, 118).
For the sexual stages, a recent study has shown that some hot
spots for ectopic var recombination are energetically likely to
form DNA secondary structures, which may act as substrates to
generate DSBs (125). Analyses of parasite populations (119)
and genetic crosses (74, 77) showed that the subtelomeric re-
gions have a high rate of recombination during the sexual
stages. Further studies are needed to ascertain whether these
events occur during meiosis or the numerous subsequent mi-
totic divisions in the mosquito vector.
Copy Number Variation
One of the best-characterized phenotypes of gain-of-function
events is the acquisition of drug resistance by copy number vari-
ation (CNV). CNVs, either amplifications or deletions, change the
number of select genes within a genomic region in order to alter
their total expression levels. Original analyses primarily used
pulsed-field gel electrophoresis (PFGE) to separate chromosomes,
but now CNV detection relies more heavily on quantitative real-
time PCR (qRT-PCR) (126), high-density tiling microarrays
(127), or whole-genome sequencing (117).
Copy number variation and drug resistance. The classic exam-
ple of the relationship between CNVs and drug resistance is the
increased tolerance to mefloquine conferred by the amplification
of a genomic region (amplicon) on chromosome 5 containing the
P. falciparum multidrug resistance gene, pfmdr1, which encodes
the P-glycoprotein homolog (Pgh-1). The W2 parasite, initially
derived from a Southeast Asian isolate, was pressured in vitro with
a stepwise increase of mefloquine over 96 weeks, generating the
mefloquine-resistant parasite W2-mef (128). Characterization of
W2-mef and its derived clones revealed that the key to resistance
was the amplification of pfmdr1. This results in increased Pgh-1
expression, which is thought to more effectively transport meflo-
quine into the digestive vacuole, away from its primary site of
action (129, 130). Amplifications in other regions in the genome
can also lead to increased drug tolerance to a variety of antimalar-
ials. These are listed in Table S1 in the supplemental material.
Additionally, genomic deletions have been described for many
parasites. Some prominent examples come from the deletion of
unnecessary genes in culture-adapted parasites (e.g., Dd2). Con-
tinuous in vitro culture is absent of host-derived selective pressure;
therefore, functions such as cytoadherence to endothelial cell sur-
face receptors in the microvasculature (131, 132) or gametocyto-
genesis (133), required for transmission to mosquitoes, can read-
ily be lost.
CNVs are generally believed to be detrimental to cell fitness
due to the imbalanced dosage of gene products, thereby perturb-
ing cellular homeostasis. For example, changes in gene dosage
have been linked to cancer and neurological disorders, such as
autism (134). In P. falciparum, the fitness costs to parasite growth
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have been observed with amplifications of gch1 (106) and pfcrt
(our unpublished results). However, in the context of selective or
diverse environments, CNVs can prove advantageous in promot-
ing adaptability, as in the case of in vitro culture growth and drug
resistance. Other CNVs, such as an amplification of adjacent plas-
mepsin2 and hap (histo-aspartic protease) genes found in a Thai
field isolate, have been speculated to increase nutrient acquisition
and may be beneficial for the parasite (132). Furthermore, in-
creasing the number of copies of genes that confer drug resistance
can allow for one copy to maintain the wild-type sequence and
functionality, while the additional copy or copies may mutate to
confer drug resistance (126). Therefore, the investigation of par-
asite CNVs may prove to be increasingly important, particularly in
the context of varying geographical drug landscapes.
Possible mechanisms of copy number variation. The mecha-
nism by which CNVs occur has yet to be proven for Plasmodium,
but a few pathways stand out as likely candidates: NAHR (Fig. 5A)
and BIR, particularly microhomology-mediated BIR (MMBIR)
(Fig. 5B) (135). Given its presumed absence, NHEJ is not likely to
play a role in CNV formation. Additionally, due to the large aver-
age amplicon size, it is unlikely that polymerase slippage during
DNA replication is a major source of CNVs (135). Therefore, it is
presumed that NAHR and/or MMBIR is the primary mediator.
NAHR differs from HR only in that the homology search per-
formed by Rad51 does not use the correct, corresponding sister
locus for repair, and in the process amplifies or deletes a given
genomic region (117, 135). Given that NAHR requires a template
for repair, it is possible that it occurs not only during the mitotic
asexual blood stage (126) but also during the mosquito stage,
where both homologous chromosomes during meiosis and sister
chromatids during sporogony are available (Fig. 1) (136). Evi-
dence of NAHR during the mosquito stage is discernible in the
progeny of experimental P. falciparum genetic crosses (81).
Amplicons have been found to vary in size from !5 kb to "100
kb. Despite this variation, sequencing of the newly formed junc-
tions (breakpoints) shows a strong preference for monomeric A/T
sequences that average about 30 bp (81, 136, 137), which are en-
riched in untranslated regions. Monomeric tracts of "10 bp that
FIG 5 Mechanisms of copy number variation (CNV). (A) Nonallelic homologous recombination (NAHR) can generate genome amplifications or deletions. In
NAHR, a DSB is repaired using an incorrect template. Resolution of the dHJ intermediate forms a crossover, which leads to a duplication of a segment (amplicon)
on one sister and a deletion on the other. (B) Microhomology-mediated break-induced replication (MMBIR) can generate amplifications or deletions. DNA
replication fork progression through a nick will generate a single-ended DSB. Microhomology can then anneal to microhomology on a replicating sister
chromatid and undergo BIR to recapitulate the remaining chromosome arm.
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speckle the genome are estimated to be, on average, about 600 bp
apart, or 5% of the genome (136). It may be that one consequence
of the genome’s A/T richness is to increase the likelihood of copy
number variants.
These short, monomeric tracts are possible substrates for
MMBIR (Fig. 5B). In this process, a short, monomeric tract re-
vealed by end resection anneals to another microhomology region
on another chromosome, independently of Rad51. This tract then
serves as a primer for polymerase extension until the telomere,
thereby copying that chromosome arm. Recently, the initial mi-
totic amplification of chromosomal regions around the pfdhodh
gene in response to the drug DSM1 was speculated to be MMBIR
based (126). Amplicons, which varied in size for each clone,
ranged from 34 to 95 kb and were arranged head to tail. Break-
points were short, monomeric tracts. As DSM1 pressure in-
creased, the amplified region containing pfdhodh was further am-
plified. But, importantly, all amplifications were exact copies of
the initial amplicon, implicating a faster, homology-based expan-
sion, such as NAHR, as the causal pathway. Therefore, it is possi-
ble that MMBIR (Fig. 5B) occurs at a low frequency in the parasite,
generating amplicons of various sizes. The close proximity of these
amplicons presumably provides substrates more ideal for NAHR
than for MMBIR under increasing selective pressure, thereby cre-
ating exact copies of the initial amplicon (Fig. 5A).
Together, the evidence collected from a number of studies de-
picts a parasite that generates copy number variants at a low but
significant frequency. Many may be detrimental to growth and fail
to establish themselves at the population level. Given the sequence
identity of breakpoints and types of amplicons produced, the par-
asite may employ several of these pathways as tools to increase its
genome diversity.
Genome Editing
Genetics in P. falciparum is currently becoming increasingly ac-
cessible with the nearly simultaneous arrival of new transfec-
tion-based technologies, which will undoubtedly deepen our
understanding of this parasite and lead to a more thorough
definition of parasite determinants of drug resistance, fitness,
pathogenesis, and overall cellular organization and developmen-
tal biology. The common factor among all the old and new tech-
nologies is the requirement for a DSB to initiate HR. It was recog-
nized early in yeast and mammalian systems that the introduction
of a single DSB significantly increases the rate of recombination
(10, 11). Genetic research in malaria was not too far behind in
recognizing the potential of DSBs, though several hurdles have
prevented their capitalization, until recently.
Established technologies. Early transfection and mutant para-
site generation began around the mid-1990s for both P. falciparum
and P. berghei. Stable transfection of P. falciparum originated by
introducing an episomal copy of the chloramphenicol acetyltrans-
ferase selectable marker (138). This was quickly followed by plas-
mid integration of a selectable marker, the dihydrofolate reduc-
tase-thymidylate synthase (dhfr-ts), into the genome, by a method
referred to as “single-site crossover” (139, 140) (Fig. 6A). Simul-
taneously, transfections in P. berghei had also produced resistant
dhfr-ts parasites with both episomal and integrated plasmids (141,
142). Both species were transfected by electroporation, using ring
stages for P. falciparum and merozoites in the case of P. berghei.
Although the number of selectable markers increased (143–
145) and alternate transfection methods were developed (146),
genetic manipulation techniques and efficiency did not change
drastically for P. falciparum, aside from the introduction of the
“double crossover” technique (Fig. 6B). This technique uses neg-
ative in addition to positive selection to remove unwanted recom-
bination events (147, 148). These methods still yield low efficien-
cies, at best 1 in 105 parasites per transfection (149, 150), and
require 2 to 3 months of continuous culture, at minimum, to
produce desired recombination events at a high enough rate to
clone the appropriate parasites. Mechanistically, double cross-
overs may occur either by SDSA (Fig. 6B) or by integration of
the plasmid via single-site crossover followed by crossover-
based excision of the negative marker by use of homology
within the plasmid.
In contrast to the fate of P. falciparum genetic manipulation,
methods in P. berghei benefitted substantially from the success of
linear DNA transfection. Linear DNA (displaying broken DNA
ends) in P. berghei was readily incorporated into the genome via
“ends-in” and “ends-out” methods, which mirror the standard
methods utilized in yeast genetics (151, 152). Use of linear DNA
and optimization of transfection technology have reduced the
time required to generate mutant parasites to less than a week,
with average efficiencies nearing 1 in 100 to 1 in 1,000 parasites per
transfection (153). These methods were also shown to work in P.
knowlesi (154).
In P. falciparum, transfection of linear DNA by use of nano-
somes has shown modest luciferase expression lasting a few days,
but no genomic integration was reported (155). To date, linearized
DNA for gene editing has not been successful in P. falciparum, even
when the plasmid is linearized in cells by use of zinc finger nucleases
(ZFNs) (our unpublished results). To date, bioinformatic studies
have not identified any differences in DNA repair pathways between
P. falciparum and P. berghei that would explain the markedly dif-
ferent efficiencies in linear DNA-based gene replacement.
Engineered endonucleases. The recent development of three
powerful gene-editing technologies has spurred enthusiasm for
the future of Plasmodium genetics, as ZFNs, Tal effector-like nu-
cleases (TALENs), and the CRISPR/Cas system have been shown
to be extremely useful in other research and translational settings.
For example, TALENs have been designed for all protein-encod-
ing genes in the human genome (156), and ZFN-mediated inacti-
vation of CCR5 in CD4 T cells can lower the HIV burden in treated
patients (157).
ZFNs and TALENs both act as heterodimers where each
monomer contains a DNA-binding domain and the nuclease do-
main of the FokI endonuclease. The DNA-binding domain, also
known as the zinc finger protein (ZFP) region, consists of an as-
sembly of three to six C2H2 zinc fingers, which each bind, on
average, three bases (14). TALENs share the same architecture as
ZFNs but differ in that the DNA-binding domain consists of a
tandem array of 34-amino-acid repeat modules where each repeat
is identical except for two amino acids, which bind a single base
(NI binds adenine, HD binds cytosine, NG binds thymine, and
NN binds guanine or adenine) (158). The benefits of TALENs
include their simple, modular design, which enables high-
throughput construction of a large number of variants to recog-
nize different targets. However, difficulties may arise due to the
inherent repetitive nature of the DNA-binding domain sequence
and the overall size of the nuclease. Fused to both the ZFN and
TALEN DNA-binding domains is the FokI nuclease domain,
which, upon DNA binding, homodimerizes and creates a DSB,
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usually generating 4- or 5-bp 3= overhangs, depending on the se-
quence that each monomer binds. Enhancements to the FokI do-
main have been made such that the nuclease heterodimerizes,
lowering its potential off-target specificity (159). The resulting
DSB can then be repaired from a plasmid template to transfer the
desired sequence change to the genome. Repair in the absence of a
homologous template can be used to generate indels through EJ, if
such a pathway exists in the organism (14).
FIG 6 Established technologies for genome editing. (A) Single-site crossover (SSC) was developed to utilize a region homologous to a genomic locus carried on
a transfected plasmid with a positive marker (green strands). SSC depends on a stochastic DSB in the genome to provide recombinogenic DNA ends that will use
the plasmid region of homology as a template for repair. Formation of a dHJ and its resolution to yield a crossover product will lead to plasmid integration into
the genome. (B) An apparent double crossover requires the parasite to incorporate the positive marker placed between two regions homologous to the gene of
interest. Recombination (e.g., by SDSA) can copy the positive marker and introduce this into the genome while avoiding the negative marker (dark gray strands).
An alternative scenario (not shown) involves two independent crossover events. In this case, the entire plasmid integrates into the genome by SSC and is followed
by recombination between the homologous sequences flanking the negative marker, thereby looping it out. Selection for both positive and negative markers will
select only for parasites that have incorporated the positive marker.
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The use of ZFNs in the Plasmodium field is currently gaining
traction. Thus far, published genes targeted in P. falciparum in-
clude pfcrt (13), a genome-integrated enhanced green fluorescent
protein gene (egfp) (13), and the phosphatidylinositol-4-OH ki-
nase [PI(4)K] gene (57). We and other laboratories have also had
success with several other genes (unpublished data). ZFNs have
also been recently used to target the P. vivax dhfr gene (171). Due
to the high A/T content of the P. falciparum genome, ZFN design
is more difficult than that for other species, but nevertheless, it is
feasible. Various factors affect the success of gene editing. ZFN
cleavage activity in the parasite generally correlates with activity in
yeast proxy assays (159; our unpublished observations). Proxim-
ity of SNPs to be incorporated into the genome to the site of ZFN
cleavage improves the chances of editing (160). The length of the
homologous region on the plasmid positively correlates with the
rate of recombination (161, 162). Lengths of homologous regions
in Plasmodium typically range around 1 kb (13) but can be longer
(57), depending on plasmid size constraints.
To date, TALENs have been designed in silico to target Plasmepsin V
andhaveshownfunctionality inayeastreportercleavageassay(163),but
no Plasmodium TALEN studies have been published to date.
The first uses of the CRISPR/Cas system in Plasmodium research
have only recently been published (172, 173). This system modifies a
prokaryotic viral defense system to cleave a specific genomic se-
quence harboring a unique motif, using an RNA-guided Cas9 endo-
nuclease (164–166). Cas9 can bind a fusion RNA sequence where one
segment is necessary for secondary structure formation and Cas9
binding and the other is complementary to a given target DNA se-
quence, which Cas9 will cleave, forming a DSB (164). This system
circumvents the relatively more arduous engineering requirements
inherent to ZFNs or TALENs. However, studies in other model sys-
tems show that the limitations of the CRISPR/Cas system lie in the
target genomic site criteria. Target genomic sites must carry a 3-bp
NGG protospacer-adjacent motif (PAM) (167) adjacent to a 20-bp
genomic recognition sequence.
Recent reports in both P. falciparum (172) and P. yoelii (173) have
successfully shown the ability of the CRISPR/Cas system to introduce
SNPs into a gene of interest, tag proteins (e.g., with gfp), and knock
out coding sequence with and without a marker (e.g., human dhfr).
The outcomes of each experiment showed a high editing efficiency
with no detectable amount of undesirable, off-target events. These
initial studies offer a glimpse of the promising future of Plasmodium
genetics and research. Harnessing DSBs enables researchers to utilize
the recombination machinery to generate novel parasites. Using these
nucleases, combined with a high-throughput method of design and
cloning, may prove to be extremely valuable both for parasitology
and for other eukaryotic pathogens, as has already been demon-
strated for higher eukaryotes (168–170).
CONCLUSIONS AND PERSPECTIVES
The current understanding of DSBR in P. falciparum is in its early
stages, as only a few reports directly studying HR have been pub-
lished. Despite this, meaningful inferences regarding DSBR can be
made from studies of antigenic diversification of var genes, linkage
disequilibrium in genetic crosses, and drug resistance-associated
gene amplifications. Whole-genome sequencing and microarray
analyses also provide insights into processes such as BIR and CNV.
Yet large gaps in our understanding of DSBR still exist. The ab-
sence of clear evidence of NHEJ and alternative EJ pathways also
remains perplexing. Nevertheless, the recent gain in popularity of
genome-editing technologies is putting greater focus on DSBR
mechanisms in P. falciparum. Understanding the nuances of
DSBR will better enable the use of these technologies to gain in-
sights into virulence, pathogenesis, drug resistance, and drug
modes of action for one of the most pernicious pathogens encoun-
tered throughout human history.
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Table S1. Amplified genes involved in antimalarial drug tolerance. 
Compound Gene Gene Description PlasmoDB ID Chromosome 
cladosporin Krs1 cytoplasmic lysyl-tRNA synthetase PF13_02620 XIII 
DSM1 dhodh dihydroorotate dehydrogenase, mitochondrial precursor MAL6P1.36 VI 
fosmidomycin dxr 1-deoxy-D-xylulose 5- phosphate reductoisomerase PF14_0641 XIV 
mefloquine mdr1 multidrug resistance protein MAL5P1.230 V 
muporicin None apicoplast-targeted isoleucyl-tRNA synthetase  PFL1210w XII 
NITD609 atp4 non-SERCA-type Ca2 -transporting P-ATPase (ATP4) PFL0590c XII 
piperaquine N/A N/A N/A V 
sulfadoxine/pyremethamine gch1 GTP cyclohydrolase I gene PFL1155w XII 
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TABLE S1 Amplified genes involved in antimalarial drug tolerance. Genes listed below have been found to 
have amplified in response to the corresponding antimalarials. Genes that confer resistance when amplified are 
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Mutations in the Plasmodium 
falciparum chloroquine resistance 
transporter, PfCRT, enlarge the 
parasite’s food vacuole and alter 
drug sensitivities
Serena Pulcini1,*, Henry M. Staines1,*, Andrew H. Lee2, Sarah H. Shafik3,  
Guillaume Bouyer1,4,5, Catherine M. Moore1, Daniel A. Daley6, Matthew J. Hoke6, 
Lindsey M. Altenhofen7, Heather J. Painter7, Jianbing Mu8, David J. P. Ferguson9, 
Manuel Llinás7, Rowena E. Martin3, David A. Fidock2,10, Roland A. Cooper6,11 & Sanjeev Krishna1
Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, are the major 
determinant of chloroquine resistance in this lethal human malaria parasite. Here, we describe  
P. falciparum lines subjected to selection by amantadine or blasticidin that carry PfCRT mutations 
(C101F or L272F), causing the development of enlarged food vacuoles. These parasites also have 
increased sensitivity to chloroquine and some other quinoline antimalarials, but exhibit no or 
minimal change in sensitivity to artemisinins, when compared with parental strains. A transgenic 
parasite line expressing the L272F variant of PfCRT confirmed this increased chloroquine sensitivity 
and enlarged food vacuole phenotype. Furthermore, the introduction of the C101F or L272F mutation 
into a chloroquine-resistant variant of PfCRT reduced the ability of this protein to transport 
chloroquine by approximately 93 and 82%, respectively, when expressed in Xenopus oocytes. These 
data provide, at least in part, a mechanistic explanation for the increased sensitivity of the mutant 
parasite lines to chloroquine. Taken together, these findings provide new insights into PfCRT function 
and PfCRT-mediated drug resistance, as well as the food vacuole, which is an important target of 
many antimalarial drugs.
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Chloroquine (CQ) rapidly became one of the most useful antimalarial drugs for first-line therapy soon 
after the Second World War. Resistance to CQ was first reported in the late 1950s in Plasmodium fal-
ciparum. It then spread globally and forced the development of alternative regimes, culminating in the 
more expensive artemisinin-based combination therapies (ACTs) used today. The locus containing the 
P. falciparum chloroquine resistance transporter gene (pfcrt) was initially mapped by classical genetic 
studies as being crucial to the development of CQ resistance, with this gene subsequently being identified 
and its role confirmed using reverse genetic approaches1–3. CQ resistance is now emerging in P. vivax, 
for which it remains the first-line treatment4.
CQ is a diprotic weak base that accumulates in the parasite’s acidic food vacuole (FV) by diffusion 
and subsequent trapping by protonation. CQ interferes with the detoxification of heme in the FV, which 
leads to parasite death5. Predicted to have 10 transmembrane domains (TMDs), PfCRT is located in the 
FV membrane1,6 and, when mutated, increases export of CQ from the FV and its target of heme polym-
erisation7. Single nucleotide polymorphisms (SNPs) in PfCRT in field isolates correlate with a resistance 
phenotype in in vitro assays and are sensitive markers for treatment failure in patients8,9. However, these 
molecular markers are not always specific because other variables such as previous exposure to malaria 
can influence treatment response in patients10.
One polymorphism at position 76 (K76T) in the first TMD of PfCRT seems to be key to CQ resist-
ance. This substitution removes a positive charge from a predicted substrate-binding site in PfCRT, allow-
ing protonated CQ to escape from the FV down its electrochemical gradient11. Other mutations (K76I 
and K76N) in this position also arise when P. falciparum is exposed in vitro to lethal concentrations of 
CQ, allowing parasites to survive and supporting the critical role of this residue1,6.
The native function of PfCRT is not clear, although it has been postulated to be involved in hemoglo-
bin catabolism, possibly by mediating the transport of hemoglobin-derived peptides/amino acids from 
the FV12, a hypothesis consistent with recent heterologous expression and metabolomics studies7,13,14. 
PfCRT has also been proposed to function as a chloride channel, a proton pump or a regulator of 
proton pumps, a general activator or modulator of transport systems (reviewed in11) or, most recently, 
a proton-coupled transporter of a broad range of cationic substrates15. There are many reasons to eluci-
date the function of PfCRT in parasites, including the suggestion that PfCRT could itself become a new 
drug target16,17, or that chemosensitizing agents could be directed against PfCRT to restore the efficacy 
of CQ16–18. Furthermore, CQ continues to be used in the treatment of non-falciparum malarias. It may 
also regain efficacy against falciparum malaria in areas where usage has been tightly regulated, since the 
withdrawal of CQ can result in dramatic decreases in the prevalence of CQ-resistant parasites19.
Here, mutations in pfcrt that alter parasite phenotype give new insights into its native function as a 
transporter. The novel and pleiotropic phenotypic characteristics associated with mutated PfCRT include 
altered FV morphology and changes in quinoline sensitivities. We also investigated the effect of these 
changes on the parasite’s sensitivity to other antimalarial classes, such as the artemisinins, that some have 
considered to act (at least in part) in the FV of the parasite20,21.
Results
New and previously described mutations in pfcrt. SNPs were identified in pfcrt in two different P. 
falciparum lines (Fig. 1a,b). The first was discovered after isolating amantadine (AMT)-resistant mutants 
of the CQ-resistant parasite strain FCB, following selection with 80 µ M of this antiviral agent. Viable par-
asites were observed in one of four drug-pressured flasks at 42 days, whereas none had emerged within 
the remaining flasks by 60 days. PCR amplification and sequencing of pfcrt in four clonal lines derived 
from the AMT-resistant culture detected a single non-synonymous SNP, g302t. This encoded the amino 
acid mutation C101F. These lines were therefore designated FCBC101F. Position 101 is predicted to lie 
within the second TMD of PfCRT (Fig. 1a). This mutation was earlier observed in a CQ-resistant Dd2 
parasite line derived by continuous piperaquine (PPQ) pressure22, although that study did not describe 
any changes in parasite morphology.
The second parasite line, derived from the CQ-sensitive strain 3D7, was selected by blasticidin (BSD) 
pressure as an inadvertent outcome of transfection experiments on an unrelated gene (that had aimed 
to achieve single cross-over homologous recombination with a tagging plasmid under BSD selection)23. 
After several weeks of selection, pfcrt cDNA transcripts of the daughter parasite line and parental 3D7 
were sequenced. A mutation at position c814t in the pfcrt coding sequence, resulting in the amino acid 
mutation L272F, was detected in the selected line, designated 3D7L272F, and was absent in its parent. This 
substitution is positioned immediately after the seventh predicted TMD, placing it in the FV compart-
ment (Fig. 1a). To our knowledge, this mutation has not been reported previously. No other mutations 
in pfcrt were detected in either of the new parasite lines.
Given that 3D7L272F arose in unusual circumstances (BSD is a general inhibitor of protein translation 
and is not thought to target the FV), whole-genome sequencing was undertaken to identify further 
mutations. This confirmed the presence of the c814t mutation in pfcrt and identified only 2 additional 
SNPs. The first was c5549g in PF3D7_1229100 (the P. falciparum multidrug resistance-associated pro-
tein 2, PfMRP2), resulting in a stop-gain mutation (S1850*) and the loss of 259 amino acids from the 
C-terminus. The second was t1032a in PF3D7_1462400 (a conserved protein of unknown function), 
resulting in a stop-gain mutation (Y344*) and the loss of 2979 amino acids from the C-terminus. 
Truncation of the latter sequence has been observed in other laboratory clones of 3D724. Furthermore, 
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there was no evidence of integrated copies of the plasmid vector containing the BSD selection marker23, 
which had been used during the generation of the 3D7L272F line.
Enlarged FVs of parasites with mutations in pfcrt. A monstrously swollen FV was observed at all 
stages that ordinarily display a vacuole in the asexual cycle of both parasite lines FCBC101F and 3D7L272F 
(Fig. 2). This phenotype was stably maintained in the parasites following repeated rounds of parasite cul-
ture and cryopreservation. The enlarged FVs were already apparent in the early to mid trophozoite stages 
of the FCBC101F line, when compared with FVs from FCB parental controls (Fig. 2a left and right panels). 
In more mature FCBC101F parasites, the FVs were strikingly clear in appearance, with hemozoin crystals 
apparently marginalized to the FV periphery and opposite the developing nuclei, although live imaging 
suggests that the hemozoin is distributed normally (Fig. 2b). The immature ring stages of development 
were indistinguishable from those of the parental strain. Similar findings were evident in the parasite 
line 3D7L272F when compared with 3D7 (Fig. 2c left and right panels). Measurement of the area of the 
FV was also undertaken and expressed as a ratio of the parasite’s area to correct for parasite age (Fig. 3a). 
This confirmed that FCBC101F and 3D7L272F parasites have a relative FV/parasite area that is approximately 
twice that of FCB and 3D7, respectively (p < 0.0001). Neither FCBC101F nor 3D7L272F parasites appeared 
to be enlarged within their host red blood cells (RBCs).
The 3D7L272F line was selected for a more detailed characterization. The appearances of parasites 
examined with transmission electron microscopy (TEM) were consistent with observations made with 
light microscopy (Fig. 3b,c), with few differences evident between parental strains and daughter parasite 
lines except for the size of the FV. Specific to this line, TEM also revealed that “knobs”, electron dense 
protrusions of the RBC membrane caused by parasite infection, which are important determinants of 
cytoadherence25 and which are often lost from infected RBCs during long term parasite culture26, were 
Figure 1. PfCRT mutations. (a) Schematic representation of PfCRT and positions of previously identified 
polymorphisms8,71 from field isolates (green circles) and from drug-pressured laboratory lines (purple 
circles). The critical CQ resistance mutation site (K76) is shaded red, and the two residues at which 
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displayed approximately 7.5-fold more on the host surface of 3D7L272F-infected RBCs than 3D7-infected 
RBCs. This is unlikely to be directly related to the mutation in pfcrt and may be due to sub-population 
selection.
Since BSD pressure has been shown to alter infected RBC permeability27–29, electrophysiological 
transport studies were also undertaken to compare 3D7 and 3D7L272F-infected RBCs, although no differ-
ences were observed (Supplementary Fig. S1).
Figure 2. Representative morphology of parasite lines FCBC101F and 3D7L272F. (a) Appearance of 
enlarged FVs in fixed FCBC101F parasites (left panel), when compared with parental FCB parasites of similar 
developmental stages (right panel). (b) Images of live FCBC101F and FCB trophozoite-stage parasites, using 
bright-field and dark-field microscopy (left and right panels, respectively). (c) Appearance of enlarged FVs 
in fixed 3D7L272F parasites (left panel), when compared with parental 3D7 parasites of similar developmental 
stages (right panel). The diameter of a RBC is ~7 µ m.
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In vitro sensitivity to antimalarials. Both cell lines with mutations in pfcrt displayed altered suscep-
tibility to antimalarials when compared with the parental strains (Table 1). Using a 72 h in vitro growth 
inhibition assay that yields IC50 values, FCBC101F parasites were found to be 83 fold less susceptible to 
AMT (used in its selection). FCBC101F showed a 5–6 fold increase in sensitivity to CQ, yet interestingly 
still retained the characteristic verapamil (VP)-reversibility of CQ-resistant parasites30. Furthermore, 
compared with FCB, FCBC101F was significantly (p < 0.01) more sensitive to quinolines (quinine (QN), 
quinidine (QD) and monodesethyl amodiaquine (MDAQ)) but not the arylmethanol, mefloquine (MQ). 
There was a small (29%) increase in sensitivity to artemisinin (ART; p <0.01). The FCBC101F line became 
approximately 2-fold more resistant to PPQ relative to controls (p < 0.05).
In similar experiments, 3D7L272F parasites, assayed over 48 h in vitro, were ~2.5 fold more sensitive to 
CQ than 3D7, with respective IC50 values of 6.1 and 15 nM (p < 0.01). The 3D7L272F parasites were also 
slightly more sensitive to QN than 3D7 parasites. VP sensitivity was not examined because unlike FCB, 
the 3D7 line is already CQ-sensitive. The increased sensitivity to CQ therefore indicates that 3D7L272F is 
Figure 3. Morphological comparisons of parasites with mutations in pfcrt compared with their parental 
controls. (a) Parasites were synchronized by sorbitol lysis and areas of FVs and parasites (approximately 
38 h post-invasion) were measured and expressed as ratios (AFV/AParasite). 3D7, FCB and Dd2Dd2 (open 
bars; n = 72, 31 and 42, respectively) and 3D7L272F, FCBC101F and Dd2Dd2 L272F (closed bars; n = 84, 58 and 
88, respectively) parasites were analyzed and significant enlargement of the FV was confirmed in 3D7L272F, 
FCBC101F and Dd2Dd2 L272F parasites relative to 3D7, FCB and Dd2Dd2, respectively (*p < 0.0001: two-
tailed, unpaired, Student’s t-test). (b,c) Transmission electron micrographs of 3D7 and 3D7L272F parasites, 
respectively, showing the food vacuole (FV) and nucleus (N). Note the enlarged electron lucent FV in 
3D7L272F (suggesting changes in the process of hemoglobin degradation and formation of hemozoin crystals). 
RBCs infected with 3D7L272F displayed approximately 7.5-fold more knobs (arrowheads) on the host surface 
than 3D7-infected RBCs, although this is likely due to sub-population selection rather than a direct link to 
the mutation in pfcrt. (insert) Detail of a knob. Bars represent 1 µ m (b,c) and 100 nm (insert).
Drug†
Mean ± SEM IC50 values for individual parasite strains/lines‡
3D7 3D7L272F FCB FCBC101F FCB + VP FCBC101F + VP
CQ 15 ± 1.8 6.1 ± 1.5* 187 ± 7.1 34 ± 1.8* 47 ± 1.2 14 ± 1.0
QN 176 ± 17 108 ± 13* 333 ± 5.8 220 ± 23* 161 ± 33 223 ± 31
QD — — 167 ± 13 62 ± 3.1* 46 ± 1.9 46 ± 2.9
MQ 87 ± 29 64 ± 17 13 ± 1.1 14 ± 0.9 8.8 ± 1.0 18 ± 2.0
AQ 25 ± 2.3 27 ± 2.1 — — — —
MDAQ 14 ± 1.5 15 ± 1.5 52 ± 4.1 18 ± 1.0* 16 ± 1.0 9.1 ± 0.7
PPQ 18 ± 4.1 22 ± 5.3 12 ± 0.6 27 ± 1.8* 13 ± 0.4 25 ± 3.1
ART 3.5 ± 1.2 4.1 ± 1.6 13 ± 0.9 9.1 ± 0.7** 9.9 ± 0.9 9.1 ± 0.5
BSD (µ M) 1.5 ± 0.6 47 ± 6.0* — — — —
AMT (µ M) — — 5.6 ± 0.6 465 ± 54* 11 ± 0.5 687 ± 32
Table 1.  In vitro sensitivity of 3D7, 3D7L272F, FCB and FCBC101F (in presence or absence of verapamil, 
VP) to antimalarial drugs. †CQ, chloroquine; QN, quinine; QD, quinidine; MQ, mefloquine; AQ, 
amodiaquine; MDAQ, monodesethyl amodiaquine; PPQ, piperaquine; ART, artemisinin; BSD, blasticidin; 
AMT, amantadine; VP, verapamil (used at 0.8 µ M). ‡IC50 values are listed in nM, except where indicated, 
and are show as the mean ± SEM. n = 3 independent assays (each performed as a single replicate for FCB 
parasites and in quintuplicate for 3D7 parasites). Significantly different mean IC50 values relative to controls 
(F-test; *p < 0.05, **p < 0.01).
250
www.nature.com/scientificreports/
6Scientific RepoRts | 5:14552 | DOi: 10.1038/srep14552
a ‘CQ-hypersensitive’ parasite line. The mean IC50 values for MQ, MDAQ, PPQ and ART were similar 
between the 3D7L272F and 3D7 parasites (Table 1).
Transfection studies. To confirm the phenotype observed in 3D7L272F, we engineered the L272F 
mutation in pfcrt using zinc-finger nuclease mediated allelic replacement31 in the Dd2 line and compared 
results with congenic controls. Figure  4a,b illustrate this strategy and provide confirmation of integra-
tion. As observed in 3D7L272F, significant FV distension (~2 fold as measured by vacuolar area relative 
to parasite area; Fig.  3a) was generated by introduction of this single amino acid change (Fig.  4c,d). 
However, a significant increase in BSD resistance was not observed between the Dd2Dd2 L272F line and its 
congenic control, Dd2Dd2 (Table  2), which suggests that the PfCRT L272F mutation was not primarily 
responsible for the BSD resistance found in 3D7L272F parasites. The parental strain Dd2 and the congenic 
control Dd2Dd2 were both CQ-resistant. However, Dd2Dd2 L272F was considerably more susceptible to CQ 
and monodesethyl chloroquine (MDCQ) than the Dd2Dd2 line, although the IC50 values of the L272F 
Figure 4. Introduction of PfCRT L272F into Dd2. (a) Schematic of zinc-finger nuclease (ZFN)-mediated 
generation of vacuole-enlarged parasites. Dd2 parasites were first enriched for the episomal pcrtDd2 L272F-
hdhfr or pcrtDd2-hdhfr donor plasmids (latter not shown). The donor plasmids encoded a cDNA copy of 
the Dd2 pfcrt allele (dark blue, plasmid), either L272F-mutated (dark blue bump) or wild-type (not shown), 
followed by a dhfr selection cassette (light grey). Each donor-enriched parasite was then transfected with 
the pZFNpfcrt-bsd plasmid, expressing the genomic (light blue) pfcrt intron 1-targeting ZFN pair (ZFN L 
and ZFN R, orange) and the bsd selection cassette (dark grey). ZFN-induced recombination in pfcrt yielded 
either control Dd2Dd2 (not shown) or Dd2Dd2 L272F parasites (dark blue, locus). (b) PCR verification of 
parental, recombinant control, and Dd2Dd2 L272F parasite clones. Primer (p) positions are shown in panel a. 
(c) Light microscope analysis of representative examples of parental, recombinant control, and experimental 
parasite clones. Ring morphology for each parasite Dd2, Dd2Dd2, Dd2Dd2 L272F, and GC03 was normal. 
Progression through the trophozoite and schizont stages showed normal morphological development 
except for the Dd2Dd2 L272F clone, which exhibited the characteristic enlarged vacuole and diffuse hemozoin 
phenotypes seen in 3D7L272F and FCBC101F Giemsa stained parasites. (d) Transmission electron micrographs 
of Dd2Dd2 (i) and Dd2Dd2 L272F parasites (ii) showing similar cytoplasmic appearances except for the enlarged 
food vacuole (FV) in Dd2Dd2 L272F. Note neither parasite exhibits knobs. This confirms similar morphological 
appearances to those of 3D7 and 3D7L272F, respectively but without knob formation. N—Nucleus. Bars 
represent 1 µ m.
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mutant remained higher than the fully CQ-sensitive reference line GC03 (Table 2). ART sensitivity, as 
measured in these IC50 assays, was unaltered across parasites. There were no differences in whole-cell 
electrophysiological properties between the Dd2Dd2 and Dd2Dd2 L272F parasite lines (Supplementary Fig. 
S1) and the RBCs infected with Dd2Dd2 L272F parasites remained knobless (Fig.  4d), suggesting that the 
increased expression of knobs in 3D7L272F-infected RBCs was not related to the L272F mutation in pfcrt.
Measurements of CQ transport via the C101F and L272F variants of PfCRT. The Xenopus 
oocyte system for the heterologous expression of PfCRT7 was employed to investigate the effect of the 
C101F and L272F mutations on the ability of PfCRT to mediate CQ transport. The L272F and C101F 
mutations were introduced into the Dd2 haplotype of PfCRT (PfCRTDd2, from the CQ-resistant strain 
Dd2; Fig. 1b) and L272F was also introduced into PfCRT3D7 (from the CQ-sensitive strain 3D7; Fig. 1b). 
The resulting variants (L272F PfCRTDd2, L272F PfCRT3D7, and C101F PfCRTDd2), as well as PfCRTDd2 and 
PfCRT3D7, were expressed in oocytes. Localization of each of the PfCRT variants to the oocyte plasma 
membrane was confirmed by immunofluorescence assay (Supplementary Fig. S2a) and a semiquantita-
tive western blot analysis32 indicated that the different PfCRT proteins were present at similar levels in 
the oocyte membrane (Supplementary Fig. S2b). The ability of the PfCRT variants to mediate [3H]CQ 
transport was measured in an acidic medium (pH 5.5), in which the majority of CQ is protonated. The 
extent to which oocytes expressing PfCRTDd2 accumulate [3H]CQ varies considerably between batches 
of oocytes from different frogs, with the PfCRTDd2-expressing oocytes accumulating between 8 and 45 
times more [3H]CQ than the control (non-injected and PfCRT3D7-expressing) oocytes. Hence, within 
each experiment uptake was expressed relative to that obtained for oocytes expressing PfCRTDd2 (in 
the absence of inhibitors). Non-injected oocytes and oocytes expressing PfCRT3D7 have previously been 
shown to take up CQ to similar (low) levels via simple diffusion of the neutral species of the drug7,32; 
this represents the ‘background’ level of CQ accumulation in oocytes, which in this study was estimated 
by measuring CQ uptake into PfCRT3D7-expressing oocytes (see Supplementary Fig. S3).
In the data presented in Fig. 5a,b, oocytes expressing PfCRTDd2 showed an 11 to 40-fold (mean and 
SEM of 21 ± 3; n = 9 separate experiments) increase in CQ uptake relative to the PfCRT3D7-expressing 
control. The component of CQ accumulation attributable to diffusion (i.e. the uptake of CQ measured 
in PfCRT3D7-expressing oocytes) was subtracted to obtain the PfCRT-mediated component of CQ trans-
port. Supplementary Figure S3 shows the total level of CQ accumulation in each oocyte and treatment 
type. The introduction of L272F or C101F into PfCRTDd2 substantially reduced the protein’s ability to 
transport CQ (by ~82% and ~93%, respectively; p < 0.001, ANOVA) whereas the introduction of L272F 
into PfCRT3D7 was without effect (p > 0.05). The addition of the CQ resistance-reverser VP (250 µ M) 
reduced PfCRTDd2-mediated CQ transport by ~93% (p < 0.001) and also dramatically decreased CQ 
uptake via L272F PfCRTDd2 and C101F PfCRTDd2 (by ~84% and ~92%, respectively; p < 0.01), such that 
the accumulation of CQ in the latter two treatments was not significantly different from that measured 
in the PfCRT3D7-expressing controls (p > 0.05).
To investigate how BSD pressure might have produced the 3D7L272F mutant, interactions between 
the PfCRT variants and BSD were assessed by measuring the uptake of [3H]CQ in the presence of 
unlabeled BSD (100 or 500 µ M; Fig.  5b). The addition of BSD reduced CQ transport via PfCRTDd2 by 
~39% (100 µ M; p < 0.001) and ~56% (500 µ M; p < 0.001) and, to a lesser degree, decreased CQ uptake 
via L272F PfCRTDd2 (by ~22% (p > 0.05) and ~49% (p < 0.01), respectively). Neither concentration of 
BSD reduced the C101F PfCRTDd2-mediated transport of CQ (p > 0.05), nor was the accumulation of 
CQ in the PfCRT3D7-expressing controls affected (p > 0.05). Note that the micromolar concentrations of 
the compounds used here to inhibit PfCRT are physiologically relevant given that when present in the 
Drug†
Mean ± SEM IC50 values for individual parasite strains/lines‡
Dd2 Dd2Dd2 Dd2Dd2 L272F GC03
CQ 97 ± 6.8 88 ± 6.8 20 ± 1.8* 13 ± 2.3
MDCQ 497 ± 43 440 ± 33 121 ± 9.0* 26 ± 3.0
MDAQ 45 ± 5.8 35 ± 3.6 22 ± 4.0** 18 ± 1.1
PPQ 32 ± 3.1 32 ± 5.8 39 ± 1.5 23 ± 5.3
ART 18 ± 1.1 18 ± 4.6 13 ± 1.9 15 ± 4.7
BSD 456 ± 46 631 ± 35*** 708 ± 54 456 ± 59
Table 2.  In vitro sensitivity of Dd2, Dd2Dd2, Dd2Dd2 L272F and GC03 to antimalarial drugs. †CQ, 
chloroquine; MDCQ, monodesethyl chloroquine; MDAQ, monodesethyl amodiaquine; PPQ, piperaquine; 
ART, artemisinin; BSD, blasticidin. ‡IC50 values are listed in nM and are shown as the mean ± SEM. n = 3 
independent assays (each performed in duplicate). Significantly different mean IC50 values between Dd2Dd2 
and Dd2Dd2 L272F (F-test; *p < 0.0001, **p = 0.07) and between Dd2 and Dd2Dd2 (F-test; ***p = 0.038).
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extracellular solution at nanomolar levels, these protonatable drugs are expected to accumulate within 
the parasite’s FV via weak-base trapping to micromolar or millimolar concentrations.
Discussion
Mannaberg stained parasites with Romanowsky’s dyes and published detailed studies on the effects of 
QN against P. falciparum, which described the emergence of a ‘dropsical distension’ (enlarged FV) in 
mature parasites33. Here, we describe a similar peculiar phenotype of P. falciparum parasites that is visible 
without the application of antimalarial drugs. This phenotype is comparable between two parasite lines 
that have mutations in pfcrt in different positions (amino acids 101 and 272) and that have been selected 
by two chemically unrelated compounds (AMT and BSD). These mutations confirm that pfcrt encodes a 
function that is critical to maintaining FV volume. In support of this function, mutations in PfCRT that 
cause CQ resistance have been reported to increase FV volume34. However, the parasite lines described 
in this present study have clearly enlarged FVs but with PfCRT mutations that render the parasites more 
CQ sensitive than their control strains (be that either CQ-sensitive 3D7 or CQ-resistant FCB), suggesting 
an alternative mechanism of FV volume regulation is induced.
An enlarged FV is also often observed in the presence of protease inhibitors, such as E64 or leupep-
tin35. Interference with the digestion of hemoglobin leads to a buildup of darkly staining FVs in electron 
micrographs and, eventually, to parasite death. The parasites described here have enlarged FVs but these 
are electron lucent (Figs  2 and 4), suggesting that the digestion of hemoglobin is relatively unaffected 
(further supported by the presence of visible hemozin within the FVs). The simplest explanation for these 
observations is that the C101F and L272F mutations interfere with the transport of the natural substrates 
of PfCRT out of the FV. The resulting increase in FV osmotic pressure would lead to water ingress and 
produce the unusual swelling observed in the FV of the FCBC101F, 3D7L272F, and Dd2Dd2 L272F parasites. 
Figure  6 presents a schematic model of this process. These morphological changes are associated with 
other phenotypic changes (which are discussed below). The natural substrate(s) of PfCRT are yet to be 
identified. Studies performed with other PfCRT expression systems have reported that the protein might 
function as a chloride channel, a proton pump, an activator of Na+/H+ exchangers and non-specific 
cation channels or, most recently, a transporter of cationic amino acids as well as a very broad range of 
other cations15. However, in many of these studies the insertion of PfCRT into the foreign membrane 
required its fusion to other proteins/polypeptides, and in the most recent study the additions to PfCRT 
were at both the N- and C- termini, almost doubled its size, and included a protein of undetermined 
function15. Moreover, in this and the previous studies, little or no interaction could be detected between 
PfCRTDd2 and known inhibitors of this protein (e.g. VP). Of significant note, the transport kinetics for 
the proposed natural substrates did not differ significantly between PfCRTDd2 and PfCRT3D7—despite 
Figure 5. CQ transport activity of the C101F and L272F variants of PfCRT in Xenopus oocytes. (a,b) 
The uptake of [3H]CQ into oocytes expressing PfCRT was measured in the absence (closed bars) or presence 
of 250 µ M VP (light grey bars; a), 100 µ M BSD (dark grey bars; b), or 500 µ M BSD (open bars; b). Within 
each experiment, measurements were made from 10 oocytes per treatment and uptake was expressed 
relative to that measured in the PfCRTDd2-expressing oocytes under control conditions. The normalized 
data obtained from 4–5 separate experiments (each using oocytes from different frogs) were then averaged 
and are shown + SEM. Both panels show PfCRT-mediated CQ uptake, calculated by subtracting CQ uptake 
measured in PfCRT3D7-expressing oocytes (i.e. the component of CQ accumulation attributable to diffusion; 
see Supplementary Fig. S3) from that measured in oocytes expressing a variant of PfCRT. In the control 
treatments, the rates of CQ uptake (pmol/oocyte/h; n = 9 ± SEM) in oocytes expressing PfCRTDd2 and 
PfCRT3D7 were 23.6 ± 2.3 and 1.3 ± 0.2, respectively. ‘ns’ denotes no significant difference (p > 0.05) in CQ 
accumulation between oocytes expressing a PfCRT variant (in the presence or absence of VP or BSD) and 
that measured in the PfCRT3D7-expressing oocytes under control conditions.
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multiple lines of evidence indicating that PfCRTDd2 imparts a substantial fitness cost13,36–38. Furthermore, 
the recent finding that much higher levels of acidic amino acids and/or short acidic peptides accumulate 
within CQ-resistant parasites than in CQ-sensitive strains7,13,14 is not readily reconciled with PfCRT 
functioning as a chloride channel, a proton pump, or a non-specific cation channel/transporter. These, 
plus other inconsistencies in the data, suggest that PfCRT does not function correctly when fused to 
other proteins and that the natural function of PfCRT remains to be resolved.
AMT is an antiviral agent with moderate antimalarial activity that is more potent against CQ-resistant 
parasites than against CQ-sensitive strains39. AMT is likely to accumulate in the FV via weak-base 
trapping40 and is a low-affinity inhibitor of the PfCRTDd2-mediated transport of CQ in the oocyte sys-
tem7. While the antiplasmodial target of AMT remains unclear, AMT resistance has been linked previ-
ously to novel PfCRT mutations (S163R, I356V and V369F; Fig. 1) selected in parasites harboring CQ 
resistance-associated alleles of pfcrt; these mutations were linked with the loss of CQ resistance in the 
AMT-resistant mutants41,42. Here, a different single mutation (C101F) in the CQ-resistant FCB strain was 
likewise associated with a gain of AMT resistance and a reduction in CQ resistance. This mutation was 
identified previously in a PPQ-pressured parasite line that appeared to have acquired an unstable PPQ 
resistance phenotype via multiple genetic changes22. One of two PPQ-revertant lines derived during that 
study was ~2-fold more resistant to PPQ than the parental Dd2 strain, which along with a reduction in 
CQ resistance, is consistent with the data reported here for FCBC101F.
It has been suggested that the S163R mutation reintroduces a positive charge into the PfCRT binding 
pocket/translocation pore, thereby compensating for the loss of the positively-charged lysine residue 
from position 7611 and resulting in a dramatic reduction in the ability of the protein to transport pro-
tonated CQ7. The S163R mutation also abolishes the CQ resistance-reversing effect of VP42. The C101F 
and V369F mutations both entail the introduction of a bulky hydrophobic residue, rather than one car-
rying a positive charge, and it is interesting to note that VP still exerted a resistance-reversing effect in 
the FCBC101F parasites (Table 1)—even though they were considerably less resistant than the FCB strain 
Figure 6. Hypothetical schematic model of the effects of PfCRT mutations. The FV is acidified by 
a vacuolar proton pump to create a suitable environment for hemoglobin digestion. The acidic nature 
of the FV also leads to near complete diprotonation of CQ, which diffuses across the FV membrane 
in an uncharged form (CQ) and accumulates as a charged form (either CQH+ or CQH22+, although 
predominantly CQH22+). CQH22+ interferes with the polymerization of toxic heme to non-toxic hemozoin, 
which leads to parasite death. In normal CQ-sensitive (CQS) parasites, PfCRT, which contains a positive 
charge in its pore (K76), exports its natural substrates but little, if any, CQH22+. Thus, CQH22+ accumulates 
in the FV and causes parasite death. In CQ-resistant (CQR) parasites, the positive change in the pore of 
PfCRT is lost (K76T) and both its natural substrates and CQH22+ are transported out of the FV. As CQH22+ 
cannot accumulate in the FV, the parasites become resistant to the drug. In 3D7L272F parasites (where the 
parent strain is already CQS), the mutation may reduce residual transport of CQH22+ out of the FV even 
further or completely, leading to a greater FV accumulation of CQH22+ and CQ-hypersensitivity or some 
other mechanism may be responsible for this phenomenon. The mutation also leads to a reduction in the 
export of natural substrates, resulting in a build-up of these substrates. This causes water to enter the FV by 
the process of osmosis, leading to swelling. In FCBC101F and Dd2Dd2 L272F parasites (where the parent strains 
are CQR), the mutations reduce the export of CQH22+ back towards levels measured in CQS lines and 
also reduce natural substrate export, leading to normal CQ sensitivity and FV swelling, respectively. Note 
mutations in PfCRT (orange graphic) are denoted by red transmembrane or loop regions, depending on the 
location of the amino acid change (see Fig. 1a).
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to CQ. These observations are consistent with our direct measurements of CQ transport via C101F 
PfCRTDd2 (Fig.  5), which confirmed that this protein possesses a relatively low level of CQ transport 
activity that can be inhibited by VP. Likewise, our finding that the introduction of L272F into PfCRTDd2 
causes a dramatic (but not complete) reduction in the protein’s capacity for CQ transport (Fig. 5) corre-
lates well with the low level of CQ resistance exhibited by the Dd2Dd2 L272F line. The phenylalanine resi-
dues are likely to be proximate to the binding site and/or translocation pore of PfCRT (Fig. 1) where their 
bulky side chains may act to significantly hinder the transport of certain drugs out of the FV, including 
CQ, QN and QD (based on the growth assay data presented in Tables 1 and 2). Another mutation that 
has arisen under the AMT pressure of a CQ-resistant strain, and which also resulted in both the intro-
duction of a phenylalanine residue (V369F) and a significant reduction in CQ resistance, did not cause 
the FV to swell41. Hence, the enlarged FV phenotype described here appears to manifest only when the 
bulky phenylalanine side chain is inserted at specific positions within PfCRT.
BSD is used commercially as a fungicide against a rice blast disease and acts by inhibiting protein 
translation. In biological research it is used to select transformed cells. BSD resistance has previously been 
linked to altered expression of clag3.1 and a decrease in the RBC membrane permeability mediated by the 
new permeability pathways, NPP28,29. Neither 3D7L272F nor Dd2Dd2 L272F parasites differed in their electro-
physiological NPP characteristics when assayed by whole-cell patch-clamp methods (Supplementary Fig. 
S1). This suggests that one or more clag3.1-independent BSD resistance mechanisms exist. Our results 
indicate that, under the conditions of the growth assay, the L272F mutation does not cause a significant 
increase in BSD resistance when introduced in isolation into Dd2 parasites (Table 3). Nevertheless, BSD 
was found to inhibit CQ uptake via PfCRTDd2 and the potency of this interaction appeared to decrease 
upon the introduction of L272F (the addition of 100 µ M BSD was more effective against PfCRTDd2 than 
against L272F PfCRTDd2; Fig.  5). A demonstration that BSD interacts with PfCRTDd2, and to a lesser 
extent with L272F PfCRTDd2, provides support for the idea that BSD also interacts with, and may be 
transported by, PfCRT3D7. BSD contains two protonatable nitrogens with pKa values that are well above 7. 
It is therefore likely to be accumulated within the FV via weak-base trapping to high micromolar, or even 
millimolar, concentrations when present in the extracellular solution at the concentration (5.4 µ M) under 
which the 3D7L272F line arose. Given that BSD inhibits protein translation, which occurs outside of the 
FV, it is possible that a PfCRT3D7-mediated efflux of BSD from the FV could increase the drug’s access to 
its main target and that the L272F mutation diminishes this activity, such that the drug remains seques-
tered within the FV. The finding that L272F PfCRTDd2 does not confer BSD resistance when expressed 
in Dd2 parasites suggests that either (1) PfCRTDd2 is already a poor transporter of BSD (noting that the 
3D7 and Dd2 haplotypes of PfCRT differ by eight mutations) and a reduction in this meager transport 
activity by the introduction of L272F has little effect on the accumulation of BSD within the FV, or (2) 
PfCRTDd2 has a very high capacity for BSD transport, such that the presence of L272F causes only a mod-
est reduction in its ability to redistribute BSD from the FV into the cytosol. In any case, it is clear that if 
L272F is directly involved in altering the parasite’s susceptibility to BSD, its effect is only evident when 
one or more other changes are present. In this regard, it is worth noting that one of the two mutations 
identified by whole genome analysis of the 3D7L272F line would result in a truncated PfMRP2 protein. 
An understanding of the contribution of this transporter to BSD susceptibility, and its possible interplay 
with the BSD transport activity of PfCRT, requires further transfection-based analysis.
A diverse range of PfCRT variants implicated in conferring CQ resistance have been shown to 
exhibit CQ transport activity (to varying extents) in the oocyte system7,32. However, CQ transport via 
the wild-type form of the protein (found in CQ-sensitive parasites such as 3D7) has not been detected 
in this assay. Although it is possible that a very low level of CQ efflux is mediated by PfCRT3D7 in situ, 
and that the introduction of the L272F mutation abolishes this activity, it is perhaps unlikely that this 
would result in the 2-fold difference in the CQ IC50 observed between the 3D7L272F and 3D7 parasites.
An alternative explanation for the hypersensitivity of the 3D7L272F line to CQ and QN entails view-
ing the effect of the L272F mutation as being equivalent to the effect of an ‘anti-PfCRT’ drug. The 
presence of the L272F mutation causes the FV to swell, probably because it significantly obstructs the 
PfCRT-mediated efflux of solutes from this compartment. A drug that binds to the substrate-binding 
site of PfCRT3D7, thereby blocking or dramatically reducing its normal activity, would achieve a similar 
effect. If such an anti-PfCRT drug were applied in combination with CQ or QN, which also exert their 
antimalarial effects in the FV, it is possible that an additive, or even synergistic, interaction would be 
observed in 3D7L272F parasites. That is, the 3D7L272F parasites have a dis-functional FV and this could 
render certain drugs more effective against them; perhaps the altered composition of the FV lumen 
alters the solubilities of CQ and QN and/or their affinities for heme. It is not immediately apparent 
why AQ, MDAQ, and PPQ are not likewise more active against 3D7L272F parasites. However, it is worth 
noting that AQ, MDAQ and PPQ are much more lipophilic than CQ and this may explain differences 
in potency43,44. Hence, the antimalarial activities of the latter drugs might be less sensitive to changes in 
FV volume and composition. Alternatively, or in addition, it is also possible that extending the growth 
assays to 72 or 96 h (from 48 h) would reveal differences in AQ, MDAQ, and PPQ sensitivity between 
the 3D7 and 3D7L272F parasites.
If artemisinins act mainly in the FV, a disputed suggestion45 (along with reports of predominantly 
non-FV-localized artemisinin targets, e.g.46,47), then their activities may also differ between the parental 
and mutant lines. There was no significant change in the ART sensitivity of the 3D7, Dd2 and GC03 lines 
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and only a < 30% change in the IC50 value obtained for FCB (which displays an IC50 value < 15 nM). 
Recent observations made in a P. berghei model using protease knockouts that alter vacuolar morphology 
also leave artemisinin sensitivity unaltered48. This is also consistent with the lack of PfCRT expression 
in early ring stages49, when artemisinins exert their major antimalarial action in vivo. Similarly, the MF 
IC50 value was unaffected in the experiments presented here. Our observations therefore relate relatively 
large changes in the activities of several aminoquinolines to an enlarged FV phenotype that is caused by 
specific mutations in PfCRT.
Our results show for the first time that mutations at position 272 and 101 in PfCRT can hypersensitize 
parasites to CQ and enlarge the FV, thereby extending the function of this key transporter to include 
maintenance of FV morphology. We suggest that the introduction of a phenylalanine residue at either of 
these positions decreases the protein’s ability to transport its physiological substrate(s) (as well as certain 
drugs) and that the resulting build-up of the physiological substrate(s) causes the FV to swell. The fact 
that these mutations do not reintroduce a positive charge into the predicted binding cavity/translocation 
pore of PfCRT, as has been observed in other examples of laboratory parasites that revert to CQ-sensitive 
status (e.g.42), indicates that there is more than one type of single mutation—and therefore more than one 
mechanism—by which the CQ transport activity of PfCRT can be abrogated. This insight extends our 
understanding of the structure-function of PfCRT (e.g.32). Moreover, the finding that single mutations 
to the protein can result in gross changes to parasite morphology emphasizes the central role of this 
transporter in the physiological processes that occur within the FV and provides a novel insight into 
one of the factors constraining the evolution of PfCRT. The observation that BSD binds to, and appears 
to exert a selection pressure on, PfCRT further broadens the diversity of chemotypes that are known (or 
suspected) to interact with the protein. Our data encourage further studies to define agents that could 
reverse antimalarial drug resistance mediated by PfCRT by inhibiting its function.
Methods
Antimalarials and reagents. CQ, QN, QD, MQ, AQ, PPQ, ART, BSD, AMT and VP were purchased 
from Sigma Aldrich Chemical Co. MDAQ was purchased from Santa Cruz Biotechnology, Inc. MDCQ 
was a gift from William Ellis (Walter Reed Army Institute of Research, Silver Spring, MD). SYBR Green 
I was purchased from Invitrogen Corp. Drug stocks were prepared to 10 mM in DMSO or 70% ethanol 
and stored below − 20 °C.
In vitro culture and selection of parasites. P. falciparum 3D7 and 3D7L272F parasites were cul-
tured in human RBC suspensions using RPMI 1640 medium (Sigma-Aldrich; Cat. No. R0883-500ML) 
supplemented with 2 mM L-glutamine, 34 mM HEPES, 0.5% (w/v) Albumax I, 0.19 mM hypoxanthine, 
and 50 µ g/ml gentamycin and maintained at 37 °C under 5% CO2. For parasite clone 3D7L272F, complete 
medium was supplemented with 2.5 µ g/ml blasticidin-S HCl (Invitrogen). Parasite growth was followed 
by microscopic examination of Field’s stained thin blood smears. Synchronization of early trophozoite 
stages was achieved by incubating infected RBCs in 5% (w/v) sorbitol for 10 to 20 min at room temper-
ature50. Following transfection studies23, parasites with abnormally enlarged FVs, as described in results, 
reappeared in culture under BSD pressure after four weeks. In order to select these parasites, the lim-
iting dilution technique was used, and cloned parasites were identified by microscopy using thin blood 
smears51.
P. falciparum FCB and FCBC101F parasites were cultured in AB+ or O+ human RBC suspensions using 
RPMI 1640 medium (Mediatech, Inc.) supplemented with 0.5% Albumax I, 29.8 mM sodium bicarbo-
nate, 25 mM HEPES, 0.37 mM hypoxanthine, and 10 µ g/ml gentamicin and maintained at 37 °C under 
an atmosphere of 90% N2, 5% CO2, and 5% O2. AMT-resistant P. falciparum was selected by single-step 
selection based on an earlier method described for CQ6. Before drug pressure, parasites of the FCB strain 
were grown to 5% mixed stage parasitemia at 5% hematocrit in 50 ml of media. This starter culture was 
then split equally into 4 flasks, with fresh media and RBCs to bring the volume in each flask to 50 ml 
and 5% hematocrit. When parasitemia of the 4 flasks had returned to 5%, the media was replaced with 
fresh media containing 80 µ M AMT. At ~14 fold the IC50 value determined for FCB (Table  2), this 
concentration of AMT rapidly kills CQ-resistant parasites. For the first week after drug application, cul-
tures were monitored daily by Giemsa-stained thin blood films. Fresh AMT-containing media changes 
were performed daily. At one week, 50% of the RBCs were replaced, and fresh AMT media was added. 
Cultures were then maintained every third day with fresh AMT media for the duration of the experiment 
and monitored by thin smear for emergent parasites. With every second media change, 50% of the RBCs 
were replaced with fresh cells. If no surviving parasites were observed after 60 days, the experiment was 
terminated. After 42 days, parasites were recovered from one of the 4 flasks, which were then cloned by 
limiting dilution52 in drug-free media. The mixed culture and four randomly chosen cloned lines were 
cryopreserved prior to DNA sequencing and drug susceptibility testing.
Morphological measurements. For comparison, thin blood films of cultured parasite samples were 
made at various time points following sorbitol synchronization and stained with Field’s stain. Pictures 
were taken under the same conditions for the 3D7 (parent) strain and the 3D7L272F line and analyzed 
256
www.nature.com/scientificreports/
12Scientific RepoRts | 5:14552 | DOi: 10.1038/srep14552
with a Nikon Eclipse TE2000 inverted microscope. Areas were measured using ImageJ 1.44o software 
and the ratio was expressed as AFV/AParasite. No image manipulations were carried out after recording.
For micrographs of FCB and FCBC101F, thin films from parasite cultures were stained with 2% (v/v) 
modified Giemsa (Karyomax® ; Gibco) for 30 min. Slides were washed for 60 s in flowing distilled water, 
air-dried and mounted with coverslips. Images were photographed in bright field, using a Lexica DMI4000 
inverted microscope under a 100X objective lens. Images were compiled in Adobe Photoshop CS5.1 and 
processed equally with a warming photo filter. Live parasite cultures were placed under coverslips and 
photographed under a 100X objective, using a Leica DM750 light microscope equipped with ICC50 HD 
digital camera. Images were adjusted for white balance with the Leica Application Suite software and 
cropped in Adobe Photoshop CS5.1.
For experiments with Dd2 parasites, thin blood smears were fixed with methanol, stained for 20 min 
in 10% (v/v) Giemsa (Invitrogen), washed, and air-dried. Images were taken with an Olympus DP12 
digital camera attached to an Olympus CX 41 light microscope with a 100X objective (N.A 1.4x). Images 
were cropped and corrected for white balance using Adobe Lightroom 3.
Electron microscopy. Samples of 3D7, 3D7L272, Dd2Dd2 and Dd2Dd2 L272F, synchronized at the mature 
trophozoite stage were fixed in 4% (v/v) glutaraldehyde in 0.1 M phosphate buffer and processed for 
routine electron microscopy, as described previously53. Samples were post fixed in osmium tetroxide, 
treated en bloc with uranyl acetate, dehydrated and embedded in Spurr’s epoxy resin. Thin sections were 
stained with uranyl acetate and lead citrate prior to examination in a JEOL1200EX electron microscope.
In vitro inhibition assays. Sensitivity to CQ and other drugs for 3D7 and 3D7L272F parasites was 
determined by measurement of [3H]-hypoxanthine incorporation over 48 h, as described previously54. 
Nine serial dilutions plus a control (no drug) were tested in quadruplicates and the experiment was 
repeated at least three times for each drug. The assay was performed always in parallel on 3D7 and 
3D7L272F parasites.
The in vitro susceptibility of FCB and the FCBC101F line of P. falciparum to antimalarial drugs was 
measured in a 72 h, 96 well microplate fluorescence assay using SYBR Green I detection as described55,56. 
Drugs were serially diluted 2-fold in the microplates, except for AMT, which was diluted 3-fold. VP was 
used at a concentration of 0.8 µ M where indicated. Synchronous (immature) ring-stage parasites were 
assayed at 0.2% parasitemia and 2% hematocrit. Assays were conducted every 48 h until three independ-
ent replicates were performed. For Dd2 parasites, the same methodology was used except parasites were 
also stained with 1.6 µ M Mito Tracker Deep Red.
Genotypic characterization of pfcrt gene. For 3D7 parasites, RNA was extracted from parasites 
collected in RNAlater, using QIAGEN RNeasy Mini Kit, and immediately used to retro-transcribe cDNA 
(QIAGEN, QuantiTect Rev. Transcription Kit). Mutation in pfcrt was investigated by PCR, as described 
previously1. The same primers (Supplementary Table S1), which amplified overlapping products, were 
used to sequence the products to cover the entire open reading frame (ORF) of the gene. Amplification 
of the gene and its sequencing was performed twice (by Beckman Coulter Genomics). Alignment of 
the reported 3D7 gene from PlasmoDB and 3D7 and 3D7L272F sequenced genes was performed using 
MacVector software (version 11.1).
For FCB parasites, 4 clonal lines of FCBC101F were used for pfcrt sequencing. All ORF sequences of 
pfcrt were amplified from P. falciparum genomic DNA57. PCR products were sequenced directly using an 
ABI 3730xl DNA analyzer (Applied Biosystems).
Whole genome sequencing and variant detection. Genomic DNA was isolated and prepared 
from the parental P. falciparum parasite line 3D7 and 3D7L272F. A total of 10 µ g of gDNA from each line 
was sheared to obtain a fragment size of ~200–400 bp using an E220 focused-ultrasonicator (Covaris) 
with the following settings: 10% duty cycle, intensity 5, 200 cycles per burst, 180 s treatment length. 
The resulting sheared gDNA was size selected on a 2% (w/v) low-melting agarose gel and then purified 
and concentrated using MinElute purification columns followed by the QIAquick PCR purification kit 
(QIAGEN). Barcoded libraries for Illumina TruSeq single-end sequencing were then constructed from 
the size-selected, sheared material using NEBNext DNA Library Preparation reagents (New England 
Biolabs) by following the standard Illumina (Illumina) library preparation protocol. Finally, barcoded 
libraries were size selected using Agencourt AMPure XP magnetic beads (Agencourt Biosciences, 
Beckman Coulter) thereby removing any adapter dimers and resulting in a highly enriched barcoded 
library of 200–400 bp adapter-ligated fragments. The quality of the final sequencing libraries was assessed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies) run alongside the original size-selected frag-
mented gDNA from the same preparation, and the concentration of each library was quantified using 
a Quant-iT dsDNA Broad-Range Assay Kit (Invitrogen). The final libraries were multiplexed with three 
barcoded samples and 20% (v/v) PhiX control DNA (Illumina, Catalog # FC-110-3001) per lane and were 
sequenced using an Illumina HiSeq 2500 Rapid Run (150 bp) system (Illumina).
Sequencing outputs were uploaded into Galaxy58, which is hosted locally at the Millennium Science 
Complex at Pennsylvania State University. Sequence reads were mapped to the P. falciparum 3D7 
reference genome v. 10.0 (http://plasmodb.org/common/downloads/release-10.0/Pfalciparum/) and 
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pCam-BSD-PfATP6-doubleHA plasmid sequence23, using the Burrows-Wheeler alignment tool59, and 
files were converted to allow for further analysis (GATK/BAM-to-SAM)60. Sequence variations were 
detected by Freebayes (version 0.9.0.a) using stringent filtering parameters based on quality and read 
depth61,62. Then SNPeff (version 3.3) was applied to annotate and determine statistical significance of 
each variant63. Genome copy number variations were detected based upon local chromosomal read depth 
using CNVnator (version 0.3) and annotated with Intansv (version 0.99.3)64. Alignments and variants 
were visualized using the Integrative Genomics Viewer65. Unique reads were selected and filtered for 
Map Quality > 30.
Plasmid construction and generation of Dd2 recombinant parasites. The donor plasmid pcrtDd2- 
hdhfr has been previously reported31. The mutation-encoding plasmid, pcrtDd2 L272F-hdhfr, was generated 
by site-directed mutagenesis of pcrtDd2-hdhfr, using primers p3527 + p3528 (Supplementary Table S2).
ZFN-editing transfection methods have been previously described31. Briefly, Dd2 parasites were elec-
troporated with either pcrtDd2-hdhfr or pcrtDd2 L272F-hdhfr donor plasmid66. On Day 1 post-electroporation, 
they were cultured in the presence of 2.5 nM WR99210 (obtained from Jacobus Pharmaceuticals Inc.). 
Once recovered, both pcrtDd2-hdhfr and pcrtDd2 L272F-hdhfr transfected parasites were electroporated a 
second time with pZFNcrt-bsd separately. On Day 1 post-electroporation each transfection was cultured 
with 2 µ g/ml blasticidin S (Invitrogen) and 2.5 nM WR99210 for six days and followed by addition of 
only 2.5 nM WR99210, generating Dd2Dd2and Dd2Dd2 L272F parasites, respectively. Clones were established 
from the bulk cultures by limiting dilution52. PCR primers for verification of parental, recombinant con-
trol, and Dd2Dd2 L272F parasite clones are shown in Supplementary Table S2.
Expression of the C101F and L272F variants of PfCRT in X. laevis oocytes and measurements 
of CQ transport. Ethical approval of the work performed with the X. laevis frogs was obtained from 
the Australian National University Animal Experimentation Ethics Committee (Animal Ethics Protocol 
Number A2013/13) in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. The C101F PfCRTDd2, L272F PfCRTDd2, and L272F PfCRT3D7 coding sequences 
were generated via site-directed mutagenesis using an approach described previously32. The mutations 
were introduced into codon-harmonized versions of the PfCRTDd2 and PfCRT3D7 coding sequences, 
which encode retention motif-free forms of these proteins that are expressed at the plasma membrane 
of X. laevis oocytes7. All of the resulting coding sequences were verified by sequencing. The in vitro tran-
scription of cRNA and the harvest and preparation of oocytes were performed as outlined elsewhere67. 
The oocytes were microinjected with 20 ng of cRNA and the uptake of [3H]CQ (0.25 µ M; 20 Ci/mmol; 
American Radiolabeled Chemicals) was measured 3–4 days post-injection as detailed previously67. The 
measurements were made over 1.5 h at 27.5 °C and in medium that, unless otherwise specified, con-
tained 96 mM NaCl, 2 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 10 mM MES, 10 mM Tris·base (pH 5.5), 
and 15 µ M unlabeled CQ. In all cases, at least three separate experiments were performed (on oocytes 
from different frogs), and in each experiment measurements were made from 10 oocytes per treatment.
Immunofluorescence and western blot analyses of oocytes expressing PfCRT. 
Immunofluorescence analyses were performed on oocytes 3 days post-injection using an approach 
described elsewhere68. Briefly, the oocytes were fixed and labeled with rabbit anti-PfCRT antibody (con-
centration of 1:100; Genscript32; ) and Alexa Fluor 488 goat anti-rabbit antibody (concentration of 1:500; 
Molecular Probes). The oocytes were embedded in an acrylic resin using the Technovit 7100 plastic 
embedding system (Kulzer) as outlined previously69 and images of 4 µ m slices were obtained with a Leica 
Microsystems inverted confocal laser microscope. At least two separate experiments were performed (on 
oocytes from different frogs) for each treatment and slices were examined from a minimum of three 
oocytes within a treatment. All of the slices taken from oocytes expressing a PfCRT variant displayed 
a fluorescent band above the pigment layer (consistent with the localization of PfCRT to the plasma 
membrane) that was not present in non-injected oocytes.
The preparation of oocyte membranes and the semi-quantification of PfCRT protein was carried out 
using a protocol described in detail elsewhere32. Protein samples prepared from oocyte membranes were 
separated on a 4–14% bis-Tris SDS-polyacrylamide gel (Life Technologies) and transferred to nitrocel-
lulose membranes. The membranes were probed with rabbit anti-PfCRT antibody (1:4,000) followed by 
horseradish peroxidase-conjugated goat anti-rabbit antibody (1:8,000; Life Technologies). The PfCRT 
band for each variant was detected by chemiluminescence (Pierce), quantified using the Image J soft-
ware70, and expressed as a percentage of the intensity measured for the PfCRTDd2 band. In all cases, at 
least three separate experiments were performed (on oocytes from different frogs), and in each experi-
ment measurements were averaged from two independent replicates.
Curve fitting and statistical analyses. Mean half-maximal inhibitory concentrations (IC50 val-
ues) were derived by plotting percent growth inhibition against log drug concentration, and fitting the 
response data to a variable slope, sigmoidal curve-fit function for normalized data using Prism 5.0d for 
Macintosh (GraphPad Software). IC50 values represent means ± standard error from 3 independent tests. 
IC50 values between mutant and parent lines were tested for statistically significant differences using an 
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F-test that determines whether the two dose response data sets are best described by single or independ-
ent curve fits (p < 0.05). In the case of the oocyte data, statistical comparisons were made using ANOVA 
in conjunction with Tukey’s multiple comparisons test. Other data were compared using the Student’s 
t-test and Fisher’s exact test as noted.
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7.5. Appendix projects  
7.5.1 Gene editing P. falciparum mlh1 and pms1 using ZFNs and CRISPR/Cas9 
To determine whether DNA repair gene mutations found in artemisinin-resistant Cambodian 
isolates are causative of the mild mutator phenotype in parasites (CHAPTER 3), we attempted to 
(A) introduce the mlh1-P203S mutation into a wild-type background, (B) introduce the pms1-
S506I mutation into a wild-type background, (C) remove the mlh1-P203S mutation from a 
Cambodian isolate, (D) remove the pms1-S506I mutation from a Cambodian isolate, (E) knock 
out mlh1 (by introduction of egfp or hdhfr), and (F) knock out pms1 (by introduction of hdhfr).  
 
Table 7.1 Guide RNA sequences for CRISPR/Cas9 experiments 
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These experiments were performed using multiple systems of engineered nucleases. For editing 
mlh1, we employed three pairs of ZFNs (Z1, Z2, and Z3; Sigma-Aldrich), two variations of the 
T7 CRISPR/Cas9 system ((125) and Marcus Lee, unpublished), and two variations of the U6 
CRISPR/Cas9 system ((126) and Marcus Lee, unpublished). 
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For editing pms1, we employed the T7 CRISPR/Cas9 and the U6 CRISPR/Cas9 systems ((125) 
and Marcus Lee, unpublished). For the CRISPR/Cas9 experiments, six gRNA sequences were 
designed to target pms1, and nine for mlh1 (Table 7.1). Plasmids constructed to engineer pfmlh1 
and pfpms1 are found in Table 7.2 and Table 7.3, respectively. Frozen plasmid stocks can be 
found using the identification numbers (No.). Identification numbers listed are either in the 
common lab bacterial stock and are denoted by “gs” followed by a number (e.g. gs2923) or a 
personal stock number (e.g. 175). Introduction of the mlh1-P203S mutation or mlh1 KO was 
performed in five separate strains using all methods of genome editing. These strains include: 
3D7, Dd2, V1/S, PH0167-C, and PH0212-C (Table 3.1 and Table 3.5). Introduction of the 
pms1S506I or pms1 knockout were performed in 3D7 and Dd2. 
 
Despite repeated attempts at genome editing using ZFNs, the U6 CRISPR/Cas9 system, the T7 
CRISPR/Cas9 system, Cas9-targeting gRNA sequences, and parasite strains, we were unable to 
yield any parasite that harbored mlh1-P203S, mlh1 KO, pms1-S506I, or pms1 KO. It is unclear 
what factors prevented successful gene editing. (A) It is possible that the mlh1 and pms1 loci are 
not genetically tractable. For instance, Cas9 endonuclease activity has been shown to be 
inhibited in vitro by nucleosome positioning (378). This hypothesis is consistent with the 
absence of evidence of binding site mutations incorporating in the genome in any gene editing 
system used above. In contrast, the highly recombinogenic, subtelomeric KAHRP locus 
(PF3D7_0202000) is readily edited using the T7 CRISPR/Cas9 system (125). (B) Currently, 
CRISPR/Cas9 usage in P. falciparum has had mixed success. Unpublished reports significant 
difficulties in generating genetic mutants at various loci and in various strains. (C) Successful 
gene editing requires that mutant strains outcompete non-edited strains post-electroporation. 
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Single mlh1-P203S and pms1-S506I mutations may confer a significant fitness cost such that 
successful gene editing is not achieved. This is unlikely given the inability to introduce silent 





Table 7.2 Plasmids generated for editing pfmlh1 using ZFNs or CRISPR/Cas9 
Plasmid gRNA Change Description No. 
pL7s-Mlh1P203S-gMlh1 M1 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
gs2923 
pL7s-Mlh1P203S_gMlh1-2_MBS2 M2 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
N/A 
pL7s-Mlh1P203S_gMlh1-3_MBS3-2 M3 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
175 
pL7s-Mlh1P203S_gMlh1-4_MBS4-4 M4 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
184 
pL7s-Mlh1P203S_gMlh1-5_MBS5-1 M5 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
176 
pL7s-Mlh1P203S_gMlh1-6_MBS6-1 M6 P203S Introduces P203S mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. (U6) 
179 
pL7s-Mlh1KO-gMlh1 - KO Knocks out Mlh1 with hdfhr cassette. Donor and 
gRNA. Transfected with pUF1 Cas9 bsd. (U6) 
gs2922 
pUF1 Cas9 bsd - - Encodes Cas9 and bsd marker. (U6) gs2944 
pDC2-CAM-Cas9_U6-Mlh1-g1-1 M1 - Cas9 and gRNA plasmid. (U6) 197 
pDC2-CAM-Cas9_U6-Mlh1-g2-1 M2 - Cas9 and gRNA plasmid. (U6) 199 
pDC2 CAM Cas9 hdhfr GG Mlh1 606 1 M1 P203S Cas9 and gRNA plasmid. (T7) 90 
pDC2 CAM Cas9 hdhfr Mlh1 168 1 M7 P203S Cas9 and gRNA plasmid. (T7) 92 
pDC2 CAM Cas9 hdhfr Mlh1 537 1 M8 P203S Cas9 and gRNA plasmid. (T7) 94 
pDC2 CAM Cas9 hdhfr Mlh1 732 1 M9 P203S Cas9 and gRNA plasmid. (T7) 96 
pDC2-cam-T7RNAPol-
Mlh1_P203S_donor-bsd-attP-1 
M1 P203S T7 RNA Pol. and P203S donor plasmid. (T7) 101 
pDC2-cam-T7RNAPol-
Mlh1_P203S_donor_606-MBS_bsd-attP 
M1 P203S T7 RNA Pol. and P203S donor plasmid. (T7) 111 
pDC2-cam-T7RNAPol-
Mlh1_P203S_donor_168-MBS_bsd-attP 
M7 P203S T7 RNA Pol. and P203S donor plasmid. (T7) 110 
pDC2-cam-T7RNAPol-
Mlh1_P203S_donor_537-MBS_bsd-attP 
M8 P203S T7 RNA Pol. and P203S donor plasmid. (T7) 112 
pDC2-cam-T7RNAPol-
Mlh1_P203S_donor_732-MBS_bsd-attP 
M9 P203S T7 RNA Pol. and P203S donor plasmid. (T7) 113 
pDC2-Cam-T7RNAP-Mlh1-HRI-2A-
GFP-hsp86-3'HRII_bsd-attP 
- KO T7 RNA Pol. and Mlh1 KO donor plasmid. (T7) 116 
pDC2-Mlh1-HRI-2A-GFP-HRII-ZFN-
bsd-2 
Z1 KO Introduces 2A-linked GFP into pfmlh1 (ZFN) gs2908 
pDC2-zMlh1-Mlh1-2A-dhfr-hrp23-bsd-
1-1 
Z1 KO Introduces 2A-linked hdfhr into pfmlh1 (ZFN) 160 
pDC2-cam-Mlh1-WTDonor-ZFNs-bsd-
1 





Z1 P203S Introduces Z1 mutated binding sites and P203S 
mutation into pfmlh1 (ZFN) 
gs2896 
pDC2-zMlh1_12_bsd-1 Z2 - Z2 ZFN only plasmid (ZFN) 188 
pDC2-zMlh1_12_Mlh1P203S_MBS12-
1 
Z2 P203S Introduces Z2 mutated binding sites and P203S 
mutation into pfmlh1 (ZFN) 
193 
pL7-Mlh1_12_KO-5 Z2 KO Donor plasmid that introduces hdfhr cassette into 
pfmlh1 into using Z2 (ZFN) 
190 
pDC2-zMlh1_34_bsd-1 Z3 - Z3 ZFN only plasmid (ZFN) 189 
pDC2-zMlh1_34_Mlh1P203S_MBS34-
5 
Z3 P203S Introduces Z3 mutated binding sites and P203S 
mutation into pfmlh1 (ZFN) 
195 
pL7-Mlh1_34_KO-5 Z3 KO Donor plasmid that introduces hdfhr cassette into 




Table 7.3 Plasmids generated for editing pfpms1 using CRISPR/Cas9 












T7 P6 KO T7 RNA Pol. and Pms1 KO donor plasmid. 155 
pfYC102-Cas9-Pms1-
gRNA1-bsd-1 
- P5 - Cas9 and gRNA plasmid. 157 
pfYC102-Cas9-Pms1-
gRNA2-bsd-1 
- P6 - Cas9 and gRNA plasmid. N/A 
pfGNR-T7R-Pms1-0167-
DonorLong_MBS2 
T7 P2 WT Introduces Pms1 WT. 158 
pfGNR-T7R-Pms1-0482-
DonorLong_MBS1 
T7 P1 S506I Introduces Pms1 S506I mutation. 159 
pL7s-2-Pms1KO-2 U6 P2 KO Knocks out Pms1 with hdfhr cassette. Donor and 




U6 P1 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 




U6 P2 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 




U6 P3 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 




U6 P4 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 




U6 P5 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 




U6 P6 S506I Introduces Pms1 S506I mutation. Donor and gRNA. 
Transfected with pUF1 Cas9 bsd. 
179 
 
Table 7.4 Summary of gene editing systems, strains, and editing strategies used 
Strain Editing system Mlh1 Change Pms1 Change 
PH0212-C Z1, M7, M8, M9 P230S to WT - 
PH0167-C Z1, M7, M8, M9 WT to P230S - 
V1/S Z1, M7, M8, M9 WT to WT 
WT to P203S 
WT to WT 
WT to S506I 
3D7 M1 - M9, P1 - P6, Z1 - Z3 WT to WT 
WT to P203S 
WT to KO 
WT to WT 
WT to S506I 
WT to KO 
Dd2 M1 - M9, P1 - P6, Z1 - Z3 WT to WT 
WT to P203S 
WT to KO 
WT to WT 
WT to S506I 
WT to KO 
Z1, Z2, Z3: 1st, 2nd, and 3rd Mlh1 ZFN pair, respectively 
M1 – M9: Mlh1 gRNA sequences from Table 7.1 




7.5.2 Investigating the outcomes of meiotic crossing over in P. falciparum 
This experiment was designed and managed by AHL. Plasmids were generated by Mariana 
Justino Lage de Almeida. Transfections were performed by M. Almeida and AHL. 
 
In CHAPTER 3, we have focused on the effects of DNA repair gene mutations in the 
intraerythrocytic, asexual cycle. It is important to note that the effects of these mutations may 
also extend to the sexual stages that genetically recombine in the Anopheles mosquito host. In 
meiosis, for instance, the complex of Mlh1-Mlh3 (MutLγ) and Exo1 has been shown to resolve 
meiotic crossovers (362). Additionally, the Mlh1-Pms1 complex (MutLα) prevents post-meiotic 
segregation and divergence from Mendelian inheritance (161).  
 
We posited that P. falciparum DNA repair mutations might reduce meiotic recombination and 
thereby contribute to the maintenance of multigenic drug-resistant traits in Southeast Asian 
strains. Such a mechanism would be consistent with the over-representation of these DNA repair 
genes in artemisinin-resistant parasites in Cambodia, which comprise genetically distinct parasite 
subpopulations whose primary resistance determinant k13 appears to be in linkage 






Figure 7.1 Strategy for 
monitoring meiotic crossovers in 
Plasmodium 
NF54 gametocytes encoding gfp 
(green cell) are crossed with 
mCherry-encoding NF54 
gametocytes (red cell). When 
crossed, the diploid cell undergoes 
meiotic replication, crossing over, 
and segregation into sporozoites. 
Mendelian inheritance produces a 
1:1:1:1 ratio of GFP+ mCherry+: 
GFP+ mCherry-: GFP- mCherry+: 
GFP- mCherry- parasites, 
observable by fluorescence 
microscopy or flow cytometry. 
 
To investigate meiosis in P. falciparum, we have designed a strategy to monitor chromosomal 
crossovers in sporozoites dissected from infected Anopheles mosquitos. This strategy, adapted 
from experiments in Arabidopsis thaliana (379), requires two strains: one encoding GFP at one 
end of chromosome XIII and another that encodes mCherry on the opposite end of the same 
chromosome (Figure 7.1). Meiotic crossovers, averaging one per chromosome in P. falciparum 
(175), are expected to display Mendelian inheritance such that sporozoites express GFP+ 
mCherry+: GFP+ mCherry-: GFP- mCherry+: GFP- mCherry- at a 1:1:1:1 ratio by observed by 
flow cytometry or fluorescence microscopy. MMR gene mutations in Cambodian isolates (Table 
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3.1), introduced by the CRISPR/Cas9 system, would then produce deviations from Mendelian 
inheritance. 
 
An NF54 strain has been previously generated to encode an ef1α-driven GFP-luciferase fusion 
integrated in the P47 locus (PF3D7_1346800) using the hdhfr selectable marker (380). This 
strain has been shown to form gametocytes and sporozoites in Anopheles stephensi mosquitos. In 
order to generate a strain expressing mCherry on the opposite arm chromosome XIII, we chose a 
locus 1.5 Mb from P47 that (A) does not disrupt an essential gene and (B) is sufficiently distant 
from P47 such that 1.2 meiotic crossovers is likely to occur in the intervening sequence, 
assuming a recombination rate of 12.1 kb/cM (175). 
 
This locus encodes an end-to-end configuration of two genes such that the non-essential P. 
falciparum integrase pfint (PF3D7_1308800) and a conserved Plasmodium protein with 
unknown function (PF3D7_1308700) share a bidirectional 388 bp 3’ UTR. In order to integrate 
mCherry without disrupting of this endogenous locus, we designed a plasmid (pLN-PfInt-hdhfr, 
gs3072) such that the shared, bidirectional 3’UTR is duplicated upon plasmid integration by 





Figure 7.2 Schematic of the pLN-PfInt-hdhfr integration into the genome 
The “wild-type locus” on chromosome XIII encodes an end-to-end configuration of pfint (orange 
box) and PF3D7_1308700 (purple box) where both genes share a bidirectional 3’ UTR. 
Homology to pfint and the pfint 3’ UTR enables single-site crossover and integration of the pLN-
PfInt-hdhfr into the parasite genome. The resulting genomic locus separates pfint and 
PF3D7_1308700 while duplicating the bidirectional 3’ UTR. Figure generated by M. Almeida. 
 
pLN-PfInt-hdhfr was constructed from pLN-CSP-gfp-bsd in three steps. (A) gfp was removed 
from pLN-CSP-gfp-bsd by PCR using primers p4405 and p4406. mCherry was then PCR 
amplified using p4411 and p4412 and subcloned to replace gfp using XhoI and SmaI. By placing 
mCherry under transcriptional control of 1258 bp of the circumsporozoite (CSP, 
PF3D7_0109600) promoter, mCherry fluorescence can be detected in sporozoites following 
meiosis. (B) A 1002 bp region of homology encoding the final 614 bp of pfint followed by the 
388 bp 3’ UTR was PCR amplified from NF54 gDNA using primers p4403 and p4404 and 
subcloned into the gfp-deleted plasmid using PstI and BamHI. (C) The bsd selectable marker was 




Table 7.5 Primers to generate pLN-PfInt-hdhfr 
Name Primer (5’ to 3’) Description 
p4403 ctgcagAAGACGGCACTAAAAGGAGCAG pfint Amplification PstI 
BamHI 
p4404 ggatccAAACATATATCATGTTCCCCTCGAC pfint Amplification PstI 
BamHI 
p4405 gcggccgcctcgagTTATATAATATATTTATGTACTCACAATGG Delete GFP and add 
XhoI and NotI unique 
sites in PLN-CSP-GFP 
p4406 ctcgaggcggccgcGAATTGTAATTTATAATATACGTGGTTTCTACTTAT Delete GFP and add 
XhoI and NotI unique 
sites in PLN-CSP-GF 
p4411 gcggccgcATGGTGAGCAAGGGCG mcherry amplification 
with NotI XhoI 
p4412 ctcgagTTACTTGTACAGCTCGTCCATGC mcherry amplification 
with NotI XhoI 
 
Two NF54 strains (Sanaria and Swiss TPH) were then electroporated independently with the 
final pLN-PfInt-hdhfr plasmid and maintained under 2.5 nM WR99210 selective pressure. 
Integration of the pLN-PfInt-hdhfr plasmid at the pfint endogenous locus was only detectable by 
PCR in the Swiss TPH strain. The Swiss TPH integrant strain was transferred to parallel cultures 
of 2.5% human serum or 10% human serum medium. However, gametocytes could not be 










Figure 7.3 Plasmid map of pLN-PfInt-hdhfr 
pLN-PfInt-hdhfr encodes (A) 1002 bp of homology to pfint and the pfint 3’ UTR (blue arrows), 
(B) CSP 5’-driven mCherry (red arrow), (C) and hdhfr (orange arrow). Glycerol stock #gs3072. 
  
7.5.3 ZFN-mediated gene editing using a PfCRT-2A-hDHFR cassette 
Screening for the correct, desired outcome is a significant rate-limiting step in the generation of 
parasites that encode novel pfcrt haplotypes. A successful transfectant must be initially validated 
by PCR of the bulk culture. If sufficient ZFN-mediated editing has occurred, the transfectant 
must then be cloned by limiting dilution in a 96-well plate. These clones must then be screened 




Figure 7.4 Plasmid map for pfcrtDd2-2A-hdhfr 
The pfcrtDd2-2A-hdhfr was built from the design of the pcrtDd2-hdhfr (Figure 4.3). The coding 
sequences for pfcrt and hdhfr linked in frame by the viral 2A “ribosome skip” peptide sequence 
(blue triangle). The pfcrtDd2-2A-hdhfr coding sequence is terminated by the pfcrt 3’ UTR. 
 
To help circumvent this issue, we construct plasmids in which the pfcrt and hdhfr coding 
sequences are linked by the viral 2A “ribosome skip” peptide (Figure 7.4). This sequence enables 
polycistronic expression pfcrt and hdhfr into independent peptides. This is also used between the 
two ZFN-coding sequences in pZFNcrtbsd (71). However, transfections with these donor 
plasmids do not yield any WR99210-selectable parasites (data not shown). We posit that because 
PfCRT is a membrane-bound protein it is translocated into the endoplasmic reticulum (ER) when 
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translated. Peptide translocation into the ER has been shown to inhibit 2A-peptide cleavage 
(381). As a result, the hdfhr gene product is likely sequestered away from its site of action, the 
cytoplasm. 
 
7.5.4 Linearization of plasmid DNA in vivo using ZFNs 
While genome engineering through the introduction of DSBs via ZFNs or CRISPR/Cas systems 
are currently actively being pursued in malaria research, the use of linearized DNA alone to 
promote recombination and genome editing is a simpler methodology that would greatly benefit 
P. falciparum research, as it is very simple and time- and resource-efficient to design. This 
method of genome editing has long been available to yeast (382) and even P. berghei (245).  
 
Previously, genome editing via linearization of DNA in vivo using the homing endonuclease I-
SceI has not proven to be possible in P. falciparum (S. Adjalley, doctoral thesis). This method 
generated an “ends-out” linear DNA fragment, such that a selectable marker flanked by two 
homology regions facing outwards when paired with a homologous target (the P. falciparum 
kahrp gene). We hypothesized that P. falciparum may be unable to undergo ends-out 
recombination, but may be able to perform “ends-in” recombination (where the homology 
regions on a linearized plasmid face inwards when paired with a homologous target). 
 
To determine if P. falciparum could produce ends-in recombination products, we transfected 
either a plasmid carrying the pfcrt-targeting ZFNs and a stretch of homology extending from the 
pfcrt 5’ UTR to exon 3 (Figure 7.5a) or the pcrtDd2-hdhfr plasmid plus a separate plasmid 
encoding the ZFNs, pZFNcrt-bsd (Figure 7.5b). Both plasmids are expected to be cleaved by 
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ZFNs in vivo to generate ends-in linear DNA. These plasmids were transfected into the 
106/114/15mut1 parasite (71), which has previously been engineered to encode binding site 
mutations, rendering the pfcrt locus resistance to ZFN cleavage. Therefore, expression of the 
pfcrt-targeting ZFNs in these parasites would cleave the plasmid, but not the genome. 
Recombination between linearized DNA and the genome would transfer the binding site 





Figure 7.5 Schematics of 
ZFN-mediated in vivo 
plasmid linearization 
a. A plasmid containing the 
pfcrt-targeting ZFNs and a 
stretch of homology 
extending from the pfcrt 5’ 
UTR to exon 3 shown above 
the pfcrt locus encoding 
ZFN binding site mutations. 
b. The pcrtDd2-hdhfr 
plasmid shown above the 
pfcrt locus encoding ZFN 
binding site mutations. 
pZFNcrt-bsd is not shown. 
 
Transfections with these plasmids were successful and plasmids were rescued by gDNA 
extraction. Restriction enzyme digest and Sanger sequencing revealed that when the ZFNs and 
donor sequence are encoded on the same plasmid (Figure 7.5a), 88% of plasmids rescued no 
longer have functional ZFNs. The coding sequences for two ZFNs were collapsed to a single 
chimeric ZFN sequence, which no longer targets pfcrt. No plasmid rescued showed evidence of 
acquiring the binding site mutations. When pcrtDd2-hdhfr and pZFNcrt-bsd (Figure 7.5b) were co-
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transfected, no plasmid rescued showed evidence of acquiring binding site mutations and no 
plasmids had been integrated into the genome. Therefore, it is likely that the inability to utilize 
linearized DNA in wild-type P. falciparum is applicable to both ends-in and ends-out 
recombination. 
 
7.5.5 Construction of the P. falciparum wrnΔ mutant 
The Werner protein (WRN) is a homolog of the yeast RecQ helicase Sgs1, involved in 
unwinding linear dsDNA during extensive DNA end resection (12). WRN has been shown in 
Xenopus extracts to resect linear DNA substrates (141), but is secondary to the Bloom helicase 
(BLM) in end resection in mammalian cells (139, 140). Together, both helicases perform 
redundant function to Exonuclease 1 (EXO1). The P. falciparum WRN homolog lacks the 5′-to-
3′ exonuclease domain that is characteristic of WRN proteins in other eukaryotes. It is therefore 
possible that PF3D7_1429900 is in fact a different RecQ helicase. 
 
Table 7.6 Primers used to generate the 106/1 wrnΔ mutant 
Name Primer (5’ to 3’) Description 
p3217 cttgcggccgcGATAGTTTTATTGTTATGGCAACGGG 5' of homology, NotI 
p3218 cttctgcagCTAATATCTGGTTTATCAATACCCATTCC 3' of homology, PstI 
p3368 CCATTTTGTATCTTTTGGTAAGCG 
 
-23 bp from PF14_0278 
translation start 
 
We sought to determine the effect of end resection gene (e.g. WRN, BLM, EXO1) knockouts on 
linear DNA transfection in P. falciparum. To date, genome modification using linearized DNA 
in P. falciparum has been unsuccessful, despite success in P. berghei (245). To generate a P. 
falciparum wrnΔ knockout strain, we generated the pcamBSD-wrn plasmid that was used to 
genetically disrupt the pfwrn (PF3D7_1429900) open reading frame. First, a 860 bp fragment of 
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pfwrn encoding NotI and PstI restriction sites was PCR amplified from Dd2 gDNA using primers 
p3217 + pp3218 (Table 7.6). This fragment was then cloned into pcamBSD (52) using cloning 
sites NotI and PstI, which encodes the bsd selectable marker, yielding pcamBSD-wrn. 106/1 
parasites were transfected with purified circular pcamBSD-wrn plasmid as described (268). One 
day post-electroporation, parasites were exposed to 2 µg/ml of blasticidin (Invitrogen). 
Blasticidin media was replaced daily until day 7 post-electroporation and every 2 days thereafter. 
Transformed parasites were maintained in blasticidin-containing media and periodically checked 
by PCR for single site crossover-based plasmid integration into the pfwrn locus. This PCR screen 
used the primers p3368 and p3369 (Table 2.1). Once plasmid integration was detected. The 
mixed culture was then cloned by limiting dilution in a 96-well plate (270). To detect clones, 
plates were screened by flow cytometry on an Accuri C6 flow cytometer coupled to a HyperCyt 
autosampler, with iRBCs labeled using 1.6 µM Mito Tracker Deep Red and 2× SYBR Green 
(Invitrogen) (271). Integration-positive clones were confirmed by PCR (p3368 + p3369).  
